VIOLIN: Vaccine Investigation and Online Information Network

Plasmodium spp.

Table of Contents

General Information
Vaccine Related Pathogen Genes
1. CSP from P. falciparum
2. STARP
3. LSA-1 from Plasmodium falciparum (Other)
4. ABRA (Protective antigen)
5. AMA-1 from P. berghei (Protective antigen)
6. AMA-1 from P. chabaudi (Protective antigen)
7. AMA1 from P. falciparum 3D7 (Protective antigen)
8. AMA1 from P. knowlesi (Protective antigen)
9. cjaA (Protective antigen)
10. CS from P. berghei str. ANKA (Protective antigen)
11. CS from P. falciparum (Protective antigen)
12. CS from P. vivax (Protective antigen)
13. CS from P. yoelii (Protective antigen)
14. CSP from P. knowlesi (Protective antigen)
15. eba-175 (Protective antigen)
16. Exported protein 1 from Plasmodium falciparum (Protective antigen)
17. FCR3S1.2-var1 (Protective antigen)
18. GLURP (Protective antigen)
19. HEP17 (Protective antigen)
20. HSP60 from P. yoelii (Protective antigen)
21. Hsp90 (Protective antigen)
22. Kbeta (Protective antigen)
23. LSA-3 (Protective antigen)
24. MSP-1 from P. falciparum (Protective antigen)
25. msp-8 (Protective antigen)
26. MSP1 from P. berghei (Protective antigen)
27. MSP1 from P. knowlesi (Protective antigen)
28. MSP1 from P. yoelii str. 17XNL (Protective antigen)
29. MSP1 from P.vivax (Protective antigen)
30. MSP2 (Protective antigen)
31. msp3 (Protective antigen)
32. MSP4 (Protective antigen)
33. MSP4/5 (Protective antigen)
34. pfCelTOS (Protective antigen)
35. Pfen (Protective antigen)
36. PfP0 (Protective antigen)
37. Pfs230 (Protective antigen)
38. Pfs25 from P. falciparum 3D7 (Protective antigen)
39. Pfs48/45 (Protective antigen)
40. PvCelTOS (Protective antigen)
41. PvDBPII (Protective antigen)
42. Pvs25 (Protective antigen)
43. RESA (Protective antigen)
44. RH5 (Protective antigen)
45. SERA (Protective antigen)
46. SERA-5 (Protective antigen)
47. SSP2 (Protective antigen)
48. SSP2 from P. knowlesi (Protective antigen)
49. SSP2 from Plasmodium falciparum (Protective antigen)
50. TRAP from P. falciparum (Protective antigen)
51. FabB/FabF (Virmugen)
52. P36p (Virmugen)
53. p52 (Virmugen)
54. PY01338 (Virmugen)
55. Py36 (Virmugen)
56. Py52 (Virmugen)
57. UIS3 (Virmugen)
58. UIS4 (Virmugen)
Vaccine Information
References

I. General Information

1. NCBI Taxonomy ID:

5820

2. Disease:

Malaria

3. Introduction

Malaria is a vector-borne infectious disease that is widespread in tropical and subtropical regions, causing disease in approximately 400 million people and killing 1-3 million, most of them young children in Sub-Saharan Africa. It is one of the most common infectious diseases, caused by protozoan parasites of the genus Plasmodium. The most serious forms of the disease are caused by P. falciparum and P. vivax, but other related species (P. ovale, P. malariae, and sometimes P. knowlesi) can also infect humans. This group of human-pathogenic Plasmodium spp. is usually referred to as malaria parasites and are transmitted by female Anopheles mosquitoes. The parasites multiply within red blood cells, causing symptoms of anemia, as well as other general symptoms such as fever, chills, nausea, flu-like illness, and in severe cases, coma and death. No vaccine is currently available for malaria; preventative drugs must be taken continuously to reduce the risk of infection. These prophylactic drug treatments are often too expensive for most people living in endemic areas. Most adults from endemic areas have a degree of long-term recurrent infection and also of partial resistance, which reduces with time and such adults may become susceptible to severe malaria if they have spent a significant amount of time in non-endemic areas (Joy et al., 2003; Escalante et al., 1998; Kaufman et al., 2005; Meis et al., 1983).

4. Microbial Pathogenesis

Malaria in humans develops via exoerythrocytic (hepatic) and erythrocytic phases. When an infected mosquito pierces a person's skin to take a blood meal, sporozoites in the mosquito's saliva enter the bloodstream and migrate to the liver. Within 30 minutes of being introduced into the human host, they infect hepatocytes, multiplying asexually and asymptomatically for a period of 6–15 d. During this "dormant" time in the liver, the sporozoites are often referred to as "hypnozoites". Once in the liver, these organisms differentiate to yield thousands of merozoites which, following rupture of their host cells, escape into the blood and infect red blood cells, thus beginning the erythrocytic stage of the life cycle. The parasite escapes from the liver undetected by wrapping itself in the cell membrane of the infected host liver cell. Within the erythrocytes, the parasites multiply further, periodically breaking out of their hosts to invade fresh erythrocytes. Several such amplification cycles occur, resulting in the classical waves of fever. Some merozoites turn into male and female gametocytes. If a mosquito pierces the skin of an infected person, it potentially picks up gametocytes within the blood. Fertilization and sexual recombination of the parasite occurs in the mosquito's gut, thereby defining the mosquito as the definitive host of the disease. New sporozoites develop and travel to the mosquito's salivary gland, completing the cycle. Pregnant women are especially attractive to the mosquitoes, and malaria in pregnant women is an important cause of stillbirths, infant mortality and low birth weight (Talman et al., 2004; Bledsoe, 2005; Sturm et al., 2006).

5. Host Ranges and Animal Models

The vast majority of malaria cases occur in children under the age of 5 years; pregnant women are also especially vulnerable. Despite efforts to reduce transmission and increase treatment, there has been little change in which areas are at risk of this disease since 1992. Precise statistics are unknown, as the majority of cases are undocumented. Although HIV/malaria co-infection produces less severe symptoms than the interaction between HIV and TB, HIV and malaria do contribute to each other's spread. This effect comes from malaria increasing viral load and HIV infection increasing a person's susceptibility to malaria infection. Malaria is presently endemic in a broad band around the equator, in areas of the Americas, many parts of Asia, and much of Africa; however, it is in sub-Saharan Africa where 85– 90% of malaria fatalities occur. The geographic distribution of malaria within large regions is complex, and malarial and malaria-free areas are often found close to each other. In drier areas, outbreaks of malaria can be predicted with reasonable accuracy by mapping rainfall (Breman, 2001; Greenwood et al., 2005; Hay et al., 2004).

6. Host Protective Immunity

Plasmodia are relatively protected from attack by the body's immune system because for most of its life cycle it resides within liver and blood cells and is relatively invisible to immune surveillance. However, circulating infected blood cells are destroyed in the spleen. To avoid this fate, P. falciparum displays adhesive proteins on the surface of the infected blood cells, causing blood cells to stick to the walls of small blood vessels, thereby sequestering the parasite from passage through the general circulation and the spleen and giving rise to hemorrhagic complications. Endothelial venules can be blocked by the attachment of masses of these infected red blood cells (RBCs). The blockage of these vessels causes placental and cerebral malaria. Although the RBC surface adhesive proteins (called PfEMP1, for Plasmodium falciparum erythrocyte membrane protein 1) are exposed to the immune system, they do not serve as good immune targets because of their extreme diversity; there are at least 60 variations of the protein within a single parasite and perhaps limitless versions within parasite populations (Chen et al., 2000; Adams et al., 2002).

II. Vaccine Related Pathogen Genes

1. ABRA

Gene Name : ABRA
Sequence Strain (Species/Organism) : Plasmodium falciparum Camp
VO ID : VO_0010926
NCBI Gene ID : 811329
NCBI Protein GI : 160047
Other Database IDs : swissprot:: P22620; GI:113005
Taxonomy ID : 5833
Gene Strand (Orientation) : ?
Protein Name : p101/acidic basic repeat antigen
Protein pI : 4.52
Protein Weight : 83059.95
Protein Length : 824

DNA Sequence : Show Sequence

>PFL1385c |MSP-9|Acid-Basic Repeat Antigen, ABRA, 101 kd malaria antigen, 2277.t00277, p101|Merozoite Surface Protein 9, MSP-9|Plasmodium falciparum|chr 12|STANFORD||Manual
ATGATGAACA TGAAAATTGT TTTATTCAGT TTATTGCTCT TTGTCATAAG ATGGAATATT
ATTAGTTGTA ATAAAAACGA CAAGAACCAA GGTGTTGATA TGAATGTTTT GAATAATTAT
GAAAATTTAT TTAAATTTGT TAAATGTGAA TATTGTAATG AACATACTTA TGTTAAAGGT
AAGAAAGCTC CTTCAGATCC TCAATGTGCT GATATAAAAG AAGAATGCAA AGAATTACTT
AAGGAAAAAC AATACACAGA TTCAGTTACA TATTTAATGG ATGGTTTTAA ATCAGCAAAT
AATTCAGCAA ATAATGGTAA AAAAAATAAC GCTGAAGAAA TGAAAAATTT AGTAAATTTC
TTACAATCTC ATAAGAAATT AATTAAAGCA TTAAAAAAGA ATATTGAAAG TATACAAAAT
AAGAAACACT TAATTTATAA AAACAAATCA TATAATCCAT TATTACTTTC TTGTGTTAAA
AAAATGAATA TGTTAAAAGA AAATGTTGAC TATATTCAAA AAAATCAAAA CTTATTTAAA
GAATTAATGA ATCAAAAAGC TACCTACTCT TTTGTTAATA CCAAAAAAAA AATTATTTCT
TTAAAATCAC AAGGTCATAA AAAAGAAACC TCACAAAATC AAAATGAAAA TAACGACAAT
CAAAAATATC AAGAAGTTAA TGATGAAGAT GATGTAAATG ATGAAGAAGA TACAAACGAT
GACGAAGATA CTAACGATGA AGAAGATACA AACGATGACG AAGATACAAA TGATGACGAA
GATACTAACG ATGAAGAAGA TACTAACGAC GAAGAAGATC ATGAAAATAA TAATGCTACA
GCATACGAAT TAGGTATCGT CCCAGTTAAC GATGTGTTAA ATGTTAATAT GAAAAATATG
ATAACAGGAA ATAATTTTAT GGATGTTGTT AAAAATACAT TAGCTCAATC AGGTGGATTA
GGAAGTAATG ATTTAATAAA TTTCTTAAAT CAAGGTAAAG AAATAGGAGA AAATTTATTA
AACATAACAA AGATGAACTT GGGAGATAAG AATAATCTTG AAAGTTTTCC TTTAGATGAA
TTAAATATGT TAAAAGATAA TTTAATAAAC TATGAATTCA TATTAGATAA TTTGAAAACA
AGTGTTTTAA ATAAATTAAA AGATTTATTA TTAAGATTAT TATACAAAGC ATATGTATCA
TATAAGAAAA GAAAAGCTCA AGAAAAAGGA TTACCAGAAC CTACTGTTAC TAATGAAGAA
TATGTTGAAG AATTAAAGAA AGGTATTCTA GATATGGGTA TCAAATTATT ATTTAGTAAA
GTTAAAAGCC TATTAAAAAA ATTAAAAAAT AAAATATTCC CTAAGAAAAA AGAAGATAAT
CAAGCAGTAG ATACCAAAAG TATGGAAGAA CCCAAAGTTA AAGCACAACC AGCTCTTAGA
GGTGTTGAAC CAACGGAAGA TTCTAATATT ATGAACAGTA TTAATAATGT TATGGATGAA
ATTGATTTCT TTGAAAAAGA ATTAATCGAA AATAATAATA CACCTAATGT TGTACCACCA
ACTCAATCAA AAAAAAAAAA CAAAAATGAA ACTGTATCTG GTATGGATGA AAATTTTGAT
AATCATCCTG AAAATTATTT TAAAGAAGAA TATTATTATG ATGAAAATGA TGATATGGAA
GTAAAAGTTA AAAAAATAGG TGTCACATTA AAAAAATTTG AACCACTTAA AAATGGAAAT
GTTAGTGAAA CCATTAAATT GATTCATTTA GGAAATAAAG ATAAAAAACA CATTGAAGCT
ATAAACAACG ATATTCAAAT TATTAAACAA GAATTACAAG CTATTTATAA TGAACTTATG
AATTATACAA ATGGAAACAA AAATATTCAA CAAATATTTC AACAAAATAT TCTAGAAAAT
GATGTTCTTA ATCAAGAAAC GGAGGAAGAA ATGGAAAAAC AAGTTGAAGC AATCACCAAG
CAAATAGAAG CTGAAGTGGA TGCCCTCGCA CCAAAAAATA AGGAAGAAGA AGAAAAAGAA
AAGGAAAAAG AAGAAAAAGA AAAAGAAGAA AAAGAAAAAG AAAAAGAAGA AAAAGAAAAA
GAAGAAAAAG AAAAAGAAGA AAAAGAAAAA GAAGAAAAAG AAGAAGAAAA AAAAGAAAAA
GAAGAAGAAC AAGAAGAAGA AGAAGAAGAA GAAATAGTAC CAGAAAATTT GACAACTGAA
GAATCAAAAT AA

Protein Sequence : Show Sequence

>AAA29462.1 p101/acidic basic repeat antigen [Plasmodium falciparum]
MMNMKIVLFSLLLFVIRWNIISCNKNDKNQGVDMNVLNNYENLFKFVKCEYCNEHTYVKGKKAPSDPQCA
DIKEECKELLKEKQYTDSVTYLMDGFKSANNSANNGKKNNAEEMKNLVNFLQSHKKLIKALKKNIESIQN
KKHLIYKNKSYNPLLLSCVKKMNMLKENVDYIQKNQNLFKELMNQKATYSFVNTKKKIISLKSQGHKKET
SQNQNENNDNQKYQEVNDEDDVNDEEDTNDDEDTNDEEDTNDDEDTNDDEDTNDEEDTNDEEDHENNNAT
AYELGIVPVNDVLNVNMKNMITGNNFMDVVKNTLAQSGGLGSNDLINFLNQGKEIGENLLNITKMNLGDK
NNLESFPLDELNMLKDNLINYEFILDNLKTSVLNKLKDLLLRLLYKAYVSYKKRKAQEKGLPEPTVTNEE
YVEELKKGILDMGIKLLFSKVKSLLKKLKNKIFPKKKEDNQAVDTKSMEEPKVKAQPALRGVEPTEDSNI
MNSINNVMDEIDFFEKELIENNNTPNVVPPTQSKKKNKNETVSGMDENFDNHPENYFKEEYYYDENDDME
VKVKKIGVTLKKFEPLKNGNVSETIKLIHLGNKDKKHIEAINNDIQIIKQELQAIYNELMNYTNGNKNIQ
QIFQQNILENDVLNQETEEEMEKQVEAITKQIEAEVDALAPKNKEEEEKEKEKEKEKEEKEKEEKEKEEK
EKEKEEKEKEKEEKEEEKKEKEEEQEEEEEEIVPENLTTEESK

Molecule Role : Protective antigen
Molecule Role Annotation : Protective antigen (Kushwaha et al., 2001)
Related Vaccine(s): Recombinant ABRA protein vaccine

2. AMA-1 from P. berghei

Gene Name : AMA-1 from P. berghei
Sequence Strain (Species/Organism) : Plasmodium berghei
VO ID : VO_0011224
NCBI Gene ID : 55149604
NCBI Protein GI : 1438889
Other Database IDs : CDD:280571
Taxonomy ID : 5821
Gene Strand (Orientation) : ?
Protein Name : apical membrane antigen-1
Protein pI : 6.68
Protein Weight : 61320.86
Protein Length : 624
Protein Note : Apical membrane antigen 1; pfam02430

Protein Sequence : Show Sequence

>AAC47192.1 apical membrane antigen-1 [Plasmodium berghei]
MKEIYYILILCSIYLINLSNCSEGPNNVISENGHINYDMIQKENTERSTKLINPWEKYTEKYDIERMHGS
GIRVDLGEDARVENRDYRIPSGKCPVIGKGITIQNSEVSFLTPVATGDQSVRSGGLALPKTDVHLSPITI
DNLKTMYKEHTEIVKLNNMSLCAKHTSFYVPGNNANSAYRHPAVYDKSNSTCYMLYVAAQENMGPRYCSN
NANNDNQPFCFTPEKIEKYKNLSYLTKNLRDDWETSCPNKSIKNAKFGIWVDGYCKDYQKHTVHDSDSLL
KCNQIIFNESASDQPKQYEKHLEDTTKFRQGVAERNGKLIGEALLPIGSYKSDQIKSHGRGYNWGNYDSQ
NKKCYIFETKPTCLINDRNFIATTALSSTEEFEEQFPCDIYKNKINEEIKVLNKNISNGNNSIEFPRIFI
STDKNSLNCPCEPTQLTESSCNFYVCNCVEKRQYIAENNDVEIKEELEVHMKAHQTREVIVIIIFICVGI
ILVILLVGYFFKSNKKGENYDRMGQADIYGKANSRKDGMLDPEVSFWGEDKRASHTTPVLMEKPYY

Molecule Role : Protective antigen
Molecule Role Annotation : Mice immunized with recombinant PbAMA-1 were partially protected from the challenge of P. berghei (Li et al., 2007).

3. AMA-1 from P. chabaudi

Gene Name : AMA-1 from P. chabaudi
Sequence Strain (Species/Organism) : Plasmodium chabaudi
VO ID : VO_0011237
NCBI Gene ID : 3488885
NCBI Protein GI : 1469500
Other Database IDs : CDD:302876
Taxonomy ID : 5825
Gene Strand (Orientation) : ?
Protein Name : apical membrane antigen 1
Protein pI : 8.37
Protein Weight : 37252.97
Protein Length : 415
Protein Note : DK is a cloned line derived from 556KA

Protein Sequence : Show Sequence

>AAB36511.1 apical membrane antigen 1, partial [Plasmodium chabaudi]
DLIPKENTERSHKLINPWEKFMEKYDIEKVHGSGIRVDLGEDARVENQDYRIPSGKCPVMGKGITIQNSK
VSFLTRVATGNQKVREGGLAFPQTDVNISPITIDNLKLMYKDHKEILALNDMSLCAKHASFYVPGTNVNT
AYRHPAVYDKSNKTCYILYVAAQENMGPRYCSNEEDNENQPFCFTPEKKDEYKNLSYLTKNLREDWETSC
PNKSIQNAKFGVWVDGYCSEYQKKEVHDNKTLLECNQIVFNESASDQPKQYEKHLEDTAKIRRGIVDRNG
KLIGEALLPIGSYRADQVKSKGKGYNWANYDKKTKKCYIFNKKPTCLINDKDFVATTALS

Molecule Role : Protective antigen
Molecule Role Annotation : Mice immunized with a refolded, recombinant, Plasmodium chabaudi AMA1 fragment (AMA1B) can withstand subsequent challenge with P. chabaudi adami (Xu et al., 2000).
Related Vaccine(s): P. chabaudi AMA1 Protein Vaccine

4. AMA1 from P. falciparum 3D7

Gene Name : AMA1 from P. falciparum 3D7
Sequence Strain (Species/Organism) : Plasmodium falciparum 3D7
VO ID : VO_0010923
NCBI Gene ID : 810891
NCBI Protein GI : 124804478
Locus Tag : PF3D7_1133400
Genbank Accession : LN999945
Protein Accession : XP_001348015
3D structure: PDB ID : 1Z40
Other Database IDs : UniProt: P22621
Taxonomy ID : 36329
Chromosome No : 11
Gene Starting Position : 1293855
Gene Ending Position : 1295723
Gene Strand (Orientation) : +
Protein Name : Apical membrane antigen 1 (AMA1); PF11_0344; AMA-1, Pf83, RMA1, RMA 1, rhoptry membrane antigen
Protein pI : 5.23
Protein Weight : 69161.85
Protein Length : 622
Protein Note : This is apical membrane antigen 1 (AMA1), or designated at PF11_0344 (PF11_0344 in GeneDB).

DNA Sequence : Show Sequence

>NC_037282.1:1293855-1295723 Plasmodium falciparum 3D7 chromosome 11, complete sequence
AATGAGAAAATTATACTGCGTATTATTATTGAGCGCCTTTGAGTTTACATATATGATAAACTTTGGAAGA
GGACAGAATTATTGGGAACATCCATATCAAAATAGTGATGTGTATCGTCCAATCAACGAACATAGGGAAC
ATCCAAAAGAATACGAATATCCATTACACCAGGAACATACATACCAACAAGAAGATTCAGGAGAAGACGA
AAATACATTACAACACGCATATCCAATAGACCACGAAGGTGCCGAACCCGCACCACAAGAACAAAATTTA
TTTTCAAGCATTGAAATAGTAGAAAGAAGTAATTATATGGGTAATCCATGGACGGAATATATGGCAAAAT
ATGATATTGAAGAAGTTCATGGTTCAGGTATAAGAGTAGATTTAGGAGAAGATGCTGAAGTAGCTGGAAC
TCAATATAGACTTCCATCAGGGAAATGTCCAGTATTTGGTAAAGGTATAATTATTGAGAATTCAAATACT
ACTTTTTTAACACCGGTAGCTACGGGAAATCAATATTTAAAAGATGGAGGTTTTGCTTTTCCTCCAACAG
AACCTCTTATGTCACCAATGACATTAGATGAAATGAGACATTTTTATAAAGATAATAAATATGTAAAAAA
TTTAGATGAATTGACTTTATGTTCAAGACATGCAGGAAATATGATTCCAGATAATGATAAAAATTCAAAT
TATAAATATCCAGCTGTTTATGATGACAAAGATAAAAAGTGTCATATATTATATATTGCAGCTCAAGAAA
ATAATGGTCCTAGATATTGTAATAAAGACGAAAGTAAAAGAAACAGCATGTTTTGTTTTAGACCAGCAAA
AGATATATCATTTCAAAACTATACATATTTAAGTAAGAATGTAGTTGATAACTGGGAAAAAGTTTGCCCT
AGAAAGAATTTACAGAATGCAAAATTCGGATTATGGGTCGATGGAAATTGTGAAGATATACCACATGTAA
ATGAATTTCCAGCAATTGATCTTTTTGAATGTAATAAATTAGTTTTTGAATTGAGTGCTTCGGATCAACC
TAAACAATATGAACAACATTTAACAGATTATGAAAAAATTAAAGAAGGTTTCAAAAATAAGAACGCTAGT
ATGATCAAAAGTGCTTTTCTTCCCACTGGTGCTTTTAAAGCAGATAGATATAAAAGTCATGGTAAGGGTT
ATAATTGGGGAAATTATAACACAGAAACACAAAAATGTGAAATTTTTAATGTCAAACCAACATGTTTAAT
TAACAATTCATCATACATTGCTACTACTGCTTTGTCCCATCCCATCGAAGTTGAAAACAATTTTCCATGT
TCATTATATAAAGATGAAATAATGAAAGAAATCGAAAGAGAATCAAAACGAATTAAATTAAATGATAATG
ATGATGAAGGGAATAAAAAAATTATAGCTCCAAGAATTTTTATTTCAGATGATAAAGACAGTTTAAAATG
CCCATGTGACCCTGAAATGGTAAGTAATAGTACATGTCGTTTCTTTGTATGTAAATGTGTAGAAAGAAGG
GCAGAAGTAACATCAAATAATGAAGTTGTAGTTAAAGAAGAATATAAAGATGAATATGCAGATATTCCTG
AACATAAACCAACTTATGATAAAATGAAAATTATAATTGCATCATCAGCTGCTGTCGCTGTATTAGCAAC
TATTTTAATGGTTTATCTTTATAAAAGAAAAGGAAATGCTGAAAAATATGATAAAATGGATGAACCACAA
GATTATGGGAAATCAAATTCAAGAAATGATGAAATGTTAGATCCTGAGGCATCTTTTTGGGGGGAAGAAA
AAAGAGCATCACATACAACACCAGTTCTGATGGAAAAACCATACTATTA

Protein Sequence : Show Sequence

>XP_001348015.1 apical membrane antigen 1 [Plasmodium falciparum 3D7]
MRKLYCVLLLSAFEFTYMINFGRGQNYWEHPYQNSDVYRPINEHREHPKEYEYPLHQEHTYQQEDSGEDE
NTLQHAYPIDHEGAEPAPQEQNLFSSIEIVERSNYMGNPWTEYMAKYDIEEVHGSGIRVDLGEDAEVAGT
QYRLPSGKCPVFGKGIIIENSNTTFLTPVATGNQYLKDGGFAFPPTEPLMSPMTLDEMRHFYKDNKYVKN
LDELTLCSRHAGNMIPDNDKNSNYKYPAVYDDKDKKCHILYIAAQENNGPRYCNKDESKRNSMFCFRPAK
DISFQNYTYLSKNVVDNWEKVCPRKNLQNAKFGLWVDGNCEDIPHVNEFPAIDLFECNKLVFELSASDQP
KQYEQHLTDYEKIKEGFKNKNASMIKSAFLPTGAFKADRYKSHGKGYNWGNYNTETQKCEIFNVKPTCLI
NNSSYIATTALSHPIEVENNFPCSLYKDEIMKEIERESKRIKLNDNDDEGNKKIIAPRIFISDDKDSLKC
PCDPEMVSNSTCRFFVCKCVERRAEVTSNNEVVVKEEYKDEYADIPEHKPTYDKMKIIIASSAAVAVLAT
ILMVYLYKRKGNAEKYDKMDEPQDYGKSNSRNDEMLDPEASFWGEEKRASHTTPVLMEKPYY

Molecule Role : Protective antigen
Related Vaccine(s): AMA 49-CPE , AMA1-C1Alhydrogel , AMA1-C1Alhydrogel + CPG 7909 , ChAd63-MVA AMA1 , FMP1/AS02A , NYVAC-Pf7 , PfAMA1-FVO/ Alhydrogel

5. AMA1 from P. knowlesi

Gene Name : AMA1 from P. knowlesi
Sequence Strain (Species/Organism) : Plasmodium knowlesi strain H
NCBI Gene ID : 7320803
NCBI Protein GI : 221056402
Other Database IDs : CDD:240241
EnsemblGenomes-Gn:PKH_093110
EnsemblGenomes-Tr:PKH_093110
GOA:B3L5E1
InterPro: IPR003298
InterPro: IPR024056
UniProtKB/TrEMBL: B3L5E1
Taxonomy ID : 5851
Gene Strand (Orientation) : ?
Protein Name : apical merozoite antigen 1
Protein pI : 6.98
Protein Weight : 62359.812
Protein Length : 647
Protein Note : apical membrane antigen 1; Provisional

Protein Sequence : Show Sequence

>XP_002259339.1 apical merozoite antigen 1 [Plasmodium knowlesi strain H]
MNKIYYILFLSAQCLVHMGKCERNQKTTRLTRSANNASLEKGPIIERSIRMSNPWKAFMEKYDLERAHNS
GIRIDLGEDAEVGNSKYRIPAGKCPVFGKGIVIENSNVSFLTPVATGAQRLKEGGFAFPNADDHISPITI
ANLKERYKENADLMKLNDIALCKTHAASFVIAEDQNTSYRHPAVYDEKNKTCYMLYLSAQENMGPRYCSP
DSQNKDAMFCFKPDKNEKFDNLVYLSKNVSNDWENKCPRKNLGNAKFGLWVDGNCEEIPYVNEVEARSLR
ECNRIVFEASASDQPRQYEEELTDYEKIQEGFRQNNRDMIKSAFLPVGAFNSDNFKSKGRGYNWANFDSV
NNKCYIFNTKPTCLINDKNFFATTALSHPQEVDNEFPCSIYKDEIEREIKKQSRNMNLYSVDKERIVLPR
IFISTDKESIKCPCEPEHISNSTCNFYVCNCVEKRAEIKENNEVIIKEEFKEDYENPDGKHKKKMLLIII
GVTGAVCVVAVASLFYFRKKAQDDKYDKMDQAEAYGKTANTRKDEMLDPEASFWGEDKRASHTTPVLMEK
PYY

Molecule Role : Protective antigen
Related Vaccine(s): P. knowlesi DNA vaccine encoding PkCSP, PkSSP2, PkAMA1, and PkMSP1p42

6. cjaA

Gene Name : cjaA
Sequence Strain (Species/Organism) : P. vivax SouthernMex-62 isolate
VO ID : VO_0010957
3D structure: PDB ID : 1Z27
Other Database IDs : CDD:270412
GOA:P94643
InterPro: IPR001638
UniProtKB/TrEMBL: P94643
Taxonomy ID : 197
Gene Strand (Orientation) : ?
Protein pI : 4.9
Protein Weight : 29158.88
Protein Length : 324
Protein Note : Substrate binding domain of ABC cysteine transporter; the type 2 periplasmic binding protein fold; cd13694

DNA Sequence : Show Sequence

>gi|154184258:1-660 Plasmodium vivax isolate SouthernMex-62 ookinete surface protein (Pvs25) gene, complete cds
ATGAACTCCTACTACAGCCTCTTCGTTTTTTTCCTCGTCCAAATTGCGCTAAAGTATAGCAAGGCAGCCG
TCACGGTAGACACCATATGCAAAAATGGACAGCTGGTTCAAATGAGTAACCACTTTAAGTGTATGTGTAA
CGAAGGGCTGGTGCACCTTTCCGAAAATACATGTGAAGAAAAAAATGAATGCAAGAAAGAAACCCTAGGC
AAAGCATGCGGGGAATTTGGCCAGTGTATAGAAAACCCAGACCCAGCAAAGGTAAACATGTACAAATGTG
GTTGCATTGAGGGCTACACTTTGAAGGAAGACACTTGTGTGCTTGATGTATGTCAATACAAAAATTGTGG
AGAAAGTGGCGAATGCATTGTTGAGTACCTCTCGGAAACCCAAAGTGCAGGTTGCTCATGTGCTATTGGC
AAAGTCCCCAATCCAGAAGATGAGAAAAAATGTACCAAAACGGGAGAAACTGCTTGTCAATTGAAATGTA
ACACAGATAATGAAGTCTGCAAAAATGTTGAAGGAGTTTACAAGTGCCAGTGTATGGAAGGCTTTACGTT
CGACAAAGAGAAAAATGTATGCCTTTCCTATTCTGTATTTAACATCCTAAACTACTCCCTCTTCTTTATC
ATCCTGCTTGTCCTTTCGTACGTCATATAA

Protein Sequence : Show Sequence

>CAA71822.1 cjaA [Campylobacter jejuni]
MKKMLLSIFTTFVAVFLAACGGNSDSGASNSLERIKQDGVVRIGVFGDKPPFGYVDEKGVNQGYDIVLAK
RIAKELLGDENKVQFVLVEAANRVEFLKSNKVDIILANFTQTPERAEQVDFCLPYMKVALGVAVPQDSNI
SSIEDLKDKTLLLNKGTTADAYFTKEYPDIKTLKYDQNTETFAALIDQRGDALSHDNTLLFAWVKEHPEF
KMAIKELGNKDVIAPAVKKGDKELKEFIDNLITKLGEEQFFHKAYDETLKSHFGDDVKADDVVIEGGKI

Molecule Role : Protective antigen

7. CS from P. berghei str. ANKA

Gene Name : CS from P. berghei str. ANKA
Sequence Strain (Species/Organism) : Plasmodium berghei ANKA
VO ID : VO_0011217
NCBI Gene ID : 3428738
NCBI Protein GI : AAA29577.1
Locus Tag : PBANKA_040320
Genbank Accession : LK023119
Protein Accession : XP_022712148
Taxonomy ID : 5823
Chromosome No : 4
Gene Starting Position : 126554
Gene Ending Position : 127576
Gene Strand (Orientation) : -
Protein pI : 5.2
Protein Weight : 35858.22
Protein Length : 340

DNA Sequence : Show Sequence

>NC_036162.1:126554-127576 Plasmodium berghei ANKA genome assembly PBANKA01, chromosome : 4
TTTAATTAAAGAATACTAATACTAATAATATTACAAATCCTAATGAATTGCTTACAATATTAAATATACT
TGAACATTTATCCATTTTACAAATTTCAGTATCAATATCTTCTAAGGTCAAATCTTCTGCTTTCTTATTT
GAACCTTTTCGTTTTCTAACTCTTATACCAGAACCACATGTTACGTTACATTGAGACCATTCCTCTGTGA
TACTATCCCTGATCTGTTTAACAAATTCTAGTATTTTTTCCGCGCTTGGGATATAAGAATCGTCATTATT
ATTATTTTTGTTATTGTTATTACCACCTGGCTGTGGTTGTGGCTGTGGTCGTGGCTGTGGTTGTGGCTGT
GGCTGTGGTTGTGGCTGTGGCTGTGGTTGTGGCTGCGGCCGTGGCTGTGGTTGTGGATTGTTATTTCCTT
GTGGTGGTGCTGGGTCATTTGGGTTTGGTGGTGGTGGGTCATTTGCGTTTGGTGGTGCTGGGTCATTTGG
GTTTGGTGGTGGTGGGTCATTTGCGTTTGGTGGTGCTGGGTCATTTGCGTTTGGTGGTGCTGGGTCATTT
GCGTTTGGTGGTGCTGGGTCATTTGCGTTTGGTGGTGCTGGGTCATTTGCGTTTGGTGGTGGTGGGTCAT
TTGCGTTTGGTGGTGGTGGGTCATTTGGGTTTGGTGGTGGTGGGTCATTTGGGTTTGGTGGTGGTGGGTC
ATTTGGGTTTGGTGGTGGTGGGTCATTTGGGTTTGGTGGTGGTGGTGGTTGTTTCAATTTATTATTACGC
TCTATTTTTTCGTTTTTTTTCTCATTTTTTTTTCCTTCGGGAGCATCGGCAAGTAATCTGTTGACTGTAT
TTCGATTGTATATTTTTCCATTCTTAGAGTTAAGCACGTGATACAATTTATTATCATTTCCTTCATTGTA
ACATAGCTCGTTTAAGTTCCTTTGGGCTTGGATGCTTTTATTTTGTCCATATCCTGGAAGTAGAGAATTA
ACTAATAAAAGTGACGCTACAACTAAAATGGTACACTTCTTCA

Protein Sequence : Show Sequence

>AAA29577.1 circumsporozoite protein [Plasmodium berghei ANKA]
MKKCTILVVASLLLVNSLLPGYGQNKIIQAQRNLNELCYNEGNDNKLYHVLNSKNGKIYNRNTVNRLLPM
LRRKKNEKKNEKIERNNKLKQPPPPPNPNDPPPPNPNDPPPPNPNDPPPPNPNDPPPPNANDPPPPNAND
PAPPNANDPAPPNANDPAPPNANDPAPPNANDPAPPNANDPAPPNANDPPPPNPNDPAPPQGNNNPQPQP
RPQPQPQPQPQPQPQPQPQPRPQPQPQPGGNNNNKNNNNDDSYIPSAEKILEFVKQIRDSITEEWSQCNV
TCGSGIRVRKRKGSNKKAEDLTLEDIDTEICKMDKCSSIFNIVSNSLGFVILLVLVFFN

Molecule Role : Protective antigen
Molecule Role Annotation : Researchers produced a prototypic malaria vaccine based on a highly versatile self-assembling polypeptide nanoparticle (SAPN) platform that can repetitively display antigenic epitopes. Researchers used this platform to display a tandem repeat of the B cell immunodominant repeat epitope (DPPPPNPN)(2)D of the malaria parasite Plasmodium berghei circumsporozoite (CS) protein. Administered in saline, without the need for a heterologous adjuvant, the SAPN construct P4c-Mal conferred a long-lived, protective immune response to mice with a broad range of genetically distinct immune backgrounds including the H-2(b), H-2(d), and H-2(k) alleles. Mice were protected against an initial challenge of parasites up to 6 mo after the last immunization or for up to 15 mo against a second challenge after an initial challenge of parasites had successfully been cleared (Kaba et al., 2009).
Related Vaccine(s): P. berghei CS Protein Subunit Vaccine , P. berghei DNA vaccine CSP-3p28 , P. berghei DNA vaccine encoding PbCSP

8. CS from P. falciparum

Gene Name : CS from P. falciparum
Sequence Strain (Species/Organism) : Plasmodium falciparum 3D7
VO ID : VO_0011218
NCBI Gene ID : 814364
NCBI Protein GI : 552191
Other Database IDs : CDD:278517
Taxonomy ID : 5833
Gene Strand (Orientation) : ?
Protein Name : circumsporozoite protein
Protein pI : 4.85
Protein Weight : 44428.05
Protein Length : 502
Protein Note : Thrombospondin type 1 domain; pfam00090

Protein Sequence : Show Sequence

>AAA63422.1 circumsporozoite protein, partial [Plasmodium falciparum]
MMRKLAILSVSSFLFVEALFQEYQCYGSSSNTRVLNELNYDNAGTNLYNELEMNYYGKQENWYSLKKNSR
SLGENDDGNNNNGDNGREGKDEDKRDGNNEDNEKLRKPKHKKLKQPGDGNPDPNANPNVDPNANPNVDPN
ANPNVDPNANPNVDPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNAN
PNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPN
ANPNANPNANPNANPNANPNKNNQGNGQGHNMPNDPNRNVDENANANNAVKNNNNEEPSDKHIEQYLKKI
QNSLSTEWSPCSVTCGNGIQVRIKPGSANKPKDELDYENDIEKKICKMEKCSSVFNVVNSSIGLIMVLSF
LFLN

Molecule Role : Protective antigen
Molecule Role Annotation : We employed a P. berghei parasite line that expresses a heterologous CSP (CS) from P. falciparum in order to assess the role of the CSP in the protection conferred by vaccination with radiation-attenuated P. berghei parasites. Our data demonstrated that sterile immunity could be obtained despite the absence of immune responses specific to the CSP expressed by the parasite used for challenge (Grüner et al., 2007).
Related Vaccine(s): NYVAC-Pf7 , P. falciparum CS expressed in irradiated P. berghei as Vaccine , Pb(PfCS@UIS4) , RTS,S/AS01

9. CS from P. vivax

Gene Name : CS from P. vivax
NCBI Protein GI : AAA29526.1
Other Database IDs : CDD:237171
CDD:395043
Taxonomy ID : 5855
Gene Strand (Orientation) : ?
Protein Name : circumsporozoite protein
Protein pI : 4.92
Protein Weight : 36224.04
Protein Length : 441
Protein Note : transcription termination factor Rho; Provisional

Protein Sequence : Show Sequence

>AAA29526.1 circumsporozoite protein [Plasmodium vivax]
MKNFILLAVSSILLVDLFPTHCGHNVDLSKAINLNGVNFNNVDASSLGAAHVGQSASRGRGLGENPDDEE
GDAKKKKDGKKAEPKNPRENKLKQPGDRADGQPAGDRADGQPAGDRADGQPAGDRAAGQPAGDRADGQPA
GDRADGQPAGDRADGQPAGDRADGQPAGDRAAGQPAGDRAAGQPAGDRADGQPAGDRAAGQPAGDRADGQ
PAGDRAAGQPAGDRADGQPAGDRAAGQPAGDRAAGQPAGDRAAGQPAGDRAAGQPAGNGAGGQAAGGNAG
GGQGQNNEGANAPNEKSVKEYLDKVRATVGTEWTPCSVTCGVGVRVRRRVNAANKKPEDLTLNDLETDVC
TMDKCAGIFNVVSNSLGLVILLVLALFN

Molecule Role : Protective antigen
Related Vaccine(s): PvCS/Montanide ISA-51

10. CS from P. yoelii

Gene Name : CS from P. yoelii
Sequence Strain (Species/Organism) : Plasmodium yoelii
VO ID : VO_0011219
NCBI Gene ID : 3800426
NCBI Protein GI : 1844509887
Locus Tag : PY17X_0405400
Genbank Accession : LM993658
Protein Accession : XP_728216
Taxonomy ID : 5861
Chromosome No : 4
Gene Starting Position : 317725
Gene Ending Position : 319008
Gene Strand (Orientation) : +
Protein pI : 4.79
Protein Weight : 42077.07
Protein Length : 427

Protein Sequence : Show Sequence

>XP_728216.3 circumsporozoite protein precursor [Plasmodium yoelii]
MKKCTILVVASLLLVDSLLPGYGQNKSVQAQRNLNELCYNEENDNKLYHVLNSKNGKIYNRNIVNRLLGD
ALNGKPEEKKDDPPKDGNKDDLPKEEKKDDLPKEEKKDDPPKDPKKDDPPKEAQNKLNQPVVADENVDQG
PGAPQGPGAPQGPGAPQGPGAPQGPGAPQGPGAPQGPGAPQGPGAPQGPGAPQGPGAPQGPGAPQGPGAP
QGPGAPQGPGAPQGPGAPQGPGAPQGPGAPQGPGAPQGPGAPQGPGAPQGPGAPQGPGAPQGPGAPQGPG
APQGPGAPQEPPQQPPQQPPQQPPQQPPQQPPQQPPQQPRPQPDGNNNNNNNNGNNNEDSYVPSAEQILE
FVKQISSQLTEEWSQCSVTCGSGVRVRKRKNVNKQPENLTLEDIDTEICKMDKCSSIFNIVSNSLGFVIL
LVLVFFN

Molecule Role : Protective antigen
Molecule Role Annotation : Study showed that immunization with irradiated sporozoites (IrrSpz) of a P. berghei line whose endogenous CS was replaced by that of P. yoelii conferred sterile protection against challenge with wild type P. berghei sporozoites (Mauduit et al., 2009).
Related Vaccine(s): P. yoelii DNA vaccine pDIP/PyCSP. 1

11. CSP from P. falciparum

Gene Name : CSP from P. falciparum
Related Vaccine(s): RTS,S/AS01 , UK39

12. CSP from P. knowlesi

Gene Name : CSP from P. knowlesi
Sequence Strain (Species/Organism) : Plasmodium knowlesi strain H
NCBI Gene ID : 7322927
NCBI Protein GI : 221060580
Other Database IDs : CDD:319368
EnsemblGenomes-Gn:PKH_134120
EnsemblGenomes-Tr:PKH_134120
GOA:B3LAV3
InterPro: IPR001841
InterPro: IPR013083
UniProtKB/TrEMBL: B3LAV3
Taxonomy ID : 5851
Gene Strand (Orientation) : ?
Protein Name : circumsporozoite protein, putative
Protein pI : 5.61
Protein Weight : 73901.662
Protein Length : 795
Protein Note : RING finger, H2 subclass, found in the PA-TM-RING ubiquitin ligase family; cd16454

Protein Sequence : Show Sequence

>XP_002260935.1 circumsporozoite protein, putative [Plasmodium knowlesi strain H]
MSISEHTGNEVSIAERKKKEEGSGGVINDKNVSPTDDGESMPHPMEKMKGAANDEKSVEVENCAPVGENE
LRSSVLCVGCSGEASHIEEGSAKFVGEENPRTEVDSDKKAQPEGILNEVKNVKNEIDVEKKHKTQISNND
TYVENAPNDNTCGEGCSNPHMNHDNKACDNGDDNDKIPNTGGTSNGGVIPNISGVLNVEDDCPLDEGNFS
ADDRPEENADSTSSFMLEEDINLSRRAYRNFHICSIFIHGTLLLMVTLLMGILCHDFIKLSPISQKEKTM
TYFCGLLLSMLALHLCLNLYMSLVLLRQSEVSKMLKSVEAKIHVIVLVYFSMCAYIYFFEDKYYPISSTF
SFAIILAIIYYFMPIFLYIILRLLFIVVILVLVFVKRKSPTPKKILKKLKIMKYVEYRKYCEEEACFGSA
YFTNWKELNGEGVSAPREATTTTAMEGGHIIATSGGDNKGEEVSSGDSTSNRNAEGKTISTATSCIRDIS
ANGSGHPKGGDPPSSSPNDRPTRSGNSSTRSNLERHLFYDRAGVAIGRGGGSDNRGGTRPNDRGRDDPAN
GNHQNGSDNANKHPPASYDNNCDAPNTSGEENGERNGGPNKDGKSAAVFEYFQKVLKKKNNSVQNDNVKV
VHENNMEEHSFHINIECSDYVCSICCVEYLNEDDICILPCNYLHYYHKECIFKWLKRNNDCPLCRKPIGK
I

Molecule Role : Protective antigen
Related Vaccine(s): P. knowlesi DNA vaccine encoding PkCSP, PkSSP2, PkAMA1, and PkMSP1p42

13. eba-175

Gene Name : eba-175
Sequence Strain (Species/Organism) : Plasmodium falciparum 3D7
VO ID : VO_0012382
NCBI Gene ID : 2654998
NCBI Protein GI : 296004911
Locus Tag : PF3D7_0731500
Genbank Accession : AL844506
Protein Accession : XP_001349207
Taxonomy ID : 36329
Chromosome No : 7
Gene Starting Position : 1358054
Gene Ending Position : 1362928
Gene Strand (Orientation) : +
Protein pI : 5.47
Protein Weight : 168527.84
Protein Length : 1502
Protein Note : Also known as eba 175; eba175

DNA Sequence : Show Sequence

>NC_004328.3:1358054-1362928 Plasmodium falciparum 3D7 chromosome 7
AATGAAATGTAATATTAGTATATATTTTTTTGCTTCCTTCTTTGTGTTATATTTTGCAAAAGCTAGGAAT
GAATATGATATAAAAGAGAATGAAAAATTTTTAGACGTGTATAAAGAAAAATTTAATGAATTAGATAAAA
AGAAATATGGAAATGTTCAAAAAACTGATAAGAAAATATTTACTTTTATAGAAAATAAATTAGATATTTT
AAATAATTCAAAATTTAATAAAAGATGGAAGAGTTATGGAACTCCAGATAATATAGATAAAAATATGTCT
TTAATAAATAAACATAATAATGAAGAAATGTTTAACAACAATTATCAATCATTTTTATCGACAAGTTCAT
TAATAAAGCAAAATAAATATGTTCCTATTAACGCTGTACGTGTGTCTAGGATATTAAGTTTCCTGGATTC
TAGAATTAATAATGGAAGAAATACTTCATCTAATAACGAAGTTTTAAGTAATTGTAGGGAAAAAAGGAAA
GGAATGAAATGGGATTGTAAAAAGAAAAATGATAGAAGCAACTATGTATGTATTCCTGATCGTAGAATCC
AATTATGCATTGTTAATCTTAGCATTATTAAAACATATACAAAAGAGACCATGAAGGATCATTTCATTGA
AGCCTCTAAAAAAGAATCTCAACTTTTGCTTAAAAAAAATGATAACAAATATAATTCTAAATTTTGTAAT
GATTTGAAGAATAGTTTTTTAGATTATGGACATCTTGCTATGGGAAATGATATGGATTTTGGAGGTTATT
CAACTAAGGCAGAAAACAAAATTCAAGAAGTTTTTAAAGGGGCTCATGGGGAAATAAGTGAACATAAAAT
TAAAAATTTTAGAAAAAAATGGTGGAATGAATTTAGAGAGAAACTTTGGGAAGCTATGTTATCTGAGCAT
AAAAATAATATAAATAATTGTAAAAATATTCCCCAAGAAGAATTACAAATTACTCAATGGATAAAAGAAT
GGCATGGAGAATTTTTGCTTGAAAGAGATAATAGATCAAAATTGCCAAAAAGTAAATGTAAAAATAATAC
ATTATATGAAGCATGTGAGAAGGAATGTATTGATCCATGTATGAAATATAGAGATTGGATTATTAGAAGT
AAATTTGAATGGCATACGTTATCGAAAGAATATGAAACTCAAAAAGTTCCAAAGGAAAATGCGGAAAATT
ATTTAATCAAAATTTCAGAAAACAAGAATGATGCTAAAGTAAGTTTATTATTGAATAATTGTGATGCTGA
ATATTCAAAATATTGTGATTGTAAACATACTACTACTCTCGTTAAAAGCGTTTTAAATGGTAACGACAAT
ACAATTAAGGAAAAGCGTGAACATATTGATTTAGATGATTTTTCTAAATTTGGATGTGATAAAAATTCCG
TTGATACAAACACAAAGGTGTGGGAATGTAAAAAACCTTATAAATTATCCACTAAAGATGTATGTGTACC
TCCGAGGAGGCAAGAATTATGTCTTGGAAACATTGATAGAATATACGATAAAAACCTATTAATGATAAAA
GAGCATATTCTTGCTATTGCAATATATGAATCAAGAATATTGAAACGAAAATATAAGAATAAAGATGATA
AAGAAGTTTGTAAAATCATAAATAAAACTTTCGCTGATATAAGAGATATTATAGGAGGTACTGATTATTG
GAATGATTTGAGCAATAGAAAATTAGTAGGAAAAATTAACACAAATTCAAATTATGTTCACAGGAATAAA
CAAAATGATAAGCTTTTTCGTGATGAGTGGTGGAAAGTTATTAAAAAAGATGTATGGAATGTGATATCAT
GGGTATTCAAGGATAAAACTGTTTGTAAAGAAGATGATATTGAAAATATACCACAATTCTTCAGATGGTT
TAGTGAATGGGGTGATGATTATTGCCAGGATAAAACAAAAATGATAGAGACTCTGAAGGTTGAATGCAAA
GAAAAACCTTGTGAAGATGACAATTGTAAACGTAAATGTAATTCATATAAAGAATGGATATCAAAAAAAA
AAGAAGAGTATAATAAACAAGCCAAACAATACCAAGAATATCAAAAAGGAAATAATTACAAAATGTATTC
TGAATTTAAATCTATAAAACCAGAAGTTTATTTAAAGAAATACTCGGAAAAATGTTCTAACCTAAATTTC
GAAGATGAATTTAAGGAAGAATTACATTCAGATTATAAAAATAAATGTACGATGTGTCCAGAAGTAAAGG
ATGTACCAATTTCTATAATAAGAAATAATGAACAAACTTCGCAAGAAGCAGTTCCTGAGGAAAGCACTGA
AATAGCACACAGAACGGAAACTCGTACGGATGAACGAAAAAATCAGGAACCAGCAAATAAGGATTTAAAG
AATCCACAACAAAGTGTAGGAGAGAACGGAACTAAAGATTTATTACAAGAAGATTTAGGAGGATCACGAA
GTGAAGACGAAGTGACACAAGAATTTGGAGTAAATCATGGAATACCTAAGGGTGAGGATCAAACGTTAGG
AAAATCTGACGCCATTCCAAACATAGGCGAACCCGAAACGGGAATTTCCACTACAGAAGAAAGTAGACAT
GAAGAAGGCCACAATAAACAAGCATTGTCTACTTCAGTCGATGAGCCTGAATTATCTGATACACTTCAAT
TGCATGAAGATACTAAAGAAAATGATAAACTACCCCTAGAATCATCTACAATCACATCTCCTACGGAAAG
TGGAAGTTCTGATACAGAGGAAACTCCATCTATCTCTGAAGGACCAAAAGGAAATGAACAAAAAAAACGT
GATGACGATAGTTTGAGTAAAATAAGTGTATCACCAGAAAATTCAAGACCTGAAACTGATGCTAAAGATA
CTTCTAACTTGTTAAAATTAAAAGGAGATGTTGATATTAGTATGCCTAAAGCAGTTATTGGGAGCAGTCC
TAATGATAATATAAATGTTACTGAACAAGGGGATAATATTTCCGGGGTGAATTCTAAACCTTTATCTGAT
GATGTACGTCCAGATAAAAATCATGAAGAGGTGAAAGAACATACTAGTAATTCTGATAATGTTCAACAGT
CTGGAGGAATTGTTAATATGAATGTTGAGAAAGAACTAAAAGATACTTTAGAAAATCCTTCTAGTAGCTT
GGATGAAGGAAAAGCACATGAAGAATTATCAGAACCAAATCTAAGCAGTGACCAAGATATGTCTAATACA
CCTGGACCTTTGGATAACACCAGTGAAGAAACTACAGAAAGAATTAGTAATAATGAATATAAAGTTAACG
AGAGGGAAGGTGAGAGAACGCTTACTAAGGAATATGAAGATATTGTTTTGAAAAGTCATATGAATAGAGA
ATCAGACGATGGTGAATTATATGACGAAAATTCAGACTTATCTACTGTAAATGATGAATCAGAAGACGCT
GAAGCAAAAATGAAAGGAAATGATACATCTGAAATGTCGCATAATAGTAGTCAACATATTGAGAGTGATC
AACAGAAAAACGATATGAAAACTGTTGGTGATTTGGGAACCACACATGTACAAAACGAAATTAGTGTTCC
TGTTACAGGAGAAATTGATGAAAAATTAAGGGAAAGTAAAGAATCAAAAATTCATAAGGCTGAAGAGGAA
AGATTAAGTCATACAGATATACATAAAATTAATCCTGAAGATAGAAATAGTAATACATTACATTTAAAAG
ATATAAGAAATGAGGAAAACGAAAGACACTTAACTAATCAAAACATTAATATTAGTCAAGAAAGGGATTT
GCAAAAACATGGATTCCATACCATGAATAATCTACATGGAGATGGAGTTTCCGAAAGAAGTCAAATTAAT
CATAGTCATCATGGAAACAGACAAGATCGGGGGGGAAATTCTGGGAATGTTTTAAATATGAGATCTAATA
ATAATAATTTTAATAATATTCCAAGTAGATATAATTTATATGATAAAAAATTAGATTTAGATCTTTATGA
AAACAGAAATGATAGTACAACAAAAGAATTAATAAAGAAATTAGCAGAAATAAATAAATGTGAGAACGAA
ATTTCTGTAAAATATTGTGACCATATGATTCATGAAGAAATCCCATTAAAAACATGCACTAAAGAAAAAA
CAAGAAATCTGTGTTGTGCAGTATCAGATTACTGTATGAGCTATTTTACATATGATTCAGAGGAATATTA
TAATTGTACGAAAAGGGAATTTGATGATCCATCTTATACATGTTTCAGAAAGGAGGCTTTTTCAAGTATG
ATATTCAAATTTTTAATAACAAATAAAATATATTATTATTTTTATACTTACAAAACTGCAAAAGTAACAA
TAAAAAAAATTAATTTCTCATTAATTTTTTTTTTCTTTTTTTCTTTTTAGGTATGCCATATTATGCAGGA
GCAGGTGTGTTATTTATTATATTGGTTATTTTAGGTGCTTCACAAGCCAAATATCAAAGGTTAGAAAAAA
TAAATAAAAATAAAATTGAGAAGAATGTAAATTAAATATATATATATATATATATATATATATATTGTAT
TATATATTTTTTTTTTATAGTTCTGAAGGAGTTATGAATGAGAATAATGAGAATAATTTTTTATTTGAAG
TTACTGATAATTTAGATAAATTATCCAATATGTGTAATACAAATATAAAAAAAAATAATAAATAAATAAA
TAATTACAAGGAAATAAAAATGATATATATTATTACATTATGTTTGTTTACTTTTATATTATCCTATAAT
ATTTATTTTTATTTTATGTTTTTTTTTTTTCAGTCAATCAACAAGTACAGGAAACTAATATCAACGATTT
TTCTGAATACCATGAGGATATAAATGATATTAATTTTAAGAAATG

Protein Sequence : Show Sequence

>XP_001349207.2 erythrocyte binding antigen-175 [Plasmodium falciparum 3D7]
MKCNISIYFFASFFVLYFAKARNEYDIKENEKFLDVYKEKFNELDKKKYGNVQKTDKKIFTFIENKLDIL
NNSKFNKRWKSYGTPDNIDKNMSLINKHNNEEMFNNNYQSFLSTSSLIKQNKYVPINAVRVSRILSFLDS
RINNGRNTSSNNEVLSNCREKRKGMKWDCKKKNDRSNYVCIPDRRIQLCIVNLSIIKTYTKETMKDHFIE
ASKKESQLLLKKNDNKYNSKFCNDLKNSFLDYGHLAMGNDMDFGGYSTKAENKIQEVFKGAHGEISEHKI
KNFRKKWWNEFREKLWEAMLSEHKNNINNCKNIPQEELQITQWIKEWHGEFLLERDNRSKLPKSKCKNNT
LYEACEKECIDPCMKYRDWIIRSKFEWHTLSKEYETQKVPKENAENYLIKISENKNDAKVSLLLNNCDAE
YSKYCDCKHTTTLVKSVLNGNDNTIKEKREHIDLDDFSKFGCDKNSVDTNTKVWECKKPYKLSTKDVCVP
PRRQELCLGNIDRIYDKNLLMIKEHILAIAIYESRILKRKYKNKDDKEVCKIINKTFADIRDIIGGTDYW
NDLSNRKLVGKINTNSNYVHRNKQNDKLFRDEWWKVIKKDVWNVISWVFKDKTVCKEDDIENIPQFFRWF
SEWGDDYCQDKTKMIETLKVECKEKPCEDDNCKRKCNSYKEWISKKKEEYNKQAKQYQEYQKGNNYKMYS
EFKSIKPEVYLKKYSEKCSNLNFEDEFKEELHSDYKNKCTMCPEVKDVPISIIRNNEQTSQEAVPEESTE
IAHRTETRTDERKNQEPANKDLKNPQQSVGENGTKDLLQEDLGGSRSEDEVTQEFGVNHGIPKGEDQTLG
KSDAIPNIGEPETGISTTEESRHEEGHNKQALSTSVDEPELSDTLQLHEDTKENDKLPLESSTITSPTES
GSSDTEETPSISEGPKGNEQKKRDDDSLSKISVSPENSRPETDAKDTSNLLKLKGDVDISMPKAVIGSSP
NDNINVTEQGDNISGVNSKPLSDDVRPDKNHEEVKEHTSNSDNVQQSGGIVNMNVEKELKDTLENPSSSL
DEGKAHEELSEPNLSSDQDMSNTPGPLDNTSEETTERISNNEYKVNEREGERTLTKEYEDIVLKSHMNRE
SDDGELYDENSDLSTVNDESEDAEAKMKGNDTSEMSHNSSQHIESDQQKNDMKTVGDLGTTHVQNEISVP
VTGEIDEKLRESKESKIHKAEEERLSHTDIHKINPEDRNSNTLHLKDIRNEENERHLTNQNINISQERDL
QKHGFHTMNNLHGDGVSERSQINHSHHGNRQDRGGNSGNVLNMRSNNNNFNNIPSRYNLYDKKLDLDLYE
NRNDSTTKELIKKLAEINKCENEISVKYCDHMIHEEIPLKTCTKEKTRNLCCAVSDYCMSYFTYDSEEYY
NCTKREFDDPSYTCFRKEAFSSMPYYAGAGVLFIILVILGASQAKYQSSEGVMNENNENNFLFEVTDNLD
KLSNMFNQQVQETNINDFSEYHEDINDINFKK

Molecule Role : Protective antigen
Molecule Role Annotation : 1 of 3 Monkeys vaccinated with EBA-175 was protected from challenge of parasitized erythrocytes (Sim et al., 2001).
Related Vaccine(s): P. falciparum DNA Vaccine encoding EBA-175

14. Exported protein 1 from Plasmodium falciparum

Gene Name : Exported protein 1 from Plasmodium falciparum
Sequence Strain (Species/Organism) : Plasmodium falciparum
NCBI Protein GI : 39843114
Other Database IDs : CDD:174853
Taxonomy ID : 5833
Gene Strand (Orientation) : ?
Protein Name : exported protein 1
Protein Length : 118
Protein Note : Circumsporozoite-related antigen (CRA); cl05880

Protein Sequence : Show Sequence

>gi|39843114|gb|AAR32120.1| exported protein 1 [Plasmodium falciparum]
MKILSVFFLALFFIIFNKESLAEKTNKGTGSGVSSKKKNKKGSGEPLIDVHDLISDMIKKEEELVEVNKR
KSKYKLATSVLAGLLGVVSTVLLGGVGLVLYNTEKGRHPFKLGSSDPA

Molecule Role : Protective antigen

15. FabB/FabF

Gene Name : FabB/FabF
Sequence Strain (Species/Organism) : Plasmodium falciparum 3D7
NCBI Gene ID : 3885996
NCBI Protein GI : 296004726
Locus Tag : PFF1275c
Genbank Accession : AL844505
Protein Accession : XP_966246
3D structure: PDB ID : 1OB1
Taxonomy ID : 36329
Chromosome No : 6
Gene Starting Position : 1061115
Gene Ending Position : 1062891
Gene Strand (Orientation) : -
Protein pI : 9.25
Protein Weight : 50967.34
Protein Length : 473

DNA Sequence : Show Sequence

>gi|86176855:1061115-1062891 Plasmodium falciparum 3D7 chromosome 6
ATCACTTTACAATTTTTTTGAAAAGTAATGCTGTGTTATGGCCTCCAAATCCCAAATTTGTATTGAGAGA
TATATCAATATTTTCCTTTGCATGAATATATTTATTAGGTGTATAATTTAGATCACAATCTGGGTCCTTA
TATTCATAATTAATAGTAGGTGGTATAATATTTGTTTGCATAGTTTTAAGACATACAATAGATTCTATAG
CTCCAGCAGCACCTATACAATGTCCTGTCATACTTTTAGTTGATGATATATATAATTTGTATGCATGATC
TTTGAAAACATTTTTAAAAACCTTGGTTTCTATTTTATCATTTAAATTTGTTGAAGTACCATGTGCATTA
ATATATTTAACGTCATTTATGTTTATATTTGCATTTTTTAATGCTTTATGAATAGAATTTGTTAAACCTT
TCCCATTAGGTTCTGGTGCAGTAATATGGTATGCATCACATTCTGAAGAATATGAAATAATTTCTCCATA
TATTGGTGCATTTCTTTTTATTGCATGTTCGTATGATTCTAGAATTAAGATGCCTGAACCTTCTCCCATA
ACGAAACCACTTCTTTTTAAATCGAAGGGTCTACAACCTTTTTTTGGATTATCGTTATAACCTGTACATA
AAGCCTTTAATGAATTGAATCCAGCAAAACTTATAGGAGTTATACTAGCTTCAGTTCCACCACATATCAT
AACATCATACTCTTTATATTTTATATATCTATAGGCTTCACCTATTGTGTTACCAGACGTAGCACATGCA
CTTAACATACCAAGAGAGATCCCTCTAATATTGTTTTCGATAGATACATATCCAGATGGAGTATTTGCTA
TCATTGCAGGTATTAAATATGGTGTTATTCTTTTATGTCCTTTTTCATACATTGTTTTCATTTCTTTTTC
TAAAAATCTTAGTCCACCTATGCCACTACCTATGATAGTACCTGTTTTATCTTTGTCTAATTTTTCCAAA
TTTAGTTTTGCATCGTCTAAAGCTAAACGTGTGGCTGCGACTGCATAATGAGTACAATCATCATTACGAT
TAACATCTTTTTTATTTGTGTAATAATCACTAGGATTAAAATCGCTTTTCTTTATTTCACTACCAATACC
ACATGACATACCGGTTATATCAAATTTTGTAATTTTATCTATTGATGTATATCCATTTATAATATTATTC
CAAAAATGTTCTATGCCAATCCCTAATCCAGTTACTACCCCTACACCTGTGCACACCACTCTAGAAGTCT
AAATAAAAAATAAAAGAATTAAGAAAATTAAAATATATATAAAAATAAATGTATAGCATATTATTACTTT
AATCATTTTTTACAATTTGTATATATCACATTTTATAAAACTATATAAATATAAATATATATATATATAT
ATATATATATTATATATATTATATATTTTATTTAGTACTTCACAAAGATTTTTCATTTCTCTCGAATTGT
ACAACTTGAAACCTTTAAAATAATTCTTGGATATTCCAGGTATACCCCTTTTAATGAAGGCATACCTTTT
ACTGTTAACCTACATATGAAAATACATGGAGTATATATTATGACATGATTAATGTTTTTTTTTTTTTTTT
TTTTTTTTTCTTTTCTACATCTAATATTCATATGGCACATGCATATGTTTGAAAGGGGAAACATATATTA
ACTATTATGTTTGTTTTATTTTATTTTTAGAATTGTAGCATTACTTGTAGCACATAAAAGAACAGGAAAT
AATATATTTTTATAATGTATTTTCTCA

Protein Sequence : Show Sequence

>gi|296004726|ref|XP_966246.2| 3-oxoacyl-acyl-carrier protein synthase I/II [Plasmodium falciparum 3D7]
MRKYIIKIYYFLFFYVLQVNSKRYAFIKRGIPGISKNYFKGFKLYNSREMKNLCETSRVVCTGVGVVTGL
GIGIEHFWNNIINGYTSIDKITKFDITGMSCGIGSEIKKSDFNPSDYYTNKKDVNRNDDCTHYAVAATRL
ALDDAKLNLEKLDKDKTGTIIGSGIGGLRFLEKEMKTMYEKGHKRITPYLIPAMIANTPSGYVSIENNIR
GISLGMLSACATSGNTIGEAYRYIKYKEYDVMICGGTEASITPISFAGFNSLKALCTGYNDNPKKGCRPF
DLKRSGFVMGEGSGILILESYEHAIKRNAPIYGEIISYSSECDAYHITAPEPNGKGLTNSIHKALKNANI
NINDVKYINAHGTSTNLNDKIETKVFKNVFKDHAYKLYISSTKSMTGHCIGAAGAIESIVCLKTMQTNII
PPTINYEYKDPDCDLNYTPNKYIHAKENIDISLNTNLGFGGHNTALLFKKIVK

Molecule Role : Virmugen
Molecule Role Annotation : A genetically attenuated parasite (GAP) with a mutation in the FabB/FabF gene is attenuated in mice by arresting in the late liver stage. It also conferred complete protection in mice from challenge with wild type Plasmodium (Butler et al., 2011).
Related Vaccine(s): Plasmodium FabB/FabF mutant vaccine

16. FCR3S1.2-var1

Gene Name : FCR3S1.2-var1
Sequence Strain (Species/Organism) : Plasmodium falciparum
VO ID : VO_0011229
NCBI Gene ID : 810160
NCBI Protein GI : 2961468
Other Database IDs : CDD:292087
CDD:283158
CDD:281064
CDD:114603
CDD:292085
Taxonomy ID : 5833
Gene Strand (Orientation) : ?
Protein Name : erythrocyte membrane protein 1
Protein pI : 5.45
Protein Weight : 244016.11
Protein Length : 2328
Protein Note : N-terminal segments of PfEMP1; pfam15447

Protein Sequence : Show Sequence

>AAC05730.1 erythrocyte membrane protein 1 [Plasmodium falciparum]
MATSGGSGGTQDEDAKHVLDEFGQKVHDEVHGEAKNYVSELKGSLSLASILGETAFTVKSMQTESKYTEL
IEANSKRNPCKKDGKGNDVDRFSVKEQAGYDNKKMKCSNGMTCAPFRRLHLCNKNFPNMNSNDSSKAKHD
LLAEVCMAAKYEGESIKTHYPKYDSKYPGSDFPMCTMLARSFADIGDIIRGRDLYLGNKKKKQNGKETER
EKLEQKLKEIFKKIHDNLKDKEAQKRYNGDEDPNFYKLREDWWTANRETVWGAMTCSKELDNSSYFRATC
NDTGQGPSQTHNKCRCDKDKGANAGKPKAGDGDVTIVPTYFDYVPQYLRWFEEWAEDFCRKKKKKLENLE
KQCRGKDKSDEYRYCSRNGYDCEQTISRKGKVRMGKGCTDCFFACHSYENWIDNQRKQFDKQKKYTKEIS
DGGGRKKRAVGGTTKYEGYEKSFYEKLKNDGYGTVDAFLGLLNNEKACKDITDGGKINFKEVNSGGGVVG
GGSGGTSGASGTNDENKGTFYRSEYCQPCPDCGVQHKGGNQWERKTKVKKMRWSKLYKPINGKMVLLLKS
LKVVKDMMILKKNWKEFCLTQNSSDGSVGSVVTTGASGGNSEKKELYDEWKCYKHNEVQKVNVQGEVEED
DDELKGAGGLCILPNPKKNKEVSEAKSQNNHADIQKTFHDFFYYWVAHMLKDSIHWRTKRLKSCISDGKT
MKCRNGCNKKCDCFEKWVKQKETEWKPIKDHFKTQEGIPEGYYFTTLELILKLQFLKEDTEENTENSLDA
EEAEELKHLQKILKLENENNLAVVNAGTEQKTLMDKLLNHELNDATKCKDCPLPEEDKSRGRSADPSPDI
FIPRPEEKEDDENEDDDEDEVRDDEETAKETTEGSATDTTTSLDVCPIVGKVLTKDNESLQDACSLKYGG
NNSRLGWRCVTPSGEPTTSSDKNGAICVPPRRRRLYIKKIVDWATKTESPQASGSEASSTSGSTTPPDSK
EALLKAFVESAAIETFFLWHRYKEEKKAVAQEGAGHGLPRVEEGSPEYDPEDKLKEGKIPDGFLRQMFYT
LGDYRDILFSGSNDTTSVSKDTPSSSNDNLKNIVLLASGSTEQEREKMNKYKEIKNFRKCSTERSAPNLV
SHPQTWWENNGKYIWHGMVCALTSKDKIAKGVEKKPQKIENPENLWDEANKKPKPPQYQYTNVKLDENSG
TSPRTTQTQASSDNTPTTLTHFVKRPTYFRWFEEWGESFCRERKKRLKQIKVDCKVENGDVGRCSGDGEA
CDSISTHDYSTVPSFNCPGCGKHCSSYRKWIERKKIEFHKQSNAYGQQKTDATRNNGNTFDKEFCKTLET
WPDAAKFLERLKNGPCKTNKEYGGDDIDFEKDSKTFQHTEYCGPCPKFKTNCQNGNCGVSGLNGNCDGKD
SIDAKEIAKMRSSTTDVVMRVSDNDTNTFEGDDLKDACQHANIFKGIRKDVWKCGYVCGVDICEQTNINE
RTDGKEYIQIRALFKRWVENFLEDYNKINDKISHCIKKGEGSKCINGCEKNSKCLEKWIEKKIAEWENIK
KRFNDQYENKDQPDYNVKSILEELIPKIAVVNDQDNVIKLCVFENSKGCTLISNTQNNKENDAIDCMLKK
LGVKAKNCPGKPSGEKQSDCKEPPPLPDEEDQNPEENTLEPPKFCPPTTQPPEEKGGETCGNKEEKKDEK
KEESEEPAKEESGPAAEEPAPTAESEETETNFPEPPGTGPAAPPSTPAPPTPDTPPPLRPQADEPFDSTI
LQTTIPFGVALALGSIAFLFLKKKTKASVGNLFQILQIPKSDYDIPTLKSSNRYIPYVSDRYKGKTYIYM
EGDSDEDKYAFMSDTTDVTSSESEYEELDINDIYVPGSPKYKTLIEVVLEPSGNNTTASGKNTPSDTRND
IQNDGIPSSKITDNEWNQLKKEFISNMLQNQPNDVPNDYTSGNSSTNTNITTTSRHNVDNNTNTTMSRDN
MEENLLLPSIHDRNLYSGEEYSYNVNMVNSMNDIPINRDNNVYSGIDLINDSLSGGKPIDIYDEVLKRKE
NELFGTENTKRTSTQNVAKITNSDPIHNQLELFHKWLDRHRDMCEKWKNKEDILNKLKEEWNKENINNSG
KTYNSDNKPSHNHVLNTDVSIQIDMDNPKTKNEITNMDTNQDKSTMDTILDDLEKYNDPYYYDFYEDDII
YHDVDVEKSSMDDIYVDHNNVTSNNMDVPTKMHIEMNIVNNKKEIFEEEYPISDIWNI

Molecule Role : Protective antigen
Molecule Role Annotation : Immunized animals were challenged in vivo with various parasite strains or clones of malaria. Immunization with the PfEMP1-DBL1 alpha domain abolished the PfEMP1-dependent sequestration of the homologous strain in immunized rats and substantially inhibited parasite adhesion in immunized monkeys. Protection against sequestration of heterologous parasite strains was also confirmed by direct or indirect challenge in the rat model (Moll et al., 2007).

17. GLURP

Gene Name : GLURP
Sequence Strain (Species/Organism) : Plasmodium falciparum 3D7
VO ID : VO_0011343
NCBI Gene ID : 810501
NCBI Protein GI : 124802897
Locus Tag : PF3D7_1035300
Genbank Accession : LN999944
Protein Accession : XP_001347628
Taxonomy ID : 36329
Chromosome No : 10
Gene Starting Position : 1399194
Gene Ending Position : 1402895
Gene Strand (Orientation) : +
Protein Name : glutamate-rich protein
Protein pI : 3.98
Protein Weight : 130731.93
Protein Length : 1233

DNA Sequence : Show Sequence

>NC_037281.1:1399194-1402895 Plasmodium falciparum 3D7 chromosome 10, complete sequence
AATGAGAAACCTTTTCCATATTACCATTTGTTTAGTTACACTTAATTTATTTATATTGGAAATAAATGCA
AAAACCAATACAAGTGAGAATAGAAATAAACGAATCGGGGGTCCTAAATTAAGGGGTAATGTTACAAGTA
ATATAAAGTTCCCATCAGATAACAAAGGTAAAATTATAAGAGGTTCGAATGATAAACTTAATAAAAACTC
TGAAGATGTTTTAGAACAAAGCGAAAAATCGCTTGTTTCAGAAAATGTTCCTAGTGGATTAGATATAGAT
GATATCCCTAAAGAATCTATTTTTATTCAAGAAGATCAAGAAGGTCAAACTCATTCTGAATTAAATCCTG
AAACATCAGAACATAGTAAAGATTTAAATAATAATGATTCAAAAAATGAATCTAGTGATATTATTTCAGT
AAATAATAAATCAAATAAAGTACAAAATCATTTTGAATCATTATCAGATTTAGAATTACTTGAAAATTCC
TCACAAGATAATTTAGACAAAGATACAATTTCAACAGAACCTTTTCCTAATCAAAAACATAAAGACTTAC
AACAAGATTTAAATGATGAACCTTTAGAACCCTTTCCTACACAAATACATAAAGATTATAAAGAAAAAAA
TTTAATAAATGAAGAAGATTCAGAACCATTTCCCAGACAAAAGCATAAAAAGGTAGACAATCATAATGAA
GAAAAAAACGTATTTCATGAAAATGGTTCTGCAAATGGTAATCAAGGAAGTTTGAAACTTAAATCATTCG
ATGAACATTTAAAAGATGAAAAAATAGAAAATGAACCACTTGTTCATGAAAATTTATCCATACCAAATGA
TCCAATAGAACAAATATTAAATCAACCTGAACAAGAAACAAATATCCAGGAACAATTGTATAATGAAAAA
CAAAATGTTGAAGAAAAACAAAATTCTCAAATACCTTCGTTAGATTTAAAAGAACCAACAAATGAAGATA
TTTTACCAAATCATAATCCATTAGAAAATATAAAACAAAGTGAATCAGAAATAAATCATGTACAAGATCA
TGCGCTACCAAAAGAGAATATAATAGACAAACTTGATAATCAAAAAGAACACATCGATCAATCACAACAT
AATATAAATGTATTACAAGAAAATAACATAAACAATCACCAATTAGAACCTCAAGAGAAACCTAATATTG
AATCGTTTGAACCTAAAAATATAGATTCAGAAATTATTCTTCCTGAAAATGTTGAAACAGAAGAAATAAT
AGATGATGTGCCTTCCCCTAAACATTCTAACCATGAAACATTTGAAGAAGAAACAAGTGAATCTGAACAT
GAAGAAGCCGTATCTGAAAAAAATGCCCACGAAACTGTCGAACATGAAGAAACTGTGTCTCAAGAAAGCA
ATCCTGAAAAAGCTGATAATGATGGAAATGTATCTCAAAACAGCAACAACGAATTAAATGAAAATGAATT
CGTTGAATCGGAAAAAAGCGAGCATGAACCAGCTGAAAATGAAGAAAGTAGTCTTGAAGAAGGTCATCAT
GAAGAAATTGTACCTGAACAAAATAATGAAGAATCAGGTGAAAGTAAATTAGTTGATAATGATGAAGGTG
GTTTTGAAGAAGCTCATCATGAAAATTTTTCATCTGAAGTAAGTAACTCTGAATTAAATGAAAATGAATT
TGTTGAATCTGACAAAAGTGTAACTGAACCTGCTGAACATGAAGAAGTTGTATCTGAAGAAAGCAACCCT
GAACCAGCTGAAAATGAAGAAAGTAGTATAGAAGAAGCTCATCAGGAAGAAATTGTACCTGAACAAAATG
ATGAAGAATCAGGTGAAAGTGGATTAGTTGATAATGAAGAAGGTGATTTTGAAGAACCTAATCATGAAGA
ATTTGAACCTGATCAAAATGACTCTGAATTAAGTGAAAATGAATTAGTTGAATCAGAAAAAAGTGTATCT
GAACCAGCTGAACATGTAGAAATTGTATCAGAAAAAAGTGTATCTGAACCAGCTGAACACGTAGAAATTG
TATCTGAAAAAAGTACATCCGAACCAGCTGAACATGTAGAAAGTGTATCTGAACAAAGTAATAACGAACC
ATCCGAAAAGAAAGATGGACCAGTTCCTTCAAAACCATTTGAAGAAATTGAAAAAGTGGATGTTCAACCT
AAAATTGTAGACCTTCAAATAATTGAACCTAATTTTGTTGACTCACAACCAAATCCACAAGAACCAGTTG
AACCATCATTTGTCAAAATTGAAAAAGTTCCTTCTGAAGAAAATAAACATGCAAGTGTTGATCCTGAAGT
AAAAGAAAAAGAAAATGTATCTGAAGTTGTTGAAGAAAAACAAAATTCACAAGAATCAGTTGAAGAAATT
CCAGTAAATGAGGATGAATTTGAAGATGTTCACACTGAACAATTAGATTTAGATCATAAAACAGTTGATC
CAGAAATAGTAGAAGTTGAAGAAATTCCTTCAGAACTACATGAAAATGAAGTGGCTCATCCAGAAATTGT
TGAAATTGAGGAAGTTTTTCCTGAACCAAATCAAAATAACGAATTTCAAGAAATTAATGAAGATGATAAA
AGTGCACATATTCAGCATGAAATAGTAGAAGTAGAAGAAATACTTCCAGAAGATGATAAAAATGAAAAAG
TTGAACATGAAATAGTAGAAGTTGAAGAAATTCTACCAGAAGATAAAAATGAAAAAGTTCAACATGAAAT
AGTAGAGGTTGAAGAAATTCTACCAGAAGATAAAAATGAAAAAGTTGAACATGAAATAGTAGAAGTTGAA
GAAATTCTACCAGAAGATAAAAATGAAAAAGGTCAACATGAAATAGTAGAGGTTGAAGAAATTCTACCAG
AAGATAAAAATGAAAAAGTTCAACATGAAATAGTAGAAGTTGAAGAAATTCTACCAGAAGATAAAAATGA
AAAAGGTCAACATGAAATAGTAGAGGTTGAAGAAATTCTACCAGAAGATAAAAATGAAAAAGTTGAACAT
GAAATAGTAGAAGTTGAAGAAATTCTACCAGAAGATAAAAATGAAAAAGGTCAACATGAAATAGTAGAGG
TTGAAGAAATTCTACCAGAAGATGATAAAAATGAAAAAGGTCAACATGAAATAGTAGAGGTTGAAGAAAT
TCTTCCAGAAATTGTTGAAATTGAAGAAGTACCATCACAAACAAATAACAATGAAAATATTGAAACTATA
AAACCAGAAGAAAAAAAGAATGAATTTAGTGTTGTTGAAGAAAAAGCAATTCCACAAGAACCCGTGGTAC
CTACATTAAATGAAAATGAAAACGTTACTCCCAAACCATCTGAAGGTGAATCCACTAAACCAGATATAGT
TCAAATTAAAATAGTACAAGAAAATAAACCAAATAAAAAGGAAACACCAGTAGTAGATGGTCCAAAACAT
GTAGAACAAAATATACAAGAAGATGATAATGATGAAGAGGATGATGATGATATAGATTTTGAAGGATTAT
CAAGAAAAGATGATGAAAAGGATTCATCAAATAAAAATAAAAAGAAATCATCTTTTATAACATATATATC
TACAAAGAAATTTAAAAAAGTATCTCAAACTATTGTAAGTGTTATGATTAATGCATATGATGGTGTTATT
CAAGTTGTAAGTACAATTAAAGGAATAGCAAAGGATATAGTAATATTTTTCCAAAACATTTA

Protein Sequence : Show Sequence

>XP_001347628.1 glutamate-rich protein [Plasmodium falciparum 3D7]
MRNLFHITICLVTLNLFILEINAKTNTSENRNKRIGGPKLRGNVTSNIKFPSDNKGKIIRGSNDKLNKNS
EDVLEQSEKSLVSENVPSGLDIDDIPKESIFIQEDQEGQTHSELNPETSEHSKDLNNNDSKNESSDIISV
NNKSNKVQNHFESLSDLELLENSSQDNLDKDTISTEPFPNQKHKDLQQDLNDEPLEPFPTQIHKDYKEKN
LINEEDSEPFPRQKHKKVDNHNEEKNVFHENGSANGNQGSLKLKSFDEHLKDEKIENEPLVHENLSIPND
PIEQILNQPEQETNIQEQLYNEKQNVEEKQNSQIPSLDLKEPTNEDILPNHNPLENIKQSESEINHVQDH
ALPKENIIDKLDNQKEHIDQSQHNINVLQENNINNHQLEPQEKPNIESFEPKNIDSEIILPENVETEEII
DDVPSPKHSNHETFEEETSESEHEEAVSEKNAHETVEHEETVSQESNPEKADNDGNVSQNSNNELNENEF
VESEKSEHEPAENEESSLEEGHHEEIVPEQNNEESGESKLVDNDEGGFEEAHHENFSSEVSNSELNENEF
VESDKSVTEPAEHEEVVSEESNPEPAENEESSIEEAHQEEIVPEQNDEESGESGLVDNEEGDFEEPNHEE
FEPDQNDSELSENELVESEKSVSEPAEHVEIVSEKSVSEPAEHVEIVSEKSTSEPAEHVESVSEQSNNEP
SEKKDGPVPSKPFEEIEKVDVQPKIVDLQIIEPNFVDSQPNPQEPVEPSFVKIEKVPSEENKHASVDPEV
KEKENVSEVVEEKQNSQESVEEIPVNEDEFEDVHTEQLDLDHKTVDPEIVEVEEIPSELHENEVAHPEIV
EIEEVFPEPNQNNEFQEINEDDKSAHIQHEIVEVEEILPEDDKNEKVEHEIVEVEEILPEDKNEKVQHEI
VEVEEILPEDKNEKVEHEIVEVEEILPEDKNEKGQHEIVEVEEILPEDKNEKVQHEIVEVEEILPEDKNE
KGQHEIVEVEEILPEDKNEKVEHEIVEVEEILPEDKNEKGQHEIVEVEEILPEDDKNEKGQHEIVEVEEI
LPEIVEIEEVPSQTNNNENIETIKPEEKKNEFSVVEEKAIPQEPVVPTLNENENVTPKPSEGESTKPDIV
QIKIVQENKPNKKETPVVDGPKHVEQNIQEDDNDEEDDDDIDFEGLSRKDDEKDSSNKNKKKSSFITYIS
TKKFKKVSQTIVSVMINAYDGVIQVVSTIKGIAKDIVIFFQNI

Molecule Role : Protective antigen
Molecule Role Annotation : Some of the S. sciureus monkeys immunized with MSP-3(212-380)-AS02 or GLURP(27-500)-alum were able to fully or partially control parasitaemia upon an experimental P. falciparum [Falciparum Uganda Palo Alto (FUP-SP) strain] blood-stage infection, and this protection was related to the prechallenge antibody titres induced. The data are indicative that MSP-3 and GLURP can induce protective immunity against an experimental P. falciparum infection using adjuvants that are acceptable for human use and this should trigger further studies with those new antigens (Carvalho et al., 2004).

18. HEP17

Gene Name : HEP17
Sequence Strain (Species/Organism) : Plasmodium yoelii
VO ID : VO_0011228
NCBI Gene ID : 3790041
NCBI Protein GI : 1399353
Other Database IDs : CDD:284100
Taxonomy ID : 5861
Gene Strand (Orientation) : ?
Protein Name : hepatocyte erythrocyte protein 17 kDa
Protein pI : 10.09
Protein Weight : 17587.89
Protein Length : 243
Protein Note : Circumsporozoite-related antigen (CRA); pfam06589

Protein Sequence : Show Sequence

>AAC47199.1 hepatocyte erythrocyte protein 17 kDa [Plasmodium yoelii]
MKINIASIIFIIFSLCLVNDAYGKNKYGKNGKYGSQNVIKKHGEPVINVQDLISDMVRKEEEIVKLTKNK
KSLRKINVALATALSVVSAILLGGAGLVMYNTEKGRRPFQIGKSKKGGSAMARDSSFPMNEESPLGFSPE
EMEAVASKFRESMLKDGVPAPSNTPNVQN

Molecule Role : Protective antigen
Molecule Role Annotation : Immunization of mice with subunit vaccines based on the Plasmodium yoelii 17kDa hepatocyte erythrocyte protein (PyHEP17), orthologue of Plasmodium falciparum exported protein 1 (PfExp1), induces antigen-specific immune responses and protects against sporozoite challenge (Dobaño and Doolan, 2007).
Related Vaccine(s): P. yoelii DNA vaccine encoding PyHEP17 Protein

19. HSP60 from P. yoelii

Gene Name : HSP60 from P. yoelii
Sequence Strain (Species/Organism) : Plasmodium yoelii strain 17X(NL)
NCBI Gene ID : 3790277
NCBI Protein GI : 3885993
Other Database IDs : CDD:185455
CDD:239460
Taxonomy ID : 5861
Gene Strand (Orientation) : ?
Protein Name : heat shock protein 60
Protein pI : 6.86
Protein Weight : 58029.5
Protein Length : 643
Protein Note : Heat shock protein 60; Provisional

Protein Sequence : Show Sequence

>AAC78150.1 heat shock protein 60 [Plasmodium yoelii]
MLSRLCGKTIQNGNADKCVSMLNKIQKRNVAKDIRFGSDARTAMLIGCNKLADAVSVTLGPKGRNVIIEQ
SFGSPKITKDGVTVAKSIEFNKKLANLGAQMVKQVAANTNDKAGDGTTTATILARSIFQQGCKAVDSGMN
PMDLLRGINKGVEKVLEYLNSIKKDVTTTEEIFNVASISANGDKNIGQLIADTMKKVGKEGTITVTEGKT
LQHELEIVEGIKFDRGYISPYFINNSKDQKVELDKPYILIHEKKISSVKSLLPVLEHVLQNQSSLLVIAE
DVDSDALATLIVNKLRLGLKICAVKAPGFGEHRKALIHDIAVMTGSKVITEEAGLKLDDPDVISYLGKAK
SINVSKDNTLIMEGEGKKEEISERCESIRNAIKNNTSDYEKEKLQERLAQITGGVALIKVGGISEVEVNE
IKDRIQDALCATKAAVEEGIVPGGGSALLFASKELDSVQTDNYDQRVGVNIIKDACKAPIKQIAENAGHE
GSVVAGNILKEKNSNMGFNAQEGKYVNMIESGIIDPTKVVKTAISDAASIASLLTTTEVAIVDSKDGKSE
EMPSHMNSVNPMGDMGGMY

Molecule Role : Protective antigen
Related Vaccine(s): P. yoelii DNA vaccine pPyHsp60-VR1012

20. Hsp90

Gene Name : Hsp90
Sequence Strain (Species/Organism) : Plasmodium falciparum
VO ID : VO_0011241
NCBI Gene ID : 2655065
NCBI Protein GI : 1093612
Other Database IDs : CDD:240341
CDD:214643
CDD:238030
CDD:278607
Taxonomy ID : 5833
Gene Strand (Orientation) : ?
Protein pI : 4.63
Protein Weight : 82921.42
Protein Length : 796
Protein Note : heat shock protein 83 kDa (Hsp83); Provisional

Protein Sequence : Show Sequence

>prf||2104278A heat shock protein 90
MSTETFAFNADIRQLMSLIINTFYSNKEIFLRELISNASDALDKIRYESITDTQKLSAEPEFFIRIIPDK
TNNTLTIEDSGIGMTKNDLINNLGTIARSGTKAFMEAIQASGDISMIGQFGVGFYSAYLVADHVVVISKN
NDDEQYVWESAAGGSFTVTKDETNEKLGRGTKIILHLKEDQLEYLEEKRIKDLVKKHSEFISFPIKLYCE
RQNEKEITASEEEEEGEGEGEREGEEEEEEKKKKTGEDKNADESKEENEDEEKKEDNEEDDNKTDHPKVE
DVTEELENAEKKKKEKRKKKIHTVEHEWEELNKQKPLWMRKPEEVTNEEYASFYKSLTNDWEDHLAVKHF
SVEGQLEFKALLFIPKRAPFDMFENRKKRNNIKLYVRRVFIMDDCEEIIPEWLNFVKGVVDSEDLPLNIS
RESLQQNKILKVIKKNLIKKCLDMFSELAENKENYKKFYEQFSKNLKLGIHEDNANRTKITELLRFQTSK
SGDEMIGLKEYVDRMKENQKDIYYITGESINAVSNSPFLEALTKKGFEVIYMVDPIDEYAVQQLKDFDGK
KLKCCTKEGLDIDDSEEAKKDFETLKAEYEGLCKVIKDVLHEKVEKVVVGQRITDSPCVLVTSEFGWSAN
MERIMKAQALRDNSMTSYMLSKKIMEINARHPIISALKQKADADKSDKTVKDLIWLLFDTSLLTSGFALE
EPTTFSKRIHRMIKLGLSIDEEENNDIDLPPLEETVDATDSKMEEVD

Molecule Role : Protective antigen
Molecule Role Annotation : A monkey vaccination trial using a Plasmodium falciparum protein fraction containing antigens of 90-110 kDa is reported. Three monkeys out of five resisted a heavy challenge dose of highly virulent parasites. Hsp90 was found in the immunoprecipitates obtained with SERP antisera. Interestingly, the response to hsp90 correlated with protection, high antibody titres being found only in the protected monkeys (Bonnefoy et al., 1994).
Related Vaccine(s): P. falciparum Hsp90 Protein Subunit Vaccine

21. Kbeta

Gene Name : Kbeta
Sequence Strain (Species/Organism) : Plasmodium falciparum 3D7
VO ID : VO_0011233
NCBI Gene ID : 813054
NCBI Protein GI : 124506397
Locus Tag : PF3D7_0524000
Genbank Accession : AL844504
Protein Accession : XP_001351796
Taxonomy ID : 36329
Chromosome No : 5
Gene Starting Position : 998752
Gene Ending Position : 1002123
Gene Strand (Orientation) : +
Protein pI : 4.54
Protein Weight : 120404.67
Protein Length : 1123

DNA Sequence : Show Sequence

>NC_004326.2:998752-1002123 Plasmodium falciparum 3D7 chromosome 5
AATGGATAAAATTGTAGAAGTTATTGAAGGATTAAGCAGCTCTGAGAGTCATATAAGAAATGAATGTGAA
AATACGTTAAATTATTATAAAAAGAATGATTTAAATAATACAGTATTATCTATATTGAAATTATTAAAAA
CCCATAAAGATAGTCAAGTTCGATTACAATGTGCTATATTAATTAGGAATATATTTCGTGTGTATATAAA
GTCCACACATGTGGATGTGGAAGAAAAAGAAAAAAATGAGAATTCGATTGGAAATGCAGAAGAAGAGAAT
TATTGGGTATTATTACCTGATAATTTAAAGAATATTGTAAAATCTGAATTGATTAGTAATATAGGAACTG
AAACAGATAAGATGGTTCGAAGTAATATATGTAATAATATTATAGATTTATCATCAAAATTATTATTACA
TAATCAATGGCCTGAGTTATTATCAGTAACATTTGAATTTTGTAATTCTAATAACGTTGATGTATTAATA
AGTGGATATAAAATATTAGGTGGTATCTTAAGTTGTATTCCAGATGAATTAGATGGAAAACAAGAAATAA
TATCTTCCATATGTATGAAAGGTTTAAATTCATCAAATGTACAAGTACGTGGAGAATGTATTAATTTAAT
ATCATGTATTGTTGAAGATAATAGTTCATCCTTAGTTAAGAGTGTACATGGTTGTATCCCATTAATATTA
CAATCATTAAGTTTGATGGCAAAGAATAGTAGTTCAGATATTGCTGTTCTAGAAGAATGTGAGAAAGTAC
TTCAATCTATTGGTAAAATGATAGATTATAATGCTAAATTTTTTACTAAGCATATAACAAGTTTGTGTGA
TATATTATTTAGTATTTGTATGAAAGATGAAAATGAATTGAACTATGATTTTGATAATAGCTTGAAGTCC
CTAAGTATTGAAGCTTTAGTTACCATTCCAGAACGTCGACCAAAAATGGCTTTATCTGTACCTCATTTTG
TAGATAAGATTATACATTTGTCTATGTTATTTATGCTTGACATTAATAATGATTGTTTTAATGAATGGAT
GAATTCTATAAAAGAAGGTAAAGACGATAGTCAGGAGTTATATGACATAGGTGAAGAGTCCTTAGATCGT
GTTGGTAAAGCATTTAGTGAGTTAGAAGAAGCTGAATTTATTCATATTCTTTTTAATAAAGTATCAGAAT
TTTTAATGAAAAATACTTGGGAACATAAATATGTCGGTATTATGGCTATTGCACAAACTATAGAATATTT
ACCAGAAGATGAAATTGAAGAACAATTAGAACATGTTATAAAAATGTTGTTACAAATATTAGTTGATCAA
GATGTTAGAGTACGTTATGCAGCATGTCAAGCCATTGGACAAATATCTTTAGATCATCAACCATATGTAC
AGAAAGAATTTTTTTCAGAAATTTTATCAGCATTAATTAATACCATGAACGATGTACATTTAAGAGTTCA
ATCACATGCTACAGCAGCTTTTGTAAATTATGCAGAAGAATTAGATAAAATGGCTTTATTACCATATGCA
GATATTATTATAGATATTTTATTACAAAAATTGAATTCTTCAAATTATTTATTAGTAAGAGAACAAGCTG
TTACTGCTATAGCGGTTATTGCAGGTGTTATTGAAGAAGACTTTTTAAAATATTATTCTACTGTTGTACC
TATGATGAAAGATATTATTCAAAAGGCAGTTTCTGAAGAAGAAAGAACATGCAGAGGTAAAGCCATTGAA
TGTATTTCAATTATTGGTTTATCGGTTGGTAAAGATATTTTTATTGAAGATGCTAAAGAATGTATGAATG
CATTATTACAAATTAGCAGTACAAAAATGGATCCTGATGATACTGTAAAAGAATATATTCAAGAAGCTAT
TGGTCGTATATGTAGAGCATTAGGTAATGACTTTTATCCATATCTAAGTAGTATAGTACCGACCATATTA
TCTGTACTCTCCGTTTTACCAAAACCATTAACAGATGATGAAGAAGATCTAACCATAACTATGGTATCTA
ATGGACAATATGTAGGATTGAAAACATCCTTATTAGAAGATCAAGAAAAAGCTTTAGATTTATTAATTAT
TATTATTGAAGTATTAAAAGAAAATTATAAGGATTATATTCAAGCAACAGCTACAGCTGTGTTGCCAATG
TTAAATTATGAATTGTCAGATGAAATTAAACAAAAGGCATTAACAGCTGTTAGTGAATTAATTGAATCAG
CAAGAATATTATCTGAAAAAACGGATAATGATAAATCCATGTTACTAGCCATATTAACAGCAGCAGCAGA
AAAAGTATTAAAAAGTCTATTAGAAACAAAATTAGATGACAATTATGAATATATATTAGATGTTATGATA
ATCGAATCCCATGGATTATATATGTGCTTACAAAAAGCGGGATCGAATGTATTGCCAGAAAATACATTAA
AATTATTTTTTAATCAAATCTTTGCCCTATTACAATATTCAACAGATAGAAGGGTAGTATATAATCAAAA
AAAAAATAATGATGATGTAGATGAAGATGAATTATTAATAATTGATAGAGAAGAGGAATTAGAACAGAAT
TATCGAACAAATTTATTAGATATCTTAGGAGTATTAATTAAATATCACCCAACACAATTCTTAAATACAT
GTTGTGAATTATGTATTGGATTTATTAATAATTATATGAATTCTCCTAATTCAGAAGATGTAGCATTAGC
ATTATATGTATGTGATGATTTGTTAGAATTCTTACAAGAAAAGAGTGTAAACCTATGGGACTTTTTCATG
AACCCATTATTATTAAATATTAATCATGCAGATGATAAAGTAAAACAAGCGGCATGTTATGGTGTTATAC
AAGCAACCAAAATTGAAGCATTTGGAAAGTATGCAAATATTGCAGTAGAATATTTATTAAAATTAGTACA
TGAAAGTACATCAAATAAAAAACCAAAAGAATATATCTCAGCTATTGATAATGCTATAGCAGCATTAGGT
GATGTTGTTCTTATGCATACATCAAAATTTAATAATGCAGAAGATCTCATAAAAGTATGGTTAAATCATT
TACCAATAAAAGAAGATGATGCAGAAGGTAGAAGAGTACATAAAAATCTTATAGATTTAGTTTCACAAAA
CCATCCTCTCTTGTTCGGAAAAGATAATTCTAATACAGCAAAAATTATTGAAATATTCTTAACAATATAT
GAAACTGATTTTTCAGATACTGACTGTAACAAAAAAATCTCAACACTTATCAATTCATTGGATAAATCAT
ATTTAAATAATTTAGCTTCTTCAACTTTGTCACATAAGCAAGCCAAAAAATTGAACAACATTTTGAATCC
AAACAGAAAATA

Protein Sequence : Show Sequence

>XP_001351796.1 karyopherin beta [Plasmodium falciparum 3D7]
MDKIVEVIEGLSSSESHIRNECENTLNYYKKNDLNNTVLSILKLLKTHKDSQVRLQCAILIRNIFRVYIK
STHVDVEEKEKNENSIGNAEEENYWVLLPDNLKNIVKSELISNIGTETDKMVRSNICNNIIDLSSKLLLH
NQWPELLSVTFEFCNSNNVDVLISGYKILGGILSCIPDELDGKQEIISSICMKGLNSSNVQVRGECINLI
SCIVEDNSSSLVKSVHGCIPLILQSLSLMAKNSSSDIAVLEECEKVLQSIGKMIDYNAKFFTKHITSLCD
ILFSICMKDENELNYDFDNSLKSLSIEALVTIPERRPKMALSVPHFVDKIIHLSMLFMLDINNDCFNEWM
NSIKEGKDDSQELYDIGEESLDRVGKAFSELEEAEFIHILFNKVSEFLMKNTWEHKYVGIMAIAQTIEYL
PEDEIEEQLEHVIKMLLQILVDQDVRVRYAACQAIGQISLDHQPYVQKEFFSEILSALINTMNDVHLRVQ
SHATAAFVNYAEELDKMALLPYADIIIDILLQKLNSSNYLLVREQAVTAIAVIAGVIEEDFLKYYSTVVP
MMKDIIQKAVSEEERTCRGKAIECISIIGLSVGKDIFIEDAKECMNALLQISSTKMDPDDTVKEYIQEAI
GRICRALGNDFYPYLSSIVPTILSVLSVLPKPLTDDEEDLTITMVSNGQYVGLKTSLLEDQEKALDLLII
IIEVLKENYKDYIQATATAVLPMLNYELSDEIKQKALTAVSELIESARILSEKTDNDKSMLLAILTAAAE
KVLKSLLETKLDDNYEYILDVMIIESHGLYMCLQKAGSNVLPENTLKLFFNQIFALLQYSTDRRVVYNQK
KNNDDVDEDELLIIDREEELEQNYRTNLLDILGVLIKYHPTQFLNTCCELCIGFINNYMNSPNSEDVALA
LYVCDDLLEFLQEKSVNLWDFFMNPLLLNINHADDKVKQAACYGVIQATKIEAFGKYANIAVEYLLKLVH
ESTSNKKPKEYISAIDNAIAALGDVVLMHTSKFNNAEDLIKVWLNHLPIKEDDAEGRRVHKNLIDLVSQN
HPLLFGKDNSNTAKIIEIFLTIYETDFSDTDCNKKISTLINSLDKSYLNNLASSTLSHKQAKKLNNILNP
NRK

Molecule Role : Protective antigen
Molecule Role Annotation : Two large fragments of PfKbeta representing the N- and C-terminal halves were expressed in E. coli. The recombinant proteins were highly immunogenic in mice, and also found to be the target for immune response in natural infections of Plasmodium spp. Immunization with recombinant PfKbeta fragments was partially protective against a heterologous challenge infection in mice (Mohmmed et al., 2005).

22. LSA-1 from Plasmodium falciparum

Gene Name : LSA-1 from Plasmodium falciparum
Sequence Strain (Species/Organism) : Plasmodium falciparum
NCBI Protein GI : 510186
Other Database IDs : CDD:183692
HSSP: 1D7M
UniProtKB/TrEMBL: Q25887
Taxonomy ID : 5833
Gene Strand (Orientation) : ?
Protein Name : liver stage antigen-1
Protein Length : 318
Protein Note : phosphodiesterase; Provisional

DNA Sequence : Show Sequence

>PF10_0356 ||LSA1, LSA-1|liver stage antigen-1|Plasmodium falciparum|chr 10|TIGR||Manual
ATGAAACATA TTTTGTACAT ATCATTTTAC TTTATCCTTG TTAATTTATT GATATTTCAT
ATAAATGGAA AGATAATAAA GAATTCTGAA AAAGATGAAA TCATAAAATC TAACTTGAGA
AGTGGTTCTT CAAATTCTAG GAATCGAATA AATGAGGAAA AGCACGAGAA GAAACACGTT
TTATCTCATA ATTCATATGA GAAAACTAAA AATAATGAAA ATAATAAATT TTTCGATAAG
GATAAAGAGT TAACGATGTC TAATGTAAAA AATGTGTCAC AAACAAATTT CAAAAGTCTT
TTAAGAAATC TTGGTGTTTC AGAGAATATA TTCCTTAAAG AAAATAAATT AAATAAGGAA
GGGAAATTAA TTGAACACAT AATAAATGAT GATGACGATA AAAAAAAATA TATTAAAGGG
CAAGACGAAA ACAGACAAGA AGATCTAGAA CAAGAGAGAC TTGCTAAAGA AAAGTTGCAA
GAACAACAAA GCGATTTAGA ACAAGAGAGA CNTGCTAAAG AAAAGTTGCA AGAACAACAA
AGCGATTTAG AACAAGAGAG ACTTGCTAAA GAAAAGTTGC AAGAACAACA AAGCGATTTA
GAACAAGAGA GACTTGCTAA AGAAAAGTTG CAAGAGCAAC AAAGCGATTT AGAACAAGAG
AGACGTGCTA AAGAAAAGTT GCAAGAACAA CAAAGCGATT TAGAACGAAC GAGAGACTTG
CTAAAGAAAA GTTGCAAGAG CAGCAAAGCG ATTTAG

Protein Sequence : Show Sequence

>gi|510186|emb|CAA82974.1| liver stage antigen-1 [Plasmodium falciparum]
MKHILYISFYFILVNLLIFHINGKIIKNSEKDEIIKSNLRSGSSNSRNRINEENHEKKHVLSHNSYEKTK
NNENNKFFDKDKELTMSNVKNVSQTNFKSLLRNLGVSENIFLKENKLNKEGKLIEHIINDDDDKKKYIKG
QDENRQEDLEEKAAKEKLQGQQSDSEQERRAKEKLQEQQSDLEQERLAKEKLQEQQSDLEQERRAKEKLQ
EQQSDLEQERLAKEKLQEQQSDLEQERRAKEKLQEQQSDLEQERRAKEKLQEQQSDLEQERLAKEKLQEQ
QSDLEQDRLAKEKLQEQQSDLEQERRAKERLQEQQSDL

Molecule Role : Other
Related Vaccine(s): NYVAC-Pf7

23. LSA-3

Gene Name : LSA-3
Sequence Strain (Species/Organism) : Plasmodium falciparum 3D7
VO ID : VO_0012381
NCBI Gene ID : 812783
NCBI Protein GI : 124801463
Locus Tag : PF3D7_0220000
Genbank Accession : LN999943
Protein Accession : XP_001349701
Taxonomy ID : 36329
Chromosome No : 2
Gene Starting Position : 796751
Gene Ending Position : 801585
Gene Strand (Orientation) : +
Protein Name : Liver stage antigen 3
Protein pI : 3.86
Protein Weight : 156020.34
Protein Length : 1558

DNA Sequence : Show Sequence

>NC_037280.1:796751-801585 Plasmodium falciparum 3D7 chromosome 2, complete sequence
AATGACAAATAGTAATTACAAATCAAATAATAAAACATATAATGAAAATAATAATGAACAAATAACTACC
ATATTTAATAGAACAAATATGAATCCGATAAAAAAATGTCATATGAGAGAAAAAATAAATAAGTACTTTT
TTTTGATCAAAATTTTGACATGCACCATTTTAATATGGGCTGTACAATATGCTAATAACGTAAGATAAAA
AACTAAATAATAAATATAAATAAAAAAAAAAAAAAAAAAAAAAAAAATCAACTATATAGTATGTATAATA
TATATATATATATATATATATATATATTTATTTTTATTTATTTATTAATTTTTTTTTTTTTTATATTATC
TTTTTAGTCTGATATAAACAAGAGTTGGAAAAAAAATACGTATGTAGATAAGAAATTGAATAAACTATTT
AACAGAAGTTTAGGAGAATCTCAAGTAAATGGTGAATTAGCTAGTGAAGAAGTAAAGGAAAAAATTCTTG
ACTTATTAGAAGAAGGAAATACATTAACTGAAAGTGTAGATGATAATAAAAATTTAGAAGAAGCCGAAGA
TATAAAGGAAAATATCTTATTAAGTAATATAGAAGAACCAAAAGAAAATATTATTGACAATTTATTAAAT
AATATTGGACAAAATTCAGAAAAACAAGAAAGTGTATCAGAAAATGTACAAGTCAGTGATGAACTTTTTA
ATGAATTATTAAATAGTGTAGATGTTAATGGAGAAGTAAAAGAAAATATTTTGGAGGAAAGTCAAGTTAA
TGACGATATTTTTAATAGTTTAGTAAAAAGTGTTCAACAAGAACAACAACACAATGTTGAAGAAAAAGTT
GAAGAAAGTGTAGAAGAAAATGACGAAGAAAGTGTAGAAGAAAATGTAGAAGAAAATGTAGAAGAAAATG
ACGACGAAAGTGTAGCCTCAAGTGTTGAAGAAAGTATAGCTTCAAGTGTTGATGAAAGTATAGATTCAAG
TATTGAAGAAAATGTAGCTCCAACTGTTGAAGAAATCGTAGCTCCAACTGTTGAAGAAATTGTAGCTCCA
AGTGTTGTAGAAAGTGTGGCTCCAAGTGTTGAAGAAAGTGTAGAAGAAAATGTTGAAGAAAGTGTAGCTG
AAAATGTTGAAGAAAGTGTAGCTGAAAATGTTGAAGAAAGTGTAGCTGAAAATGTTGAAGAAAGTGTAGC
TGAAAATGTTGAAGAAAGTGTAGCTGAAAATGTTGAAGAAAGTGTAGCTGAAAATGTTGAAGAAATCGTA
GCTCCAACTGTTGAAGAAAGTGTAGCTCCAACTGTTGAAGAAATTGTAGCTCCAAGTGTTGAAGAAAGTG
TAGCTCCAAGTGTTGAAGAAATTGTAGTTCCAACTGTTGAAGAAAGTGTAGCTGAAAATGTTGAAGAAAT
CGTAGCTCCAAGTGTTGAAGAAATCGTAGCTCCAAGTGTTGAAGAAATCGTAGCTCCAACTGTTGAAGAA
AGTGTAGCTCCAACTGTTGAAGAAATTGTAGCTCCAAGTGTTGAAGAAAGTGTAGCTCCAAGTGTTGAAG
AAATTGTAGTTCCAACTGTTGAAGAAAGTGTAGCTGAAAATGTTGAAGAAAGTGTAGCTGAAAATGTTGA
AGAAATCGTAGCTCCAAGTGTTGAAGAAATCGTAGCTCCAAGTGTTGAAGAAATCGTAGCTCCAAGTGTT
GAAGAAATCGTAGCTCCAAGTGTTGAAGAAATCGTAGCTCCAAGTGTTGAAGAAATCGTAGCTCCAAGTG
TTGAAGAAATCGTAGCTCCAAGTGTTGAAGAAATCGTAGCTCCAAGTGTTGAAGAAATCGTAGCTCCAAC
AGTTGAAGAAATCGTAGCTCCAACAGTTGAAGAAATTGTAGCTCCAAGTGTTGAAGAAATCGTAGCTCCA
ACTGTTGAAGAAAGTGTTGCTGAAAACGTTGCAACAAATTTATCAGACAATCTTTTAAGTAATTTATTAG
GTGGTATCGAAACTGAGGAAATAAAGGACAGTATATTAAATGAGATAGAAGAAGTAAAAGAAAATGTAGT
CACCACAATACTAGAAAACGTAGAAGAAACTACAGCTGAAAGTGTAACTACTTTTAGTAACATATTAGAG
GAGATACAAGAAAATACTATTACTAATGATACTATAGAGGAAAAATTAGAAGAACTCCACGAAAATGTAT
TAAGTGCCGCTTTAGAAAATACCCAAAGTGAAGAGGAAAAGAAAGAAGTAATAGATGTAATTGAAGAAGT
AAAAGAAGAGGTCGCTACCACTTTAATAGAAACTGTGGAACAGGCAGAAGAAGAGAGCGCAAGTACAATT
ACGGAAATATTTGAAAATTTAGAAGAAAATGCAGTAGAAAGTAATGAAAATGTTGCAGAGAATTTAGAGA
AATTAAACGAAACTGTATTTAATACTGTATTAGATAAAGTAGAGGAAACAGTAGAAATTAGCGGAGAAAG
TTTAGAAAACAATGAAATGGATAAAGCATTTTTTAGTGAAATATTTGATAATGTAAAAGGAATACAAGAA
AATTTATTAACAGGTATGTTTCGAAGTATAGAAACCAGTATAGTAATCCAATCAGAAGAAAAGGTTGATT
TGAATGAAAATGTGGTTAGTTCGATTTTAGATAATATAGAAAATATGAAAGAAGGTTTATTAAATAAATT
AGAAAATATTTCAAGTACTGAAGGTGTTCAAGAAACTGTAACTGAACATGTAGAACAAAATGTATATGTG
GATGTTGATGTTCCTGCTATGAAAGATCAATTTTTAGGAATATTAAATGAGGCAGGAGGGTTGAAAGAAA
TGTTTTTTAATTTGGAAGATGTATTTAAAAGTGAAAGTGATGTAATTACTGTAGAAGAAATTAAGGATGA
ACCGGTTCAAAAAGAGGTAGAAAAAGAAACTGTTAGTATTATTGAAGAAATGGAAGAAAATATTGTAGAT
GTATTAGAGGAAGAAAAAGAAGATTTAACAGACAAGATGATAGATGCAGTAGAAGAATCCATAGAAATAT
CTTCAGATTCTAAAGAAGAAACTGAATCTATTAAAGATAAAGAAAAAGATGTTTCACTAGTTGTTGAAGA
AGTTCAAGACAATGATATGGATGAAAGTGTTGAGAAAGTTTTAGAATTGAAAAATATGGAAGAGGAGTTA
ATGAAGGATGCTGTTGAAATAAATGACATTACTAGCAAACTTATTGAAGAAACTCAAGAGTTAAATGAAG
TAGAAGCAGATTTAATAAAAGATATGGAAAAATTAAAAGAATTAGAGAAAGCATTATCAGAAGATTCTAA
AGAAATAATAGATGCAAAAGATGATACATTAGAAAAAGTTATTGAAGAGGAACATGATATAACGACGACG
TTGGATGAAGTTGTAGAATTAAAAGATGTCGAAGAAGACAAGATCGAAAAAGTATCTGATTTAAAAGATC
TTGAAGAAGATATATTAAAAGAAGTAAAAGAAATCAAAGAACTTGAAAGTGAAATTTTAGAAGATTATAA
AGAATTAAAAACTATTGAAACAGATATTTTAGAAGAGAAAAAAGAAATAGAAAAAGATCATTTTGAAAAA
TTCGAAGAAGAAGCTGAAGAAATAAAAGATCTTGAAGCAGATATATTAAAAGAAGTATCTTCATTAGAAG
TTGAAGAAGAAAAAAAATTAGAAGAAGTACACGAATTAAAAGAAGAGGTAGAACATATAATAAGTGGTGA
TGCGCATATAAAAGGTTTGGAAGAAGATGATTTAGAAGAAGTAGATGATTTAAAAGGAAGTATATTAGAC
ATGTTAAAGGGAGATATGGAATTAGGGGATATGGATAAGGAAAGTTTAGAAGATGTAACAGCAAAACTTG
GAGAAAGAGTTGAATCCTTAAAAGATGTTTTATCTAGTGCATTAGGCATGGATGAAGAACAAATGAAAAC
AAGAAAAAAAGCTCAAAGACCTAAATTGGAAGAAGTATTATTAAAAGAAGAGGTTAAAGAAGAACCAAAG
AAAAAAATAACAAAAAAGAAAGTAAGGTTTGATATTAAGGATAAGGAACCAAAAGATGAAATAGTAGAAG
TTGAAATGAAAGATGAAGATATAGATGAAGATATAGAAGAAGATGTAGAAGAAGATATAGAAGAAGATAA
AGTTGAAGATATAGATGAAGATATAGATGAAGATATAGATGAAGATATAGGTGAAGACAAAGATGAAGTT
ATAGATTTAATAGTCCAAAAAGAGAAACGCATTGAAAAGGTTAAAGAGAAAAAGAAAAAATTAGAAAAAA
AAGTTGAAGAAGGTGTTAGTGGTCTTAAAAAACACGTAGACGAAGTAATGAAATATGTTCAAAAAATTGA
TAAAGAAGTTGATAAAGAAGTATCTAAAGCTTTAGAATCAAAAAATGATGTTACTAATGTTTTAAAACAA
AATCAAGATTTTTTTAGTAAAGTTAAAAACTTCGTAAAAAAATATAAAGTATTTGCTGCACCATTCATAT
CTGCCGTTGCAGCATTTGCATCATATGTAGTTGGGTTCTTTACATTTTCTTTATTTTCATCATGTGTAAC
AATAGCTTCTTCAACTTACTTATTATCAAAAGTTGACAAAACTATAAATAAAAATAAGGAGAGACCGTTT
TATTCATTTGTATTTGATATCTTTAAGAATTTAAAACATTATTTACAACAAATGAAAGAAAAATTTAGTA
AAGAAAAAAATAATAATGTAATAGAAGTAACAAACAAAGCTGAGAAAAAAGGTAATGTACAGGTAACAAA
TAAAACCGAGAAAACAACTAAAGTTGATAAAAATAATAAAGTACCGAAAAAAAGTAGAACGCAAAAATCA
AAATA

Protein Sequence : Show Sequence

>XP_001349701.1 liver stage antigen 3 [Plasmodium falciparum 3D7]
MTNSNYKSNNKTYNENNNEQITTIFNRTNMNPIKKCHMREKINKYFFLIKILTCTILIWAVQYANNSDIN
KSWKKNTYVDKKLNKLFNRSLGESQVNGELASEEVKEKILDLLEEGNTLTESVDDNKNLEEAEDIKENIL
LSNIEEPKENIIDNLLNNIGQNSEKQESVSENVQVSDELFNELLNSVDVNGEVKENILEESQVNDDIFNS
LVKSVQQEQQHNVEEKVEESVEENDEESVEENVEENVEENDDESVASSVEESIASSVDESIDSSIEENVA
PTVEEIVAPTVEEIVAPSVVESVAPSVEESVEENVEESVAENVEESVAENVEESVAENVEESVAENVEES
VAENVEESVAENVEEIVAPTVEESVAPTVEEIVAPSVEESVAPSVEEIVVPTVEESVAENVEEIVAPSVE
EIVAPSVEEIVAPTVEESVAPTVEEIVAPSVEESVAPSVEEIVVPTVEESVAENVEESVAENVEEIVAPS
VEEIVAPSVEEIVAPSVEEIVAPSVEEIVAPSVEEIVAPSVEEIVAPSVEEIVAPSVEEIVAPTVEEIVA
PTVEEIVAPSVEEIVAPTVEESVAENVATNLSDNLLSNLLGGIETEEIKDSILNEIEEVKENVVTTILEN
VEETTAESVTTFSNILEEIQENTITNDTIEEKLEELHENVLSAALENTQSEEEKKEVIDVIEEVKEEVAT
TLIETVEQAEEESASTITEIFENLEENAVESNENVAENLEKLNETVFNTVLDKVEETVEISGESLENNEM
DKAFFSEIFDNVKGIQENLLTGMFRSIETSIVIQSEEKVDLNENVVSSILDNIENMKEGLLNKLENISST
EGVQETVTEHVEQNVYVDVDVPAMKDQFLGILNEAGGLKEMFFNLEDVFKSESDVITVEEIKDEPVQKEV
EKETVSIIEEMEENIVDVLEEEKEDLTDKMIDAVEESIEISSDSKEETESIKDKEKDVSLVVEEVQDNDM
DESVEKVLELKNMEEELMKDAVEINDITSKLIEETQELNEVEADLIKDMEKLKELEKALSEDSKEIIDAK
DDTLEKVIEEEHDITTTLDEVVELKDVEEDKIEKVSDLKDLEEDILKEVKEIKELESEILEDYKELKTIE
TDILEEKKEIEKDHFEKFEEEAEEIKDLEADILKEVSSLEVEEEKKLEEVHELKEEVEHIISGDAHIKGL
EEDDLEEVDDLKGSILDMLKGDMELGDMDKESLEDVTAKLGERVESLKDVLSSALGMDEEQMKTRKKAQR
PKLEEVLLKEEVKEEPKKKITKKKVRFDIKDKEPKDEIVEVEMKDEDIDEDIEEDVEEDIEEDKVEDIDE
DIDEDIDEDIGEDKDEVIDLIVQKEKRIEKVKEKKKKLEKKVEEGVSGLKKHVDEVMKYVQKIDKEVDKE
VSKALESKNDVTNVLKQNQDFFSKVKNFVKKYKVFAAPFISAVAAFASYVVGFFTFSLFSSCVTIASSTY
LLSKVDKTINKNKERPFYSFVFDIFKNLKHYLQQMKEKFSKEKNNNVIEVTNKAEKKGNVQVTNKTEKTT
KVDKNNKVPKKSRTQKSK

Molecule Role : Protective antigen
Molecule Role Annotation : In chimpanzees (Pan troglodytes), the primates most closely related to humans and that share a similar susceptibility to P. falciparum liver-stage infection, immunization with LSA-3 induced protection against successive heterologous challenges with large numbers of P. falciparum sporozoites (Daubersies et al., 2000).
Related Vaccine(s): P. falciparum LSA-3 Protein Vaccine

24. MSP-1 from P. falciparum

Gene Name : MSP-1 from P. falciparum
Sequence Strain (Species/Organism) : Plasmodium falciparum 3D7
VO ID : VO_0010958
NCBI Gene ID : 813575
NCBI Protein GI : 124507147
Locus Tag : PF3D7_0930300
Genbank Accession : AL844508
Protein Accession : XP_001352170
Other Database IDs : CDD:289698
CDD:304395
Taxonomy ID : 36329
Chromosome No : 9
Gene Starting Position : 1201811
Gene Ending Position : 1206973
Gene Strand (Orientation) : +
Protein Name : merozoite surface protein 1
Protein pI : 6.46
Protein Weight : 187682.63
Protein Length : 1720
Protein Note : clinical isolate

DNA Sequence : Show Sequence

>NC_004330.2:1201811-1206973 Plasmodium falciparum 3D7 genome assembly, chromosome: 9
AATGAAGATCATATTCTTTTTATGTTCATTTCTTTTTTTTATTATAAATACACAATGTGTAACACATGAA
AGTTATCAAGAACTTGTCAAAAAACTAGAAGCTTTAGAAGATGCAGTATTGACAGGTTATAGTTTATTTC
AAAAGGAAAAAATGGTATTAAATGAAGAAGAAATTACTACAAAAGGTGCAAGTGCTCAAAGTGGTGCAAG
TGCTCAAAGTGGTGCAAGTGCTCAAAGTGGTGCAAGTGCTCAAAGTGGTGCAAGTGCTCAAAGTGGTGCA
AGTGCTCAAAGTGGTACAAGTGGTCCAAGTGGTCCAAGTGGTACAAGTCCATCATCTCGTTCAAACACTT
TACCTCGTTCAAATACTTCATCTGGTGCAAGCCCTCCAGCTGATGCAAGCGATTCAGATGCTAAATCTTA
CGCTGATTTAAAACACAGAGTACGAAATTACTTGTTCACTATTAAAGAACTCAAATATCCCGAACTCTTT
GATTTAACCAATCATATGTTAACTTTGTGTGATAATATTCATGGTTTCAAATATTTAATTGATGGATATG
AAGAAATTAATGAATTATTATATAAATTAAACTTTTATTTTGATTTATTAAGAGCAAAATTAAATGATGT
ATGTGCTAATGATTATTGTCAAATACCTTTCAATCTTAAAATTCGTGCAAATGAATTAGACGTACTTAAA
AAACTTGTGTTCGGATATAGAAAACCATTAGACAATATTAAAGATAATGTAGGAAAAATGGAAGATTACA
TTAAAAAAAATAAAACAACCATAGCAAATATAAATGAATTAATTGAAGGAAGTAAGAAAACAATTGATCA
AAATAAGAATGCAGATAATGAAGAAGGGAAAAAAAAATTATACCAAGCTCAATATGATCTTTCTATTTAC
AATAAACAATTAGAAGAAGCACATAATTTAATAAGCGTTTTAGAAAAACGTATTGACACTTTAAAAAAAA
ATGAAAACATAAAGAAATTACTTGATAAGATAAATGAAATTAAAAATCCCCCACCGGCCAATTCTGGAAA
TACACCAAATACTCTCCTTGATAAGAACAAAAAAATCGAGGAACACGAAGAAAAAATAAAAGAAATTGCC
AAAACTATTAAATTTAACATTGATAGTTTATTTACTGATCCACTTGAATTAGAATATTATTTAAGAGAAA
AAAATAAAAAAGTTGATGTAACACCTAAATCACAAGATCCTACGAAATCTGTTCAAATACCAAAAGTTCC
TTATCCAAATGGTATTGTATATCCTTTACCACTCACTGATATTCATAATTCATTAGCTGCAGATAATGAT
AAAAATTCATATGGTGATTTAATGAATCCTCATACTAAAGAAAAAATTAATGAAAAAATTATTACAGATA
ATAAGGAAAGAAAAATATTCATTAATAACATTAAAAAAAAAATTGATTTAGAAGAAAAAAACATTAATCA
CACAAAAGAACAAAATAAAAAATTACTTGAAGATTATGAAAAGTCAAAAAAGGATTATGAAGAATTACTT
GAAAAATTTTATGAAATGAAATTTAATAATAATTTTAACAAAGATGTCGTAGATAAAATATTCAGTGCAA
GATATACATATAATGTTGAAAAACAAAGATATAATAATAAATTTTCATCCTCTAATAATTCTGTATATAA
TGTTCAAAAATTAAAAAAGGCTCTTTCATATCTTGAAGATTATTCTTTAAGAAAAGGAATTTCTGAAAAA
GATTTTAATCATTATTATACTTTGAAAACTGGCCTCGAAGCTGATATAAAAAAATTAACAGAAGAAATAA
AGAGTAGTGAAAACAAAATTCTAGAAAAAAATTTTAAAGGACTAACACATTCAGCAAATGGTTCCTTAGA
AGTATCTGATATTGTAAAATTACAAGTACAAAAAGTTTTATTAATTAAAAAAATAGAAGACTTAAGAAAG
ATAGAATTATTTTTAAAAAATGCACAACTAAAAGATAGTATTCATGTACCAAATATTTATAAACCACAAA
ATAAACCAGAACCATATTATTTAATTGTATTAAAAAAAGAAGTAGATAAATTAAAAGAATTTATACCAAA
AGTAAAAGACATGTTAAAGAAAGAACAAGCTGTCTTATCAAGTATTACACAACCTTTAGTTGCAGCAAGC
GAAACAACTGAAGATGGGGGTCACTCCACACACACATTATCCCAATCAGGAGAAACAGAAGTAACAGAAG
AAACAGAAGAAACAGAAGAAACAGTAGGACACACAACAACGGTAACAATAACATTACCACCAACACAACC
ATCACCACCAAAAGAAGTAAAAGTTGTTGAAAATTCAATAGAACATAAGAGTAATGACAATTCACAAGCC
TTGACAAAAACAGTTTATCTAAAGAAATTAGATGAATTTTTAACTAAATCATATATATGTCATAAATATA
TTTTAGTATCAAACTCTAGTATGGACCAAAAATTATTAGAGGTATATAATCTTACTCCAGAAGAAGAAAA
TGAATTAAAATCATGTGATCCATTAGATTTATTATTTAATATTCAAAATAACATACCTGCTATGTATTCA
TTATATGATAGTATGAACAATGATTTACAACATCTCTTTTTTGAATTATATCAAAAGGAAATGATTTATT
ATTTACATAAACTAAAAGAGGAAAATCACATCAAAAAATTATTAGAGGAGCAAAAACAAATAACTGGAAC
ATCATCTACATCCAGTCCTGGAAATACAACCGTAAATACTGCTCAATCCGCAACTCACAGTAATTCCCAA
AACCAACAATCAAATGCATCCTCTACCAATACCCAAAATGGTGTAGCTGTATCATCTGGTCCTGCTGTAG
TTGAAGAAAGTCATGATCCCTTAACAGTATTGTCTATTAGTAACGATTTGAAAGGTATTGTTAGTCTCTT
AAATCTTGGAAATAAAACTAAAGTACCTAATCCATTAACCATTTCTACAACAGAGATGGAAAAATTTTAT
GAGAATATTTTAAAAAATAATGATACCTATTTTAATGATGATATCAAACAATTCGTAAAATCTAATTCAA
AAGTAATTACAGGTTTGACCGAAACACAAAAAAATGCATTAAATGATGAAATTAAAAAATTAAAAGATAC
TTTACAGTTATCATTTGATTTATATAATAAATATAAATTAAAATTAGATAGATTATTTAATAAGAAAAAA
GAACTTGGCCAAGACAAAATGCAAATTAAAAAACTTACTTTATTAAAAGAACAATTAGAATCAAAATTGA
ATTCACTTAATAACCCACATAATGTATTACAAAACTTTTCTGTTTTCTTTAACAAAAAAAAAGAAGCTGA
AATAGCAGAAACTGAAAACACATTAGAAAACACAAAAATATTATTGAAACATTATAAAGGACTTGTTAAA
TATTATAATGGTGAATCATCTCCATTAAAAACTTTAAGTGAAGTATCAATTCAAACAGAAGATAATTATG
CCAATTTAGAAAAATTTAGAGTATTAAGTAAAATAGATGGAAAACTCAATGATAATTTACATTTAGGAAA
GAAAAAATTATCTTTCTTATCAAGTGGATTACATCATTTAATTACTGAATTAAAAGAAGTAATAAAAAAT
AAAAATTATACAGGTAATTCTCCAAGTGAAAATAATAAGAAAGTTAACGAAGCTTTAAAATCTTACGAAA
ATTTTCTCCCAGAAGCAAAAGTTACAACAGTTGTAACTCCACCTCAACCAGATGTAACTCCATCTCCATT
ATCTGTAAGGGTAAGTGGTAGTTCAGGATCCACAAAAGAAGAAACACAAATACCAACTTCAGGCTCTTTA
TTAACAGAATTACAACAAGTAGTACAATTACAAAATTATGACGAAGAAGATGATTCCTTAGTTGTATTAC
CCATTTTTGGAGAATCCGAAGATAATGACGAATATTTAGATCAAGTAGTAACTGGAGAAGCAATATCTGT
CACAATGGATAATATCCTCTCAGGATTTGAAAATGAATATGATGTTATATATTTAAAACCTTTAGCTGGA
GTATATAGAAGCTTAAAAAAACAAATTGAAAAAAACATTTTTACATTTAATTTAAATTTGAACGATATCT
TAAATTCACGTCTTAAGAAACGAAAATATTTCTTAGATGTATTAGAATCTGATTTAATGCAATTTAAACA
TATATCCTCAAATGAATACATTATTGAAGATTCATTTAAATTATTGAATTCAGAACAAAAAAACACACTT
TTAAAAAGTTACAAATATATAAAAGAATCAGTAGAAAATGATATTAAATTTGCACAGGAAGGTATAAGTT
ATTATGAAAAGGTTTTAGCGAAATATAAGGATGATTTAGAATCAATTAAAAAAGTTATCAAAGAAGAAAA
GGAGAAGTTCCCATCATCACCACCAACAACACCTCCGTCACCAGCAAAAACAGACGAACAAAAGAAGGAA
AGTAAGTTCCTTCCATTTTTAACAAACATTGAGACCTTATACAATAACTTAGTTAATAAAATTGACGATT
ACTTAATTAACTTAAAGGCAAAGATTAACGATTGTAATGTTGAAAAAGATGAAGCACATGTTAAAATAAC
TAAACTTAGTGATTTAAAAGCAATTGATGACAAAATAGATCTTTTTAAAAACCCTTACGACTTCGAAGCA
ATTAAAAAATTGATAAATGATGATACGAAAAAAGATATGCTTGGCAAATTACTTAGTACAGGATTAGTTC
AAAATTTTCCTAATACAATAATATCAAAATTAATTGAAGGAAAATTCCAAGATATGTTAAACATTTCACA
ACACCAATGCGTAAAAAAACAATGTCCAGAAAATTCTGGATGTTTCAGACATTTAGATGAAAGAGAAGAA
TGTAAATGTTTATTAAATTACAAACAAGAAGGTGATAAATGTGTTGAAAATCCAAATCCTACTTGTAACG
AAAATAATGGTGGATGTGATGCAGATGCCACATGTACCGAAGAAGATTCAGGTAGCAGCAGAAAGAAAAT
CACATGTGAATGTACTAAACCTGATTCTTATCCACTTTTCGATGGTATTTTCTGCAGTTCCTCTAACTTC
TTAGGAATATCATTCTTATTAATACTCATGTTAATATTATACAGTTTCATTTA

Protein Sequence : Show Sequence

>XP_001352170.1 merozoite surface protein 1 [Plasmodium falciparum 3D7]
MKIIFFLCSFLFFIINTQCVTHESYQELVKKLEALEDAVLTGYSLFQKEKMVLNEEEITTKGASAQSGAS
AQSGASAQSGASAQSGASAQSGASAQSGTSGPSGPSGTSPSSRSNTLPRSNTSSGASPPADASDSDAKSY
ADLKHRVRNYLFTIKELKYPELFDLTNHMLTLCDNIHGFKYLIDGYEEINELLYKLNFYFDLLRAKLNDV
CANDYCQIPFNLKIRANELDVLKKLVFGYRKPLDNIKDNVGKMEDYIKKNKTTIANINELIEGSKKTIDQ
NKNADNEEGKKKLYQAQYDLSIYNKQLEEAHNLISVLEKRIDTLKKNENIKKLLDKINEIKNPPPANSGN
TPNTLLDKNKKIEEHEEKIKEIAKTIKFNIDSLFTDPLELEYYLREKNKKVDVTPKSQDPTKSVQIPKVP
YPNGIVYPLPLTDIHNSLAADNDKNSYGDLMNPHTKEKINEKIITDNKERKIFINNIKKKIDLEEKNINH
TKEQNKKLLEDYEKSKKDYEELLEKFYEMKFNNNFNKDVVDKIFSARYTYNVEKQRYNNKFSSSNNSVYN
VQKLKKALSYLEDYSLRKGISEKDFNHYYTLKTGLEADIKKLTEEIKSSENKILEKNFKGLTHSANGSLE
VSDIVKLQVQKVLLIKKIEDLRKIELFLKNAQLKDSIHVPNIYKPQNKPEPYYLIVLKKEVDKLKEFIPK
VKDMLKKEQAVLSSITQPLVAASETTEDGGHSTHTLSQSGETEVTEETEETEETVGHTTTVTITLPPTQP
SPPKEVKVVENSIEHKSNDNSQALTKTVYLKKLDEFLTKSYICHKYILVSNSSMDQKLLEVYNLTPEEEN
ELKSCDPLDLLFNIQNNIPAMYSLYDSMNNDLQHLFFELYQKEMIYYLHKLKEENHIKKLLEEQKQITGT
SSTSSPGNTTVNTAQSATHSNSQNQQSNASSTNTQNGVAVSSGPAVVEESHDPLTVLSISNDLKGIVSLL
NLGNKTKVPNPLTISTTEMEKFYENILKNNDTYFNDDIKQFVKSNSKVITGLTETQKNALNDEIKKLKDT
LQLSFDLYNKYKLKLDRLFNKKKELGQDKMQIKKLTLLKEQLESKLNSLNNPHNVLQNFSVFFNKKKEAE
IAETENTLENTKILLKHYKGLVKYYNGESSPLKTLSEVSIQTEDNYANLEKFRVLSKIDGKLNDNLHLGK
KKLSFLSSGLHHLITELKEVIKNKNYTGNSPSENNKKVNEALKSYENFLPEAKVTTVVTPPQPDVTPSPL
SVRVSGSSGSTKEETQIPTSGSLLTELQQVVQLQNYDEEDDSLVVLPIFGESEDNDEYLDQVVTGEAISV
TMDNILSGFENEYDVIYLKPLAGVYRSLKKQIEKNIFTFNLNLNDILNSRLKKRKYFLDVLESDLMQFKH
ISSNEYIIEDSFKLLNSEQKNTLLKSYKYIKESVENDIKFAQEGISYYEKVLAKYKDDLESIKKVIKEEK
EKFPSSPPTTPPSPAKTDEQKKESKFLPFLTNIETLYNNLVNKIDDYLINLKAKINDCNVEKDEAHVKIT
KLSDLKAIDDKIDLFKNPYDFEAIKKLINDDTKKDMLGKLLSTGLVQNFPNTIISKLIEGKFQDMLNISQ
HQCVKKQCPENSGCFRHLDEREECKCLLNYKQEGDKCVENPNPTCNENNGGCDADATCTEEDSGSSRKKI
TCECTKPDSYPLFDGIFCSSSNFLGISFLLILMLILYSFI

Molecule Role : Protective antigen
Molecule Role Annotation : Aotus monkeys were challenged with the virulent Vietnam Oak Knoll (FVO) strain of P. falciparum. Vaccination of A. nancymai with yMSP1(19) induced protective immune responses. Both of the A. nancymai vaccinated with yMSP1(19) self-resolved an otherwise lethal infection (Kumar et al., 1995).
Related Vaccine(s): ChAd63-MVA MSP1 , NYVAC-Pf7 , P. falciparum MSP1 from transgenic mice with Freund's adjuvant , P. falciparum vaccine Combination B

25. msp-8

Gene Name : msp-8
Sequence Strain (Species/Organism) : Plasmodium yoelii
VO ID : VO_0011221
NCBI Gene ID : 3792405
NCBI Protein GI : 58197887
Other Database IDs : CDD:315598
Taxonomy ID : 5861
Gene Strand (Orientation) : ?
Protein Name : merozoite surface protein 8
Protein pI : 4.67
Protein Weight : 45677.49
Protein Length : 476
Protein Note : EGF domain; pfam12947

Protein Sequence : Show Sequence

>AAW65717.1 merozoite surface protein 8 [Plasmodium yoelii]
MKKSSQIIIFLLLSLFCKFSIGNCNENGNGNINKANNNSIIRKERKRKSKSDFSKGEPENKEHEIINLYD
DVQELLGPDEMNMLDKYSILGIDDCSNENENNKIISEYDLKAMKSVLLYKNRISRASINNLDDVKTVFKR
CFNKDDPELSKSYEQIQNQVANEGTTIIDYLSNYISNIYIKINDEFVKNEEFQLSKYIPELEIINYVLYN
GPKEIGNKIKNELIEINNLIISESLTSIYSSVVSGLNINCKIKDDLITILNLANGKYFKVNFSSQATMII
PEQYSHESEHMKKISEYFIEKNRVCKNENCPINSNCYVIDSVETCRCIPGFSKNEESENLECLINESTSC
ENNNGGCDVNANCILLEDKIMCECNNKFNGDGIYCSSAIYYGMNVFIFFLISIVCIYIM

Molecule Role : Protective antigen
Molecule Role Annotation : Immunization with Plasmodium yoelii merozoite surface protein (PyMSP)-8 protects mice from lethal malaria but does not prevent infection (Petritus and Burns, 2008).

26. MSP1 from P. berghei

Gene Name : MSP1 from P. berghei
Sequence Strain (Species/Organism) : Plasmodium berghei
VO ID : VO_0011225
NCBI Protein GI : 1762646
Taxonomy ID : 5821
Gene Strand (Orientation) : ?
Protein Name : merozoite surface protein 1
Protein pI : 4.24
Protein Weight : 9906.72
Protein Length : 184

Protein Sequence : Show Sequence

>AAC47502.1 merozoite surface protein 1, partial [Plasmodium berghei]
SGQSSTEPASTGTPSSGEVSTGTSTGGASAGVTNTGAATTGTSTGGASAGVTNTGAATTGTTGTGAATTG
TTGAEAVTTGNTGAEVTQVQIVPTLTPEEKKKKMDGLYAQI

Molecule Role : Protective antigen
Molecule Role Annotation : Mice vaccinated with recombinant rMSP1 (rPbMSP1), which was generated from Plasmodium berghei, in alum mounted significant protective immunity against challenge infection (P < 0.01). On day 121 after the booster, three out of ten mice immunized with rPbMSP1 in PBS survived parasite infection (P < 0.05) and eight out of ten mice vaccinated with r MSP1 in alum did (P < 0.01). Hence, immunization with MSP1 in alum obviously has conferred protective effects, which prevented death from P. berghei lethal infection in mice (P < 0.01) (Wan et al., 2007).
Related Vaccine(s): P. berghei MSP1 Protein Vaccine

27. MSP1 from P. knowlesi

Gene Name : MSP1 from P. knowlesi
Sequence Strain (Species/Organism) : Plasmodium knowlesi strain H
NCBI Gene ID : 7320035
NCBI Protein GI : XP_002258582.2
Other Database IDs : CDD:284802
CDD:289698
CDD:289699
EnsemblGenomes-Gn:PKH_072850
EnsemblGenomes-Tr:PKH_072850
GOA:B3L2X8
InterPro: IPR010901
InterPro: IPR024730
InterPro: IPR024731
UniProtKB/TrEMBL: B3L2X8
Taxonomy ID : 5851
Gene Strand (Orientation) : ?
Protein Name : merozoite surface protein 1, MSP-1
Protein pI : 5.06
Protein Weight : 192886.042
Protein Length : 1931
Protein Note : Merozoite surface protein 1 (MSP1) C-terminus; pfam07462

Protein Sequence : Show Sequence

>XP_002258582.2 merozoite surface protein 1 [Plasmodium knowlesi strain H]
MKALLFLFSLIFFVTKCQCETEDYKQLLVKLDKLEGLVVDGYELFHKNKISLDNIDAVQNIDGNNVNALA
YKIRDIVGKYLELQIPGHGNLLHMIRELALDANGLKYLVENYEEFNQLMHVINFNYDLLRAKLNDMCAHE
YCKIPEHLKISAKELDMLKKVVLGYRKPLDNIKDDIGKMEAFINKNKETINNINQLITAENAKIVGHPIN
GVNVTGASSDAVANTGTPVAAAAGAAAAAVPGAIASPSPVESSTPENYDQKKVIFQAIYNFIFYTNQLEE
AQKLMQVLEKRVKLLKEHKSIKALLEQIATEKNNLTTNNATTGGATTIPEEVQKKIADLEKQIVAIAKTV
NFDMDGLFTNVEELEYYLREKAKMAGTLIGPESSQSTGTPGKAVPTLKETYPYGITYALPERTIYELIEK
FGSEESFGDLQNPDNGRQPNKGIIINETKRKTLVDKIMSKIKLEEEKLPKLKKEYDEKMEQYKQKVQDFL
PTLKYFYEGKLDNTLVGSKFDEFKNKREAYMKEKEELEKCTYEQSINLINKLKKQLTYLVDYTLKKDVTE
DEINYFSDLEWKLKNEIYELAKEVRKNENKLIMENKFDFSGVLELQIHKVLMIKKIGALKNVQNLLKNAK
LKDKLYIPKVYKTGQKPEPYYLIVLKKEIDKLKDFIPKIETMIATEKAKAPTEPVKVRAQSLRGASETAP
SEPPTATESGSTTSASTAVQQPTQQAAQAAQAASPVTVTQPTETVTQTPAPATETAGEAAQETSPVSPTA
PAVVSEAGTEGGEGTTEVVAQPEAASGETQTPTPGAVDASPAAPVPAGTPGTTDAAPEASVPAPAGSALP
ATTAPAAAAPAAPAMSKLEYLEKLLEFLKSSYACHKHIFLTNSTMNPELLKQYALTTDEEKKIKESACDE
LDLLFNVQNNLPSMYSIYDTMINDLQNLYIELYQKEMVYNIYKNKDTDTKIKAFLETLKSNAASVTPAVV
PAAAPVVTPAPAEPVVTPAPAPGQAAPAAAPTTTNPSTTPSGTTTNAVSPTTAVTPGAQDTTQTTTQDTT
VTEEGGVTVQASSEEEPETNIVNVEKIYEKHLSQMDKYNDYFIKFLESQKEKITSMTEEQANALGAEIEA
LKKKVQVSLDHYGKYKLKLERFLEKKNKISNSKEHIKKLTSLKNKLERKLNFLNNPTSVLKNYIIFFNKK
KEAEKKEVENTLKNTEILLKYYKARAKYYIGEPFPLKTLSEESLQKEDNYLNLEKFRVLSRMEGRLGNNI
NLEKENISYLSSGLHHVFTELKEIIKNKKYTGNDHAKNTTAVKEALQAYEELLPKVATQTASLPPVAPPA
VVPPVVPEAEAEAEAEAEAEPATSTQPATADTAAPTQTPAAPTQTPAEPATATATTGETAAAPAAPAPVE
VQNAEVKAQEYGEDYDKVITLPLFGNDEDDVEDQEEKQIITGEAENAQPENIVPEGINEYEVVYIKPLAG
MYKSIKKQLENHVAAFNTNITDMLDSRLKKRNYFLDVLDSELNPFKYSSSGEYIIKDPYKLLDLEQKKKL
LGSYQYIGASVDKDLITAKDGMEYYNKMGELYKQHLEAVNAQIKEIEASVPGEQSQLNAQKEELKKYLPF
LNSIQKEYESLVNMAHTYKENLKKFINNCQIEKKETEIIVKKLEDYTKIDENLEIYKKSKKESDVRSSGL
LEKLKNSKLINEEESKKVLSQLLNVQTQMLNMSSAHKCIDTNVPENAACYRYLDGTEEWRCLLGFKEVGG
KCVPASITCEENNGGCAPEAECTMDDKKEVECKCTKEGSEPLFEGVFCSSSSFLSLSFLLLILIFFLSME
L

Molecule Role : Protective antigen
Related Vaccine(s): P. knowlesi DNA vaccine encoding PkCSP, PkSSP2, PkAMA1, and PkMSP1p42

28. MSP1 from P. yoelii str. 17XNL

Gene Name : MSP1 from P. yoelii str. 17XNL
Sequence Strain (Species/Organism) : Plasmodium yoelii
VO ID : VO_0011212
NCBI Gene ID : 3791597
NCBI Protein GI : 82596427
Locus Tag : PY17X_0834400
Genbank Accession : LK934636
Protein Accession : XP_726257
Taxonomy ID : 5861
Chromosome No : 8
Gene Starting Position : 1276003
Gene Ending Position : 1281321
Gene Strand (Orientation) : +
Protein pI : 5.05
Protein Weight : 188296.05
Protein Length : 1772

DNA Sequence : Show Sequence

>NC_036180.1:1276003-1281321 Plasmodium yoelii genome assembly PY17X01, chromosome : 8
AATGAAGGTGATTGGACTTTTATTTTCTTTCGTTTTTTTTGCTATAAAATGCAAATCTGAAACAATTGAA
GTTTATAATGATCTCATTCAAAAGTTAGAAAAATTAGAATCATTGTCAGTGGATGGGTTAGAACTATTTC
AAAAAAGTCAAGTAATTATAAATGCAACACAACCAACTGAAACTATTGATCCATTTACAAATCATAACTT
TGCACAACAAGTACAAGATTTTGTTACAAAATTTGAAGGATTAGGATTTACAGAACAAACAGAATTAGTC
AATTTAATAAAAGCATTAACCCCAAATAGATATGGAGTAAAATATTTAATTGAAAGTAAAGAAGAATTTA
ATGGATTAATGCACGCAATAAATTTTTATTATGATGTACTTAGAGATAAATTAAATGATATGTGTGCAAA
TAATTATTGTGAAATTCCTGAACATCTTAAAATTAGTGAAGAAGAAACAGAAATGCTTAAAAAAGTAATT
TTAGGTTATAGAAAACCAATAGAAAATATTCAAGACGATATTGAAAAGTTAGAAATTTACATAGAAAGAA
ATAAAGAAACTGTTGCAGCTTTAAACGCTCTTATTGCTGAAGAAACAAAAAAAATACAACCTGAAGGTAA
CGAAGATTGCAATGACGCTAGTTGTGATAGCGATAAATATAATAAAAAAAAACCAATATACCAAGCTATG
TACAATGTTATATTTTACAAAAAACAATTAGCTGAAATACAAAAGGTTGTCGAAGTCTTAGAAAAACGAG
TTTCTACATTAAAGAAAAATGATGCCATCAAACCATTATGGCAACAAATTGAAGTTCTCAATGCTGCCCC
CGTCGTCACTGCCGAAACACAAATAGTTACAGGAGGACAATCTAGTACAGAACCAGGTAGTGGTGGATCA
AGTGCATCGGGAACAAGTTCATCAGGACAAGCTAGTGCAGGAACAGGTGTAGAACAAGCTAACACTGTAG
CATCTGTTACAGTAACACCTAGTGTAGGACAAAATGGTGAAGCATCAACTAATCCACAAACAGCTCAAGT
GCAACCCGTTCCAACTCTTACATTAGAAGAAAAACAGAAAAAAATAGCCGGACTTTATGCTCAAATTAAA
GAAATTGCAAAAACTATAAAATTCAACTTAGAAGGAATATTTGTAGATCCAATCGAATTAGAATATTTCA
AAAAAGAAAAAAAAAAAGAAAGTTGCAATTTATCAACTTCATCCTGTAAAAAAAATAAAGCATCCGAAAC
TATAATACCATTAACTATACGTTATCCAAATGGTATTAGTTACCCATTACCTGAAAATGATGTTTACAAT
AAAATTGCCAATAATGCCGCTGAAACAACATATGGTGATTTGACACATCCCGATAATACACCATTAACAG
GAGATTTAGCCACAAATGAACAAGCCAGAAAAGATCTAATAAAAGCTATTAAAAAGAAAATAAAAGCAGA
AGAAAAAAAATTAGAAACATTAAAAACGAATTATGATAATAAACTTACAGAATTTAATCAACAAAAAACT
CCATTCAAAGAAGCAGCTAAAGAATTTTATGAATCAAAATTTAGAAATAAATTGACTTCTGAAATTTTTG
AAAAATTCAAAACAAAAAGAGATGAATATATGACCAAGAAAACCGAATTAAACACTTGTGAATATGGAAA
TACTAAAGAATTAATTAATAAATTAAATAAACAACTTAATTATTTACAAGATTATTCATTAAGAAAAGAT
ATAATTAGTAATGAAATTGAATATTTTTCAAATAAAAAAAAAGAATTACAATATAATATTAATAGATTAG
CAGAAGCTGTTCAAGCAAAACAAAATGTATTAGTTGCATCAAAAGATGTACCACTTTCAACACTTGTAGA
ATTGCAAATACAAAAATCTTTATTAACAAAACAAATTGAGCAATTAAATAAAACTGAAGTATCTTTAAAC
AAAGCTCAATTAAAAGACAAACTATATGTTCCAAAAACATACGGTAATGAAGGAAAACCAGAACCATACT
ATTTAATAGCTGTAAAAAAAGAAGTTGACAGACTTGCCCAATTTATTCCAAAAATCGAAAGTATGATTGC
TAAAGAGAAGGAAAGAATGGAACAAGGACCTGCAATTACTGGAGAATCTGAAGAAGTACCATCTGGCCCT
AGTGCTGAATCATCAACAGATAGATCAACACAATCTTCAACATCCTCATCCTCATCCTCATCTTCAACCC
CAGCAGCAGCAGAATCCTCCTCAGCCACATTACCAGAAGCACCCGCACCAGCAGAAGCAGCATCCCCATC
AACAGAAGCATCAGAAGAAACAACAATACCCCCTACCACACAAGAAACACAACCATCACAAGCTGCATCA
TCCACAACACCTGCAAAACCAGTTATGACAAAATTATATTATCTTGAAAAATTACAAAAATTTTTAGTAT
TCTCATATTCATGCCATAAATACGTTTTACTACAAAACTCTACCATAAACAAAGATGCTTTAAGCAAATA
TGCTCTTACATCTGAAGAAGATAAAATAAGAACATTAAAAAGATGCAGTGAATTAGATGTATTATTAGCT
ATTCAAAATAATATGCCTACTATGTATTCACTTTATGAAAGTATAGTTGATGGTTTACAAAACATTTATA
CTGAATTATATGAAAAAGAAATGATGTATCATATATATAAATTAAAAGATGAAAACCCATCTATTAAATC
TTTATTGGTAAAAGCTGGCGTCATTGAACCAGAACCAGTAGCAGCACCAACACCAGTAACTCCAGCAGCA
ACAGAACAACAACAACAACAAGCAACACCTGATGTACAATCAGATGCACCAGCACCATCAGATGTCTCGC
AACAACCAGAAACACCAGTAACATCCACGACACCAGAGGTAACAACCTCAACAGAAGCATCATCATCAGC
ACCTGGCGAAGGTACACCATCAGGAGAAGCAGGAGCATCAGGAACAGAAGGAGCAACAGCATCTAACGCA
GCCACACCAGCAGGAACATCAGCATCAGGATCAGCAGCATCTAACGCAAGTACAACCTCAGATGTAACAC
CCCCAGCAGCAGCGGCAGCAGTACCATCAACATCTACACCAGCACCTGCACAACCACCAGCAGCAAATTC
TCAATCAGGAAACCCTGACTCAGGTATTAGATCACGAGCAGAAAGTGAAGAGGATATGCCTGCCGATGAT
TTTGAATTAGACAATTTATACAAATCTTACTTACAACAAATTGATGGAAATAATACTGAATTCATAAATT
TTATAAAATCTAAAAAAGAATTAATAAAAGCATTGACACCTGAAAAAGTTAATCAATTATATCTTGAAAT
CGCTCACTTAAAGGAATTATCAGAACATTATTATGATCGTTATTCTACATATAAATTAAAATTAGAAAGA
TTATATAACAAACATGAACAAATTCAACTAACCAATCGACAAATTAGAGATCTTAGTATATTGAAAGCAC
GATTATTAAAAAGAAAACAAACTCTTAATGGCGTATTTTATATATTAAATGGTTATGTAAATTTCTTTAA
CAAGAGAAGAGAAGCTGAAAAACAATATGTAGATAATGCATTAAAAAATACTGATATGTTATTAAAATAC
TACAAAGCTCGTACTAAATATTTTACTTCTGAAGCTGTTCCTTTAAAAACATTATCTAAAGCATCACTTG
ACAGAGAATCCAATTATTTGAAAATCGAAAAATTCAGAGCATACAGTCGATTAGAATTAAGATTAAAAAA
AAATATTAATTTAGGAAAGGAAAGAATTTCATATGTATCAGGAGGTTTACACCACGTATTTGAAGAATTT
AAAGAACTTATAAAAGATAAAGACTATACCGGAAAAAAAAACCCTGATAATGCCCCTGAAGTTACCAATG
CATTCGAACAATATAAAGAATTGCTTCCAAAGGGAGTAACAGTTTCAACTCCAGCAGTCGCAGTTACAAC
GACACTAGCAGCTGACGCACCAGCAACACCAGAAGGAGCAGTACCAGGAGCAGTACCAGGAGCTGTACCA
GGTGCAGTACCAGGAGCAGTACCAGGTGCAGTACCAGGATCAGGAACCGATACACGGGTAGCTGGAAGCA
GTGTTGATGATAATGAAGACGATGATATATATCAAATTGCAAGTGGTCAATCCGAAGATGCACCAGAAAA
AGATATTCTTTCCGAATTTACAAATGAAAGTTTGTATGTATACACAAAAAGGTTGGGTAGTACATATAAA
TCATTAAAGAAACACATGTTAAGAGAATTTTCAACAATTAAAGAAGACATGACAAATGGATTAAATAATA
AATCACAAAAAAGAAATGATTTCCTTGAAGTATTAAGCCATGAATTAGATTTATTCAAAGATTTAAGTAC
CAACAAATATGTTATTAGAAATCCATATCAATTATTAGATAATGATAAAAAAGACAAACAAATAGTAAAC
TTAAAATATGCTACTAAAGGTATAAATGAAGATATAGAAACAACTACTGACGGAATTAAATTCTTTAACA
AAATGGTTGAATTATACAACACTCAATTAGCTGCAGTAAAGGAACAAATTGCTACCATAGAAGCTGAAAC
TAACGATACCAATAAAGAAGAAAAAAAGAAATATATTCCAATCCTTGAAGATCTTAAAGGATTATATGAA
ACCGTAATAGGTCAAGCAGAAGAATATTCAGAAGAATTACAAAATAGACTTGATAATTATAAAAATGAAA
AAGCTGAATTTGAAATATTAACAAAAAATTTAGAAAAATACATACAAATTGACGAAAAACTTGACGAATT
TGTAGAACATGCAGAAAATAATAAACACATAGCCTCAATAGCTTTAAACAACTTAAATAAATCTGGTTTA
GTAGGAGAAGGTGAATCAAAGAAAATATTAGCAAAAATGCTTAACATGGATGGTATGGATTTATTAGGTG
TAGACCCTAAACATGTATGTGTTGATACAAGAGATATTCCTAAAAATGCTGGATGTTTTAGAGATGATAA
TGGTACTGAAGAATGGAGATGTTTATTAGGTTACAAAAAAGGTGAAGGTAATACATGTGTAGAAAATAAT
AATCCTACTTGTGATATCAACAATGGTGGATGTGATCCAACTGCTAGTTGTCAAAATGCGGAAAGTACGG
AAAATTCCAAAAAAATTATATGTACATGTAAAGAACCAACCCCTAATGCATATTATGAAGGTGTATTCTG
TAGTTCTTCCAGCTTTATGGGATTATCAATTTTATTAATTATCACATTAATTGTATTTAATATATTTTA

Protein Sequence : Show Sequence

>XP_726257.1 merozoite surface protein 1 [Plasmodium yoelii]
MKVIGLLFSFVFFAIKCKSETIEVYNDLIQKLEKLESLSVDGLELFQKSQVIINATQPTETIDPFTNHNF
AQQVQDFVTKFEGLGFTEQTELVNLIKALTPNRYGVKYLIESKEEFNGLMHAINFYYDVLRDKLNDMCAN
NYCEIPEHLKISEEETEMLKKVILGYRKPIENIQDDIEKLEIYIERNKETVAALNALIAEETKKIQPEGN
EDCNDASCDSDKYNKKKPIYQAMYNVIFYKKQLAEIQKVVEVLEKRVSTLKKNDAIKPLWQQIEVLNAAP
VVTAETQIVTGGQSSTEPGSGGSSASGTSSSGQASAGTGVEQANTVASVTVTPSVGQNGEASTNPQTAQV
QPVPTLTLEEKQKKIAGLYAQIKEIAKTIKFNLEGIFVDPIELEYFKKEKKKESCNLSTSSCKKNKASET
IIPLTIRYPNGISYPLPENDVYNKIANNAAETTYGDLTHPDNTPLTGDLATNEQARKDLIKAIKKKIKAE
EKKLETLKTNYDNKLTEFNQQKTPFKEAAKEFYESKFRNKLTSEIFEKFKTKRDEYMTKKTELNTCEYGN
TKELINKLNKQLNYLQDYSLRKDIISNEIEYFSNKKKELQYNINRLAEAVQAKQNVLVASKDVPLSTLVE
LQIQKSLLTKQIEQLNKTEVSLNKAQLKDKLYVPKTYGNEGKPEPYYLIAVKKEVDRLAQFIPKIESMIA
KEKERMEQGPAITGESEEVPSGPSAESSTDRSTQSSTSSSSSSSSTPAAAESSSATLPEAPAPAEAASPS
TEASEETTIPPTTQETQPSQAASSTTPAKPVMTKLYYLEKLQKFLVFSYSCHKYVLLQNSTINKDALSKY
ALTSEEDKIRTLKRCSELDVLLAIQNNMPTMYSLYESIVDGLQNIYTELYEKEMMYHIYKLKDENPSIKS
LLVKAGVIEPEPVAAPTPVTPAATEQQQQQATPDVQSDAPAPSDVSQQPETPVTSTTPEVTTSTEASSSA
PGEGTPSGEAGASGTEGATASNAATPAGTSASGSAASNASTTSDVTPPAAAAAVPSTSTPAPAQPPAANS
QSGNPDSGIRSRAESEEDMPADDFELDNLYKSYLQQIDGNNTEFINFIKSKKELIKALTPEKVNQLYLEI
AHLKELSEHYYDRYSTYKLKLERLYNKHEQIQLTNRQIRDLSILKARLLKRKQTLNGVFYILNGYVNFFN
KRREAEKQYVDNALKNTDMLLKYYKARTKYFTSEAVPLKTLSKASLDRESNYLKIEKFRAYSRLELRLKK
NINLGKERISYVSGGLHHVFEEFKELIKDKDYTGKKNPDNAPEVTNAFEQYKELLPKGVTVSTPAVAVTT
TLAADAPATPEGAVPGAVPGAVPGAVPGAVPGAVPGSGTDTRVAGSSVDDNEDDDIYQIASGQSEDAPEK
DILSEFTNESLYVYTKRLGSTYKSLKKHMLREFSTIKEDMTNGLNNKSQKRNDFLEVLSHELDLFKDLST
NKYVIRNPYQLLDNDKKDKQIVNLKYATKGINEDIETTTDGIKFFNKMVELYNTQLAAVKEQIATIEAET
NDTNKEEKKKYIPILEDLKGLYETVIGQAEEYSEELQNRLDNYKNEKAEFEILTKNLEKYIQIDEKLDEF
VEHAENNKHIASIALNNLNKSGLVGEGESKKILAKMLNMDGMDLLGVDPKHVCVDTRDIPKNAGCFRDDN
GTEEWRCLLGYKKGEGNTCVENNNPTCDINNGGCDPTASCQNAESTENSKKIICTCKEPTPNAYYEGVFC
SSSSFMGLSILLIITLIVFNIF

Molecule Role : Protective antigen
Molecule Role Annotation : Researchers found that the cysteine-rich, carboxyl-terminal region of the MSP-1 protein from the rodent malarial parasite Plasmodium yoelii yoelii can be expressed in a native configuration as a fusion protein in Escherichia coli. This recombinant polypeptide elicits antibodies in mice which recognize the native parasite MSP-1. Most significantly, both inbred and outbred mice immunized with the fusion protein in Ribi adjuvant are partially and in some cases completely protected against challenge infection with an otherwise lethal parasite strain (Daly and Long, 1993).
Related Vaccine(s): P. yoelii DNA vaccine encoding MSP1 , rBCGMSP1-15

29. MSP1 from P.vivax

Gene Name : MSP1 from P.vivax
Sequence Strain (Species/Organism) : Plasmodium vivax
VO ID : VO_0011230
NCBI Nucleotide GI : AF435639.1
NCBI Protein GI : 26985160
3D structure: PDB ID : 2NPR
Other Database IDs : CDD:299863
CDD:284802
CDD:289698
CDD:289699
Taxonomy ID : 5855
Gene Strand (Orientation) : ?
Protein Name : merozoite surface protein 1
Protein pI : 7.06
Protein Weight : 187587.32
Protein Length : 1844
Protein Note : The Bin/Amphiphysin/Rvs (BAR) domain, a dimerization module that binds membranes and detects membrane curvature; cl12013

Protein Sequence : Show Sequence

>AAN86248.1 merozoite surface protein 1 [Plasmodium vivax]
MKALLFLFSFIFFVTKCQCETESYKQLVAKLDKLEALVVDGYELFHKKKLGESDIQVETNASANNNNNNQ
VSVLTSKIRNFVGKFLELQIPGHTDLLHLIRELAFEPNGIKYLVESYEEFNQLMHVINFHYDLLRAKLHD
MCAHDYCKIPEHLKISDKELDMLKKVVLGYRKPLDNIKDDIGKLETFITKNKITIKNISDLIIAENKKRS
GHPTTTTNGAGTQPANGSIAAASSETTQISGSSNSGSTGHGSSNSGSTGHGSSNSGSSGTGSSNSGSSGT
GSTGNGQSPPATADASSTNANYEAKKIIYQAVYNTIFYTNQLQEAQKLIAVLEKRVKVLKEHKDIKVLLE
KIATEKGKFPNNNLNVENPTDEQKTAKSNIADLEKKIEAIAKTVNFDLDGLFTDAEELEYYLREKAKMAG
TLIIPESTKSAGTPGKTVPTLKETYPHGISYALAENSIYELIEKIGSDETFGDLQNPDDGKQPKKGILIN
ETKRKELLEKIMNKIKIEEDKLPDLKKEYEEKYTVYEQKVKEFQPEFNYFYEARLDNTLVGEKFGEFKKK
REEYMKEKKKLESCSYEQNTNLINKLKKQLTYLEDYVLRKDIADDEIKHFSFMEWKLKSEIYDLAQEIRK
NENKLTIENKFDFSGVVELQVQKVLIIKKIEALKNVQNLLKNAKVKDDLYVPKVYKTGEKPEPYYLMVLK
REIDKLKDFIPKIESMIATEKNKPTVAAADIVAKGQSLRGASETGTTGNTVNAQTAVVQQPQHQVVNAVT
VQPGTTGHQAQGGEAETQTNSVQAAQVQQTPAGAGGQVASTQTTSQAPAPTQASPEPAPAAPPSTPAAAV
APAPAMSKLEYLEKLLDFLKSAYACHKHIFVTNSTMDKKLLKEYELNADEKTKINQNKCDELDLLFNVQN
NLPAMYSIYDSMSNELQNLYIELYQKEMVYNIYKNKDTDKKIKAFLETSNNKAAAPAQSAAKPSGQAGTT
PVTTTAPVTTTTVTPSPQTSVVTSTPPTPQAEENQRVGGNSEEKPEADTAQVEKFYEKHLSQIDKYNDYF
KKFLESKKEEIIKMDDTKWNALGKEIEELKKKLQVSLDHYGKYKLKLERFLKKKNKISNSKDQIKKLTSL
KNKLERRQNLLNNPTSVLKNYTAFFNKKRETEKKEVENTLKNTEILLKYYKARAKYYIGEPFPLKTLSEE
SMQKEDNYLNLEKFRVLSRLEGRLGKNIELEKENISYLSSGLLHVLTELKEIINDKKYSGKDHAKNIAEV
KKALQAYQELIPKVTSQESTSVAVTVPGAVVPGVPTAAAAGSGASGAVPPATGGVVPGVVESAEAQTQTQ
AQDYAEDYDKVIALPLFGNNDDDGEEDQVTTGEAESEAPEILVPAGISDYDVVYLKPLAGMYKTIKKQLE
NHVNAFNTNITDMLDSRLKKRNYFLEVLNSDLNPFKYSSSGEYIIKDPYKLLDLEKKKKLIGSYKYIGAS
IDKDLATANDGVAYYNKMGELYKTHLDGVKTEIKKVEDDIKTHDEKLQKLGSEVSQNSEKTQLNAKKAEL
EKYLPFLNSLQKEYESLVSKVNTYTDNLKKVINNCQLEKKEAEITVKKLQDYNKMDEKLEEYKKSEKKNE
VKSSGLLEKLMKSKLIKENESKEILSQLLNVQTQLLTMSSEHTCIDTNVPDNAACYRYLDGTEEWRCLLT
FKEEGGKCVPASNVTCKDNNGGCAPEAECKMTDSNKIVCKCTKEGSEPLFEGVFCSSSSFLSLSFLLLML
LFLLCMEL

Molecule Role : Protective antigen
Molecule Role Annotation : Immunization of BALB/c mice and Aotus monkeys with PvMSP-1 induced IgG antibodies (titer > 10(6)) that cross-reacted with P. vivax parasites. Immunized monkeys displayed partial protection against a challenge with P. vivax blood stages (Valderrama-Aguirre et al., 2005).

30. MSP2

Gene Name : MSP2
NCBI Gene ID : 812660
NCBI Protein GI : CAA70446.1
Other Database IDs : CDD:144541
GOA:O00790
InterPro: IPR001136
UniProtKB/TrEMBL: O00790
Taxonomy ID : 5833
Gene Strand (Orientation) : ?
Protein Name : merozoite surface antigen 2
Protein pI : 5.69
Protein Weight : 27708.58
Protein Length : 333
Protein Note : FC27 variant

Protein Sequence : Show Sequence

>CAA70446.1 merozoite surface antigen 2 [Plasmodium falciparum]
MKVIKTLSIINFFIFVTFNIKNESKYSNTFINNAYNMSIRRSMANKGSNTNSVGAKAPNADTIASGSQRS
TNSASTSTTNNGESQTTTPTAADTIASGSQRSTNSASTSTTNNGESQTTTPTAADTPTATESISPSPPIT
TTESSKFWQCTNKTDGKGEESEKQNELNESTEEGPKAPQEPQTAENENPAAPENKGTGQHGHMHGSRNNH
PQNTSDSQKECTDGNKENCGAATSLLSNFSNIASINKFVVLISATLVLSFAIFI

Molecule Role : Protective antigen
Related Vaccine(s): P. falciparum MSA-2 subunit vaccine

31. msp3

Gene Name : msp3
Sequence Strain (Species/Organism) : Plasmodium falciparum
VO ID : VO_0011220
NCBI Gene ID : 810502
NCBI Protein GI : 113207288
Other Database IDs : CDD:284533
InterPro: IPR010784
UniProtKB/TrEMBL: Q0KGB6
Taxonomy ID : 5833
Gene Strand (Orientation) : ?
Protein Name : merozoite surface protein 3
Protein pI : 4.26
Protein Weight : 33643.59
Protein Length : 383
Protein Note : Merozoite surface protein (SPAM); pfam07133

Protein Sequence : Show Sequence

>CAJ44236.1 merozoite surface protein 3, partial [Plasmodium falciparum]
SKEIVKKYNLNLRNAILNNNSQIENEENVNTTITGNDFSGGEFLWPGYTEELKAKKASEDAEKAANDAEN
ASKEAEEAAKEAVNLKESDKSYTKAKEACTAASKAKKAVETALKAKDDAEKSSKADSISTKTKEYAEKAK
NAYEKAKNAYQKANQAVLKAKEASSYDYILGWEFGGGVPEHKKEENMLSHLYVSSKDKENISKENDDVLD
EKEEEAEETEEEELEEKNEEETESEISEDEEEEEEEEEKEEENDKKKEQEKEQSNENNDQKKDMEAQNLI
SKNQNNNEKNVKEAAESIMKTLAG

Molecule Role : Protective antigen
Molecule Role Annotation : Immunization with a recombinant yeast-expressed Plasmodium falciparum merozoite surface protein 3 (MSP3) protected Aotus nancymai monkeys against a virulent challenge infection (Tsai et al., 2009).
Related Vaccine(s): MSP3-CRM-Vac4All/ Alhydrogel® , P. falciparum MSP3 Protein Subunit Vaccine

32. MSP4

Gene Name : MSP4
Sequence Strain (Species/Organism) : Plasmodium falciparum 3D7
NCBI Gene ID : 812662
NCBI Protein GI : 124801002
Locus Tag : PF3D7_0207000
Genbank Accession : AF295306
Protein Accession : XP_001349580
Taxonomy ID : 36329
Chromosome No : 2
Gene Starting Position : 277493
Gene Ending Position : 278455
Gene Strand (Orientation) : -
Protein pI : 4.29
Protein Weight : 28762
Protein Length : 272

DNA Sequence : Show Sequence

>NC_037280.1:277493-278455 Plasmodium falciparum 3D7 genome assembly, chromosome: 2
CTTAATTTATTAACAATATAACAACAAATATTGTTATAAATGAATTAAAAATTAAATTTAAAGAAGAAGA
TGCTAAGGATAATAATTCAACACATTCAATACCTTCTAATTTATATCCTTCTTTACATTTACATTTTACT
CTTCTATTCCCAACATATTCACATAATTTATCATCTCCACAACCCCCATTATTATGTTTACATAAATCTT
CATCTTCCAAATCGTCCTTATTATAAGTATCATCATCTTCGTCATCGTCATCTTCTTCATGTTCTTCCTC
CTCTTCATGTTCTCCTTCTCCTTCGTTGTGGTCTTCCTCCTCTCCAACATGGCCACCTACAAAGGGCCAA
TGAAGAGTTGAAATTTATACGATGGGGTATGCAATAGGTATAAATATTAATTTAAACGTATAAATAAATA
TGTAAATACATACATATATATATATATATACATAAGAATATATAACATTTTATTATTTACCTGAATTTGA
TGAACTTGGTTGAACTACCTTTTTAGGGATAGCTTCAGTTTTTTTTTTATCATCAACCATTTGGGATTCT
TTTGGAGACTTTTCTAGAACCTTTTCTTGAACCTTGTCTGTTTTTCCATCATCTTTTTTTTCATTAGTTT
TTTTTTCTTCTTTAACATCATCCTTACCATTCGCGCTTTCTTGGGAATTTTCTTTTTTATGACTTTCTTC
TCCTTGTTCAGAAGCTTCTTTTTCATCCTTTTTTTCTGCTGCGTCAGATAAATTGGGGGAAGCACTTGAA
GATTCATTTCCTCCAGGAGTATTACTAGTACTTACTCCGTCCACATTTGGTTTTTCTTCCCCTAGAATTC
TCATATTTAACATTCTTCCATTTTCTGGTACTATATTATAAGAATAACTGATATACAATTTATCAAAGTT
TATGGTACAAATTATAAAAAAATGAACTACTATTAAAAATTTAACTATCCACA

Protein Sequence : Show Sequence

>XP_001349580.1 merozoite surface protein 4 [Plasmodium falciparum 3D7]
MWIVKFLIVVHFFIICTINFDKLYISYSYNIVPENGRMLNMRILGEEKPNVDGVSTSNTPGGNESSSASP
NLSDAAEKKDEKEASEQGEESHKKENSQESANGKDDVKEEKKTNEKKDDGKTDKVQEKVLEKSPKESQMV
DDKKKTEAIPKKVVQPSSSNSGGHVGEEEDHNEGEGEHEEEEEHEEDDDDEDDDTYNKDDLEDEDLCKHN
NGGCGDDKLCEYVGNRRVKCKCKEGYKLEGIECVELLSLASSSLNLIFNSFITIFVVILLIN

Molecule Role : Protective antigen
Related Vaccine(s): P. falciparum MSP4 with AFCo1 Adjuvant

33. MSP4/5

Gene Name : MSP4/5
Sequence Strain (Species/Organism) : Plasmodium yoelii
VO ID : VO_0011236
NCBI Gene ID : 3800676
NCBI Nucleotide GI : AY563017.1
NCBI Protein GI : 49798469
Other Database IDs : CDD:289699
Taxonomy ID : 73239
Gene Strand (Orientation) : ?
Protein Name : merozoite surface protein 4/5
Protein pI : 4.1
Protein Weight : 18420.75
Protein Length : 253
Protein Note : EGF domain; pfam12947

Protein Sequence : Show Sequence

>AAT68597.1 merozoite surface protein 4/5, partial [Plasmodium yoelii yoelii]
VHEISLINTKKYQRNIFCAKRILGDPPSANPSTSLNQNEDNHNSNPDANKGNTNKSDKLNGDNIPNSQSK
SENTNLSESPKTGTASNPPQPEPSVQPGNTNGDSQNSIHSDDEEEDDEDEDDDEEDCSVNNGGCGENLLC
EKMESGIIKCSCPSGYKLNGTSCIELLSAHS

Molecule Role : Protective antigen
Molecule Role Annotation : Oral immunization of mice with Escherichia coli-expressed Plasmodium yoelii merozoite surface protein 4/5 or the C-terminal 19-kDa fragment of merozoite surface protein 1 induced systemic antibody responses and protected mice against lethal malaria infection (Wang et al., 2004).
Related Vaccine(s): P. yoelii MSP1 and MSP4/5 Proteins Subunit Vaccine

34. P36p

Gene Name : P36p
Sequence Strain (Species/Organism) : Plasmodium berghei str. ANKA
NCBI Gene ID : 3424772
NCBI Protein GI : 68068733
Locus Tag : PB000799.01.0
Genbank Accession : CAAI01001447
Protein Accession : XP_676277
Taxonomy ID : 5823
Gene Starting Position : 1477
Gene Ending Position : 2586
Gene Strand (Orientation) : -
Protein pI : 8.96
Protein Weight : 24816.97
Protein Length : 223

DNA Sequence : Show Sequence

>gi|68142845:1477-2586 Plasmodium berghei strain ANKA contig PB_RP1657, whole genome shotgun sequence
CTTACTGCATTAATTTGATATCTTTAAAATTAAATCCTTTTTTCCCTGTCACATTAAAAGTAATATATCC
TTCCCTTTGAGCTGAAATACAATTTTTAACATCATCATCAAAAAATATTATTTCGTTAATATTAACAGAA
AATTCATTTCTTATCTGTAAAGAGAAACGAATAAAATAGGGAATATTTAACCATCTTACCCACACATTTA
TATATATAATTCATATTGTGAAAATATAAAAAAAATGTTACAGTTGATTATTATTTATAAATTTTTTTAG
AGACTATACCCTTTTTAAATGATAAGATTTGTCGTTGGACATTGGCTCTTTTAATCCAAGGGCCATATAT
TTTTTCGGTTCCTTATAATAACTAAAAAAATATGAACATAAAAAAGTAGTTTATATTTTCGCTAGTTTAT
GAGTTGTTTCGCTAGTTTTATGAATTTTGTGTATTTCGTATTACTAGGGGTAATATGCATAAACCCGTTC
TATTTTGGTTTCACAATTGCTATTTTTAATACAATGCTGAATTAATTCTTCTCCTGCGATCAAAGATGGT
GACTTTCCCTTACTATATCGAATCGTCTCGTCATCTATTCAGGCGTTAAATATGAAAATAAAAAAATGGT
CAGGTAAAATAAGAAATGATCAGGCAAAATAAGAAATGGTCAGGTAAAATAAGAAATGAAAACATGCTCA
CGCATTTCACCTGAAAACGTTGCAACAGTTATTTTAATATCATTTTCATAAAGCCTCTTTGATAAAATTT
TAAAAGCATTTGTGACAGATGTTCCTATATCTTCAATATCATTGAGTTTGTCGATATATCCACCTGTACA
ACCATGCAAAGAAAGGAGTTAAACATAAATAAGTGACAAAATATATGTGTGCGTACATATAGCCATTGCA
TATTATGTTACAAGTACCTGAGTGTTTTCCTATTAGGGTCAAGTCAAAATCGAAAACAGCCATCTTTATG
TTTATCTTTTTAAGGAGATCAACAAAGCCATGAATACCTTTAGATATAGAAACAAAATAAACAATTAAAT
GAAATAAAAATATGCACGTATAAAATATTATATATATAGCAGAAAGTCCTATAATTTTCA

Protein Sequence : Show Sequence

>gi|68068733|ref|XP_676277.1| P36-like protein [Plasmodium berghei strain ANKA]
MKIIGLSAIYIIFYTCIFLFHLIVYFVSISKGIHGFVDLLKKINIKMAVFDFDLTLIGKHSGGYIDKLND
IEDIGTSVTNAFKILSKRLYENDIKITVATFSDDETIRYSKGKSPSLIAGEELIQHCIKNSNCETKIERV
YAYYPYYYKEPKKYMALGLKEPMSNDKSYHLKRIRNEFSVNINEIIFFDDDVKNCISAQREGYITFNVTG
KKGFNFKDIKLMQ

Molecule Role : Virmugen
Molecule Role Annotation : Genetically attenuated P36p-deficient Plasmodium berghei sporozoites provide protection against sporozoites challenge in mice (Douradinha et al., 2007).
Related Vaccine(s): P. berghei p36p mutant vaccine

35. p52

Gene Name : p52
Sequence Strain (Species/Organism) : Plasmodium falciparum 3D7
NCBI Gene ID : 9221796
NCBI Protein GI : 124505231
Locus Tag : PF3D7_0404500
Genbank Accession : AL844503
Protein Accession : XP_001351357
Other Database IDs : CDD:429455
Taxonomy ID : 36329
Chromosome No : 4
Gene Starting Position : 240910
Gene Ending Position : 242346
Gene Strand (Orientation) : -
Protein Name : Sporozoite surface protein P36p
Protein pI : 6.99
Protein Weight : 54200.54
Protein Length : 478
Protein Note : Sporozoite surface protein P52

DNA Sequence : Show Sequence

>NC_004318.2:240910-242346 Plasmodium falciparum 3D7 genome assembly, chromosome: 4
ATTATGTTGAATATATATATATTAAAAATATGAATAATATTAAGAAATTATTAAATAATATATATTTAGA
AGAAGATAATCCAAAAAGATTTTGCCAGAATGTTCTTGTTCGTATTCTTGTTCTATCAGAATGTAAATCA
TATTTATTATTATAATGATATGTATCATATTGATCGTGAATATTTGTATTAGTTTTATAACTATTTTTAG
AATTTTTTTCATGGTCATAATTTTTATAATGTTCATTTATATATTTGGAAATATCATCATAATTATAATT
TACATTATTAATTTTATTTTCATAATTATTATATTGATTGTTATTATGATGTTCCTCATTATTTATATAA
TTATCATCTGTATTCATTTTTTTATCATATTCATTTCCTTCATCCTTTTTATATTCTTTTTTTTTCATAT
ATTTATTTTGAAAAATCTGTTCTTCATCATTATTATTATTATTATTATCAAACATTAAGCTGTTAATATT
TTTTGTGTAAATGATCATGGTACCAACGAATTCATCTCGTTTACATGTACAGCTAATTTTAATATTTTCA
GTTAAATTATTCGGTAATATTAAATAGGAAGAAAAAGAATGATTTCTAGATAATTTGACATCTGATGAAG
GGTCAGGGATAACTCTAGAATTAGGTATTACATTTTTAGAATTTAATATAAGATCAGCTCCAAAATAAAC
ATCATGAAAACAATTACTAGGATTTAATTCTAAATTATTATTATAAGAATTATTAATTTCTTTTTTAAAA
CAATTTATGCCCAATACATCATTTGAATAAGCATGAATAATACAACTAGATCGTTCATTCAAACTTAAAC
TATTAGTTAGATCCCTTTTGGAAGGTATATTATCACCAAAATCACAACCCTTAATTTTTTTCCTTGTTTT
TTTTATATTTATTCTCATTATATGTTTTACTTTGTCTTGTTTATCTCCGTAACACAAGCAACTAAAATCA
ATATCCATATTTGAATAAGGAGTACTATATAAACTATATGTGTCATTTAATCTGTTTTCGTTCGTACCAA
ATAAATTCGGATAAATACTATAAGTATCAACCTCGGGGGAATTTTCGGTTGGATTACTTTGATTAACAAA
GGCTCTAGAAGGGCAATTTTCTGGGTGAGTTTTTGCCGTAGTACTAAAAGCATCATTCATATTACACACA
AATAATAACAACTTCCCAAATTCATTATTCAATATGCATTCTTGAGCTTCATCTGAATTTACATTCACTA
CACAGATGTCTACATTACCAATGCTTATAACATCTTGAATCACATTGCTACACACAAAATTGATATTAAT
ATTAAAATTAAAATTAATAATAAATGACAAAAAAATAAAATATACAAACAACTTTTTTCTCTTCATTGTA
AAATGGTAACACATATGAATAAGCACCAATACATACA

Protein Sequence : Show Sequence

>XP_001351357.1 6-cysteine protein P52 [Plasmodium falciparum 3D7]
MYVLVLIHMCYHFTMKRKKLFVYFIFLSFIINFNFNININFVCSNVIQDVISIGNVDICVVNVNSDEAQE
CILNNEFGKLLLFVCNMNDAFSTTAKTHPENCPSRAFVNQSNPTENSPEVDTYSIYPNLFGTNENRLNDT
YSLYSTPYSNMDIDFSCLCYGDKQDKVKHIMRINIKKTRKKIKGCDFGDNIPSKRDLTNSLSLNERSSCI
IHAYSNDVLGINCFKKEINNSYNNNLELNPSNCFHDVYFGADLILNSKNVIPNSRVIPDPSSDVKLSRNH
SFSSYLILPNNLTENIKISCTCKRDEFVGTMIIYTKNINSLMFDNNNNNNDEEQIFQNKYMKKKEYKKDE
GNEYDKKMNTDDNYINNEEHHNNNQYNNYENKINNVNYNYDDISKYINEHYKNYDHEKNSKNSYKTNTNI
HDQYDTYHYNNKYDLHSDRTRIRTRTFWQNLFGLSSSKYILFNNFLILFIFLIYIYST

Molecule Role : Virmugen

36. pfCelTOS

Gene Name : pfCelTOS
NCBI Gene ID : 811213
NCBI Nucleotide GI : AB194052.1
NCBI Protein GI : 62954730
Other Database IDs : CDD:163532
Taxonomy ID : 5833
Gene Strand (Orientation) : ?
Protein Name : PF cell-traversal protein
Protein pI : 4.42
Protein Weight : 18979.58
Protein Length : 248
Protein Note : lysine-2,3-aminomutase; TIGR03820

Protein Sequence : Show Sequence

>BAD97684.1 PF cell-traversal protein [Plasmodium falciparum]
MNALRRLPVICSFLVFLVFSNVLCFRGNNGHNSSSSLYNGSQFIEQLNNSFTSAFLESQSMNKIGDDLAE
TISNELVSVLQKNSPTFLESSFDIKSEVKKHAKSMLKELIKVGLPSFENLVAENVKPPKVDPATYGIIVP
VLTSLFNKVETAVGAKVSDEIWNYNSPDVSESEESLSDDFFD

Molecule Role : Protective antigen
Molecule Role Annotation : Immunization with PfCelTOS resulted in potent humoral and cellular immune responses and most importantly induced sterile protection against a heterologous challenge with P. berghei sporozoites in a proportion of both inbred and outbred mice (Bergmann-Leitner et al., 2010).
Related Vaccine(s): FMP012 with AS01B adjuvant system , P. falciparum pfCelTos protein vaccine

37. Pfen

Gene Name : Pfen
Sequence Strain (Species/Organism) : Plasmodium falciparum 3D7
VO ID : VO_0011223
NCBI Gene ID : 810313
NCBI Protein GI : 124802328
Locus Tag : PF3D7_1015900
Genbank Accession : LN999944
Protein Accession : XP_001347440
Taxonomy ID : 36329
Chromosome No : 10
Gene Starting Position : 637137
Gene Ending Position : 639010
Gene Strand (Orientation) : +
Protein pI : 6.54
Protein Weight : 45501.97
Protein Length : 446

DNA Sequence : Show Sequence

>NC_037281.1:637137-639010 Plasmodium falciparum 3D7 chromosome 10, complete sequence
AATGGCTCATGTAATAACTCGTATTAATGCCCGTGAAATTTTAGGTATAGATATTTTAATGTTATATATT
TTTTCACTTTGTATATAAATACCTTATTATATGTTTTTAAATAAATGTATATTCAAAGAGCTATATTCAT
TTTTAACTTTTTTTATTTTATATTATAAGAATGAATATGATAGATAAATAAAGATATATATATTATATAT
ATATATATATATATATATTTATTTATTTATTTATTTATACATTAATGTATTAATATGTTTATTTTATGAA
TCCACGTGATATTTCTTTATGAATATGTATTCTATAGTTAACATATAATAATACATACGTATATAATAAG
AATAACATAAGAATAAAATTTTTTTTTATTTTTTTTTTTGTAATACAATAATTTTTTTGTGTATCATTTT
ATTTTATTTTATTTTTAATATCTGAACATATATAATTAAATGTGAAAATTATTTACAATATATATATATA
TATATATATATATATATATATGTTACATTATTACTAATATCTGTATTTTATTTATTTTCTGTTGTTATAT
ATTTTTTTTATATATAGATTCTAGAGGAAACCCAACTGTAGAAGTTGACTTAGAGACCAACTTAGGTATT
TTCAGAGCTGCCGTACCATCTGGTGCCTCCACTGGTATTTATGAAGCCTTAGAATTAAGAGATAATGACA
AGAGCAGGTACTTAGGAAAGGGTGTTCAAAAAGCTATCAAGAACATTAATGAAATTATTGCTCCAAAATT
GATTGGAATGAATTGTACTGAACAAAAGAAAATTGACAATTTAATGGTTGAAGAATTAGATGGAAGTAAA
AATGAATGGGGATGGTCAAAAAGTAAATTAGGAGCTAATGCTATTTTAGCTATATCCATGGCTGTATGTA
GAGCTGGTGCAGCTGCTAATAAAGTATCTTTATACAAATATTTGGCACAATTAGCTGGAAAGAAAAGTGA
CCAAATGGTATTACCAGTACCTTGTTTAAACGTTATCAATGGAGGATCCCATGCAGGAAACAAATTATCT
TTCCAAGAATTTATGATAGTGCCAGTTGGTGCTCCATCATTTAAAGAAGCCTTAAGATATGGTGCTGAAG
TATATCATACCTTAAAATCAGAAATTAAAAAGAAATATGGTATTGATGCAACCAATGTAGGTGATGAAGG
TGGATTTGCTCCAAATATATTAAACGCTAATGAAGCTCTTGATTTATTAGTAACTGCCATTAAATCAGCT
GGTTATGAAGGAAAGGTTAAAATTGCTATGGATGTTGCAGCTTCTGAATTTTACAACAGTGAAAACAAAA
CATACGATTTAGATTTCAAAACTCCAAATAATGACAAATCATTAGTTAAGACTGGAGCTCAATTAGTTGA
CTTATACATTGATTTAGTAAAGAAATATCCAATTGTTTCTATTGAAGATCCATTTGATCAAGATGATTGG
GAAAATTATGCTAAATTAACAGCAGCTATTGGAAAGGATGTTCAAATTGTTGGTGATGATTTATTAGTTA
CAAACCCAACCAGAATTACTAAAGCTCTTGAAAAAAATGCTTGCAATGCTTTACTTCTTAAAGTTAACCA
AATCGGTTCTATTACTGAAGCTATTGAAGCTTGCTTATTATCTCAAAAAAATAACTGGGGTGTTATGGTT
TCTCACAGATCTGGTGAAACCGAAGATGTTTTTATTGCTGATTTAGTTGTTGCTTTAAGAACCGGACAAA
TCAAAACAGGAGCACCATGCAGAAGTGAAAGAAACGCCAAATATAACCAATTATTAAGAATTGAAGAATC
TTTAGGAAACAATGCTGTTTTTGCTGGAGAAAAATTTAGATTACAATTAAATTA

Protein Sequence : Show Sequence

>XP_001347440.1 enolase [Plasmodium falciparum 3D7]
MAHVITRINAREILDSRGNPTVEVDLETNLGIFRAAVPSGASTGIYEALELRDNDKSRYLGKGVQKAIKN
INEIIAPKLIGMNCTEQKKIDNLMVEELDGSKNEWGWSKSKLGANAILAISMAVCRAGAAANKVSLYKYL
AQLAGKKSDQMVLPVPCLNVINGGSHAGNKLSFQEFMIVPVGAPSFKEALRYGAEVYHTLKSEIKKKYGI
DATNVGDEGGFAPNILNANEALDLLVTAIKSAGYEGKVKIAMDVAASEFYNSENKTYDLDFKTPNNDKSL
VKTGAQLVDLYIDLVKKYPIVSIEDPFDQDDWENYAKLTAAIGKDVQIVGDDLLVTNPTRITKALEKNAC
NALLLKVNQIGSITEAIEACLLSQKNNWGVMVSHRSGETEDVFIADLVVALRTGQIKTGAPCRSERNAKY
NQLLRIEESLGNNAVFAGEKFRLQLN

Molecule Role : Protective antigen
Molecule Role Annotation : Mice immunized with r-Pfen (recombinant P. falciparum enolase protein) showed protection against a challenge with the 17XL lethal strain of the mouse malarial parasite Plasmodium yoelii (Pal-Bhowmick et al., 2007).
Related Vaccine(s): P. falciparum Pfen Protein Subunit Vaccine

38. PfP0

Gene Name : PfP0
NCBI Gene ID : 810860
NCBI Protein GI : EWC88043.1
Other Database IDs : CDD:240285
CDD:240221
Taxonomy ID : 5843
Gene Strand (Orientation) : ?
Protein Name : 60S acidic ribosomal protein P0
Protein pI : 6.38
Protein Weight : 33348.94
Protein Length : 395
Protein Note : 60S acidic ribosomal protein P0; Provisional

Protein Sequence : Show Sequence

>EWC88043.1 60S acidic ribosomal protein P0 [Plasmodium falciparum NF54]
MAKLSKQQKKQMYIEKLSSLIQQYSKILIVHVDNVGSNQMASVRKSLRGKATILMGKNTRIRTALKKNLQ
AVPQIEKLLPLVKLNMGFVFCKDDLSEIRNIILDNKSPAPARLGVIAPIDVFIPPGPTGMDPSHTSFFQS
LGISTKIVKGQIEIQEHVHLIKQGEKVTASSATLLQKFNMKPFSYGVDVRTVYDDGVIYDAKVLDITDED
ILEKFSKGVSNVAALSRATGVITEASYPHVFVEAFKNIVALIIDSDYTFPLMENIKKMVENPEAFAAVAA
PASAAKADEPKKEEAKKVEEEEEEEEDGFMGFGMFD

Molecule Role : Protective antigen
Related Vaccine(s): PfP0 P-BSA

39. Pfs230

Gene Name : Pfs230
NCBI Gene ID : 812682
Gene Strand (Orientation) : ?
Protein Name : PFB0405w, transmission-blocking target antigen s230 precursor
Protein Note : PlasmoDB:PFB0405w; TGAD:PFB0405w

DNA Sequence : Show Sequence

>PFB0405w |||transmission-blocking target antigen s230 precursor|Plasmodium falciparum|chr 2|TIGR||Manual
ATGAAGAAAA TTATAACGCT GAAGAATCTA TTCCTCATTA TCCTGGTATA CATATTTAGC
GAGAAAAAAG ACCTGCGTTG TAATGTGATA AAGGGAAATA ATATTAAGGA TGATGAAGAT
AAGAGATTCC ACTTATTTTA TTATTCCCAC AACCTTTTTA AGACACCCGA AACAAAAGAA
AAGAAGAATA AAAAGGAGTG CTTTTATAAA AATGGTGGTA TTTATAATTT ATCTAAAGAA
ATAAGGATGA GAAAGGATAC ATCCGTAAAA ATAAAACAAA GAACATGTCC CTTTCATAAA
GAAGGAAGTT CATTTGAAAT GGGTTCAAAG AATATTACAT GTTTTTATCC TATCGTAGGG
AAGAAGGAAA GGAAAACACT GGACACAATT ATTATAAAAA AGAATGTAAC AAATGATCAT
GTTGTTAGTA GTGATATGCA TTCCAATGTA CAAGAAAAAA ATATGATATT AATAAGAAAT
ATAGATAAAG AAAATAAAAA TGATATACAA AATGTTGAGG AAAAAATACA AAGGGATACA
TACGAAAATA AAGATTATGA AAGTGATGAT ACACTTATAG AATGGTTTGA TGATAATACA
AATGAAGAAA ACTTTTTACT AACTTTTTTA AAAAGGTGCT TGATGAAAAT ATTTTCTTCA
CCCAAAAGAA AAAAAACTGT AGTACAAAAA AAACATAAGT CTAATTTTTT TATAAACAGT
TCGTTGAAAT ATATATATAT GTATTTAACC CCCTCGGATA GCTTTAACCT AGTACGTCGA
AACAGAAATT TGGATGAGGA AGACATGTCG CCCAGGGATA ATTTTGTAAT AGATGATGAG
GAAGAAGAGG AGGAGGAAGA AGAAGAGGAA GAGGAAGAAG AGGAAGAAGA AGAAGAAGAG
GAGGAGGAAG AATATGATGA TTATGTTTAT GAAGAAAGTG GGGATGAAAC AGAAGAACAA
TTACAAGAGG AACATCAGGA AGAAGTAGGT GCTGAATCTT CAGAAGAAAG TTTTAATGAT
GAGGATGAAG ATTCTGTAGA AGCACGGGAT GGAGATATGA TAAGAGTTGA CGAATATTAT
GAAGACCAAG ATGGTGATAC TTATGATAGT ACAATAAAAA ATGAAGATGT AGATGAAGAG
GTAGGTGAAG AGGTAGGTGA AGAGGTAGGT GAAGAGGTAG GTGAAGAGGT AGGTGAAGAG
GTAGGTGAAG AGGTAGGTGA AGAGGTAGGT GAAGAGGTAG GTGAAGAAGA AGGTGAAGAG
GTAGGTGAAG GGGTAGGTGA AGAGGTAGGT GAAGAAGAAG GTGAAGAGGT AGGTGAAGAA
GAAGGTGAAT ATGTAGATGA AAAAGAAAGG CAAGGTGAAA TATATCCATT TGGTGATGAA
GAAGAAAAAG ATGAAGGTGG AGAAAGTTTT ACCTATGAAA AGAGCGAGGT TGATAAAACA
GATTTGTTTA AATTTATAGA AGGGGGTGAA GGAGATGATG TATATAAAGT GGATGGTTCC
AAAGTTTTAT TAGATGATGA TACAATTAGT AGAGTATCTA AAAAACATAC TGCACGAGAT
GGTGAATATG GTGAATATGG TGAAGCTGTC GAAGATGGAG AAAATGTTAT AAAAATAATT
AGAAGTGTGT TACAAAGTGG TGCATTACCA AGTGTAGGTG TTGATGAGTT AGATAAAATC
GATTTGTCAT ATGAAACAAC AGAAAGTGGA GATACTGCTG TATCCGAAGA TTCATATGAT
AAATATGCAT CTAATAATAC AAATAAAGAA TACGTTTGTG ATTTTACAGA TCAATTAAAA
CCAACAGAAA GTGGTCCTAA AGTAAAAAAA TGTGAAGTAA AAGTTAATGA GCCATTAATA
AAAGTAAAAA TAATATGTCC ATTAAAAGGT TCTGTAGAAA AATTATATGA TAATATAGAA
TATGTACCTA AAAAAAGCCC ATATGTTGTT TTAACAAAAG AGGAAACTAA ACTAAAGGAA
AAACTTCTCT CGAAACTTAT TTATGGTTTA TTAATATCTC CGACGGTTAA CGAAAAGGAG
AATAATTTTA AAGAAGGTGT TATTGAATTT ACTCTTCCCC CTGTGGTACA CAAGGCAACA
GTGTTTTATT TTATATGTGA TAATTCAAAA ACAGAAGATG ATAACAAAAA AGGAAATAGA
GGGATTGTAG AAGTGTATGT AGAACCATAT GGTAATAAAA TTAATGGATG TGCTTTCTTG
GATGAAGATG AAGAAGAAGA AAAATATGGT AATCAAATTG AAGAAGATGA ACATAATGAG
AAGATAAAAA TGAAAACATT CTTTACCCAG AATATATATA AAAAAAATAA TATATATCCA
TGTTATATGA AATTATATAG CGGAGATATA GGTGGTATTC TATTTCCTAA GAATATAAAA
TCAACAACGT GTTTTGAAGA GATGATACCT TATAATAAAG AAATAAAATG GAATAAAGAA
AATAAAAGTT TAGGTAACTT AGTTAATAAT TCTGTAGTAT ATAATAAAGA GATGAATGCA
AAATATTTTA ATGTTCAGTA TGTTCACATT CCTACAAGTT ATAAAGATAC ATTAAATTTA
TTTTGTAGTA TTATATTAAA AGAAGAGGAA AGTAATTTAA TTTCTACTTC TTATTTAGTA
TATGTAAGTA TTAATGAAGA ATTAAATTTT TCACTTTTCG ATTTTTATGA ATCATTTGTA
CCTATAAAAA AAACCATACA AGTAGCTCAA AAGAATGTAA ATAATAAAGA ACATGATTAT
ACATGTGATT TTACCGATAA ATTAGATAAA ACGGTTCCTT CTACTGCTAA TGGGAAGAAA
TTATTTATAT GTAGAAAGCA TTTAAAAGAA TTTGATACAT TTACCTTAAA ATGTAATGTT
AATAAAACAC AATATCCAAA TATCGAGATA TTTCCTAAAA CATTAAAAGA TAAAAAGGAA
GTATTAAAAT TAGATCTTGA TATACAATAT CAAATGTTTA GTAAATTTTT TAAATTCAAT
ACACAGAATG CAAAGTATTT AAATTTATAT CCATATTATT TAATTTTTCC ATTTAATCAT
ATAGGAAAAA AAGAATTAAA AAATAATCCT ACATATAAAA ATCATAAAGA TGTGAAATAT
TTTGAGCAAT CATCTGTATT ATCTCCCTTA TCTTCCGCAG ACAGTTTAGG GAAATTATTA
AATTTTTTAG ATACTCAAGA GACGGTATGT CTTACGGAAA AGATAAGATA TTTAAATTTA
AGTATCAATG AGTTAGGATC TGATAATAAT ACATTTTCTG TAACATTTCA GGTTCCACCA
TATATAGATA TTAAGGAACC TTTTTATTTT ATGTTTGGTT GTAATAATAA TAAAGGTGAA
GGGAATATCG GAATTGTTGA ATTATTAATA TCTAAGCAAG AAGAAAAGAT TAAAGGATGT
AATTTCCATG AATCTAAATT AGATTATTTC AATGAAAACA TTTCTAGTGA TACACATGAA
TGTACATTGC ATGCATATGA AAATGATATA ATTGGATTTA ATTGTTTAGA AACTACTCAT
CCTAATGAGG TTGAGGTTGA AGTTGAAGAT GCTGAAATAT ATCTTCAACC TGAGAATTGT
TTTAATAATG TATATAAAGG ATTGAATTCT GTTGATATTA CTACTATATT AAAAAATGCA
CAAACATATA ATATAAATAA TAAGAAAACA CCTACCTTTT TAAAAATTCC ACCATATAAT
TTATTAGAAG ATGTCGAAAT TAGTTGCCAA TGTACTATTA AACAAGTTGT TAAAAAAATA
AAAGTTATTA TAACCAAAAA TGATACAGTA TTATTAAAAA GAGAAGTGCA ATCTGAGTCT
ACATTAGATG ATAAAATATA TAAATGTGAA CATGAAAATT TTATTAATCC AAGAGTAAAT
AAAACATTTG ATGAAAATGT AGAATATACA TGTAATATAA AAATAGAGAA TTTCTTTAAT
TATATTCAAA TATTTTGTCC AGCCAAAGAT CTTGGTATTT ATAAAAATAT ACAAATGTAT
TATGATATTG TAAAACCAAC AAGAGTACCA CAATTTAAAA AATTTAATAA TGAAGAATTA
CATAAATTAA TTCCTAATTC AGAAATGTTA CATAAAACAA AAGAAATGTT AATTTTATAT
AATGAAGAAA AAGTGGATCT ATTACATTTT TATGTATTCT TACCAATATA TATAAAAGAC
ATATATGAAT TCAATATAGT ATGTGATAAT TCAAAAACAA TGTGGAAAAA TCAATTAGGA
GGAAAAGTTA TATATCATAT TACTGTTTCA AAAAGAGAGC AGAAAGTAAA AGGTTGTTCA
TTTGATAATG AACATGCACA TATGTTTAGT TATAATAAAA CTAATGTAAA AAATTGTATT
ATAGATGCTA AACCTAAAGA TTTGATAGGT TTCGTTTGTC CCTCTGGTAC CTTAAAATTA
ACAAATTGTT TTAAAGATGC AATAGTACAT ACAAATTTAA CAAATATTAA TGGTATACTT
TATTTAAAAA ATAATTTGGC TAACTTTACA TATAAACATC AATTTAATTA TATGGAAATA
CCAGCTTTAA TGGATAATGA TATATCATTT AAATGTATAT GTGTTGATTT AAAAAAAAAA
AAATATAATG TCAAATCACC ATTAGGACCT AAAGTTTTAC GTGCTCTTTA TAAAAAATTA
AATATAAAAT TTGATAATTA TGTTACTGGC ACTGATCAAA ATAAATATCT TATGACATAT
ATGGATTTAC ATTTATCTCA TAAACGTAAT TATTTAAAGG AATTATTTCA TGATTTAGGT
AAAAAAAAAC CAGCAGATAC AGATGCTAAC CCTGAATCTA TTATCGAATC TTTAAGTATT
AATGAATCTA ATGAATCTGG ACCTTTTCCA ACCGGGGATG TAGATGCAGA ACATTTAATA
TTAGAAGGAT ATGATACATG GGAAAGTTTA TATGATGAAC AATTAGAAGA AGTTATATAT
AATGATATTG AATCTTTAGA ATTAAAAGAT ATTGAACAAT ATGTTTTACA AGTTAATTTA
AAAGCTCCAA AATTAATGAT GTCTGCTCAA ATTCATAATA ATAGACATGT ATGTGATTTC
TCAAAAAATA ATTTAATTGT ACCAGAATCA TTAAAAAAAA AAGAAGAGCT TGGTGGTAAT
CCAGTAAATA TTCATTGTTA TGCATTATTA AAACCTTTAG ATACATTATA TGTAAAATGT
CCTACATCAA AAGATAATTA TGAAGCTGCT AAAGTAAACA TATCTGAAAA CGACAATGAA
TATGAGTTAC AAGTTATATC ATTAATCGAA AAAAGATTTC ATAATTTTGA GACGTTAGAA
TCGAAGAAAC CTGGAAATGG AGATGTAGTA GTACATAATG GTGTTGTAGA TACTGGACCT
GTATTAGATA ACAGTACATT TGAAAAATAT TTTAAAAATA TAAAAATAAA ACCAGATAAA
TTTTTTGAGA AAGTTATAAA TGAATATGAT GATACTGAAG AAGAAAAAGA TTTAGAAAGT
ATATTACCTG GGGCTATTGT TAGTCCTATG AAAGTTTTAA AAAAAAAGGA TCCTTTTACA
TCATATGCTG CTTTTGTTGT TCCACCAATT GTTCCCAAAG ATTTACATTT TAAAGTAGAA
TGTAATAATA CAGAATATAA AGATGAAAAT CAATATATAA GTGGATATAA TGGTATAATA
CATATTGATA TATCAAATAG TAATAGGAAA ATTAATGGAT GTGATTTCTC TACGAACAAT
AGTTCTATTT TAACATCCAG TGTAAAATTA GTAAATGGAG AAACTAAAAA TTGTGAAATA
AATATAAATA ATAATGAAGT ATTTGGTATC ATATGTGATA ATGAAACAAA TTTAGATCCA
GAAAAATGTT TTCATGAAAT ATATAGTAAA GATAATAAAA CTGTAAAAAA ATTTCGTGAA
GTTATACCTA ATATAGATAT ATTCTCATTA CATAATTCTA ATAAGAAAAA AGTTGCATAT
GCTAAAGTAC CTTTAGATTA TATTAATAAA TTATTATTTT CTTGTTCATG TAAAACATCA
CATACTAATA CAATAGGTAC CATGAAAGTT ACTCTAAATA AAGATGAAAA AGAAGAAGAA
GATTTTAAAA CAGCTCAAGG TATTAAACAT AATAATGTAC ATTTATGTAA TTTCTTTGAT
AATCCTGAAT TAACATTTGA TAATAATAAA ATAGTTTTAT GTAAAATCGA TGCAGAACTG
TTCTCAGAAG TAATTATACA ATTACCAATA TTTGGAACAA AGAATGTAGA AGAAGGAGTA
CAAAATGAAG AATATAAAAA ATTTTCATTA AAACCATCAT TAGTTTTTGA TGATAACAAT
AATGATATTA AAGTTATAGG AAAAGAAAAA AATGAAGTAT CTATTAGTTT AGCTTTGAAA
GGGGTTTATG GAAATCGAAT TTTTACTTTT GATAAAAATG GAAAAAAAGG AGAAGGAATT
AGTTTTTTTA TACCTCCAAT AAAACAAGAT ACAGATTTAA AATTTATAAT TAATGAAACA
ATAGATAATT CAAATATTAA ACAAAGAGGA TTAATATATA TTTTTGTTAG GAAAAATGTA
TCAGAAAATT CATTTAAATT ATGTGATTTC ACAACAGGTT CGACTTCATT AATGGAATTA
AATAGTCAAG TAAAAGAAAA AAAGTGCACT GTTAAAATTA AAAAAGGAGA TATTTTTGGA
TTGAAATGTC CTAAAGGTTT TGCTATATTT CCACAAGCAT GTTTTAGTAA TGTTTTATTA
GAATATTATA AAAGTGATTA TGAAGATAGT GAACATATTA ATTATTATAT TCATAAAGAT
AAAAAATATA ATTTAAAACC TAAAGATGTT ATTGAATTAA TGGATGAAAA TTTTAGAGAA
TTACAAAATA TACAACAATA TACAGGAATA TCAAATATTA CAGATGTGTT ACATTTCAAA
AATTTTAATT TAGGTAATCT ACCATTAAAT TTTAAAAATC ATTATTCTAC AGCATATGCT
AAAGTACCAG ATACCTTTAA TTCTATTATT AACTTCTCAT GTAATTGTTA TAATCCAGAA
AAACATGTAT ATGGTACTAT GCAAGTTGAG TCTGATAATC GAAATTTTGA TAATATTAAA
AAAAATGAAA ATGTTATAAA AAATTTCCTT TTACCTAATA TAGAAAAATA TGCACTACTA
TTAGATGATG AAGAAAGACA AAAAAAAATA AAACAACAAC AAGAAGAAGA ACAACAAGAA
CAAATATTAA AAGATCAAGA TGATAGATTA AGCAGACATG ATGATTATAA TAAAAATCAT
ACATATATAC TATATGATTC AAATGAACAT ATATGTGATT ATGAAAAAAA TGAATCACTC
ATATCAACAT TACCTAATGA TACAAAAAAA ATACAAAAAA GTATCTGTAA AATTAATGCA
AAAGCATTAG ATGTTGTTAC AATTAAATGT CCTCATACAA AAAATTTTAC GCCTAAAGAT
TATTTTCCTA ATTCTTCATT AATAACTAAT GATAAAAAAA TTGTGATTAC TTTTGATAAG
AAAAATTTTG TTACTTATAT AGATCCTACA AAAAAAACAT TTTCTTTGAA AGATATATAT
ATACAAAGTT TTTATGGTGT TTCTCTTGAT CATCTTAATC AAATAAAAAA AATACATGAA
GAATGGGATG ATGTACATTT ATTTTATCCT CCTCATAATG TATTACATAA TGTTGTACTT
AATAATCATA TAGTCAACTT ATCATCTGCA TTAGAAGGAG TCTTATTTAT GAAATCAAAA
GTTACTGGAG ATGAAACAGC TACAAAAAAA AACACTACAC TACCAACTGA TGGTGTATCA
AGTATTTTAA TTCCACCATA TGTAAAGGAA GATATAACAT TTCATCTTTT TTGTGGGAAA
TCTACAACAA AAAAACCAAA CAAAAAGAAC ACATCTCTTG CACTTATTCA TATACATATA
TCATCAAACA GAAATATTAT TCATGGATGT GATTTCTTAT ATTTAGAAAA TCAAACAAAT
GATGCTATTA GTAATAATAA TAATAATTCA TATTCTATAT TTACACATAA TAAAAATACA
GAGAATAATC TAATATGTGA TATATCTTTA ATTCCAAAAA CTGTTATAGG AATTAAATGT
CCTAATAAAA AATTAAATCC ACAAACATGT TTTGATGAAG TGTATTATGT TAAACAAGAA
GATGTACCTT CGAAAACTAT AACAGCTGAT AAATATAATA CATTTAGTAA AGACAAAATA
GGAAATATAT TAAAAAATGC AATCTCTATT AATAATCCAG ATGAAAAGGA TAATACATAT
ACTTATTTAA TATTACCAGA AAAATTTGAA GAAGAATTAA TCGATACCAA AAAAGTTTTA
GCTTGTACAT GTGATAATAA ATATATAATA CATATGAAAA TAGAAAAAAG TACAATGGAT
AAAATAAAAA TAGATGAAAA AAAAACAATT GGTAAAGATA TATGTAAATA TGATGTTACT
ACTAAAGTTG CTACTTGTGA AATTATTGAT ACAATTGATT CGTCTGTATT AAAAGAACAT
CATACAGTAC ATTATTCTAT TACATTATCA AGATGGGATA AACTTATTAT TAAATATCCA
ACAAATGAGA AAACACATTT CGAAAATTTT TTTGTTAATC CTTTTAATTT AAAAGATAAA
GTTTTATATA ATTATAATAA ACCAATAAAT ATAGAACATA TCTTACCAGG AGCCATTACA
ACAGATATAT ATGATACCAG AACAAAAATT AAACAATATA TATTAAGAAT TCCACCATAT
GTACATAAAG ATATACATTT CTCATTAGAA TTTAACAATA GCCTAAGTTT AACAAAACAA
AATCAAAATA TTATTTATGG AAATGTAGCC AAAATTTTTA TTCATATAAA TCAAGGATAT
AAAGAAATTC ATGGATGTGA TTTCACAGGA AAATATTCCC ATTTATTTAC ATATTCAAAA
AAACCTTTAC CAAATGATGA TGATATATGT AATGTAACTA TAGGTAATAA TACATTCTCA
GGTTTTGCAT GCTTAAGCCA TTTTGAATTA AAACCAAATA ACTGCTTCTC ATCTGTTTAT
GATTATAATG AAGCCAATAA AGTTAAAAAA TTATTCGATC TATCCACAAA AGTAGAATTA
GACCATATCA AACAAAATAC TTCAGGATAT ACACTATCAT ATATTATTTT TAATAAAGAA
TCCACAAAAC TTAAATTCTC ATGTACATGC TCATCCAACT ATTCAAATTA TACTATACGA
ATCACATTTG ATCCTAATTA TATAATCCCA GAACCTCAAT CAAGAGCCAT CATTAAATAT
GTAGATCTGC AAGATAAAAA TTTTGCAAAA TACTTGAGAA AGCTTTAA

Protein Sequence : Show Sequence

>PFB0405w |||transmission-blocking target antigen s230 precursor|Plasmodium falciparum|chr 2|TIGR||Manual
MKKIITLKNL FLIILVYIFS EKKDLRCNVI KGNNIKDDED KRFHLFYYSH NLFKTPETKE
KKNKKECFYK NGGIYNLSKE IRMRKDTSVK IKQRTCPFHK EGSSFEMGSK NITCFYPIVG
KKERKTLDTI IIKKNVTNDH VVSSDMHSNV QEKNMILIRN IDKENKNDIQ NVEEKIQRDT
YENKDYESDD TLIEWFDDNT NEENFLLTFL KRCLMKIFSS PKRKKTVVQK KHKSNFFINS
SLKYIYMYLT PSDSFNLVRR NRNLDEEDMS PRDNFVIDDE EEEEEEEEEE EEEEEEEEEE
EEEEYDDYVY EESGDETEEQ LQEEHQEEVG AESSEESFND EDEDSVEARD GDMIRVDEYY
EDQDGDTYDS TIKNEDVDEE VGEEVGEEVG EEVGEEVGEE VGEEVGEEVG EEVGEEEGEE
VGEGVGEEVG EEEGEEVGEE EGEYVDEKER QGEIYPFGDE EEKDEGGESF TYEKSEVDKT
DLFKFIEGGE GDDVYKVDGS KVLLDDDTIS RVSKKHTARD GEYGEYGEAV EDGENVIKII
RSVLQSGALP SVGVDELDKI DLSYETTESG DTAVSEDSYD KYASNNTNKE YVCDFTDQLK
PTESGPKVKK CEVKVNEPLI KVKIICPLKG SVEKLYDNIE YVPKKSPYVV LTKEETKLKE
KLLSKLIYGL LISPTVNEKE NNFKEGVIEF TLPPVVHKAT VFYFICDNSK TEDDNKKGNR
GIVEVYVEPY GNKINGCAFL DEDEEEEKYG NQIEEDEHNE KIKMKTFFTQ NIYKKNNIYP
CYMKLYSGDI GGILFPKNIK STTCFEEMIP YNKEIKWNKE NKSLGNLVNN SVVYNKEMNA
KYFNVQYVHI PTSYKDTLNL FCSIILKEEE SNLISTSYLV YVSINEELNF SLFDFYESFV
PIKKTIQVAQ KNVNNKEHDY TCDFTDKLDK TVPSTANGKK LFICRKHLKE FDTFTLKCNV
NKTQYPNIEI FPKTLKDKKE VLKLDLDIQY QMFSKFFKFN TQNAKYLNLY PYYLIFPFNH
IGKKELKNNP TYKNHKDVKY FEQSSVLSPL SSADSLGKLL NFLDTQETVC LTEKIRYLNL
SINELGSDNN TFSVTFQVPP YIDIKEPFYF MFGCNNNKGE GNIGIVELLI SKQEEKIKGC
NFHESKLDYF NENISSDTHE CTLHAYENDI IGFNCLETTH PNEVEVEVED AEIYLQPENC
FNNVYKGLNS VDITTILKNA QTYNINNKKT PTFLKIPPYN LLEDVEISCQ CTIKQVVKKI
KVIITKNDTV LLKREVQSES TLDDKIYKCE HENFINPRVN KTFDENVEYT CNIKIENFFN
YIQIFCPAKD LGIYKNIQMY YDIVKPTRVP QFKKFNNEEL HKLIPNSEML HKTKEMLILY
NEEKVDLLHF YVFLPIYIKD IYEFNIVCDN SKTMWKNQLG GKVIYHITVS KREQKVKGCS
FDNEHAHMFS YNKTNVKNCI IDAKPKDLIG FVCPSGTLKL TNCFKDAIVH TNLTNINGIL
YLKNNLANFT YKHQFNYMEI PALMDNDISF KCICVDLKKK KYNVKSPLGP KVLRALYKKL
NIKFDNYVTG TDQNKYLMTY MDLHLSHKRN YLKELFHDLG KKKPADTDAN PESIIESLSI
NESNESGPFP TGDVDAEHLI LEGYDTWESL YDEQLEEVIY NDIESLELKD IEQYVLQVNL
KAPKLMMSAQ IHNNRHVCDF SKNNLIVPES LKKKEELGGN PVNIHCYALL KPLDTLYVKC
PTSKDNYEAA KVNISENDNE YELQVISLIE KRFHNFETLE SKKPGNGDVV VHNGVVDTGP
VLDNSTFEKY FKNIKIKPDK FFEKVINEYD DTEEEKDLES ILPGAIVSPM KVLKKKDPFT
SYAAFVVPPI VPKDLHFKVE CNNTEYKDEN QYISGYNGII HIDISNSNRK INGCDFSTNN
SSILTSSVKL VNGETKNCEI NINNNEVFGI ICDNETNLDP EKCFHEIYSK DNKTVKKFRE
VIPNIDIFSL HNSNKKKVAY AKVPLDYINK LLFSCSCKTS HTNTIGTMKV TLNKDEKEEE
DFKTAQGIKH NNVHLCNFFD NPELTFDNNK IVLCKIDAEL FSEVIIQLPI FGTKNVEEGV
QNEEYKKFSL KPSLVFDDNN NDIKVIGKEK NEVSISLALK GVYGNRIFTF DKNGKKGEGI
SFFIPPIKQD TDLKFIINET IDNSNIKQRG LIYIFVRKNV SENSFKLCDF TTGSTSLMEL
NSQVKEKKCT VKIKKGDIFG LKCPKGFAIF PQACFSNVLL EYYKSDYEDS EHINYYIHKD
KKYNLKPKDV IELMDENFRE LQNIQQYTGI SNITDVLHFK NFNLGNLPLN FKNHYSTAYA
KVPDTFNSII NFSCNCYNPE KHVYGTMQVE SDNRNFDNIK KNENVIKNFL LPNIEKYALL
LDDEERQKKI KQQQEEEQQE QILKDQDDRL SRHDDYNKNH TYILYDSNEH ICDYEKNESL
ISTLPNDTKK IQKSICKINA KALDVVTIKC PHTKNFTPKD YFPNSSLITN DKKIVITFDK
KNFVTYIDPT KKTFSLKDIY IQSFYGVSLD HLNQIKKIHE EWDDVHLFYP PHNVLHNVVL
NNHIVNLSSA LEGVLFMKSK VTGDETATKK NTTLPTDGVS SILIPPYVKE DITFHLFCGK
STTKKPNKKN TSLALIHIHI SSNRNIIHGC DFLYLENQTN DAISNNNNNS YSIFTHNKNT
ENNLICDISL IPKTVIGIKC PNKKLNPQTC FDEVYYVKQE DVPSKTITAD KYNTFSKDKI
GNILKNAISI NNPDEKDNTY TYLILPEKFE EELIDTKKVL ACTCDNKYII HMKIEKSTMD
KIKIDEKKTI GKDICKYDVT TKVATCEIID TIDSSVLKEH HTVHYSITLS RWDKLIIKYP
TNEKTHFENF FVNPFNLKDK VLYNYNKPIN IEHILPGAIT TDIYDTRTKI KQYILRIPPY
VHKDIHFSLE FNNSLSLTKQ NQNIIYGNVA KIFIHINQGY KEIHGCDFTG KYSHLFTYSK
KPLPNDDDIC NVTIGNNTFS GFACLSHFEL KPNNCFSSVY DYNEANKVKK LFDLSTKVEL
DHIKQNTSGY TLSYIIFNKE STKLKFSCTC SSNYSNYTIR ITFDPNYIIP EPQSRAIIKY
VDLQDKNFAK YLRKL

Molecule Role : Protective antigen
Related Vaccine(s): Pfs230D1-EPA/Matrix-M

40. Pfs25 from P. falciparum 3D7

Gene Name : Pfs25 from P. falciparum 3D7
Sequence Strain (Species/Organism) : Plasmodium falciparum 3D7
NCBI Gene ID : 810460
NCBI Protein GI : 124802764
Locus Tag : PF3D7_1031000
Genbank Accession : LN999944
Protein Accession : XP_001347587
Taxonomy ID : 36329
Chromosome No : 10
Gene Starting Position : 1253416
Gene Ending Position : 1254069
Gene Strand (Orientation) : -
Protein pI : 6.74
Protein Weight : 22455.55
Protein Length : 217

DNA Sequence : Show Sequence

>NC_037281.1:1253416-1254069 Plasmodium falciparum 3D7 genome assembly, chromosome: 10
TTTACATTATAAAAAAGCATACTGAAAATAGTATAAACATAATGCTTAGATTTAAAATATTATATGCTGA
AAAAGCAGTACATATAGAGCTTTCATTATCTATTATAAATCCATCTTTACAATCACATTTATAAATTCCA
TCAACAGCTTTACAGGTTTCATTTTCTTTTAAGCATTTTAATGAGCATTTGGTTTCTCCATCTTTTGAAC
ATTTATTTTGATCTTGTACATTGGGAACTTTGCCTATATTACATGAGCAAACTCCAGTTTTAACAGGATT
GCTTGTATCTAATATACATTTACCGTTACCACAAGTTACATTCTTACATTCATTTGGTATACAAACATTA
TTTACCATATCATATCCAAGATTACATTTACAAGCGTATGAAACGGGATTTCCATCTATTTTAATACATT
TGGAAAAATCTCCACATGGTTTATTTACAGTCTTTTCGTCACATTTCAGAACTTTTTCTTCACATGTTTC
TTCATTTACTAACACCAAATCATTTTCACATTTACATTCCAAATGACCACTCATCTGAATTAAAAATCCT
CTTTTGCATACAGTATCCACGGTAACTTTCGCATTATTATATTTTATGCTAAGTTGAATGAAAAGGAAAA
GAAACAAACTGTAAAGTTTATTCA

Protein Sequence : Show Sequence

>XP_001347587.1 ookinete surface protein P25 [Plasmodium falciparum 3D7]
MNKLYSLFLFLFIQLSIKYNNAKVTVDTVCKRGFLIQMSGHLECKCENDLVLVNEETCEEKVLKCDEKTV
NKPCGDFSKCIKIDGNPVSYACKCNLGYDMVNNVCIPNECKNVTCGNGKCILDTSNPVKTGVCSCNIGKV
PNVQDQNKCSKDGETKCSLKCLKENETCKAVDGIYKCDCKDGFIIDNESSICTAFSAYNILNLSIMFILF
SVCFFIM

Molecule Role : Protective antigen
Related Vaccine(s): ChAd63/MVA Pfs25-IMX313 , NYVAC-Pf7 , Pfs25 VLP-FhCMB , Pfs25-EPA / AS01 , Pfs25-EPA/Alhydrogel , Pfs25-IMX313/Matrix-M , Pfs25/ Montanide ISA 51

41. Pfs48/45

Gene Name : Pfs48/45
NCBI Gene ID : 814212
NCBI Protein GI : AHA91190.1
Other Database IDs : CDD:173430
Taxonomy ID : 5833
Gene Strand (Orientation) : ?
Protein Name : Pfs48/45
Protein pI : 6.23
Protein Weight : 29155.45
Protein Length : 329
Protein Note : sexual stage antigen s45/48; Provisional

Protein Sequence : Show Sequence

>AHA91190.1 Pfs48/45, partial [Plasmodium falciparum]
DNTEKVISSIEGRSAMVHVRVLKYPHNILFTNLTNDLFTYLPKTYNESNFVSNVLEVELNDGELFVLACE
LINKKCFQEGKEKALYKSNKIIYHKNLTIFKAPFYVTSKDVNTECTCKFKNNNYKIVLKPKYEKKVIHGC
NFSSNVSSKHTFTDSLDISLVDDSAHISCNVHLSEPKYNHLVGLNCPGDIIPDCFFQVYQPESEELEPSN
IVYLDSQINIGDIEYYEDAEGDDKIKLFGIVGSIPKTTSFTCICKKDKKSAYMTVTIDSA

Molecule Role : Protective antigen
Related Vaccine(s): Pfs48/45 in Matrix-M

42. PvCelTOS

Gene Name : PvCelTOS
NCBI Gene ID : 5476572
NCBI Protein GI : VUZ98878.1
Other Database IDs : CDD:408441
Taxonomy ID : 5855
Gene Strand (Orientation) : ?
Protein Name : cell traversal protein for ookinetes and sporozoites
Protein pI : 4.57
Protein Weight : 20195.26
Protein Length : 284
Protein Note : Cell-traversal protein for ookinetes and sporozoites of P. vivax

Protein Sequence : Show Sequence

>VUZ98878.1 cell traversal protein for ookinetes and sporozoites [Plasmodium vivax]
MHLFNKPPKGKMNKVNRVSIICAFLALFCFVNVLSLRGKSGSTASSSLEGGSEFSERIGNSLSSFLSESA
SLEVIGNELADNIANEIVSSLQKDSASFLQSGFDVKTQLKATAKKVLLEALKAALEPTEKIVASTIKPPR
VSEDAYFLLGPVVKTLFNKVEDVLHKPIPDTIWEYESKGSLEEEEAEDEFSDELLD

Molecule Role : Protective antigen
Related Vaccine(s): Ad-MVA PvCelTOS , Ad-protein PvCelTOS , Ad-VLPs PvCelTOS

43. PvDBPII

Gene Name : PvDBPII
NCBI Gene ID : 5471431
NCBI Protein GI : ACJ54188.1
Other Database IDs : CDD:432515
CDD:140204
Taxonomy ID : 5855
Gene Strand (Orientation) : ?
Protein Name : duffy binding surface protein region II
Protein pI : 8.76
Protein Weight : 43358.23
Protein Length : 479
Protein Note : Duffy binding protein N terminal; pfam12377

Protein Sequence : Show Sequence

>ACJ54188.1 duffy binding surface protein region II, partial [Plasmodium vivax]
DYETSSNGQPAGTLDNVLEFVTGHEGNSRKNSSNGGNPYDIDHKKTISSAIINHAFLQNTVMKNCNYKRK
RRERDWDCNTKKDVCIPDRRYQLCMKELTNLVNNTDTNFHSDITFRKLYLKRKLIYDAAVEGDLLLKLNN
YRYNKDFCKDIRWSLGDFGDIIMGTDMEGIGYSKVVENNLRSIFGTGKNAQQHRKQWWNETKAQIWRAMM
YSVKKRLKGNFIWICKINVAVNIEPQIYRWIREWGRDYVSELPTEVQKLKEKCDGKINYTDKKVCKVLPP
CQNACKSYDQWITRKKNQWDVLSNKFISVKNAEKVQTAGIVTPYDILKQELDEFNEVAFENEINKRDGAY
IELCVCSVEEAKKNTQEVVTNVDNAAKSQATNSNPISQPVDS

Molecule Role : Protective antigen
Related Vaccine(s): ChAd63 MVA PvDBP , PvDBPII/Matrix-M1 , PvRII/ AS02A , PvRII/ Montanide ISA 720 , PvRII/ Alhydrogel

44. Pvs25

Gene Name : Pvs25
Sequence Strain (Species/Organism) : Plasmodium vivax
NCBI Gene ID : 5471385
NCBI Protein GI : 156081935
Locus Tag : PVX_111175
Genbank Accession : AAKM01002769
Protein Accession : XP_001608460
Taxonomy ID : 5855
Chromosome No : 6
Gene Starting Position : 700541
Gene Ending Position : 701593
Gene Strand (Orientation) : +
Protein pI : 4.62
Protein Weight : 22709.65
Protein Length : 219

DNA Sequence : Show Sequence

>NC_009911.1:700541-701593 Plasmodium vivax chromosome 6, whole genome shotgun sequence
TGCTAAAACGGAAGAAAATAAAATCAAACAAAAAAAATAAAAAATTATATAAAAAACAAATTAACTTTAT
TCATTTCCTTTTTTTAATCCAAAAAAATAAAACTTTTCTTTAGTCCTTTCTCTTCTCCATTCACCTTGTT
CTGACTTTCGTTTCACAGCACTGATTTTTTTGTTCGACCGCTCAATTCGCCACTTGCCATTTTCGATTGT
TTGCTTGTTTGCTTTTTTGCTTATTCGCCCGTTTTTCCGCTTGCCCGTTCGCCCGCTCCACAACGCGCCG
CTGCAAAGGTTGCCCACCACCGACCACAAAAACTTATTCACCACCATCCGAGCGGAAAGGAACGCCGCCC
ACTGTGCTGCCTACCTCCCCGAATAACAACTCCACTTAGCCAAAATGAACTCCTACTACAGCCTCTTCGT
TTTTTTCCTCGTCCAAATTGCGCTAAAGTATAGCAAGGCAGCCGTCACGGTAGACACCATATGCAAAAAT
GGACAGCTGGTTCAAATGAGTAACCACTTTAAGTGTATGTGTAACGAAGGGCTGGTGCACCTTTCCGAAA
ATACATGTGAAGAAAAAAATGAATGCAAGAAAGAAACCCTAGGCAAAGCATGCGGGGAATTTGGCCAGTG
TATAGAAAACCCAGACCCAGCACAGGTAAACATGTACAAATGTGGTTGCATTGAGGGCTACACTTTGAAG
GAAGACACTTGTGTGCTTGATGTATGTCAATACAAAAATTGTGGAGAAAGTGGCGAATGCATTGTTGAGT
ACCTCTCGGAAATCCAAAGTGCAGGTTGCTCATGTGCTATTGGCAAAGTCCCCAATCCAGAAGATGAGAA
AAAATGTACCAAAACGGGAGAAACTGCTTGTCAATTGAAATGTAACACAGATAATGAAGTCTGCAAAAAT
GTTGAAGGAGTTTACAAGTGCCAGTGTATGGAAGGCTTTACGTTCGACAAAGAGAAAAATGTATGCCTTT
CCTATTCTGTATTTAACATCCTAAACTACTCCCTCTTCTTTATCATCCTGCTTGTCCTTTCGTACGTCAT
ATA

Protein Sequence : Show Sequence

>XP_001608460.1 ookinete surface protein Pvs25 [Plasmodium vivax]
MNSYYSLFVFFLVQIALKYSKAAVTVDTICKNGQLVQMSNHFKCMCNEGLVHLSENTCEEKNECKKETLG
KACGEFGQCIENPDPAQVNMYKCGCIEGYTLKEDTCVLDVCQYKNCGESGECIVEYLSEIQSAGCSCAIG
KVPNPEDEKKCTKTGETACQLKCNTDNEVCKNVEGVYKCQCMEGFTFDKEKNVCLSYSVFNILNYSLFFI
ILLVLSYVI

Molecule Role : Protective antigen
Related Vaccine(s): P. vivax PVS25 with Montanide ISA-720 , Pvs25 mRNA–LNP , Pvs25-IMX313/Matrix-M1

45. PY01338

Gene Name : PY01338
NCBI Nucleotide GI : 23485916
NCBI Protein GI : 23485917
Protein Accession : EAA20641.1
Taxonomy ID : 73239
Gene Strand (Orientation) : ?
Protein Name : hypothetical protein

DNA Sequence : Show Sequence

>gi|23485916|gb|AABL01000353.1| Plasmodium yoelii yoelii 17XNL contig MALPY00354, whole genome shotgun sequence
AATATATTAATTAACTATCTTAATATTTTATTATGTAAATCTGTGAAGTTGTGGCAAAAAAAAATGAAAA
ATTATTATAGATTAATTTAAATGCATAAAGAACGTTCCCAGTTATTTTATTTTTTATATGATCCTTTACA
ACAGATAATAAATATAATATTATTTTTGAGTCGATATTATTAGGGTTATTTAGAATACCATTTTTATTTA
TAGTAGAATTGAATATATCTTTGATTTCTATTACAATTGAATTGGGTGCTATATTTTTAATTTTTTTATA
AGAATAGCACTCAACCCATTCTTTGCTTGAAATATCTAATTGAGGATTTATTTTTATGATATCTTCGGCA
TTTCGTGTTTTGTTTTCGATGTTTCGTTTTGATTGTTCATTATTATTTAGTAAATAATTTAAATTTTTAA
TGTAATCACCCTTTTTATTATTTATTTCAATTCCCCTTTCCTTGTTCACATTTGTATTCGAAGAAATGAA
CCAAGGATCAAAGTCATATTCATATTTTACATATATGTTTAAGAATAAGTGATACAATTTATCCTTTGAA
TTTCTCACTGACTCTGTTTTATCCATATTGTCTATTTTTTCGACATTTTGGTCATTACTTTCATCTCTAT
CGTTTTCAATTTTTTTAATATCTTCGTTTTCCCCTCTATAATTAAATTCCTTTTGTGTATCTATAGATTT
CGTCATATAATTTTTGCATGATTGACTATCCAATTTTTCATGGTGAATATTTTCAGGTATGATAATTTCT
CTATTATTCTTCGCTACATTTTTATTGATTTTTTTTTTCTTTTTTCCCCCAATTTGACTTATCTCTTCTT
CTTGACTATCAAAATTGGAGTAATCAAAAAAGTTGTTTTTTTCGATTAAATTATTTAGGTATACAAAATA
TTTGTTAAGAAAAGTTGAAGACACTAGATTAATCGAGTTAAATAAAAAGAAGTTCATATTTTTACATATA
AAACCTAAATACCTAATAATACAACAAATGGCTCGATCTTTTTCTACCTTCCTATTTCCTCTTATAATTA
ACAATAATATGTAAATATATTCAATATAAGAAATTAAATAAATGCTGGTTGAAAAATCATCATGTTTGTT
GTCTCGAGGATTTTGAATATTTTTTAATTTGGTATCTATACATATACTCCGGGAATTTTTTTTTTGTTCT
ATGCAACTATTGTTCTCAATCCTCTCATTTTTTGAATTAGACAAATTATATATTCTTTCAATGCCACTTT
CATTACTAGAAAATTTTTCGGTTCCTATAAATGTGGAAATCGATGATCCAGGAATCTCCGAATATTCATT
TTCTTCATATGTTTTTGTAGCCGATTTTGGCGACTGAATAAACTCAAGTTTGGAAGCTTGGGTATGGTGA
TCATTTTCATTATCTGAATTATACGTTTTTTTGAGTATTTTTTTACTCTTTAATTTTTTTTCCTTTTTTT
TGTTATTAAAATTATATAATTTTAAATCATTTACATTTGTAGATATGTTAATATTGTTTATAAAACTTAT
AAATTCGTTAATATCTTTATTTTCTTCACTATTGTGATTACTATAATAAGAAAAGCTTTTTATATTATTT
TGGGTAAAATAAAAAGGAATGTATGAGCTCGCGATCTCACATATACAGTTATATATATAGTATTTTAAAT
CTACAAAAGACTCATTGTAAAATTTTATTATGTGAATAATAATATAAATATATATATAATATAATTCAAA
TAATTTTTTTTCGTTTTTCTGTTTCCTTAACATGTAAATACTATTATTAAGTGTGTTATTGTCTTCTTTG
GGGTTAATTTGAGAGTTTTCTAGTTTACTATTGTTATAATGGTTTTCGTTTTCTATATTGTCATTATTTT
TTCTATCATCAGTAGATTGATGTGATATATTATCTAAACTTCCTGTGTGCTCTTTTTCGTACATTAAAAT
ATCATTACTATGTTTTATATTAATTTTACTGATGTATTTATTTGTATTAGCTTCCATTTTTTTTAATTTA
TCGTTTTTGAAATAATCATTGCTATTATCACTTTCTTTTTGTGATATAGTTTGATAATTATCAAATTTAA
TAAATCTATTTGTGTTCATATTTTTAAATGAATCTTTATCACTTGTTTCTTTTTTTGTCTCATTATCTGC
ATTAAAATCGGTAAAATATTGTTCTTCATTGTTTATATTTTCTATTTCTTGTTTTCTATTATGAACGATA
CTATTACATATGCTAGTATCATTATTGTCATTCCTATAATTATCTACCTCGATTTGTCTATTTTTACAAA
AAGGTTTGTCAGAAGAATGATTTCGACTACTCTTATTCATATTTTGTAAGCATTGTTGAGATTTATCAGA
AAGAGTATTATTAAGTGTAGAAATATGATTAGACAAATTGTTTTTTTGAAAAAACTCATTAGAATTTGGT
GAAACTAAAAATGGAGAAGCACGACTATTTTCATGAATATCTTGTTCAATTCCGTAGTACTTTTCTTGTT
TATTTTGTGAAGAATTTAAGAAAGAACATTTTTTAAAGTTGCTTATTTGATCTGTTTTCAACATATTCAT
ATAATTATTATTTCTACTTGTTTCATTTTGACGGGATTCATTAGTTTGTATATTAGAACCAGAAGGCGAA
ATGGAATTTTCATCGAGTAGAATGTCAATATTGAAGTTATTTTTTGTTACGTGAAAATTATTTTGGGTAG
AAAGAATATTATTATAATATACATTTGCTGAATTTATATGTAAGAGATTAATTTTTTTTTCATACATTTG
TATAAATTTTTTATTAAAGGTAAATATATATTTAATAATATATTTACTGAGTGTAGTAATTATATTGCAT
TTGATATTATTCACACAAGACGAAATTAAATTAGTTAATTTTTGTATATCTTCAATTTTTAAAACTTTAA
AACCTTCATAACTTAGTTGAGATATACATATAATTGTATTAAAGAATACATGCTTTATTTTATTTCTTTT
ATTAATTGTATCATTATCTATTTTATTTATGCTGTGTATATGCATTAATATATATTTTCTAAACAAATAT
ATCATATCTCTTTCTACTAGTTTCATAAATTTGTTTTTTTGATAATTTTTGTAATTTTCTTGGCATTTCG
AATTGTTAATATGATTGCTATTATTTTCTCTTTGTTTATTCATGTTTCCATCCTTCTCACGCTTGTCAAA
ATGAATACCATTTTTTTTATCGTTACTATTTTTATATATTTGTTGATTTCCCCTTTTAATATTTGTAAAA
TTGTATAAATCACTTTTTGAGGTTTTAAACTCATTTATTGTATCAGAATAATTTTTTCTTTCCTCATCCG
GTTGTGCAGAACCATTCAAATGATTGTTTTTTATTTTTTTCATCTTTTTTCCTTCTTGTGAACTTCCACC
GATATTAGTTTGTTCTGAAACATCACCATTGGTGAATATAGAACTGTTTTTAGCATTGTCTTTTGCTTTT
AAAACTGAAAGTTCGGATTCATCACTATTATTATTATCAATAGTCTTATCTTCGTAGTAGGCGTTTATAA
AAGTAAAAATATCAATCACTATTTTAATAGAAATTATTTTTATATTTATATTTTCTGATTGCAAAAAATA
TTCCAACAAGGTTTTTACATCGTTCCAGCAATGCATGTAACAAAATAAATAATATTTCAACGTCTTTTGA
AAAACTACAAACATATTTTTAAATATTTGCATATCATAAGGTATCAAATTATATTTATCAAATATATTTA
CGTTTTTATTCTTGTTAAATTCTCTTTGTGTATATGATGTGATGTACTTGTTGAAAAGTTCAGTATATGA
ATTGTTGATAGAAGTTTTTTTGTCGTTAAGGTAATTATTTTTGTTACTACAAATTTCCATATTATTGTAA
CTCTCGATATTATTATAGATTGTTTTGTTATCAAAATTAGTATTGTAGTCATTATTTATTATCCCGTTCT
TCTGACCCGTTTCATATTTGATATTTGTGCTAAACTGGTTATTATTTATCACACCACAATTTTTATTGTT
ATAATCGTCCTCATTTTGAAGATTCCCTTTTATAACATGATTAAAAGTGTCATTAATATTGTAAGTTGAA
GTATTACCTATATTGGTTATTAAATTATTCTTTACCTCATCACATGTCTGATAAAATATTTTATATAAAA
ATATAAGCATGAAATATATCAATTGCACAAAGGAGATGTTGTACAAATAATTTTGAGTAGAATTTTCACA
AAATATATTTCGATTGTTTAAGGTTTTATTTATATTTTTTCTGTAAATATTGGTGCATAAAAAATTATAT
ATATCATCATTATATTCACATAACAAAACTGAAAAAATGTTTATAATAACAGTTATTGTACATATATATT
TTGAATTCTTTGAATATTCATTGCAATATAATACTCGTATTAACAGTTCATAAGTTTTTTTGCATAAAAG
CTTTCTATTTATTTTGTTAATATTTTTATACAAATAAGATATTTCGTTTTCATTTTTGTTCATTTGTATA
TTTGGTTTCATTTCGTCATTTTGGAATATTTGAAAAAATTCCTTATTTTTATTTTTTCTTCTTTTTTCTG
TTTTTTTATCAGAATATATCGAAATGATGTCTTCTTCTATATGCTCCCTTTTCATTCCACATTTACTTTC
ATCGCTTTTATGGTCTTTGATATTGCAAATCATTTCGTCATCATTAAAATCGTTAGTATTTTGGACCCTA
TCATAGAAACTTCTGAAATATTGGATATTCCCATTATGTGTTTCGGTATTTTCCATATTTTCAATAATAT
CCAAATTATTGCCTTTATAAACATCATGTTTGCCGATTTTGTGATTATCTATATCGAGATGTTTTGTTTT
TATTTTTTCATCAATTGTATTTTTCATCGATTCTTTATCTTTGAATTTGTTATTAATTTTTTCCTTTTTA
TAATTAAAGTATGTTTCGTTTTCAATATCTTCTTGTAAAAATTGTTTTGTATCTATTTCTACATCTTTAT
ATTTTATTTTATTTATTGTTTTATTCCCATAAGAATTATCATTATGTTCACTATTATACAAGAGACATTT
TAAATTGTTTTTCAATTCTTTTTCATGATAAGAATATGATTTCTCAGCATCTTTTATTATATAAATGTTA
TCTTCTTCATATCTCTCCATTTGTTTGAAACATCCTGAACTATTATTTAGCGTTTTAAATAAGTGTTCTT
CACCTATATAATCATTTTCTACGATTTGAGCTGAGATGTCAGAAGTATTTTGAATGAATGATTGTGTTTT
GCGAATATTTTGAGAATTGTGCTCATCTATGATATAAAGAAAATTGTTTGAAAGAGTGTGAGTTTTTTTT
TTATTTTTTTTTATTTCTCCATTATTTATAGATTGGTCATTATTTAAAAATGTCAACTCATTATCGCTGT
TATTATGTAATATATGTTGTTTTTTATTTTTTAAATTATTTTTATTTTGAACTACTTTTTTCCCACAAAA
TGGTAACATATCTCCATTATTAAAATATATAAGATATTTTAATAAATAGAAAAAAGATATTTTTAAAATT
TTCATTAATAAGTTTTTATATTTTTTTAATAACATAGATTGTGAAACTCGCAAAAAAAATCGATAAATAT
TTAATCTGTCTATTGGTGTATAGAAATTATCTTCATTATTTAATAAGTACGTTTTATTTATTAATTTAAT
TAAGTGAGATAATATTTTTATAATATTATCTTCTATAATTAATTTTTTATAATTTATATTGCCATTTTTG
TAATCTGTTTCTCCATGTGTTTGTATAGAATAATCCAAATTTTTATTCCCTTTGTTCATATTTGTATGTG
TCGATCCTTTTTTATGTATTTTATTTTGTTCATTTTGTTTTTCTAAGGATTTTTGATAATTTGAGTTAAT
TTCTTCAATGATTTTTCCACGGGCATAAATGTCTTTATCATTTTCGTTGTCTAGTTTTTTATTTATGATA
CATTCACTGCTCTCACTATTGTTATCATTTACAATATTTTTTAGACTTGATAAATTTTCTGGACATATAG
CATTCCTCATTTGAGTATCAGTATAATTATATTTAATTTTCGTTTCGTTTTCTGCACATGTATATTTTCT
TAAAGACATATCATCATTCACCATAACCATTAAGGAATATCCTTGTTTATGGGCATATGTATCATTTAAT
GGTTGTTGATAATATTTTCCCCTATTAGTGGGGTCTATATTTTTTTCAATTTTGTTATGATCGTTACTAT
TATTAAAACTACTATGACTGTTATTGTCTTTGGATTGATCCATAGCCATATTAGAGACACTGATTGCGCT
TTCTTCGTCCTTTAAAGCCGATTGACCATTACTAAAGTCATTAGTGTCTGAATTATAAATATTAGTTTTT
AATAAAAACCAATATTTGAGTTGCTTACAATCGAATAAATATTTTAAACATAAAATCGAATTAGTTCTCA
ATTTTTGATTATGATCATTTATAATTATAGTTAAAAATATTGGAATGCGCTCATTCGTATTTTCGTTATA
ATAATAAAGAATTTTATCCCAGTTGTTTATATAAATATGAGAAAACATCTTTATAAGTGTTTGCATAGAG
CATAGTAAATTATTTCGCATATAAATTGACAATTCATCGTCAGTATTTTTTTTTATATGATTTTTTGCAT
CCATAATAGAATTCTTTGAGTGAATAATATGTTCTTTATTTTGTTTGTCTAATATTTCATTGAATATTTC
ATTACTAGTATTGTTGATATATTCAAATGTATTTTCCCTTCGATTTTTTTCAGAACACTGTAATTTATAA
TCGATAAAATCGGAATTTTCATTATAAAATTTATTTATGTTTTCATTTTGTTGTTTCCTTTTAAGTGTTT
GATCATAGTTATTGCCAATATTTATAAAATCCTCTATTTTTTCCATCGAATTTCCTCGTGAATGTTTATT
CGAATAATAGCTTTCATAGTTGTTAGAACTACTGGAATCGCTTCTACTATTGCAATAACTACTGTCACAT
GAGCTGGTTAATATTTTTGTCAGAATTTTTACCTCGTTTTTTTCATTCATTTTTGGAAAATTACTATAGT
ATGTTGTGTTCAGAAAGAAAAATGGTTTGAGTGCTTCATACAAAGGAAACGCAATTAATTCTTCTTTTTT
TTTATTTCTTGATATTACCCTTATTTTCCCATATTCTATAATAATTTCGTTGAAGGTATTTATAAAAGAT
ATCAAAATTTCAAGTGATTCTTTATCCATTGGATGATTTTCATTATTATTAAAATATATTTTAAAATGTT
CGTGTAATTTTTGAAATATATATCTGTATAAATTTAATAAAAAAAACCATGTCTTATCAATAATCGAAAT
TGGATTCATTAAGATTAATTTAACAATACAATGTGCACATACTTTAATTATATGAAAAATATATACCCCG
AAATTTAGTAAAAAAAATAAATTTTTTACAACAATACAAATATTATATAGTATAGATGAGTTACATTTAT
ATATATAATTAGAATTTAGAAATGCTAGAAATGCTTCAAAATATTTATTTAAATTAAAAAAAAATTGTTC
ATAATTATTTTCTCTTAATTTTATTAAATATAAATTAAGTTCAGTTCGTTTCTTTTTTTTTAGCAAATCA
CTATTCACGTATAGATCGTTGAAAATTTTGTTACTGTATTGAAGAATGTTCTGTATTACATAACATATTG
TGGTGCTGCTACTTTCTTTTATAATATTCCTGATGTTAAATTTCCCTTCAATAATGTAGTTATTCAAATT
ATCATTTTTTTCCGTGTCTGCATTTGTTCGAATTATTGCTTCATTGTTACTAATAAATATTTCATTCTTA
ATTTGGTTATTTGTGTTAATATAGTATTCGATTGTTTCATCATCATTTTGAACCAAAAAGTCGTTAATAT
ATATTTTGTTGGGAGTACTAATATTTTCATATTTTGATTTTGTTCTCTCCTGATCTATATGCTTTATTTC
ATTAAAATAAAAATTAGGATGTCTAAAATTATAATCGTTATTTTGTATCTCTGCTGTATTATTTTTTATT
TGTAAAAAACTTTGAGGATTTACTGATTTATTTTTAAAAGTTTTTAAATTATAATCTTTTTGATATGATT
TATATTTTCCATTTTCTGTTATATTTTTAGTATTTGCTTTATCGTTTATATTGACTGATGGAGATAAATT
GTTCCTGTTATATTTTCCATTAACATTGTACTTCTCATTATTGATGTTCGTGTTAAGCATGTCTTTATAT
TTTCTAAAGCAATTTATGTTTTCGTTGTTATACAGTTTGTTTTCTTCCATTTTACCATTAATATAATAAT
ATTCACCAGTTAAATATTCAATATTTTTCTCATCTTCCAATTTTGTAATACCATCAAAAGAACTCATTTT
AGTAGATCCTAATAAATTTTCGTCATCATTTATAATATGTGTTGGCATAAAATTTTTGTTAATATATTGA
TTTGATAGATTAATATTTGTAGTATCATTTATATCTAATAGCTGATTATGTTTAAAGTCATTATAATTTA
TATTATAATATTTTCTTTTATAATCTTTTACATATTCATAATTTATTGAGTTTGATTGTTGGGATAATTT
AAAATTTGCGCTAGTAGTGTTAATACTATTATTCGAGATTAAATCTTTTCCTTGATTGTTTACCTCTTTT
AAATTATTTGAGTATTTATTCAAGCTTTGTTCCCATTTTTTTCTACTATTTTGATCATGGAAAACGGGAT
AATCATTAGAATGAATTTCATCAAATTTTAATTTCATATTTCTGTTGCAATTTGCATATGAATCATTTTT
TGCAGAGCCTATATTTTCCAGTTCATCAAAATATGAAAGCTTCTTATTATAAAGTTCATTTACTTGTCTA
TTATTGTGGTATATTATATCTTTCCCGAGTTTATTAGTATCACTATTTATTATTGGGTTTTCTGAATCCA
TAAAAACATTTTTGATTAGTTTTATATCATTTTTCATAATTTGTCTATTATTATTTTCTGTGCTATTTTC
TGAGCATTTTCTTGAATTTATTACCATGTCTGTATTGTTAATATTTAGATCATTATTATTTTTCTTTGGT
TTTTCATTTTTTAAATCGTATAATTTATTCATATTACTTGACACGCTCATTTTATCAGCATTATATATAT
CGGTGTTATCTAGATATGTTTTTTTTATCCAGTGTTTTTCTTTATTTATATTATTCATACTAGCTATGTT
ATTGATCATGTTACTATTATTATTCCATTTCATATTGGAGGCTATTGTATTGATAATATTCCCCCCATTG
GATGAATTTATGTCGTTGATATATGTTTCCTTTTTTACATTTTTTACATTTTCTTTTGCTTCTTCTTTAT
TTCTATAACTTATCATTAGTTTGTTTATATTATTTGTACAATTTTTTACATGTAAATTGCTTATACCAGT
TTTGGAGTGAAATTTTAGATCGACATTGGTATTTAGTGCGCTATTTATATTATTTGCATTATTATTTTCC
ACATTTTTGTCATATAAACTTGTAGAAGCGTTACCATTGATTATTCTGCTACCCAAATTGGATGTTTCGT
TTATGAATGGTCCATCCTGCGATTTGGGTGGTATGTTTTCTCGAACAATTTTATGAATGTTGGATGTGTT
CATGTTATTTACATCGTTCTGTATATATTCTAGATTTTGATTTATATAATTGTAGCTATTGTATAATTTA
TTATTTTTGTATATAATTGGCTTGGTATAAATTGTATGATTGTTTTTTATAAAATTATTGTTTTTCAATT
TTTGTAGGTTAACTAAACTCGTGTTGTTTCTATTTCCATCAGTAGTAATTACCTCAATCTCATTATTATT
TTGTTTTATGTAATTGCTTATTACATATTGATCATTGTAGTTTTCTTTTCCTCGAGTTATTTTTTGATTT
AAACTAATATCACCTGAATAGCATTGATATGGAAAATCTTTTATATCTTGTTCAAAAATATAATTATTTT
CACTAGATTTATTTGGAAATAAATTTTTATTATTATCTGTGTTATAATAATTGTCTATCTCTGTGTTGAA
ATAATTTCCATTATTTCTAAATTTCTGAACATATTCCTCTTCAATTTTATTATATAAATTTTGTGGTTTA
TAATTTATTTCGTGTAGTTTGTCCTTTATATTTTGTATTTTTTTTTCAGTTTGAATATTTTCTTTTGCAC
TTTTAGTGAAGCTTGAAATGATGAATTTATTGTAGTTATCATTGTCTATGTCATCATTTTCACTGCTGAT
ATTATCCTTATTAGAAATAAAATTACTTTCTTCATTTTTCATGTAATAAATGACATTTTTTTGTTCATTA
TTTACGAATATATTATATCTGGTATTGAAATTTTCTAATTTCATATCAGAATTCCTATTCAAAATGTTTT
GTATATCTTTAGTGGAACTTTTGAATGAATTATAATCCTCATCATTTCGATTTTCGAATGTATAATTTTT
TTGACTGCTATTATTATTACTACTACTGTACTTTTCATAAGAATTATTAGAGAAGTAAAAAGAACCAGGA
TTTTCTTTTTTTTCGTTTTTATTCTCGCATGTATCTAAAAATACCAATTTATTGTTAGAATCCAGGTTAT
TTAAAATTGAATTTCCTAATTTATAAAATTGCTTTTTTTTTTTCTTTCTTTTGTCTTTTTCATTTTGTAA
GTAGAAATATTTTGGTTCAAGATTTTCTATATTCTTTAAATTTTCATCTAATTCATTATTTATTTTTAAT
GTACGATGTAAATCATTTTCATGCTCTGATTGCTTTTCTTGAAATTTATTTTTATTATCATTTAATATAG
CACCATTTTTATCGTTTTTATTTCTTGCCTTTAAATTGTTCAATCCAATATTTAATTCATCTTGTGAAGT
ATTTTGCTTTAATTCGCAAATCTTACTGTGAATATTTTTATTCATTTTTTAAAATCAGTTTTACAACAAG
GACAATATTTCATAAAGATGCCAATTATATTCGTAAGAACAACAACAGGTGTGTTGTCTATCACTTTTAG
AAAATGTATGTATAATTTGTATATATATATATATATATATATATAGTATTATTTTATGGGGAATGAATAG
GAAATTATGCATAAATATATTTGTGAATGATGTAATGACACAAAAATAGGCTAATAAGTATGTATGTATA
TATATATACTCCCCAATTTTAAGGAAATTCCAATCCAGAAGTGATTCTAAAAATGTACAACAATATTTTT
AAATTAAAAATTATGTACTAAAAGAAACCATATAGTATATACATCCACTTGAGTATCTATTTTTTGGTCT
GTGTTTTATAAGTGTATATATTTATCACTTCTTTAAATGCTAATAAAATAAACAACGCCAATTGACAATG
ATACATAAGACAAATAAAAAAGGAAATAATAAAGGTTTGATATGGTTAGAAATAATTATATGTTAAAAAG
AGAAAAAGACAACACGCATTTAGACTCTAATGTACAATGGAATACATATTGTGTAACCATTGAACTTGTT
GTGCAAATAATAATCAAACGTAATTAAATATTTTAAAAACAAATAAAATTGCATTTTTTTTTTAAATTGC
ACGTGCATATTTGTAAGAAAGTGTTTTTTAMCAGCCTGATCATGTTTATGTGCAAAATTATAACAAATTT
ATAAGCGTTAATATTCACTTAATATTATTTTTTGCAATGTTTATTCCACAAATTCGATAAAGAAAGTATG
ATTATTAATAATGAAGCTATATTATTTAAAATTTTATGTTTATAAGAATAACATTTTTTAAATAATGAAT
GAAAGCATATATGCACAAGTCTACATAGATATGAACATATGCATAAACTTGTAATATTTCATATATATAT
AAAGATGTATATATATTATTATATAAAAAGAAAAATTATATATTTGAATATTTTATAAACATGTGAAAAT
GTTAATAATATGAAAAATAAATAATTAAAAATGTTGATAAATAGAACAAATTTTACAACTTGTACATATA
TATATATTATTGACGAAATATTAAATAAATTTGTTTAAGTTTAGGGTATAAATTGATGAAAAATAACTCT
TCTTATAATAAAGCTTAGAAAGAAATGGATAATATAATCCCTTTAAATAATATAGGTATGTATGTATATC
CAAACATGATCAGAAATTATATGCTATATACAAAAGAGTGAAAATAGCTATGAATATTTTTCTACATATA
GTATAGATGATAAAAAAATATATGTTTTACATATATACTCATGAAGGAAAGTAGACTAATAAATAAATAA
ATAGCTATGTATATAAATGTGAATACTTTATAAGTCATAGAAATATATAAAAATTAGTTAATAGGACCAT
GAACATATAAAAATTAATATTAAGTTTATGTGATCAATATTCATTTAAATATAAATGAATTATATCATGG
ATTTAATGTGTTTTATATTTTTTGTGTTATGATTTTATTGTATATGGTGTTATATGCAACTAGATATATA
ATCTGAATATTCATTATATGTGTGTAACAATGTACATGGGAATTTATAAACCCGTAAAATATCCACACAT
GTATGCTTGGATAAGTCTTCGTTGTGAATAACCTATTTGGTTGTTCATAAAAAACGAAAAAAAATATTCT
ACGTCTAATTATGATGACATCATATTAATACCAAATTAAGGAAATCAACACACTATAGATAAATATTATA
TGTAAATATAAAAAAAGGAAAACAGTGAAAATAGGAATATAAATAATGAAAAATATAGAAATATATTACA
GTTTTACAAAAAAGCGAAACAAAGGAATATAAAGCATACTATTATGTATATTCGAAGATTAATGTAATCA
TAAGCAACTTGATAAAAGATTTATTCATTTATTATTATACAACAATTAGGTTATATATTCCATTAATGTT
TTTTCTAGTTTTTTTTGTGTTTATTGTTTTATAATTAATATAAAAAATATATATTTTAAAAATTGTATTT
GTTATTCTTTATTTGATTATTCATTTATTTTTATTTAATTTTTTACTTGGTGTGTTTTTTTATTTTTATT
TACTATCATTTTATTTTTATTTGAATTAAATTATTTTAATTTAAAAGAAGACATAAGAATACACAAGCAT
GCACACATATAACTAATTATAATACACACACCTAGTTTATCCACATTATATCCTTGCAGGATATACAATC
ATGCAACTGATACTATTATCTCAATACATTAAGCCCACATTATAAACTTATGCAAATGATAACAAAATAT
AATAAGCCCACATAATTCATCCACATATATGATACATATTTACAAAAAAATTAATAAAATAAATTAACAT
GCATAATTTCACATTAAAAAGTTAGAATAGAAAAAACATTTATATTTTGTTTTTATTTTATGATTATGTT
TCATGATCTTATGATAATATACCTGGGTAAACATGATGTCGTGGTGTTTATTTTAAGCTTTCTACAATGT
GGTTTTTATAATTGTATTTATCCGCTATATATATAAATATACAAGTATATTTTATAATAATAATCAAACG
ATTTTCATAGAGAATATGCACAAATATCAGCATACACACCAGAGGAAATACAAAAAAAACATATTTGGTT
GCACACACATTAAAGCAAGTTATTGAGAAAACAGTTTTTATAGCATTTAAAAGGCTGATATGATATTAAA
ATAGCAAATATGTGTCACATATATGTATACAAATGATAATAAAATAGAAAAAAAATATATATTTTTTTAT
GCATAAGAATATTTCGATTGATAGCTCAAAATGATAGTATAAAAATAACTTGAATTAAAAAGTTATTCAA
AATATATATGCACATGCATAAACTCGAAGTGTGCATATAAGTAAATTGGCAAATATAATCGTTAAGAATA
ATAATTCTCATAAGATAATTTTGAAGGTCAAATTATAACGTGGAAATATTCGTGTCATCCAACAATAAAT
ATTTGAGCATAATAGAAAATGTGTACTTTATTTATTTTAACATTTTTCCGTGTAATTAAAAATAGAGACC
AATTATTTTGGAATATTCTTGATTTTCCTTTTATGTCGCAATTAATTTATAGTAAAAAAACACCAACAAT
AATAGCTTTCTTATTATTTAAAAATTAAAATATGTTTTGTTGTTACTTATTAAAGTGTTGTTTCCGTTTT
ATAATATATTTTTTGTGTGTGTGTAATTTAAACAAATATAAAAGTTCTTAAAGTTAATAATGTTAAATAT
ATGATAAGATTATAAGTACTTTATAAAATTGTAATGAACGTTATTATATATATACTTATTAGTAGTCCGA
TAAAATACATCTCTAGTACTCTCTATGCATTTCCTGTGTATGAATCGGCTTATTAATTTACATGCAAATA
AATATAAAACAATGTATCCAAATTATATATTTTTATTCAATGGTGAAAAAACTTTCACGTATTAAAATTA
TAGATTGTGGAATTTCCATGTTTATATTTATTCAGGCATTTATTTTGTTATATTTTAGAGTCTTAAATTT
TCTCTTATTAAAGTATAACAATTTGCATTCACAAAGTTATGATTGTTTATTTTTTTAATTTTTAATTTCT
TTATATAAAAATTAAACATTAAAAAATGTTTGTATGTTTGGAATGCCAGGATATGACATGGTTGCATGTA
TACAGAATCGCCATGCTATGGATAGTGTAGCACATTTTTTTCAAATAGACATTTTCATCTTTGAACATAT
AAAAATAATTTTGTTATTATTAAAAGTTTTTTACTCATTTTTCCATTTTTATTAATTTTTTTCATGGTAT
AAAGTTGTTTATTTTTTATTTTGTTATGGAAACACCTTTTTCGTTTTTTTAATGGAAAATTATCCCAGGA
AGGTATATTTATGTTTTCACAAAGTGACACATATTTTTAAAAACTCAACAAATTTATCACATGTTCAAAT
TCGTGCATGTATACAAGTATATATTCATGCTTAAGAAGGTTTTCCGTCATCATTTTATATCTGTTCATAT
AAAAAGAGGAAACTGATGAGGGATTTTGTTCTTTGAAAACTCGATATATTATGAATTGTTTAAAAAAACA
ACTATGCATTGCAAAAATCAATTTGCAAGAAAATTTTTTTTTTCTTTGGATTCACATGTTTATGTATATA
AATTTATAATTCTTATTTATTACTTGTATCAAATTTTACATGCTTAAAATAAAGCATACATTAGATCTTC
TTTTGGGATAATTTGTTTAATCTGCATGTGTTGTAAAGCTTAATAGACACAAAAAATTAAGGGGCTCTCT
TATTTTATTTATGAATATAAAATTGTTTTAAGGATTGCGAAAATTATTCCATTTTATTAAATAATTTATT
TTTTGCTTATCACGCTCCAAATACATAAATATTTTTTCTACATTAAAGCAAAATATTGCATTTGTGGTAA
GGCAAATCATTAAAGACACAACACATATATTGAATTATATATATTTACGATTTATTTTAATAACATTATA
AGACATTCATATATTATGATGTCCACTATTACCGTTTGTTGTTTTTTATTTAAAAATAAATTATGCTACT
AAGCAAGATTTATTTGTTAAAATGTTATAAATATATTACATTTTTTACATTATATTTTTTTGAAAATTAT
AATATCACAGTAAGGAAAAAAATAAAAATTGAAGCACTTTGCAACAATTTGATTCTTGGTGTTCACAAAG
TGTGTTTGTGCTCTTTTTTCGTCGATTTGTTCCCCCCTTCAATGTGATACATATTTTGAGAATAATAGTA
AATGATGAAACGTCGAAGCATTTTCATGTACTACTGTTTCTGTTTCTTATTGAAATATGTAGCCTTTAGC
AATGTGCCAAATCCTAATACGACCATAGGACACTTTGAAATTTGTGAAGTAAATACATCTTCAGGTGATG
CCGAAGAATGTGTTTTAGAAAATGAATTTGGGAAAATGTTTTTATTTATTTGTGATATTGATTACAATGA
GATGTCAAAAAATATAGTGCTTCCGTCAGAATGTGCTAAAAAAACATATATAGACCATGTAAACCCAAAT
GGAACATCGCCAGAAGTTAATACTTATGATATATTTCCAGATTTGATCGCAGCAAATGAATCCCAATTTC
GTGATAAATTTTATTTTTATGGAACCCCATATTCATCTAAAGACATTGATTTTATATGTTTATGTTTTTC
TGAAACAAAACCAGATATAAAACATGTAATGAAAATGAGTTTTAAAAAAATGACAAAAAAAATAAAAGGA
TGTGATTTTGGAGATAATATACCAACGAAAAAAGATTTAACAAATGGGAAAGCATTATATGAAAATTCTA
GTTGTCATATATATGCATATCCAGGAGACGTAATTGGAATAAATTGTTATAAAAAAGACATTAATAATAT
TTATAATAATAATTTAGAATTACAGCCAAATAATTGTTTTCATAATGTTTATTATGAAGATGATATATTA
TTATCGTCAAAAAATTTAATACCTAATTCTAGAGTTATACCAGATCCGAGTAACGATGTTAAATTATCAA
AAATGCATTCATATATGTCTTATATTATACTCCCTGACGAAATAAATGAAAATGTTAAAATTAGTTGTGC
ATGCAAAAGAGATGAATATATCGGCACTATGTTTTTATATGTAAATACATCGAAAAATATTTTAACATCC
CCTGACAACAACGTAGAAGAAATTGCTCCTTTGAATGACCACTATATTTCAATTGGAGACATGTGGGACA
TGGGTTTACATGAAAACCCTGAGCAAATACAAGGCATTATTAGCAATCATGCAAATAAAAAATATTATGA
ACATATGAAAATTTACAAAAGCAATAAAATGGATTCTAGTGATGATGATGAATCGAATGAGACTGAATCG
AGTGAGAATGAATCAAATGAGCGCACACACAATGGTAATAGAGCAAATAAAGATGCTAATAATAGTGAGA
AAATGACTGGTAATAGAAGGAAAAAAAATAATTCTATCAATAATACTAATTACTATAGTAATTATGAGGA
TGACAATGGAATTAATATATCTACCCATGATAAATATTATGAGGACCAACATTTTGGTAACAATGGACCT
TTGAGAAAGAAAAGAACATTTTGGCAAAATATGTTTGGTACCTCTTCTTCTTATTATGAGGTCTTTAACT
ATTTTTCAATCGCATTTATTCTAATTATTCATATGCTCCTCTTATGATGAAGTACAATATGTGCATAGTG
TCAATATATGCCCACTATTCGAATTTTTGGTTGATATAACATACGAAATAAAATTATTTTATTTTTGCCA
CTACAAATTCACAGACTGTATATATGTACACATTTGCATAAACTATTCCCTTTATTTTGTTTATTCGTAT
ATATATATCTATCTGTTTTGCCCTAACACATATTCCTCATGTTATTACGTTTATGCATTGCTACGCTTTT
TTTCAATGCAATTATTCCTAATATATTTTTAATTCATTACACATATATCATATTTTTACATATCATTTTT
GATACATATTGAATATGCATTTAAGTATCAAATATAATGTTTTTTTATAGCTTCATTAAATTATGTAGCC
ACATTTATTCAACCATTTCCATACGACATGTTAATGTGTAAATAGTGTACTAAAATGTGTATATAACCAA
CTAGCAATGATAACTTTTTTTTGCATGAATGACATTATTGAAAACCTTAATATTAAAAATATATATATAT
AAAAGCATTAAATTCAAATAACAATGTAAGACGAGTGTATGAAAATGGAAGCATCATGCGAAAAAGAAAA
CAATTCTGCATAAAAGACAGAAAAAAATAATAAATAAAAATAAGAGAATAAGAGAATAAGAGAAACAGGG
TTAACATGTATATAAAATGCAAACAACTCTCAATTAATGAAACAATAAATGGCTATGCATGTATATACAC
ACATTTTTTTAAATTATAACAAAAAAATCATATATAATAAATAAAATACAATTAAAGATAAAAATATTAA
ATAGCATGTGTAACAATATATATATTAAAAAAAACCTTTATTATTTTAATCATGTGAAAAAAATGTTTTT
TTTGAGGATTAATTTTAAAAACAGTACAAAAATATATAACCTTAAAAACGGTTCACCCTTTTGAGATTCA
TCCTATGTGAAAGTTGCATGCATATCAATAAAGCGGAGAAAAGACCATTTAATAATTTAATCCTTAAATA
ATAAAATATATTTTTTCATGGGAAATATTTAATTTATGATTTTTTTTCAAATATTATTTTAATGTTTTAT
TCCATTAAAGAGAATTAAAAATAAAATGAATTTAAATTTGTTAATGGTATGCATTTTTTTGAAAATATAA
GATATGCATAATATCTCAAAAACACGAAAGATAAAGAATTTAAAATATATCTTTTGAAATGAACACATTG
TTTTATTTAATCCATATTTTGCTATAAATTTTAAAAAACTTTTAGGATTTTTGATATTTTGAAGGAATTA
ATAAATATTGTGTGACATAAAGAGGAGGGACAAGGCAAATATACAATATATGCTTATGTCTTCACATAGC
CAAACACATTTCGATCTGTCTCATATATAGTGATGCTTATGCGTAAACAATTCCCAATTTTTATATTGCA
GAATGTTTTTTAGTTGCAGCAATGAATAATCATAATTGTAACAAATAAATAACGCATACTTCAGTTTTAA
TGTAAGAATTCTTTATTACGATAACTTTTGGTTGTTTCTTTGAATCGACAGTTATCATACTTGAAGCATT
TTTGTTGACTCTACCGTTTGAAGATTTAAAAAAATATATTATATACATATATATATATATATATATATAT
GTGAAAAGTTTATTGACGATTGTACATATATTTATTTTTATTATTTTTGTTGATTATGAAACAATATGAG
TTCGCACGCCATATTATATGTCATATTAACACATATTTTTCCGTAGCGCAAAATATGCTTTTTTCTATTT
TTCTATATTATGCATTTTCGATTTTAATATTTTTATCAATTTTTGTTTTTAAGATGAGAAAAGCATTATA
TTCTTTGTTATTTTATATGTGTATATGCTTATATATATATACCCCTGTTTTTATGGCGAATTTAAAAGAA
ATAGAAGTTGGCAATTATTTCATATGTAACTTAAGAGACTATCCAACGGGAAACTGTAGTGTTGATCATG
ATTATAACAAGACAATAAAATTGCTTTGCCCTATTGTCAATAATAAGAATAACAGTAATAAGACATATGA
TCCTTCATATTGTTTTAAATATGATGGGATAAAAGATGAATTTATTATAAATAATAAACAAGCTTACATA
CACAACACTTTACCTGGAGTTATATTAACAAATAATATAGAAAATGATACTTATAATTTGAGTATATATC
CACCTTTTGTTGTAAAAGAAGATGTAACTATTGTTTGTATATGTGACAGTGAAAAAGGAAACGAAGGAAT
AACGCCGTATCTTAAAATAAACATAAAAAAAACACATGGATTGAATAATGATTTAGAAGGCGATTATATA
AAAGGGTGCGATTATGGAAACAATCAAGGGAAATATAAATTTTTAACAAAACCTGTAAAATATACTAGTA
ATCCCATTTGTGAAATAGATGCATATCCTGGGGATGTTGTTGGAATAAATTGTAATAGTTATACTACTAA
AATGCAAGGCGCCCGTTTAGAACCAGAAGGTTGTTTTGCTATGGTGTATTTTTCTATTTTAACAATGAAA
TTTATAAAAACTAATGTAAATAATATAATGCCTAATGCAAAATATTATCCCGATTTAGCATCTCATCCTG
GCAATCAAAATTCTAAAATATTCTTAACGTCATACTTATTGATACCTAATGAGGTAGATAGGGACATTTT
AATATATTGTAATTGCTCATATAATGGGAACAAAGGATTAGCAATATATCGCATTTTCTCCACAAAAGCA
AGTTAATATGTGATGTATGTAGAAGAGTGAGAAAGTTGAAATATAGAAGACAGCATTTCTCACGCAATTC
ATACAATTTTGTTTATGTTTTAATGACACATAATAGTGCAATTTGTTTAACTTTTTTAAATATGTTATAT
TCTCACTTTTTATATTTTTTATAAGTTAAATCAATATGTGTTCTTATTAGTTTTCAATTAAAGTACTTAA
TTTGTATTTTTCCTTTTTTTTAACATTATTTTTAAATTAAAAGTAAAAATCATAATAAAAAATTATAAAT
CGGTTGATTATTAAAAATAAGTATGCATGTGTATATTTATAAACAATAGCATCTTAATATATGCCACAAA
TTTTAGTTTGTTACTGTTTTCTATTTGAAGTGTTTGTTTAATTATTCCATATGATCGAATATTAATTGTA
CTATAACAAATATGCGTATGAACAAATAAATTTGTATTCATTTATAGAATAATAGTAATGTAGACATTAT
ATTTTTTTATTAGTATGAAATAAAACAATTAACAAAATTTACGTTATTAAATGAGTTGATTGTAATAAAA
TTATAAGCATAAATTAATTATGTAACTCGTTTTTGGTCAAATTATATTTTAAAACTTTAAAAAATTCAAT
GTAAAGGTTATTCGTTCTGATCTTATGTTTATTTTTTTTTTACAATTCTTTCTAGAGAAATTTCAAGGTG
AGCTTTTCACAGTAGCATCTTTTTGTTTTTATTTTATAATACTTTATTAATTTACTAATTTACTGTGATG
TCTCTTTTGCAATAATAATAAATGTCCAATACCATAATTTATCATATCAGATTATAGCATATCGTAATGG
TAATTCATAATATACATATAATGTTATGAAAGGAATAATCATTTTTCATTATGCTTATCTTTTCTCACGA
CATACCCAAATATAATGATAGCAAAAAATATAGTATCAAAAACGTTCGAACTAAAAAAAATTGGTTTCCA
ATTTTAAGTAGTAAATTGAAGAATATTTGAATTGATTGKATATATATATATTTTTTTTTTTATTTCCATT
TGTATTGTAATTTTTCCGGTGTGCCTCAATACTTAATGAGTAAAAAAAGAGATAACGTAAAATATAACAA
AAAGGATATAACAGACGAAAATAAAATAAATTAATATAATAATTATTTTGTATATAATTTATATAAAATA
AATTGGATTTAATTAAAATTACGAAATTATTTGCATTATGATTACCGCTTTATGAAAAAGAATAAAATTA
TATATTATGCATAACTGGAATAATATATAAGCGGGATAATTAAAAGATTAAACGCGAATACCCGAAAAAT
CAATAAAAACATATAAGTAGTAATTAGGTAAAATAAATAATAATATAATGAAAAATAAAAAGTTTAAACA
AGTAAAATAAAATTTTCATACCATCATAGGTTTGTTTATAAATCACAAATTTGATAAGCATGAGAATATA
ATAACTAATYTAAATATATCAAATATAAACAAACCACTGTATAATAGATAAAAAATTATATGCTTGTATT
GCATATATTTTTACACACCACTATATTTTTGTTTGCATAAGGATACAATCTTGAAAATTTTATGGACATT
TTTTCAAAGAGGGTTAACTGTTTCTATTAATAGCTTAATAGCACTATGGTATGACAAACTTCAAAAGAGG
AGAAAAATTTGTGGAAAAACCACAAACACAAAAACAAATAGAATAATAAAAAGGAATAATGAGAAAAAAA
ATAGAGCATATACAATTATTACATATATGTATATGTATGGAGATAAATAACAAAAGTTGAATACATTATA
TAAGCTTCATTATCTCTCTCTACAATGCTAAAGTATATTTATGCAATACATATATTTTTCTAATTTTATT
TATATTTTTAATTTAGAATTTAGATTTAAATGAATCCAAGGATGGAAATTCTAAAATTCAGAATTCCAAG
AAGTGAGTGAAAAAAATATAATGTATATATATGCAGTAAATAACCAATCTATATATTTTTTTCAATGAAC
ATATACTTATATATATTATTAGTATTAAGCTCAATGAAATTGATATATTTTTATGGTTAATACATGAATA
TATGACCTATATATGAGTATATTATAAAGGCAATATTTGTTTGCAAATATATGGACGTCTTTGCAACGCG
TAGCGTGTAAAGCGATATAACGCTGTTCTAAAGCATCACCTATATATAAACTAATTTTTTGTTCGCATTT
AGGCATAATATAGAAAAAAATGACACCCATACCAAAGTAAATACAAAAAGAAACAAAATATGAAAAGGAA
GTAGAAAACTGCTACTAAATTTGGAAGATAAAACTAAAGTTCATATTTATATACAAATTATTTATTATAT
ATTTTTGAACCTCTTAACAGATTGCAAAGATAGGCTCTAGTTCTCCAGATATCCACAACGAGGACATTCA
AGGTAAATGTTAATTGAACAAGGGAATTAATAATAACAACTGATGAGTTTGTATTACATATATACGTCAT
ACATGTTTACATTATTTATACTAACCACATTTACTTCTTTAAAAAATTAGGCGAGAACCAATCATTATAT
GAATATCATCCTTCTAACAACGAAGGAGAAAGTGTGAATTGCGAAAAAGATGTCTTAGATTACTCAAATA
ATAATAATAGCGAAATCGAAAGAGATAAAAATATTGTAACTGAAAATGACAATGATTATAAATATAGAGG
CAAAAAAAAGAAAAAAAAAAAATTTAAAGAACATAAGGATGTAACTAATCATGAAAATGAAAAACCCCAA
AAAATTAAAGAAAAGCATATTGATAAGGAGAAAAAAAATAAGATGGTTAAAAAATTTCAACAAAATAGTA
CAAAAAATGTAGTGATAAATCCGACCGAAATGAGGAATCCTGATGGCTCTAATATTGAGAGAAAAACTGA
TAAAGAGGAGGAAGACAATGATGATAAGAATAGGGATAATAAAGATGTCATTGAGAACAGCGACGAGGAA
GGAGATGAAGAAGAATATGAGGAAGAAGATGAAGAAGAAGATGAAGAAGAAGATGAAGAAGATGAAGAAG
AAGATGAAGAAGAAGATGAAGAAGATGAAGAAGAAGATGAAGAAGAAGATGAAGAAGAAGATGAAGAAGA
AGATGAAGAAGAAGAAGAAGAAGATGATGATGAAGATAATGAAAAGGAAGAGAAGGAAGATGTAAAAGGA
GGAGAAACTAAACCTGAAGGAGAGGAAGAAGAAAAAGAGAAAGAACACGATGATGCAAAAGATGAAGAAG
AAGATAAAGAACATAGTGATACGCAAAATGAAGAAGAAGATAAAGAACATAGTGATGCGAAAAATGAAGA
AGAAAATAAAGAACATAGTGATACGCAAAATGAAGAAGAAGATAAAGAACATAGTGATACAAAGGATGAA
GACGATAAAGAAAAAATTAAATTAAACAATAAGGATAATTCATCTGAACACGATGACGATGAAAAAACCA
GCAATAATGAAAAAAGCGTCATGGATGACGAAGATGAACAAAGCAGTGTAGCTAAAACACAAAAAAGGTA
CAAAAAATTATATATGTGTATATTGAAATTAAAACCTATAGCTGCTAAGATGAGGGATAATTACCCGTGA
TCTATATCATTATAATTGTTTTCATGTAATATGATTTTTCCTTTTTAATATAATTATTTTTAACTTTTTT
TATAATAGCAATGAAAGCGTATGTAGCGAATATGGGGATATCAAAAAAAATGACCGACTTTTTGCATCAT
TGGTAATTTAATAGAATATATTTGTGTTTTTTGTTACATTATTATTTTTTTCTCTCATTAATTTATATAC
ATGCATTAATAATGCCAAATATGTAATCGTAAAGTAATATGAGAATGTTAAAAAAATATCTTCTTTGTCA
AATATATTTTCATCATATATCCATATACTTTATTTTGATCTTCAGAATGATGCCAATTCACCCAATAAAC
TATTTAGTGAATATGTAGGAACCTTAAATATATTTGGGGGAAAGGGTTTAGATTTGGAAAAATTACAGAA
AAATATAGATAAAAAAAAAAAAGTAATAGATGAAAAAAAGGATATTAAAATGATCGAAGAAGAAAACCCA
TTTGGTATTATCATAAAACAAACATTTGCACAAGTTTTGCATATAATATTAATAGACATGAAAACATGCA
TTTGTAATACTTATCCACTTTGTTATGCCCCTTTTTTTGCTCAATTTTCATTATTTTTCTTCATATTTAT
TACAATTTTTTAGAAAATGAAGAGATAATATACTCAGAAAATACTATAAAGATAAACAAATTTGTTAAGA
AAGACGGGAAACAAGAATGGTCAGGTTATTTACCAGTAAAAATTCAAATAATGAAAAATAAAGAAAATGA
TAAATATCGAATTTTATGTTTTCAAAAAGGAAGTGGAAGATTATTTTTGAATACGGACATTTTCGAGGGA
TTTAAAATTATTCCCTCAAAAAAATTGTCCGCCTTATTTAATGGGCGTGATATAGGTATGTGATAGAAGT
TGCGAAGGTGTATTAGGACAAACTCGCAAATTTCGTTACTGCATATATGTATATATATGTATGGGTGAAA
CAAAGCCACATTTATTCTTTTTCTTTTTATTGTTAATACAGGTAATGAAAAAATAATAACCCAATATATA
GTAACGTTTATTAGTAGTTCTTCAAGAGATGATTTTATCAGTAAAATTAATGACATTTCCAAAAAAAAAT
AATAATTAATTAAAAATATGAAAACTTATACGAAGTGTAAACTTAAAAAAATGTTTCTCAAACACTCTTA
AAATATTTATTTTTAATTTTTGTTGTAAAGCTATTCCATTTTATATATTTTAATCCCTCTTTCACATTTT
TGATTTAGTTTTTCCAGTCACATAAAAAATTAAGGAAAATTTATGAAAATATTTAGCTTTCTTTTATTGT
AATATATATAATATATTGGTGTTGTTTAAACGTTTTTTTTATTTCAATTTTTGGATTTACTGGTATCTAT
GTGTACTACTTGTATATATATATAACCACACGTATATTGTATAAATAAAGAAATATGCATTATACATGTA
CATAGGATCGAAAATATAATACTATACATGTATTAATTTATTCGTTCTTACAGATACATATTTCGAAAAA
AAATATTTTTCATAAGTATACATTTCGATTTCGCTTTTTTTTTATTCATCCATTTTATATTTATCCTTTT
TTTTGATATATTTAAAAACCTTTTGAAATTTTTAATAAAAAAATAATCATATTTACATTTTTTCATATTT
CCAAGAATTGGCTTATAACGATTAATTGATTTATACACGTATCGAAATAAATGTATATGTGCTAGAGATG
TGATAAATTACACATAAACATACAATAATAAAATTGAATAATTGTAGCAATATAACATGTAAGGTATTAG
ATTTATTGCATATAGGTCGATTTATCTCGTTTAAAATATTAATAACTTAATAAAAAGGCAAAATAATAAT
ATATACATACAAGCTATGCTTATATAGTTGTTTATACATTTTTTTAATCCGCAAAAATTGAATGAAAAAA
GAAGTGGACGAGCGTTATGGTATATATAATTGATAAATTGTATTTTCCATACTGATATATTTTTTTTAAA
TGTGCTAATTATATACTATTTTGTGGACTAAAAGTGAAGAATTGCTTCATTTTTTGAAATATTGATTCAT
TATTGTGGGAAGACGAAAATGCCATAAATACGGCTATTTAAGGTTCTCCGACTGTTTATTGTAATAATAA
TAATTGATATTGCTGATGTTATTACTTTTTTTAACGGACCTATGAATAGAGTTGTGAGAAACTTTACCAA
TAATAGAGGGATAAACAACCCAAGCAAAATAAAAACATTTAACAATTTTTGCGATGAAAATTTGAAAAAG
TCGTTTGAAAAAATAGCTATAGGTAACCCTCCAAGAGCCAAAATAAATAGTATTCTAAATTTTTTAATAA
AATCAAAAATATTAAATACAGAATGGTCCAAATCACAAATTATTGATGAGATATATAAAAGGAGAGTAGA
TAAACAGCTTTCTTTTCATTTAAATGTATTATATGGTTTAGGGTCGAAAGGAATCCATTTAAATAAAAAA
GGAATAATATCGCCAGTATTATTTTATCCTTTAATGGATTACGACCAGTTTAAGACTATTGTACAGGTAT
GATTGACTCACATAAAAGTATGTGAATCAATACAAATTAAATGATATTAATATGAGCATATATGTACACC
TACATCCATATTTCCACTTTTTTGCAATAGGTAATGCAAGTTGCAGATAAAGAAAGAAAACTTGGGATAT
ATGAAGAAAAACAATTTTTTGAAAATTTATTTAAGAAATAAACTGTGCATAAAAAATTTACTTAAAGCAA
ATTACAAATTAAGTTATAAAATTTAAAGAGCTCATAGAAATCAATTGAATATATCCCTATTAATATATAT
ATCTTATGATATGTGTGCGTTTTTTTGTATTATTTTATATAAGACCTTAAATTAATATGCACCGCTTTAT
GGGCATTCGTATGCAACAATTCTAATATTATACTATTTATTATTTTTCTGAGTAAATAACATAAAATTTA
TTTTATGAGAAAAACGAGGAAATATATATTTGTGCAAATATCTACGGATGTTTAGTGTTGCAAGTGGTCG
ATTATGCGTAGGAATATAGGATTATTCTTATGTGTTAATATTTGGAAATGGATAATATATGTAAGTTTTA
ATACATATTAAACATGAAAGAGAAAAAAAGACTAAAGAGTGTAGTATAGTAAAGAAAAGCTATATATTAT
AAAGGGAGAATGATACCTACCAGTGGTAGTTTTTTTTTGCATGCACTCATTTGTTTATTTTGTATGATTA
TTGTAATAATTTTTATACGACCTATTTTTTTGTTTCATTCTTTACGTTTTTTTTAAATGAAAATTTGCGA
GTTTACTATTTTTTTAAGTATTAAATTATTTTGCTCATATAAATAAAACCAGTTTATCAAAAATATATCA
TTCTTACTAAAACAAGCTATAAAAAAGAGCAAAAAAATAGTTGTAACTACTTCAACATAAGCAATAGGGA
TGTTTGCAGTTTACATTTTGAGGTAATTATTTTTATTTATTTAATAATAGCACTTGGCTTTTTAATGCAA
TTTTGTGAAATCAATATGTTTTATCCATATTATTCTATGCTTTCCCTTTTGTTTCCTATTTTTTTGTGTT
ATGAAAAAATCTAAATCTTAAAAATGCACCTGTTGCATATTATATATATGTGTGTATATATTTATATATT
GTTCAATGATTTTATAATTAATGTATAAAATAAGATACTTAAAAACAAGCCTGAATTAATATATGCACAT
TCATGTAATAAACATACTAGTAAATACAATGTTTTATCGAAACTAAAATGTAAATGCTCAAAATAAATAA
TATGTACATGTTTTTTTTTATATGATATTTTAGATATTTCTATAAGCTTATAACCACAAATAAATAATAT
CCCATGATAAAATTACGATGCATATATATGCATACATGAGTATTCATTTGTTTTATTTATTTATTTTGTA
ATTTCGATGTGCTCCTATTATTGCATAGCAATACATTGGTTGTTCTATTTATGAAGCTATAAATAGTATT
ATATATATTAAAGTAGATAAGTGTATATAAACGAATTTTTATTATGTATAAAAATATTAATTAACGTAAT
AAGCATTGTCTTATATAAAAATTAGAAGAATCAATAGAATGCTCGAATTTAGTAATATTATATAAGCAAC
GTATTAAAGTAGTGAACAGTATATATAATATGCAAGAGACAGGCAGTATATAATTTGAAGAAAATAGTTA
AGACATGGCACTAATGGTATGTTGCATCTGTATATTTTTGTTAATGTCATTATTTTTTTATTTATTTTGA
AAATTTTCAGAATATTATATATACACCTTATACTATGCATATTTTTCCGTTTATTTTAAACTCCTATTTT
CCGTACTTTCTCTAAAATATGTATATATCATAAGGTATTTTTTTCTTAAAACTTTTTTTTTCATATAATA
TATTTTTTTGGATTTGATTAGATACATATTTTATCAATATTTGAATATTTTTTTTTTGTCCAAATAATAT
ATGTACATATTTTGAAGCGATGATGCGCATATAAAAAGATATGTAAAGGAACTGGCACTATATGCATGTA
TAAATTTGTGAATGTGCAACTGTGTCAAAAAAAAATAAGTTACATATATATGTTATTTTTATAAAAAGTT
TAAAAATAAAATATAGACTACATGAATGAAGGTGGAATTAAAGATAAACCATTGGAAGAGGATAATTTGG
GTCTTTTTACAGAGAACATTTCAAATATATCAAAGTTGAGGAGCAAAAATTTAAATAATGTTAAGGATGA
TCTAAAAAAAGAGGAAGAACCCAAAGAAAAAAAATATAATGGTCATAGTAAGAAAAATGCACAAGAAAAT
AGTTTTGACATGATTTGTTCTAACAGTAACCAAGAAAAAAGAAGATATGATCAATATAATTTATCACCAT
ATTTTGAAAAGGAAAAATATAATAATTCGAATGTAGCAATAAGCCCATATCAATACAGTAAAAACCATTA
CAAATGTAACCCACTGGATTATATAGAAAATAAAATAATAATGAACAAAGAAGCAAATAAAAAATTGAAT
AATACAAGAAAAAAGAAACTATTAAAAAGCCAAAAAAGTATAATTAAATTGTATAATAGAGAGATAAAAA
CAGGAGGAGTGGTACGTTGTAAAAATACCAAAAATGACGATATATCTCTAAATTTTGAGGAAGAAAAAAA
CGAAGTAAAATGTAGAGAAACTAATAGTAATGATAATAAGAATCAATTGAACATAGATGTAGTAGAGAAC
CTGTACAATTACAATGATTTTTTGTGTTTTTCCCCAAATGAAATTCATAAACATAATATTAATGGTACCA
ATGATAATAAAATAGATACAGTTATAATAGAAGTGTGTAATAATATAAAGAAAATAGAGAAAAATAGTAA
GATAATAAGTGAAAAAGAAAGAAGTGATAAATTGCGTAAAAAAGAGGGTTATGAAGGTATAAGAAATAAT
GACATGACTAATACAGAGAAAGAAATAAAAAAAATACGAACGAACTTTAGTGATGATATTTCTACTAATA
TCGGGGATAAAAAGGCTGATAGAAACAAATATCTTCCAAATATTAATAAAAAGATCAGTTGTCTAGAAAA
TATAATAGTCAATGAAAATGATGAAAAATGGGATGCGGAAAAAATGCTCTATAATAATATACCGCAAAAA
ATGGAGCATAATAATAGTGATATTGTGTGTGACATAGACAAATTACGTATTGATAATCTCAATATGCCAA
AGGTAATATTACCAATAAACAGTCAAGAAAATAAAAAGGAAGCGAATAATATATCCGAAAGGACAAGCAT
AATATATAGAGATAAGCATAATGTGTGTTTAAATAGTAAACCAAATAGTAAAATACATTTAATTAAAATT
TTGGAAAAAAAAACGTATAAAGACAGTATGATTGTAAATCCAATTGATAAAGATAATTCTTCTGATAAAA
CAAATGTGCTTCATATTAGATATAAAAACAACCCCCTATCAAAATGTTGTGATAAAATTAATAAACTAAA
TCATGAGAATAATGAAAATGTGAAAAAACATAATAATATATCAAAAACTGATCTGGGTGTTAGCAGATTA
AAAGTTGGAAATAGGACGGCATCCTCTTTAAATGAAGATGAAGAAAATGTTAATGAATATGGTAAAGGAA
TAACTACGGGGTGCAATGTTATGAATAAAAATTCAAAAGAAGACGAAAACAACATACATATAAAAACGGA
TAATAAGGAAAAAAAAATTAGCGACCAAAATTTTGTCGATGTATGCACTACAAATGCTAGTAAATGTGAT
GAAGATATGAAAGATACTAAAAATAGTGATTCCATAAATAACGAAGATAATAATATCAGGGAAGAGTATG
GATTAAAAAAAAAAAAAACATGCTTCTTAAATAAATCAACTACTACAGTTATTTGTGAAAAAAATAATGA
CCGTGTTAATGGAAAAGAGAATAACACGTATGATAATAATGCATTATTTGGGATTGAATATGAAAGTGAA
TTCAAAGGGGATAAACGAAAAATTTCATACAAAAATTCATTGGATATTTTGTTAAAAAGTGAAAAAGAAA
ATAAATTAGGAGACGAAGAAAAATATGTTTTTAAGAATGAGTCTCCTTTTATAAATGACATAAAAAGTGA
AGAAACAAATTATCCCTCAAAATGTGTGTCAACAGATGATGTAAATAATGTTTTATTAAATTATGGAAAA
AAAAGTGTTAATAATTATGAAAACCTGAACAATTGTAATGATAATTATACTAATAATTATAAGAAGAAAA
AAAAAAGAACAGGTATACCATTGAACGAAAGAAAATATTATAGAGTACTTGCTAAGCAAATGGTGAAGAT
ACAAGGATTGACATTTGATCATAATCAAATTAGATGGATAGCATATTGGAAAAATGAAAACAATAAACAG
ATTCAGAAACATTTCCCTGTGTGCAAATATGGGTTTTATAAAGCTAGACAGCTAGCTCTAGAGTTTCGGA
ACTCGAAAATCAATGAAAAGGATGGAAATGGAAAATATGAAAAGAATAAAACTATTAATAAGAGTGAAAC
AACATATGCAAAAGTGAACAAGAAAGAACTCTCCAAAAAAGGATCAGAGAAAATAGAATCAATTCTGAAT
AGCGGCAAAAATGTTACGGGTGCGCATCTAAGTTATCATCCCAAGAGCATTTCATCTATGCATGGGAATG
TGAAAAGCAAGAGTAAAATTTCAGGAAATAAAGAAAGTGTAATTTTTGACAAAGGGAATAATACTAACAA
TGTATGCAATATAAATAGTGATAAAATTATACCTTCGAAAGAAAAAAAATATGATTTCAATTTTATAGAA
AACGAAAACATATGGGTAAATGATGCTTCAAATTTTTTAAGAAACAATGAGCATCTTAATGTTATGTTTA
CAAATAATGGGAAAATAAATGATATAAACTTCTCAAATATATTAAACAGTGAAGTGAACACAAAACTTTA
TGATAACAATGGATTGATAGGTAATGTTTCATCATTTCACAAACAAAAACAGTTTTCAAATTGTGTGCCT
ATTTCTTCAGACATAACTAATTCGGGGAATTTTCTTTGTCAATCAAAAAATGAAAATGTTAAAGATGATG
AAATTAATATGCAACAAAATTCAATGAGCAATGAACGAATTTACCCTAATGAGGTTCCCAACAATTGTAC
AAATAGTTATTGTGAAAATAATAATGGAAATTGTGTACATAATTATAAAAATTGCAATTCAAATGTGAAT
ATTTGTATGAATATTTTTGAAAATACATATTATAACAAATCGAATAATCCTACTTTTTCTGGTGACCAAA
ATAAAACGCCATTATGGGCGTATCCTCAAAATGATGTTGGATATGCTAATTACTTCAATAAATTTGAAGG
AAGCAATAGTATTAATAATAGAGATATGAATGGTATATATACTGAAAATAAACAAATTGAGGATAAAAAA
TTTACAGAATGGAATCCACAGCCACAATATTTAACTTGCAATAGCAAAGAGAGAAATGATTATTATTATA
AAAATGATAATTGTACAAATTTTAGTGAAAAGGTATTTATGCACACTAATAATATAGGAACAGAGAAAGA
AGGAGTGAATTATACTGCTGAAGTGGAACGATTAGATTGGAAGTCTCGTTATAATTTTAACTATGTTAAT
AATATTATAAAAAATGATAATGATCTTGATGGGGTTAGCATTGAAAGGAAAAACGAAGAGCATAACAATG
ATACAAAAAGTATACGTAATTATGATTTGACTAATAATGGGAATAATATTTTATCGAATAAAAATTGCAT
TTATCAATATCGAACTAGTGACAATTATTTTTACGATGTGAACAATAATATTGGAAACCTTTCAAATGGT
GATGTAATAAGTAGAGAAAAATATGAAAAAAATAACGAATTTGACAATACTTCAAGCATGACGAAAAATA
CCATTTTACATAAAGATGTAGAAAATAGTGTAGCTTTGAATAAGAAAATAGAAATTGTGGATAGTAATAA
ATGTAATCGTGTTATCAGAAAAAATCGAAAGGGAGATTCGAAAAGCATTTTAAATGTATTTCATGATAAT
AGAAACAATAATTTGTATTATAATAAAGGTATGTTACACACGTACTTAAGTAATAGAAACGAAAACAATG
AGCAAGATTTTACTACAAAATTTGGCGATAATAATAATTATTTTGAAAATGTAAGTAATATTGTAAATGT
AAAGAAAAAAAACATTTTAAAAAATAATAGAATAAATAAAATTTCAAACTCTGAAAAAATATTGGAAAAG
GAGAAAAATGAAATAAGTTGTAACTATAGTAGCAAAGCTGAAACACAGAATAGCACAGTTGGGAGGTCGA
GAAAAAAGAAAAAAAAGGGAGAAGACAACACCGGAGTGGAGAAAGAAAGAAACAAAAACGATTTTAATAT
GACAGAGAAGATTAATAATATATTGGAAGGGGACCTAAATAATAAAAACCCTGAAAAGGAAGCAATTTTA
GATGAGATAATTTTAAAAAATAGGAACAAAGTAAAATCCTCGATAGAAAAAATAAACACAATTCATGAAT
TTTACAAAAATGGTGAAAGAAAAGAAGATGGAGAAATCATAGGGACAAAGGGGAAAGAGAAAAAACAAAA
ATCAAAAAATAGAAAAAAAGGAAGCACAGAAAAAATGTTTATTAGTGTAGATGAAAATCTTTCAAATCAT
TCTACCTCTATGCTACAATTAATTGATATAAACAATCGATGTGTAAATAAAAATTATTCAGATAATACAT
GTTTAAATTTTTTTAAAAAGGAAACGAACAATTTAATTTACCATACTAGAATTGGTGAAATAAATGATAC
TAGTTATATTGAAAATAAATTTCCAAATTCAATTATAGACAATAAAAAAAGTGATAAAAAATATAGACCA
TCAAAAAATGAGATAAAAAATCGAAACAATGAATTATATATAGATGAAAATAATATAAAATATGTTTACA
ATGACGATATAGCAGGGGAACCAAAAATTGGAGACGGTATAAACGAGCCATATATAATAAGAAAAAGTGA
AGAAAATAATTTCACCATCGAAATTGATAATATGTGTTATTCTGGAATAAATGCAAATAAGAAGAGAAAA
AAAAAAAAAAAAAAAGGAAATGAATCAAGTGAGGTAAAAAATGATGATAACATTGACAAGGTAAGTGATG
GTAACTTCAAAAACTGTATTGAAAACGTACGAGAAGGTGAACTAGATAAATTGGAAATATGCAGTTATAA
ACTGAAAGGTGATAATGAGAAAAATACCAAAGAAGATAGTAACATAAATTATTACCATAAAATTATGAAG
ATACCCAAAATGAAAGGAGTACATTTTGATATTAGACAAAAAAGATGGTGTGCATATGGATACAAAAAAA
AAGAATGTTTTTCTGTTTATAGATATGGGTTTTTAGCAGCAAGAGAATTAGCTGTTAGAAGCAGATTAAA
TGTTCAAAAAAGGAGAAACAATTTAAGATTAAAAAAGAAAACCAAAAATGATATTAGTGTATCAAAACGA
AAAAGCATTCCATTGAGAAATATTCCATCTAAGAAAAAAAGGAAAAAAGAGTGTGAAGCTATTAGTAATG
ACAACATTGATAATACTAATATAAATGGAAATATACTTTTAAAAGTGAACGGAATAGTTAGTGAAAATAA
TAATGGGATATATGAATTACCCAATTTAAATAAGAACAACGAACTAATTAGGAATATATATTCCGTATCT
GACTCACACCTATACGATATTCAAAATGACAATTTGATTTCTCAAAATGATTATTACAAAGGTTTGGGAA
CTGATATATCTGGTGAAAATGCTTTTAGAAATTATCAAGCAGGGCATATTTCGATATCAAGTTATCCAAA
AAATGATATTCTGGGGGATCGAAATTTTAAAAATGTTACAAGTGATACAAATGATATGGGTAATGCATAT
TTGTTATGTGGTTATAACAATAATGTTGTAATTGGTAATAATAAACAAAACTATAATAGACTCGATAATG
CACCCTATTTAGTTGGAATAAAAATGACATACGATGGAAAAATAATGGAGAATCAAAACAGTCTCACCAA
TGAATATAATTTAAGCACAATAGACATGGACACTCAAATTAATAATAGAACTGAATTAAATAAAATAAAT
GATGAAAATTATTTTGGAAATTATAATATTAATAGTATAAATATAAAACAAGATATTGGTACAAACAATT
ATATAAATAGTTATTCTAATAATGAAATGTGTCTAATGGATGGAGATAGAAATAATAATTATGTTTTTAT
GAAAAATATTGAAAAAAATTTTAATATAAATAGCTATGACAATGAATATCCCTATTTTAATCACACCAAT
TTAAATATTCCTAATGAAGAAATATTAAGCAAATGTTTTATAGGCCCCAATACACGAATACCATTAGCAG
ACAAATATATAAATCATGGAGAAAGGATTGAAAAATATTTTTATAAAAAAATAAACCCATATGAAATGGA
AAATAATGAGGAGGCATACTATCATGATACATTTAATAATGTAGATACGATAAAAAAATTAAACAGGACA
GAAAATTACACCAATAAATTTTTTGAAACAATTTTAAATAATGTTGAAAATAATAATACGGTTATTATGA
GTGAAAATACATTTAGAAATGACGTCATTAATAGAATCAGCAGTGATAACAACATTGATAATTTGAACAA
CTTTTGTCATGAAAACACGATGAAAGAAAACAATTTGAATGTTGAAAAAGAAAACGCAACGCTTTTGAAT
TGGAATTGTAATACATATTCAAAATATGATGAAGGAATGTGGAATAATGGAATAGGAAAGGGTGATAATA
TGGGTAAGCATAAAATCGAATATAGCAATAACTATAATACTTACAATGGAAATATATCTATGCCTTTTTT
AGAATATTATAATAATAATTTTAATGACGTAGAATGTACTAAATCGTGCAATATTGTGGGTAAAGAATAT
TTCAATAATGGAGAACATGGTATGGATAACAAATCAGAAATTAGCAATATAAATTATTGTATAGAAAATA
AAAATTTAAATATACCAAAAATACATTTATCGCAAAATCAATATGAAATAACGAATTTTAATAAAAATAT
GTGGATAAGTGAACATCCCAAAGAAAACGAAAATAATCAGTTCGCTATAAATGAGACAAATATTGATCAA
AATTATTTAAATTCTAATAAAATTAATAAAAAGGACAACAACAATAATTATTATATTTTCCCTGATTGTA
ACATTTATAATGGTGCAAATATCGAATGTCAAAATACAAGTCTATCTAATGATATGTTGACAATAAATCC
AACTGATGTTTCTGAGTTTATGGAGCAGACAAACACTCAAAATGGGCAAAGTTTTTACCAAGATAATGTT
AACAATGTAGGAAATTTTAGTAATATCTATTGTAATGGCACCAACAGAAGACGTAATCTTTGTGGGCAAA
ATAAGAGTGGAATTTCTGTTGAAATGGTACAAATAAATTCACCATTTCTTCAGAAAACTTATGGGGAAAC
TGAAGCAAAATTAATACGTTTTGGTGATAATAATACAAATACCCCTAAAATAAATAATGAAAAATTATCG
TACAGCATAAATGATAATCAAATAAATAAAAATTTCATTAMCGATATAGAAGCAAATAATAACAATTCCG
AATATAAACATAATAACATTTATCCTGATGTATGGAGAAACTCATTTGATTTACATTATACAGATAGAAA
AAATATACCAATTAAAATCTCATTTTTATCACCAAACACACATAAAGTTGACAAAGTTGTTACTATTGAT
GAAAATCTAGAAAATTTTAATAATGAAAATAATTTTTTATTTAATTCTAAAAATAATACTAATAAGGATT
GCATTGGAAATAGAGATGACGAAAAAGAAACAACAGATTTGAGAATTACACCCAATAAATATAGTGATAT
AAATAACTGCCAAAATAATAATATATATATGAGCAGAAATGATATATATACGGATTATCATAATTCCAAT
AATTTTAACGAGGAAAACACAAATTTAAAGATCGAAAATGAAGATTTGTGCAACAATGGAAGTAAAATGA
ATGAATTCACAAATAGCTTTAGTCATGAAAGCAAACAAATTTATCATGAGCAAAATAAAATAGACGATTT
GTGGTGGGAAAATAACAATGAAAGAGTTTTTACAGATCCAACAATTTATCCTAATAATAGCATCCCATAT
ACATGTGAACCAAATAATTTATTGAATTCATATGTTAATAATATAAGTGATAAGCATAAATTTTTATTTA
ATTATAACAACTATGAAGATATAAATTTAAAAAAAAACGAACTGAATATAGGTACTGAATTTTCCCGTAG
TATTTCTGCAAATGAAATAGAAATAAATATGCAATCATATGATGAAAGAAAAAACGAAAAAAAAAAAAAT
ATATGTCATTATATTAACAACGATATGGAATATATAAGGCAAGGGTAGTAGTTTAATAAATGGAAAGGAA
GTAAATCCTGATCAAAGCTTTATGAATATGTGTAATTTGCCTAAACGATTACAAAATGATAMCCGTGAAA
AGAGAAATAMCAAACTAAATAAATATAATGMCAATAATAATAGCAATAGAAATGATGAAATGAATCAAAA
CATAAATGGTGACCTAATTAGAGATTTAAATAATCTTAATAATGTAAAAATAAATAATGATTTAATTCCA
AGGTATAATCCATACATTTTTTTCAACAATCATACAAGTAGAAATTATAATGATGGTAATAATTTTTATA
ATGAACAAAACTGTGTTACGAAAATCAAAAACGAAAATAAGGAATACTATGATATGGAAGGATATAAAGG
TGTATTCAATTCCGTGGAAGGGCATTTTGGCGATGTAGAACAAGTGCCAAAAAGAGGGAACGGATTTAAC
AGAAATGAAAATATGTTCGAAAGAAGTATAGATACAATAAGTGATGAGAGTACACATCTCAATATAGGAG
GACGACGGAACTTCATGCAGAGCAACGTTGTAAATCATTTTGTGAATGATCCAATTAAAAGTCAAAATAT
GAATCCACTTGTTGAAAATATAAAAAATATAAAAAATATTAATAAAAGAAATGAAACTTGTACGAGTTTA
GAGTGTGATTTAAATTGTTATGCTATAAAAAGGGATAATACGGAAAATAATTCTGAAGAAATAATCAATA
GTAATGAAAAAAGGATAGATGATGAAGAAGAAATGCGTATAGATGTAGCGGATAATTATAACATTCTTGA
TGATGATATAGAAAAAGGGCGAAAAAACCCAAAAATAATAAAACATATAAATAATTTCACATATACAGAT
AATAATATTCTTAAAAATATAAAATTTTCTAGCCAAACCAACAATATCAAAAAGGGGGAAACATTTATAG
ATAATAATAAATACATTTCAAACATTTTTGAAAAAGAAAAACATAACAAGAAAATTTTTCATCACGAAAG
GAAATATAAATGGATGACAGATGATAGGGATATAAGCATATGTTTTCAAAAAGGGCATAATAATAATGTT
AATGGTATTAATTCTGTTGGTAGCTCTATTCATAGAATTAATAAAAAAGGGACAATATTAAAAAATGTGC
AAATAACGAACAAATTCAATAATAAATTTATGAAAAAATGCCTACAAATAGATATAAGCTTTGATAAGAA
TTTAAAAAAGAAATATACACAAAATGAGAAATTAATTAATAATTACCACATATCCATATTCAAAAATATT
AGCATTAGCAATATTTTATCGCTTCGATGCAACATTAGAAGGAAAGATACATTAATGGAATCCTATTGCG
AATATATTTGCCTAACATTACACGTAATTTTTTTTTAACATGAAAAAATGGTGTATACTTATGAATTGTT
TTTTTCGAAATGTTCAAGTCGCTGAATTATTCATTTTTTTTATATGCATAAATGTGCGTCATTAATATCA
AACAGGAAGTATAGAAAATGTGATTGGTCTAATGTATATGTTTATACTTTTATTTTATTCTGCGCATATC
TTTTATTTCGATCATATTTTATTTTTTATAACTTTTACAGGATATAAACGTGAATAGATCTAAAGATGCA
AGCAAGACAATTTACTTTAAAAAGGTGATATACAAATTTTTAATCATTGATTTGTTTAAAAATTTAAACC
CCATAGATTTTTCAAATAATGGGAATATAGTGGAAAATAATGATAAGCTAGGTAAACATCCATTGTTTGA
AAATTTATTACGTGAAAAAAAAATACAAAAATATATTAATATATTAAAAAAAGTTGAAAAATATCATATC
GATATTATAAACAACATGTATGATCTCAAATCCATACAATTGTATATAGATATTTTTGTTACATGCTTAC
TAAAAAATATCCCATCAAGCAAGTTGTCATATGATGAACACAATATGCTCATAAGATCACTTTTGTTGTT
TTACTTTGATAGTAATAAATAGGTAGCTATAAAGGGAGGAAATTCAGTGCTCACTTGAATTCCCCCCTTC
AAATTAGCTAGCTACTGTGGTTAAATGGTAAAATGAAGTAACAGAAAAATTATTAATCGCTAGCATGATA
AATGGAGCAATATGATGGTATATTGACATGATAATACAATGGTGATATATTTATCACTACATAGTTTTTA
TTTTTTTTTTCATGGCAAACTATATTTTGTATAGTATATAAATATTTATGAGTTTTATTGTTATTTTGAT
TTGTAATAATTAAAATTCCCAACGTTGTTTATGTATTAATTATTTGTTTTTTATGTAGCATTTATTTTTT
TTTTTAATATTTTTTTCTCTCAAAAAAATTGCACTTTAATTCTTATTTCGTTATGGCATTACAACATTGT
GTGCACATGAGTGTAAAACGTATACAACAATTTTTAACGATGTTTAAAAGTAAACTTGTATTTTTATACT
AATATATTTTCGCTCATTCTTTTACAAGTCACAACTGTTATACTTATTTTTTAAAATTGATAGACAAAAT
TAAATTAATGTATTTTTTTCAAATTACAAAATTATAAAAATAATTTTTTTTATATTAATAATATTTTTTA
ATATTTCGTGGTGATGGTGTCTGGTATTTCTCATGATTTATTGTGGAATATTATTTTTTTTTAATACCAA
GAAATTAATTGTAGTGTGATTTATTTATGTATTCATTATTATTGTTATATGTGTACTATTTTATATATAT
TTTCTGTTCATTATTAACTCTGCGATATTGATATATTTTTGCATCGCCAGCAGATAAATCACTTATTCGC
GATATTATTTTGGCTTTTTCGGTTTATATTAATTTTGTAAAATGGAACAAAAAGGAGACAGGAAAAAGAA
AAAAAAAAAAAAGGAAAAAGAGAAGGAGCCCAGCTATTTCTCCGATACCATAACAGTAAATATAGAAAAA
AAAATATATATGTATAAATATAATGAAATATGTGATAAAAGAAATTGTTGGCTATGATGAAAGTAGACGA
AATGCTTTGTGTTTTATGTCGTTTCCTCGGCTTCATCACGTGTAAAAATCGTTTTATTTTATTTCATCAA
ACTTTTCGAAAAGATTATACTACATATATATATGTTTATACGTTTTACTATATCACCACATTCGTTTGAT
TCTCATTTGTATTAATTTTTATACATGGCTATATATTTATTCCCATTTTCTACATATAGTTTTGTGGAAC
TTTCATGCGTGATTCTATGATAAGCGCAGCAGAAGTTGTTCAAAATAACTATTACCCCATTAAAGAATCG
ATAATAAGTATATACGATCAGTATTTTAGTGAGAACAATCATCAAAGTAATACTCGAATTACTGGGAATG
TCCCAATTTTTATGGTGAAGACAAGTGATACAAAGTCCAAATAAGGGTATATTCATTTGTTTAGTTTTAT
CTCTTTTTTTAATGATAGTATGGTGATAAACATTGGTTAATTATGGATAATAAATATAAACGAAATTAAA
ATGCTCACAAAATAAACATATTCACGTATACATATGTATATGCGAAAATATGCGGAGATTTTTGAAAATG
GCAATTTTGCCGAAACAAAAAAAATATAATTTTAAAATATGAATTTCGTTTGCCCGAAATGATAAAGAAA
AGAAGAGACAAAAAAATATATATGTAATGATAATAGTATAGGATGAAATCGGGTGAAGGAGCCACTATTT
CATCTGTCAAATAAAAAGCATATATATAAAAATAAAAATTACACATATATGTCGCATGTGTGAACACATA
CGATAATTTATATTTATGACAACATATTTTACAAGGAAATTAGCCCAATTAGGTATGAATAAAGCGGGTA
TTAATGTATGCATCAATTTAATTAATGCTATATGATAAAGTAAAGAAAGAAGGAAATTTTGATATACAAA
GTGATTTCCAAGTAGCATACCACAATCAATCGAGTGGTAAAATTTTGTGTCCCTTTAAACCGGTTGTGGG
TCATAGCTTAAGCCATTCATTATCTTTAATTATTTCTCGATTTCTCTCACCATAATCGATTAGCAATTCT
TCTCCTTTTTGTATGTCTCTAGAGGCGATGAAAAAAAGTCTGGGTAAAAAATCAACGGTTAGTACTTTAG
GAATTAAATTTGAGTTTTTTTTTGAGTGATTTACTAATCTAGCAAAAGATCTTAAGAAATATTTTTTATT
AGTATAATTGATAGCCGCGTCTATACTTTCTTCAGTTCCATCTATACAATATCTTTTATTTTCATGTTTA
AAATAGAACATGTAACAACCTTTTTTTTTATTTTTAATATATATTTGCTCTCGTTCCATAGCTTCATTAT
GTGTTAATAATTCACCAACATATTCAAAAACAAAATCAAATTTATTAATTTGTGTATCTGCATATATGCA
TCTACCTTTTGTAGAGTCAAAAATAACTTTTATACATGCAAACATATTCATTTTAAGATTTTCTTCATAT
ATAATATTTCTACTTTTTTCTTTTAAGTAAGATAATGGAATGGTATTAATTTCAGCTTCTTTATCAATGA
ATAGATCAATAAGCTGTTGTTTATTTAATTTGTTTATGGTTCTATCATATTCATATTTTCCATAATATTC
TATCCTGGATTTTTTTAATTTTTCGATTTTTCTGCTATTTATATTTTGAAGAAATTTATCAATAAAATTT
ACACTATCTTTTAATTTCATAATTTCTATGTCTTGTTTTTTATTTTGTGACTTTCCGTAATAAGAAATAC
AAGAATCATAAAAATCTGCAAGCCCTTGTTTTGCTTCTTTCTTCCCACCGTTTTCATTTTCTTGTTCTCT
TTTTTCAGAAAAAAATTTATATAATTTTTCAAAACATATATCTAGATCGATGATATATTTTCTAAAATGT
AAAGAAATGTTCCACAAGAGGTCAGGAGAATAGGTAGAAATAGTTGTTAATTTTATATTTTCAGTATTTT
TTATCAAATAAATTAAAATTTGTATAATAATTTTTTTCGGTAATATTTTTACCTTATCATAACTATGACC
TGTATCATTAAATTTAATATATATATAATCTCCTTGCTTTAGTTTTTTTTCTAAGGATTTATGTTTTTTG
CTAATAAAAGCAAATATAATATCTGTATCTGTAACTAGTTCTGTGTTTTCAGATATGTCTTCTAGTTTCT
GATCATTGCAATCTTTGTTGAATTCAGTAGGAATGCTGTTTTGGGTTAGGTGATTTGTCTCTGTTATGCC
TTCTTTTGATAAGACATTTCCTTCCGTTTTCAATTTCTCTTTAACATCAATTCCCTCTTTGAAACTCGAA
TAGGATTTCCCTTCTATATCAACATTTTCTGTGGTAATACGTTCATTCTGAAATGCATGATAGTTGTCTT
GAGATTCCGAAATGAAATTTTCGACATTGGGTTCTGTTGGTATATATTTTTTAAAGTAATTAAAAATATC
GTTATCTTCAAAATTTTGAACATCATTTTCAATTGTTTGATCTGATAATTCGTATAAATAATTTTGGTTT
TTAAAATGCTCTTTTTTATCACATGTGTAAAAATCTTCATCATCAATTATAAATATTTTATAATTGTTTT
TATATAAAGTTTCAATTCGCTCAAAACTTTTAGATAAAGAATTTAAATGTGGTTTCTTTTTATCCAAAAT
ATTTTTTAATATTTTATTTATATATATATCGATGCAATCTTTATCTAATTTATTTTTTTTAAATATATGA
CTATTAATTTTATTCTGTTGATCTTCTAAATTATTATAAAACATATTTTTAAAACAATTTACATATTCAT
AATTCTCTAATTTATATAATTTGGATGATTCTAAAATAAGTTTTGTATTTTCGTTTAAATTTATCGGTTT
ATTAGTGTTATTTTCCTTAATACAAATATTTTTTGTTTTTAAATTTTCTTTATTTTTTTCTTTTTGTGTT
TCGGTATCATTTTCGATGGTAGTATCTTCTATATTGACACAATGATTTTTCATTCCTTCTAATTTTGTTG
AGCTATTATCATTATCATTTTTATTATCTAGTTCTTTTCCGTCATTCCTACATTTTAATTTGTCTATTTC
GTTATTTGCATCATATATATTGTTTTGGGATTGACCAATATGAGAACAATTGAAATTATTTTCTCGACAA
TATTTATCAGTTTCAAAATATTCATTATGTTCTCCATCTTTTACACCTGTATTGACTTCATTGGTGTTTT
CTATGTAAATTTCGTGGTTAGCAACTATAGAGTCGGGTTTTTCATCATCATCATCGGTCATATCGTTACT
ACTACTATGACAATAATACCATGTTTTTCTTTTCTTCCTTTTTGCATTATTATTAATAGAGATATGATTA
TCTGTGTCACTAATGATAATTGGTTTTTCTTGATTCCCATTTTTTTCATTTTTTTGAGTATTACAACTAC
TATTATTAATGATTTGACTTTTATTTTCTGTATCTTCCATTTTTACTTTATTTTGATTAAGAAATGTTGC
TTTTTTTTTCTGCATTTTGATTAACTTGTTCAAATTTTCATTTTCATTTTCATTAGTAAGACAAGAAAAG
CTATTAATATTGCTGGACTTTTTTTGGTTACATTTATCAGTATTTTTATTTTTTTTTCCAGCCTCTTCTA
TTTTTATTTTTAAGCGATACCATTTTACATCATTAATATCATTTGAATTATCTTCTAAAATATTTTTATT
ATTTTTTAATCCATTTAAATATAAATATTTTATTTGATCGTTATTAAACATATTACCATTTTTACTATCA
TGTTTATTAGCATTTTCATTTCTTCTTTTATTTAATTCATAACTGTTAAACTGATTGTCTGTTGTATTTT
CATATTTGTTATAAGCGCTATTGTAAATGGATGTGTACATATCCAATTCGTCATATATATTGTATTTATT
AATACAATCTTGGATTCCCAATTTTGTATTTATATTTAGTCTCTGTCTTTTTACCTTAGATTTTTCGAAT
AAAAAATGAAGACTCCAGAAGTAATAACGATCGTAAATTAGGAGAGGAATATGATTATTTCGATATCCGC
ACATAGGCTGCATTCATTGATAAAGAAAAATTAATGAATATATAGGGCACTGGATAAAGCGTAGGAATAA
AAGCACTTATTTGTTTGGAGAAAATAATCAGCATATATAAATATTTTTTCTATTATTTTATTTTTTTGAG
TACATACCGATATATCAAGTGCTATGTTAAAACTGTTATCATCAAACAATAGATATACCTTGGATATTAT
AGAGGTGTCATTCCCCTGATTTATGGGATTTTTATTTAAATCATCAAAATATTTGGATAGATCTGCATAT
AATGGTATATGAACGATCGAATCTAATTTTTCTTTTTCAATCCATATTATAGATGCTAAATCTTTGCAAG
AAGAGTTAATATTTTCAAACGTATCATTATCAGTGTTTTTACTACTTTCAAAGGTTATATTTATTTTGTT
TTTTTTCATTTTTCGAATTATCTAGCATGACACATGCATATATAGATATACATATATGTTTTTATTTATA
TGGGGAAATGCGCAGAGGGTTCCTCTTTCTTTCAAACGGAATTCAGAAGAAAGAAATATATATACATATC
GAAAATACAACCGAATTATACATTTTTATCAAAAAATTATAATAAAAAAAATGCAAAAATTCACTAGTAC
GGGAATTTTTTTTGATCTTTTGAAATATATATATATAATGAAAATAAAAAATAAAATACAATGAGCAAAA
AGAAGGTAATTTAAATTTTTTTTAATATTTAAAATAATAAAAAAGAAATAAGAACATCTTCAAAGAGGAC
AAGAAATAATAAAGTTCAATGAAAATAATAAGGTTGTGTATAATAATATAAGAATTACCAATAAAATATT
TTAATAAATTAAAAAAATATATACGTAAATAAAGATCTCTAAAATATACAAGTGAATAATCAACGTGTTA
TATGCACGCACATATATATCCATAATAATCTAGCCAAAATATTATAAATCATTAAAATTATGTATACATA
CAAATTTTTACTAAAATAAAATGGTGAAAAATAAGCAATAAAATGTGTAAATTCAATGGATTTTAATATA
TCAATATTACCTTTATATGGATATTAGATTTTTTCATACAGGATAACTATCTTTTATATTTTAAAAATTA
TAATTTCAGTTATTTTGCAAAAAAGGATGTATATAAACATAAATTTTTTAATGTTTTGCAACAATTATTT
ATATATTATTATATGTGAAAAAGACTATATGTGGGGAAATAAAATAAGATTCTATATACTTATATGCTTT
ATTATAAACTGGCAAATTCTTTTTTTTTAAAGAAAAACTGAATAAAAAATATTGTTTAAAAGATGAAAAT
TAAAAAATATATTAGAATAATACATATATATATGTATGTAAAAGGTATAGTTAATTTTTTGAGTGTTGAT
CAGCTTTGTATAATTAATAACATCTTTATAAAATAAATCATATATTCCTTTTTTAGATAGTATTTTTCGT
TTTAATAATACATAAAAAATAGCTATTTAAATAATAATACGATTTCTTATTAAGAGAAACAAAATCATGA
GTCTAATGAAGAAATAAAAACTGCTAATACATATATACTTACTACCATAATATGATATTATGAATAATAA
CACCCAATTTGTATGGTTATACATATATATATGTTTAATGAACATATATGCCCATATTTTTAAAATTTAT
ATTGAAGCTTTTATTTTTTTATGAACAAAACTATTTTCTTTAATTATATCATAGG

Molecule Role : Virmugen
Molecule Role Annotation : Deletion of P52 and P36 in Plasmodium yoelii were attenuated and provided protection against challenge in mice (Labaied et al., 2007).

46. Py36

Gene Name : Py36
Sequence Strain (Species/Organism) : Plasmodium yoelii 17XNL
NCBI Protein GI : 23479924
Other Database IDs : CDD:185624
Taxonomy ID : 73239
Gene Strand (Orientation) : ?
Protein Name : p36 protein
Protein Length : 231
Protein Note : p36-lilke protein; Provisional

Protein Sequence : Show Sequence

>gi|23479924|gb|EAA16624.1| p36 protein [Plasmodium yoelii yoelii]
MSENSTIEGNDIGEKVAAIKKYLEAFDHQNEAKSIHGFVDLLKKINIKMAVFDFDLTLIGKHSGTCNIMC
GYIDKLNDIEDIGTSVTNAFKILSKRLYENNIKITVATFSDDEAIRYSKVKSPSLIAGEELIQHCIKHSN
CETKIERVYAYYPYYYKEPKKYMALGLKEPMSNDKSYHLKRIRNEFSVNINEIIFFDDDVKNCISAKKEG
YITFNVTGKKGFNFKDIKLMQ

Molecule Role : Virmugen
Molecule Role Annotation : A genetically attenuated parasite (GAP) with deletions in p52 and p36 are attenuated in mice. Mice immunized with the mutant were completely protected against challenge with wild type Plasmodium sporozoites (Labaied et al., 2007).
Related Vaccine(s): P. yoelii p36/p52 mutant vaccine

47. Py52

Gene Name : Py52
NCBI Nucleotide GI : 15193061
NCBI Protein GI : 15193062
Protein Accession : AAK91678.1
Taxonomy ID : 5861
Gene Strand (Orientation) : ?
Protein Name : Py52
Protein Note : member of the 6 cysteine family of Plasmodium proteins; putative membrane-bound protein; sporozoite expressed

DNA Sequence : Show Sequence

>gi|15193061|gb|AF390552.1| Plasmodium yoelii Py52 mRNA, complete cds
ATGAAACGTCGAAGCATTTTCATGTACTACTGTTTCTGTTTCTTATTGAAATATGTAGCCTTTAGCAATG
TGCCAAATCCTAATACGACCATAGGACACTTTGAAATTTGTGAAGTAAATACATCTTCAGGTGATGCCGA
AGAATGTGTTTTAGAAAATGAATTTGGGAAAATGTTTTTATTTATTTGTGATATTGATTACAATGAGATG
TCAAAAAATATAGTGCTTCCGTCAGAATGTGCTAAAAAAACATATATAGACCATGTAAACCCAAATGGAA
CATCGCCAGAAGTTAATACTTATGATATATTTCCAGATTTGATCGCAGCAAATGAATCCCAATTTCGTGA
TAAATTTTATTTTTATGGAACCCCATATTCATCTAAAGACATTGATTTTATATGTTTATGTTTTTCTGAA
ACAAAACCAGATATAAAACATGTAATGAAAATGAGTTTTAAAAAAATGACAAAAAAAATAAAAGGATGTG
ATTTTGGAGATAATATACCAACGAAAAAAGATTTAACAAATGGGAAAGCATTATATGAAAATTCTAGTTG
TCATATATATGCATATCCAGGAGACGTAATTGGAATAAATTGTTATAAAAAAGACATTAATAATATTTAT
AATAATAATTTAGAATTACAGCCAAATAATTGTTTTCATAATGTTTATTATGAAGATGATATATTATTAT
CGTCAAAAAATTTAATACCTAATTCTAGAGTTATACCAGATCCGAGTAACGATGTTAAATTATCAAAAAT
GCATTCATATATGTCTTATATTATACTCCCTGACGAAATAAATGAAAATGTTAAAATTAGTTGTGCATGC
AAAAGAGATGAATATATCGGCACTATGTTTTTATATGTAAATACATCGAAAAATATTTTAACATCCCCTG
ACAACAACGTAGAAGAAATTGCTCCTTTGAATGACCACTATATTTCAATTGGAGACATGTGGGACATGGG
TTTACATGAAAACCCTGAGCAAATACAAGGCATTATTAGCAATCATGCAAATAAAAAATATTATGAACAT
ATGAAAATTTACAAAAGCAATAAAATGGATTCTAGTGATGATGATGAATCGAATGAGACTGAATCGAGTG
AGAATGAATCAAATGAGCGCACACACAATGGTAATAGAGCAAATAAAGATGCTAATAATAGTGAGAAAAT
GACTGGTAATAGAAGGAAAAAAAATAATTCTATCAATAATACTAATTACTATAGTAATTATGAGGATGAC
AATGGAATTAATATATCTACCCATGATAAATATTATGAGGACCAACATTTTGGTAACAATGGACCTTTGA
GAAAGAAAAGAACATTTTGGCAAAATATGTTTGGTACCTCTTCTTCTTATTATGAGGTCTTTAACTATTT
TTCAATCGCATTTATTCTAATTATTCATATGCTCCTCTTATGA

Molecule Role : Virmugen
Molecule Role Annotation : A genetically attenuated parasite (GAP) with deletions in p52 and p36 are attenuated in mice. Mice immunized with the mutant were completely protected against challenge with wild type Plasmodium sporozoites (Labaied et al., 2007).
Related Vaccine(s): P. yoelii p36/p52 mutant vaccine

48. RESA

Gene Name : RESA
Sequence Strain (Species/Organism) : Plasmodium falciparum 3D7
VO ID : VO_0010959
NCBI Gene ID : 813159
NCBI Protein GI : 124505681
Locus Tag : PF3D7_0102200
Genbank Accession : AL844501
Protein Accession : XP_001350954
Taxonomy ID : 36329
Chromosome No : 1
Gene Starting Position : 98818
Gene Ending Position : 102281
Gene Strand (Orientation) : +
Protein Name : RESA, ring-infected erythrocyte surface antigen, Pf155, MAL1P1.13
Protein pI : 4.13
Protein Weight : 117293.03
Protein Length : 1085
Protein Note : Also known as Pf155

DNA Sequence : Show Sequence

>NC_004325.2:98818-102281 Plasmodium falciparum 3D7, chromosome 1
TATGAGACCTTTTCATGCATATAGTTGGATTTTTTCTCAACAATATATGGATACAAAAAATGTTAAGGAA
AAAAATCCCACCATATATTCATTTGATGATGAAGAAAAAAGAAATGAAAATAAGAGCTTTTTAAAGGTGT
TGTGTTCTAAACGTGGTGTTCTTCCAATTATTGGAATACTATATATCATTTTAAATGTAAGTTTTTTTTT
TTTTTTTTTTTTTTGAAATAAAATACATATTTTTTATATTTAATTTTTTATGTTAATGCTTATTTTATTT
TATTCTATTCTTTTTTATATGTCATGCATATTTTATATATTATAATACCGTTTTTAATAATATATAATAT
ATCTTTGTTATTATATATAATTTTTTTTTTTTTTTTTTTTTTTTTTTCATAGGGTAATCTTGGATATAAT
GGAAGTTCATCTTCTGGCGTACAATTTACTGATAGATGTTCAAGAAATTTATACGGGGAAACATTGCCAG
TAAACCCATATGCTGATTCTGAAAACCCAATAGTTGTAAGTCAGGTATTTGGTTTACCCTTCGAAAAACC
TACGTTTACCTTAGAAAGTCCTCCTGATATTGATCATACAAATATTTTGGGTTTTAATGAGAAGTTCATG
ACTGATGTAAATAGATATCGATATTCTAATAACTATGAAGCCATTCCTCATATAAGTGAGTTCAATCCAC
TTATTGTAGATAAAGTTCTTTTCGACTATAACGAAAAGGTTGATAACTTAGGAAGAAGTGGAGGAGACAT
TATAAAAAAAATGCAAACTTTATGGGATGAAATAATGGATATTAATAAAAGAAAATATGATTCTTTAAAA
GAAAAATTACAGAAAACTTACAGTCAGTACAAGGTTCAATATGATATGCCAAAAGAAGCATATGAGAGCA
AATGGACACAATGCATAAAACTTATTGATCAAGGAGGAGAGAACCTTGAAGAAAGATTGAACTCACAATT
TAAAAACTGGTACAGGCAGAAATATTTAAATCTTGAAGAATATAGAAGATTGACTGTGTTGAACCAAATC
GCTTGGAAAGCTTTATCCAACCAAATTCAATATTCATGCAGAAAAATTATGAATAGTGACATTTCTTCCT
TTAAACATATAAATGAATTGAAAAGTTTAGAACACAGAGCCGCAAAAGCTGCAGAAGCAGAAATGAAGAA
AAGAGCTCAAAAACCGAAGAAGAAAAAAAGTAGAAGAGGATGGTTATGTTGTGGGGGGGGAGATATCGAA
ACAGTTGAACCACAACAAGAAGAACCAGTCCAAACCGTTCAAGAACAACAAGTAAATGAATATGGTGATA
TATTACCATCATTAAGGGCCAGTATTACTAATTCAGCTATTAATTATTATGATACCGTAAAAGATGGTGT
ATACTTAGACCATGAAACATCAGATGCTCTTTATACAGATGAAGATTTGTTATTTGATTTGGAAAAACAA
AAATATATGGATATGTTAGATACATCTGAAGAAGAATCTGTTAAAGAAAATGAAGAAGAACACACTGTTG
ATGATGAACATGTAGAAGAACACACTGCTGATGACGAACATGTAGAAGAACCAACTGTTGCTGATGATGA
ACATGTAGAAGAACCAACTGTTGCTGATGAACACGTAGAAGAACCAACTGTTGCTGAAGAACATGTAGAA
GAACCAACTGTTGCTGAAGAACACGTAGAAGAACCAGCTAGTGATGTTCAACAAACTTCAGAAGCAGCTC
CAACAATTGAAATCCCCGATACATTATATTACGATATATTAGGTGTTGGTGTTAATGCTGATATGAACGA
AATTACTGAACGTTATTTTAAGTTAGCTGAAAATTACTATCCATACCAAAGATCAGGTTCTACTGTTTTC
CACAACTTTAGGAAAGTCAACGAAGCCTACCAAGTTTTAGGAGATATTGATAAAAAAAGATGGTACAATA
AATACGGATATGATGGAATAAAACAAGTCAACTTTATGAATCCATCCATCTTTTATTTATTATCTAGTTT
AGAAAAATTTAAAGATTTTACCGGAACACCCCAAATAGTAACTCTTTTGAGATTCTTTTTTGAAAAGAGA
TTATCTATGAATGATTTAGAGAATAAAAGTGAACATTTATTAAAATTTATGGAACAATATCAAAAAGAAA
GAGAAGCACATGTATCTGAATATTTATTAAATATATTACAACCATGTATAGCTGGTGATTCAAAATGGAA
TGTACCAATTATAACAAAACTTGAAGGTTTAAAAGGATCTCGCTTTGATATACCAATATTAGAATCTTTA
AGATGGATATTCAAACATGTCGCTAAAACACATTTGAAAAAATCCTCAAAATCAGCTAAGAAACTTCAAC
AGAGAACCCAGGCTAATAAACAAGAATTAGCAAATATAAATAATAACCTAATGAGTACATTGAAAGAATA
TGTAGGAAGTAGTGAACAAATGAATTCAATAACATACAATTTCGAAAACATCAATTCCAATGTTGATAAC
GGAAACCAATCAAAAAATATTTCAGATTTAAGTTATACAGATCAGAAGGAAATATTAGAAAAAATTGTTA
GTTATATAGTAGATATTTCCCTTTATGATATAGAGAACACAGCTTTAAATGCCGCTGAACAATTGTTGTC
AGATAATTCAGTAGATGAAAAAACTCTTAAAAAGAGAGCTCAATCATTAAAAAAATTATCATCCATTATG
GAGAGATATGCAGGTGGTAAAAGAAACGATAAAAAAGCAAAAAAATATGATACCCAAGATGTTGTAGGAT
ATATTATGCATGGAATTAGCACAATTAATAAAGAAATGAAAAACCAAAATGAAAATGTACCCGAACATGT
ACAACATAATGCTGAAGCAAATGTAGAACATGATGCTGAAGAAAATGTAGAACATGATGCTGAAGAAAAT
GTTGAAGAAAATGTAGAAGAAAATGTAGAAGAAAATGTAGAAGAAAATGTAGAAGAAAATGTAGAAGAAA
ATGTAGAAGAAAATGTAGAAGAAAATGTAGAAGAAAATGTTGAAGAAAATGTAGAAGAAAATGTTGAAGA
AAATGTAGAAGAAAATGTAGAAGAAAATGTTGAAGAATATGATGAAGAAAATGTTGAAGAAGTAGAAGAA
AATGTTGAAGAATATGATGAAGAAAATGTTGAAGAAGTAGAAGAAAATGTAGAAGAAAATGTAGAAGAAA
ATGTAGAAGAAAATGTTGAAGAATATGATGAAGAAAATGTTGAAGAAGTAGAAGAAAATGTAGAAGAAAA
TGTAGAAGAAAATGTTGAAGAAAATGTAGAAGAAAATGTTGAAGAAGTAGAAGAAAATGTAGAAGAAAAT
GTAGAAGAAAATGTAGAAGAGAATGTTGAAGAGAATGTTGAAGAGAATGTTGAAGAATATGATGAAGAAA
ATGTTGAAGAACACAATGAAGAATATGATGAATA

Protein Sequence : Show Sequence

>XP_001350954.1 ring-infected erythrocyte surface antigen [Plasmodium falciparum 3D7]
MRPFHAYSWIFSQQYMDTKNVKEKNPTIYSFDDEEKRNENKSFLKVLCSKRGVLPIIGILYIILNGNLGY
NGSSSSGVQFTDRCSRNLYGETLPVNPYADSENPIVVSQVFGLPFEKPTFTLESPPDIDHTNILGFNEKF
MTDVNRYRYSNNYEAIPHISEFNPLIVDKVLFDYNEKVDNLGRSGGDIIKKMQTLWDEIMDINKRKYDSL
KEKLQKTYSQYKVQYDMPKEAYESKWTQCIKLIDQGGENLEERLNSQFKNWYRQKYLNLEEYRRLTVLNQ
IAWKALSNQIQYSCRKIMNSDISSFKHINELKSLEHRAAKAAEAEMKKRAQKPKKKKSRRGWLCCGGGDI
ETVEPQQEEPVQTVQEQQVNEYGDILPSLRASITNSAINYYDTVKDGVYLDHETSDALYTDEDLLFDLEK
QKYMDMLDTSEEESVKENEEEHTVDDEHVEEHTADDEHVEEPTVADDEHVEEPTVADEHVEEPTVAEEHV
EEPTVAEEHVEEPASDVQQTSEAAPTIEIPDTLYYDILGVGVNADMNEITERYFKLAENYYPYQRSGSTV
FHNFRKVNEAYQVLGDIDKKRWYNKYGYDGIKQVNFMNPSIFYLLSSLEKFKDFTGTPQIVTLLRFFFEK
RLSMNDLENKSEHLLKFMEQYQKEREAHVSEYLLNILQPCIAGDSKWNVPIITKLEGLKGSRFDIPILES
LRWIFKHVAKTHLKKSSKSAKKLQQRTQANKQELANINNNLMSTLKEYVGSSEQMNSITYNFENINSNVD
NGNQSKNISDLSYTDQKEILEKIVSYIVDISLYDIENTALNAAEQLLSDNSVDEKTLKKRAQSLKKLSSI
MERYAGGKRNDKKAKKYDTQDVVGYIMHGISTINKEMKNQNENVPEHVQHNAEANVEHDAEENVEHDAEE
NVEENVEENVEENVEENVEENVEENVEENVEENVEENVEENVEENVEENVEENVEENVEEYDEENVEEVE
ENVEEYDEENVEEVEENVEENVEENVEENVEEYDEENVEEVEENVEENVEENVEENVEENVEEVEENVEE
NVEENVEENVEENVEENVEEYDEENVEEHNEEYDE

Molecule Role : Protective antigen
Related Vaccine(s): P. falciparum vaccine Combination B

49. RH5

Gene Name : RH5
Sequence Strain (Species/Organism) : Plasmodium falciparum 3D7
NCBI Gene ID : 814549
NCBI Protein GI : 124505127
Locus Tag : PF3D7_0323400
Genbank Accession : AL844502
Protein Accession : XP_001351305
Other Database IDs : CDD:240419
Taxonomy ID : 36329
Chromosome No : 3
Gene Starting Position : 980705
Gene Ending Position : 983965
Gene Strand (Orientation) : -
Protein Name : Reticulocyte-binding protein homolog 5
Protein pI : 6.74
Protein Weight : 121419.86
Protein Length : 1086
Protein Note : PfRH5

DNA Sequence : Show Sequence

>NC_000521.4:980705-983965 Plasmodium falciparum 3D7 genome assembly, chromosome: 3
ACTAATTCTGATTACTATAATAAAATACATTTTCATATATACATGTTTGATGATCTACTTGGAAATCATC
ATAGATAACACTATTGCCTATTTTTTTTTTCAAATATATAATAGTGTGAAATATTTCATTTTTAATTTGA
ACTTCTATATTACCTGCTGTTGGATAATCATAATAAAATACGTAAGATTCTTTTGAGTTATTTATTTTCC
AAATAATTTGGTTATATATATATGAAAATTCGATCATACCACATGCTCCAAGAATAATAGATGCATCGTC
ATTATATTGGAATGTAAAACTTTCATCATACTCATTTGTATTAGGTACACAAGAATCATCTTTATTTTTA
TAATTTTCTTTACATGTACAATTAATTTTACTATATTTAAATGTACACTCTGAATTTCTAGAGCAGCCTC
CATTATCTTTTAGACAAGGGTTTTGTATTAAACATACACCATCTTTTTTATAATAATTATATGTACATAC
ACATATTGGTTCTTTATTCATTACATTTACACATATAGAATTTTCTGAACATTTTTTATTATGTACACAT
TTATCTTCTAAAACACATTTTCCATTGACAGCTACATGACCTTGTTTATTACATACACATTCATGTGGTT
TATATTCTCTATAAATACATTTTGAATCTTTTGGACAATTCCCTTCATTAATTAAACAGGAGTTTTCATA
AATACATTCTCCTTTATTATTTTTTTTAAGATTTTCTTTACATACACATTCTGGTTTAAAGTTTACAATA
GAACATTCTTCATTTTCTTTACAATTAATATCTTTACAATAATCATTTAATATACATTCACCTCTTGATG
ATCTATAATAATGTTCTTTACATTCACATTTTACAATATCTGTTTCTTCATTATAAGCACACATTTCATT
TGGATTTGTACAAATATTTTCATATTCTTTTCTTTTACATTTATTTTTGGCTATACAATTAATACCATCT
TCCATTTTATAATCATTAGCACATATACACACACCATTCTCTAGAACAAAACGTTCTGAACATTTACATG
TTTGTTTTCCATTTTCGATAACACAAACTTTGTTTGATGGGCATGAAAGATCACATTTGTTGTCTGGAAC
ACATTTACCTTTAACATTTTTATATCCTTCTTCACATTGACATATTAATTTATCATTTGGAAGAATTTGA
CAAACTTGATTTTGTGAACACAAAACAGATTCACAATCATTTGGACGTTCACATAATTTATTTCCATATT
TTGAAATATAAGGATTATCACAAAAACAATCATAATTAAATCTGTTCCCATAGCATGTAGAATTGTTATG
ACATTTATTACATAAATTGGAGCAGCTGTAAGATACAAAAAGATATTGATCATTAATACAATAAGTATCA
AAATGGTATATTAAACCAATATCACATTCTGATAAATCATTACAATATGATTTTAAAGAATTCGTCAAAA
GCAAATCATTACATCCTTCCCCACCTTTTAAAATTGCTTTATCAATATTTATTTTTCCCCCTTGACATTG
TAATTTACTTGAAAAACGACTTCTGAAGATTTCTACCTTTTTAATATTCATATTGTTTATATTATTACTA
TTTGTGTGTGGATCTGTACTAAACTGATTTGAATTGTGTGAGGATATTTCATTTTGTATTTCTAGCATGG
ATATATTGTTATGAGGATATTGGTTGGTTCGACTATTTCTTGAAATCAAATGGAATTTAGATTTATTAAT
ATCTGGTAGAATACTTGAATTATATAATGATGGTATATTAGAATGAAGATGTGAATTCTTATCTGAAGTA
ATATTTTGATTATTGAATACACATAAATAATCATATTTAAATATTGTATTAAAATTATTACATATATTAT
GATGATTTAAATCATCTATTGGATCTATTGTATTTCCATAAGCACATTTGGTTTTCCCATCACACATTTT
TTTTAATGATTCTGTAACATATTTCAATTTGTTTAGATTGAATGAAACTCTATAACATGATACATATGCA
TTAATAACTTCTATAGAGAACCCATTTTCACATTGCATAAAAATATATTCTGGTTTTAATGCTTTTCCTT
GATATAAATTATTTTTATAAAATTTTTCTTTTTTATGTGGTTCTATTTTTATGGCTAATTCTAAATCATT
TTTTGTATAACATTTATTATTGTGATAATATTTACCATTTTCACATTTACATTCAGCTTTTTTCCCATTT
CCTATTTGTTCACATGTGGAATTTTCAGGACAATTTAAAACTGTACATAAATCGTTGTATTCACAATTGT
TTTTAGCTGATGGTAATAATGATGTTTTGCATGTACATGTTTCATTTTCTCCGTCACAAAATTGATTTAC
TGAACATATATCTTGTGTACATCTATAATTTTCTTCACAAACATTTTTTAATAATTCTATTTTATTAAAA
CCATATTTGCATGTTGCTTTATGTGTATCATCATTATATACGTCACACATTTCATTTTCCTGTAGATTCA
GAGGACTTATGCATTGATATTGTATATTAATAAAAAACAAATAATGAGTAAGTGATTTATTTTCATATTT
TATTGAATCAAAATCGAATTTACAATTGTTTTTTCCGTCACATAAATTTTTAATATATGTAAGTGTTTCT
TGTTGTAATATAGCATTGTGTGTATGTACATGTACAGATCTTAGAGATATATACATACCTTGGCAATTAA
TTTGATCATTTTTTCCTTTTTCAAAAAATGTTTCTTCATAAACAACATGAGGTTCTAATAAAAGTGGTTG
TGATATGTAATAAATGATTATATGTGTAGAATTGAAATGTGCACAATAAAGTTTGTCATTTGTTATTTTA
TTTGTTTTTATTTCTTCACTATTTGGTATTACTACTCCGCAAAATGTTTTTTTATAACATATTTGATTTG
TTTTATCACTTGAATTATATTCTTTTGATATAAAATAATCACATGATTTCATGTCTTTATTATGAGAAAA
AAATGTTTTAATTTTTTCTGTTGAATCACGATTTAATATAGTATAAACGTATTTGTTTAAATAAGCATAA
TCATTTTCCCCATTATTATTTAAAATCAAATCTGTTTTTAAATTATCTCTAACTCTATGATCGAGAGAAA
ATGTTAATTTATCTATTTCATTTTTTTCATAAAAAATTCCTTCTATTAAATCAATTGCCGATGTTTTCTT
GATTAATATTATTATAAGAAGGGTAAAAAAAATTCTGAACA

Protein Sequence : Show Sequence

>XP_001351305.1 Rh5 interacting protein [Plasmodium falciparum 3D7]
MFRIFFTLLIIILIKKTSAIDLIEGIFYEKNEIDKLTFSLDHRVRDNLKTDLILNNNGENDYAYLNKYVY
TILNRDSTEKIKTFFSHNKDMKSCDYFISKEYNSSDKTNQICYKKTFCGVVIPNSEEIKTNKITNDKLYC
AHFNSTHIIIYYISQPLLLEPHVVYEETFFEKGKNDQINCQGMYISLRSVHVHTHNAILQQETLTYIKNL
CDGKNNCKFDFDSIKYENKSLTHYLFFINIQYQCISPLNLQENEMCDVYNDDTHKATCKYGFNKIELLKN
VCEENYRCTQDICSVNQFCDGENETCTCKTSLLPSAKNNCEYNDLCTVLNCPENSTCEQIGNGKKAECKC
ENGKYYHNNKCYTKNDLELAIKIEPHKKEKFYKNNLYQGKALKPEYIFMQCENGFSIEVINAYVSCYRVS
FNLNKLKYVTESLKKMCDGKTKCAYGNTIDPIDDLNHHNICNNFNTIFKYDYLCVFNNQNITSDKNSHLH
SNIPSLYNSSILPDINKSKFHLISRNSRTNQYPHNNISMLEIQNEISSHNSNQFSTDPHTNSNNINNMNI
KKVEIFRSRFSSKLQCQGGKINIDKAILKGGEGCNDLLLTNSLKSYCNDLSECDIGLIYHFDTYCINDQY
LFVSYSCSNLCNKCHNNSTCYGNRFNYDCFCDNPYISKYGNKLCERPNDCESVLCSQNQVCQILPNDKLI
CQCEEGYKNVKGKCVPDNKCDLSCPSNKVCVIENGKQTCKCSERFVLENGVCICANDYKMEDGINCIAKN
KCKRKEYENICTNPNEMCAYNEETDIVKCECKEHYYRSSRGECILNDYCKDINCKENEECSIVNFKPECV
CKENLKKNNKGECIYENSCLINEGNCPKDSKCIYREYKPHECVCNKQGHVAVNGKCVLEDKCVHNKKCSE
NSICVNVMNKEPICVCTYNYYKKDGVCLIQNPCLKDNGGCSRNSECTFKYSKINCTCKENYKNKDDSCVP
NTNEYDESFTFQYNDDASIILGACGMIEFSYIYNQIIWKINNSKESYVFYYDYPTAGNIEVQIKNEIFHT
IIYLKKKIGNSVIYDDFQVDHQTCIYENVFYYSNQN

Molecule Role : Protective antigen
Related Vaccine(s): ChAd63-MVA RH5 , PfRH5 DNA Vaccine

50. SERA

Gene Name : SERA
NCBI Protein GI : AAF37557.1
Other Database IDs : CDD:185641
Taxonomy ID : 5833
Gene Strand (Orientation) : ?
Protein Name : serine-repeat antigen protein
Protein pI : 5.07
Protein Weight : 106099.12
Protein Length : 1077
Protein Note : Serine-repeat antigen protein; Provisional

Protein Sequence : Show Sequence

>AAF37557.1 serine-repeat antigen protein [Plasmodium falciparum]
MKSYISLFFILRVIFNKNVIKCTGESQTGNTGGGQVGNTVGGQAGNTVGDQAGSTGGSPQGSTGASQPGS
SEPSNPVSSGHSVSTVSVSQTSTSSEKQDTIQVKSALLKDYMGLKVTGPCNENFIMFLVPHIYIDVDTED
TNIELRTTLKETNNAISFESNSGSLEKKKYVKLPSNGTTGEQGSSTGTVRGDTEPISGSSSSSSSSSSSS
SSSSSSSSSSPSSSSSSSSSSESLPANGPDSPTVKPPRNLQNICETGKSFKLVVYIKENTLIIKWKVYGE
TKDTTENNKVDVRKYLINEKETPFTNILIHAYKEHNGTNLIESKNYSLGSDIPEKCDTLASNCFLSGNFN
IEKCFQCALLVEKENKNDVCYKYLSEDIVSKFKEIKAETEDDDEDDYTEYKLTESIDNILVKMFKTNENN
DKSELIKLEEVDDSLKLELMNYCSLLKDVDTTGTLDNYGMGNEMDIFNNLKRLLIYHSEENINTLKNKFR
NAAVCLKNVDDWIVNKRGLVLPELNYDLEYFNEHLYNDKNSPEDKDNKGKGVVHVDTTLEKEDTLSYDNS
DNMFCNKEYCNRLKDENNCISNLQVEDQGNCDTSWIFASKYHLETIRCMKGYEPTKISALYVANCYKGEH
KDRCDEGSSPMEFLQIIEDYGFLPAESNYPYNYVKVGEQCPKVEDHWMNLWDNGKILHNKNEPNSLDGKG
YTAYESERFHDNMDAFVKIIKTEVMNKGSVIAYIKAENVMGYEFSGKKVQNLCGDDTADHAVNIVGYGNY
VNSEGEKKSYWIVRNSWGPYWGDEGYFKVDMYGPTHCHFNFIHSVVIFNVDLPMNNKTTKKESKIYDYYL
KASPEFYHNLYFKNFNVGKKNLFSEKEDNENNKKLGNNYIIFGQDTAGSGQSGKESNTALESAGTSNEVS
ERVHVYHILKHIKDGKIRMGMRKYIDTQDVNKKHSCTRSYAFNPENYEKCVNLCNVNWKTCEEKTSPGLC
LSKLDTNNECYFCYV

Molecule Role : Protective antigen
Related Vaccine(s): NYVAC-Pf7

51. SERA-5

Gene Name : SERA-5
Sequence Strain (Species/Organism) : Plasmodium falciparum
VO ID : VO_0011210
NCBI Gene ID : 812668
NCBI Protein GI : 238629807
3D structure: PDB ID : 3CH2
Other Database IDs : CDD:185641
Taxonomy ID : 5833
Gene Strand (Orientation) : ?
Protein Name : serine repeat antigen 5
Protein pI : 6.14
Protein Weight : 28688.67
Protein Length : 362
Protein Note : Serine-repeat antigen protein; Provisional

Protein Sequence : Show Sequence

>ACR49652.1 serine repeat antigen 5, partial [Plasmodium falciparum]
TGGGQAGNTGGGQAGNTGGGQAGNTVGDQAGSTGGSPQGSTGASQPGSSEPSNPVSSGHSVSTVSVSQTS
TSSEKQDTIQVKSALLKDYMGLKVTGPCNENFIMFLVPHIYIDVDTEDTNIELRTTLKKTNNAISFESNS
GSLEKKKYVKLPSNGTTGEQGSSTGTVRGDTEPISDSSSSSSSSSSSSSSSSSSSSSSSESLPANGPDSP
TVKPPRNLQNICETGKNFKLVVYIKENTLILKWKVYGETKDTTENNKVDVRKYLINEKETPFTNILIHAY
KEHNEQT

Molecule Role : Protective antigen
Molecule Role Annotation : Researchers constructed a new recombinant molecule of SERA5, namely SE36. Vaccination of Squirrel monkeys with SE36 protein and aluminium hydroxyl gel (SE36/AHG) conferred protection against high parasitemia and boosted serum anti-SE36 IgG after P. falciparum parasite challenge (Horii et al., 2010).
Related Vaccine(s): P. falciparum Subunit SE36 Protein Vaccine

52. SSP2

Gene Name : SSP2
Sequence Strain (Species/Organism) : Plasmodium yoelii
NCBI Gene ID : 3830241
NCBI Protein GI : 45645179
Other Database IDs : CDD:240420
CDD:238748
CDD:214559
Taxonomy ID : 73239
Gene Strand (Orientation) : ?
Protein Name : Sporozoite surface protein 2
Protein pI : 4.42
Protein Weight : 90008.58
Protein Length : 925
Protein Note : sporozoite surface protein 2 (SSP2); Provisional

Protein Sequence : Show Sequence

>sp|Q01443.2|SSP2_PLAYO RecName: Full=Sporozoite surface protein 2; Flags: Precursor
MKLLGNSKYIFVVLLLCISVFLNGQETLDEIKYSEEVCTEQIDIHILLDGSGSIGYSNWKAHVIPMLNTL
VDNLNISNDEINVSLTLFSTNSRELIKLKGYGSTSKDSLRFILAHLQNNYSPNGNTNLTSALLVVDTLIN
ERMYRPDAIQLAIILTDGIPNDLPRSTAVVHQLKRKHVNVAIIGVGAGVNNEYNRILVGCDRYAPCPYYS
SGSWNEAQNMIKPFLTKVCQEVERIAHCGKWEEWSECSTTCDEGRKIRRRQILHPGCVSEMTTPCKVRDC
PQIPIPPVIPNKIPEKPSNPEEPVNPNDPNDPNNPNNPNNPNNPNNPNNPNNPNNPNNPNNPNNPNNPNN
PNNPNNPNNPNNPNNPNNPNNPNNPNNPNNPNDPSNPNNPNPKKRNPKRRNPNKPKPNKPNPNKPNPNEP
SNPNKPNPNEPSNPNKPNPNEPSNPNKPNPNEPSNPNKPNPNEPLNPNEPSNPNEPSNPNAPSNPNEPSN
PNEPSNPNEPSNPNEPSNPNEPSNPKKPSNPNEPSNPNEPLNPNEPSNPNEPSNPNEPSNPEEPSNPKEP
SNPNEPSNPEEPNPEEPSNPKEPSNPEEPINPEELNPKEPSNPEESNPKEPINPEESNPKEPINPEDNEN
PLIIQDEPIEPRNDSNVIPILPIIPQKGNNIPSNLPENPSDSEVEYPRPNDNGENSNNTMKSKKNIPNEP
IPSPGDNPYKGHEERIPKPHRSNDDYVYDNNVNKNNKDEPEIPNNEYEEDKNKNQSKSNNGYKIAGGIIG
GLAILGCAGVGYNFIAGSSAAGLAGAEPAPFEDVIPDDDKDIVENEQFKLPEDNDWN

Molecule Role : Protective antigen
Related Vaccine(s): P. yoelii DNA vaccine encoding PySSP2

53. SSP2 from P. knowlesi

Gene Name : SSP2 from P. knowlesi
Sequence Strain (Species/Organism) : Plasmodium knowlesi strain H
NCBI Gene ID : 7322479
NCBI Protein GI : 221058683
Other Database IDs : CDD:240420
EnsemblGenomes-Gn:PKH_121770
EnsemblGenomes-Tr:PKH_121770
InterPro: IPR000884
InterPro: IPR002035
UniProtKB/TrEMBL: B3L8N1
Taxonomy ID : 5851
Gene Strand (Orientation) : ?
Protein Name : sporozoite surface protein 2, putative
Protein pI : 4.27
Protein Weight : 60249.802
Protein Length : 675
Protein Note : sporozoite surface protein 2 (SSP2); Provisional

Protein Sequence : Show Sequence

>XP_002259987.1 sporozoite surface protein 2, putative [Plasmodium knowlesi strain H]
MKLLQNKSYLLVVFLLYVSIFARGDQKIVDEVKYNEEVCNEKVDLYLLVDGSGSIGYANWITRVIPMLTG
LIENLNLSKDSINLYMSLFASHTTELIRLGSGPSMDKKQALNVVRDLRKGYEPYGNTSMSSALSEVEMHL
KDRVNRPNAIQLVILMTDGIPNNKYRALELSRALKERNVKLAVIGIGQGINHQYNKLMAGCRPRERSCKF
YSSADWSEAISLIKPFIAKVCTEVERIAKCGPWDDWTPCSVTCGKGTHSRSRPLLHAGCTTHMVKECEMD
ECPVEPEPVPVPAPVPPTPEDENPRTTDEEDDHPNFHQGLDVPDVENDVPPENDGGDGNPFEENFFPPGD
DTVPDESNVIPVPPTVPGGSNSEFSSDVENAAQYPENPENPENPENSENPENPENQNNPEDFPMEPDMSA
DNKINEPTNPSDSGQGIPENVIPTPINNEKDIINKNKAVYPNGSNQSHDRYPKPHRNAGGYDNNPNANSD
IPEGPFSSEEEQPEDKGKKSSNNGYKIAGGVIAGLALVGCVGFAYNFVSSGGAAGMAGEPAPFDEAMAED
EKDAGEADQFKLPEDNDWN

Molecule Role : Protective antigen
Related Vaccine(s): P. knowlesi DNA vaccine encoding PkCSP, PkSSP2, PkAMA1, and PkMSP1p42

54. SSP2 from Plasmodium falciparum

Gene Name : SSP2 from Plasmodium falciparum
Sequence Strain (Species/Organism) : Plasmodium falciparum
NCBI Protein GI : 160691
Other Database IDs : CDD:185620
CDD:29244
CDD:199489
Taxonomy ID : 5833
Gene Strand (Orientation) : ?
Protein Name : sporozoite surface protein 2
Protein Length : 574
Protein Note : sporozoite surface protein 2 (SSP2); Provisional

Protein Sequence : Show Sequence

>gi|160691|gb|AAA29767.1| sporozoite surface protein 2 [Plasmodium falciparum]
MNHLGNVKYLVIVFLIFFDLFLVNGRDVQNNIVDEIKYREEVCNDEVDLYLLMDCSGSIRRHNWVNHAVP
LAMKLIQQLNLNDNAIHLYASVFSNNAREIIRLHSDASKNKEKALIIIKSLLSTNLPYGKTNLTDALLQV
RKHLNDRINRENANQLVVILTDGIPDSIQDSLKESRKLSDRGVKIAVFGIGQGINVAFNRFLVGCHPSDG
KCNLYADSAWENVKNVIGPFMKAVCVEVEKTASCGVWDEWSPCSVTCGKGTRSRKREILHEGCTSELQEQ
CEEERCLPKREPLDVPDEPEDDQPRPRGDNFAVEKPNENIIDNNPQEPSPNPEEGKGENPNGFDLDENPE
NPPNPPNPPNPPNPPNPPNPDIPEQEPNIPEDSEKEVPSDVPKNPEDDREENFDIPKKPENKHDNQNNLP
NDKSDRYIPYSPLSPKVLDNERKQSDPQSQDNNGNRHVPNSEDRETRPHGRNNENRSYNRKHNNTPKHPE
REEHEKPDNNKKKAGSDNKYKIAGGIAGGLALLACAGLAYKFVVPGAATPYAGEPAPFDETLGEEDKDLD
EPEQFRLPEENEWN

Molecule Role : Protective antigen
Related Vaccine(s): NYVAC-Pf7

55. STARP

Gene Name : STARP
Sequence Strain (Species/Organism) : Plasmodium falciparum
Other Database IDs : PlasmoDB:PF07_0006
Chromosome No : 7
Gene Starting Position : 152127
Gene Ending Position : 154096
Gene Strand (Orientation) : ?
Protein Name : starp antigen

DNA Sequence : Show Sequence

>PF07_0006 |||starp antigen|Plasmodium falciparum|chr 7|SANGER| unspliced DNA
ATGATACATA TTTTTTATAG GACAGCCATA TTTACTCTCT CAATCTGGAC AACACTGTTA
TATTCTAATA AAGTAAGATA AAAAGAATTA GAATTAAAAA TTGAAAATTA AAATTTAAAA
ATGATATATA TGCAAATAAT TTTAATTATA TATATATATA TATATATATA TATATATATG
TATCTTTTTA TTTTTCCAAT ACATATTTAA TATATAATTA TTTATATTTT TTTTTTTTTT
TTAATATTAC TTTTTAGAAT TTAAAATGTA ATTTTTATTA TAATAACAAC AACTTATCAA
CATACGTTAT AAAGCATAAC AGATTTTTAT CAGAATATCA ATCGAACTTT CTTGGTGGGG
GATATAGTGC AGCTTTAAAA TTAGTAAATA GTAAAAAATC CGGAACAAAT GTAAATACAA
AGTATAATTC AGAAAATACC AATACAAATA ATAATATACC AGAAAGTAGT AGTACATATA
CAAATACAAG GTTAGCAGCA AATAACAGTA CAACTACAAG CACTACAAAA GTAACAGATA
ATAATAAAAC AAATATTAAA TTAACAGGAA ACAATAGTAC AACTATAAAT ACAAATTCAA
CAGAAAATAC TAGTGCTACC AAAAAAGTAA CCGAAAATGT TATTACAAAT CAAATATTAA
CAGGAAATAA CAATACAACC ACAAATACAT CCACGACAGA ACATAATAAT AATATTAACA
CAAATACAAA TTCAACAGAA AATACTAGTG CTACCAAAAA AGTAACCGAA AATGTTATTA
CAAATCAAAT ATTAACAGGA AATAACAATA CAACCACAAA TACATCCACG ACAGAACATA
ATAATAATAT TAACACAAAT ACAAATTCAA CAGATAATAG TAATACTAAT ACAAATTTAA
CCGATAATAC TTCTACAACT AAAAAGTTGA CTGATAATAT AAACACAACA CAAAATTTAA
CAACAAGTAC TAATACAACT ACAGTATCAA CCGATAATAA TAATATAAAT ACAAAACCCA
TTGATAATAA TAACACAGAT ATAAAATCGA CAGATAATTA TAACACAGGC ACAAAGGAAA
CAGATAATAA GAACACAGAC ATAAAAGCAA CAGACAATAA TAATATTACA ACAACCACGG
ATAATACTAA TACAAATGTA ATATCAACAG ATAATAGTAA AACAAATGTA ATATCAACAG
ATAATAGTAA AACAAATACA ATATCAACAG ATAATGATAA TGCAGATACA ATATTAACAG
ATAATGATAA TAATACAGAT ATAATATTAA CAGATAATAA TAATACAGAT ACAATATCAA
CAGATAATGA TAATGCAGAT ACAAAAGCAA CAGATAATAA TAATAATACA AATACAAAAG
CAACAGATAA TAATAATACA AAAATAATAT CACCAGATAA TAATAATACA AAAACAACAT
CAACAGATAA TAATAATAAT ACAAATACAA AAGCAACAGA TAATAATAAT ACAAAAACAA
TATCAAACGA TAATAATAAT ACAAAAACAA TATCAACAGA TAATAATAAT ACAAAAACAA
TATCAAACGA TAATAATAAT ACAAATACAA TATCAACAGA TAATAATAAT AATAATACAA
ACCAATATGT CTTTGCTAAC AATTATAATG AAACAACTTC TGATGATGAA CTAAATAAAG
ATTCCTGTGA TTATTCAGAA GAAAAAGAAA ATATAAAATC AATGATTAAC GCTTATTTAG
ACAAGTTAGA TTTAGAAACT GTTCGTAAAA TACATTCAGA TATAAGTACA TGTATTGAAA
AAAAAAATAA TCCTAGGAAT CAAATAACAC ATTTAAACAA TTTAAAAAAT ATGTATAATA
TAATTAAATT TATAGTGGTT ATATATATTG CTTTTAATTG GAGTGAAGTA ATATATAAAT
ATGTAGGAAA ATTAATTTTA GCTTTTGCTT TATATATGTT AATTAATTAA

>PF07_0006 |||starp antigen|Plasmodium falciparum|chr 7|SANGER|Spliced DNA
ATGATACATA TTTTTTATAG GACAGCCATA TTTACTCTCT CAATCTGGAC AACACTGTTA
TATTCTAATA AAAATTTAAA ATGTAATTTT TATTATAATA ACAACAACTT ATCAACATAC
GTTATAAAGC ATAACAGATT TTTATCAGAA TATCAATCGA ACTTTCTTGG TGGGGGATAT
AGTGCAGCTT TAAAATTAGT AAATAGTAAA AAATCCGGAA CAAATGTAAA TACAAAGTAT
AATTCAGAAA ATACCAATAC AAATAATAAT ATACCAGAAA GTAGTAGTAC ATATACAAAT
ACAAGGTTAG CAGCAAATAA CAGTACAACT ACAAGCACTA CAAAAGTAAC AGATAATAAT
AAAACAAATA TTAAATTAAC AGGAAACAAT AGTACAACTA TAAATACAAA TTCAACAGAA
AATACTAGTG CTACCAAAAA AGTAACCGAA AATGTTATTA CAAATCAAAT ATTAACAGGA
AATAACAATA CAACCACAAA TACATCCACG ACAGAACATA ATAATAATAT TAACACAAAT
ACAAATTCAA CAGAAAATAC TAGTGCTACC AAAAAAGTAA CCGAAAATGT TATTACAAAT
CAAATATTAA CAGGAAATAA CAATACAACC ACAAATACAT CCACGACAGA ACATAATAAT
AATATTAACA CAAATACAAA TTCAACAGAT AATAGTAATA CTAATACAAA TTTAACCGAT
AATACTTCTA CAACTAAAAA GTTGACTGAT AATATAAACA CAACACAAAA TTTAACAACA
AGTACTAATA CAACTACAGT ATCAACCGAT AATAATAATA TAAATACAAA ACCCATTGAT
AATAATAACA CAGATATAAA ATCGACAGAT AATTATAACA CAGGCACAAA GGAAACAGAT
AATAAGAACA CAGACATAAA AGCAACAGAC AATAATAATA TTACAACAAC CACGGATAAT
ACTAATACAA ATGTAATATC AACAGATAAT AGTAAAACAA ATGTAATATC AACAGATAAT
AGTAAAACAA ATACAATATC AACAGATAAT GATAATGCAG ATACAATATT AACAGATAAT
GATAATAATA CAGATATAAT ATTAACAGAT AATAATAATA CAGATACAAT ATCAACAGAT
AATGATAATG CAGATACAAA AGCAACAGAT AATAATAATA ATACAAATAC AAAAGCAACA
GATAATAATA ATACAAAAAT AATATCACCA GATAATAATA ATACAAAAAC AACATCAACA
GATAATAATA ATAATACAAA TACAAAAGCA ACAGATAATA ATAATACAAA AACAATATCA
AACGATAATA ATAATACAAA AACAATATCA ACAGATAATA ATAATACAAA AACAATATCA
AACGATAATA ATAATACAAA TACAATATCA ACAGATAATA ATAATAATAA TACAAACCAA
TATGTCTTTG CTAACAATTA TAATGAAACA ACTTCTGATG ATGAACTAAA TAAAGATTCC
TGTGATTATT CAGAAGAAAA AGAAAATATA AAATCAATGA TTAACGCTTA TTTAGACAAG
TTAGATTTAG AAACTGTTCG TAAAATACAT TCAGATATAA GTACATGTAT TGAAAAAAAA
AATAATCCTA GGAATCAAAT AACACATTTA AACAATTTAA AAAATATGTA TAATATAATT
AAATTTATAG TGGTTATATA TATTGCTTTT AATTGGAGTG AAGTAATATA TAAATATGTA
GGAAAATTAA TTTTAGCTTT TGCTTTATAT ATGTTAATTA ATTAA

Protein Sequence : Show Sequence

>PF07_0006 |||starp antigen|Plasmodium falciparum|chr 7|SANGER||Manual
MIHIFYRTAI FTLSIWTTLL YSNKNLKCNF YYNNNNLSTY VIKHNRFLSE YQSNFLGGGY
SAALKLVNSK KSGTNVNTKY NSENTNTNNN IPESSSTYTN TRLAANNSTT TSTTKVTDNN
KTNIKLTGNN STTINTNSTE NTSATKKVTE NVITNQILTG NNNTTTNTST TEHNNNINTN
TNSTENTSAT KKVTENVITN QILTGNNNTT TNTSTTEHNN NINTNTNSTD NSNTNTNLTD
NTSTTKKLTD NINTTQNLTT STNTTTVSTD NNNINTKPID NNNTDIKSTD NYNTGTKETD
NKNTDIKATD NNNITTTTDN TNTNVISTDN SKTNVISTDN SKTNTISTDN DNADTILTDN
DNNTDIILTD NNNTDTISTD NDNADTKATD NNNNTNTKAT DNNNTKIISP DNNNTKTTST
DNNNNTNTKA TDNNNTKTIS NDNNNTKTIS TDNNNTKTIS NDNNNTNTIS TDNNNNNTNQ
YVFANNYNET TSDDELNKDS CDYSEEKENI KSMINAYLDK LDLETVRKIH SDISTCIEKK
NNPRNQITHL NNLKNMYNII KFIVVIYIAF NWSEVIYKYV GKLILAFALY MLIN

56. TRAP from P. falciparum

Gene Name : TRAP from P. falciparum
Sequence Strain (Species/Organism) : Plasmodium falciparum 3D7
VO ID : VO_0010920
NCBI Gene ID : 814170
NCBI Protein GI : 124513464
Locus Tag : PF3D7_1335900
Genbank Accession : AL844509
Protein Accession : XP_001350088
Taxonomy ID : 36329
Chromosome No : 13
Gene Starting Position : 1464894
Gene Ending Position : 1466618
Gene Strand (Orientation) : -
Protein Name : Thrombospondin-related anonymous protein (TRAP), SSP-2, SSP2, Sporozoite specific protein 2, Sporozoite surface protein 2
Protein pI : 4.7
Protein Weight : 61465.35
Protein Length : 574

DNA Sequence : Show Sequence

>NC_004331.3:1464894-1466618 Plasmodium falciparum 3D7 chromosome 13
TTTAATTCCACTCGTTTTCTTCAGGTAATCTGAATTGTTCAGGTTCGTCCAAATCTTTATCTTCTTCACC
TAATGTTTCATCAAAAGGTGCAGGTTCTCCGGCATAGGGTGTTGCTGCTCCTGGTACTACGAATTTATAA
GCAAGTCCAGCACATGCGAGTAAAGCTAATCCTCCAGCTATTCCACCTGCAATTTTATATTTATTATCTG
ATCCTGCTTTTTTTTTATTATTATCTGGCTTTTCATGTTCTTCCCTTTCAGGATGTTTTGGAGTATTGTT
ATGTTTTCTATTGTATGATCTATTTTCATTATTTCTACCATGTGGACGTGTTTCTCTATCTTCACTATTA
GGTACGTGCCTATTTCCATTATTATCTTGACTTTGGGGGTCACTTTGTTTCCTTTCATTATCCAAAACTT
TTGGAGATAATGGTGAATATGGAATATATCTATCACTTTTATCATTTGGTAAATTATTTTGATTATCGTG
CTTATTTTCGGGTTTCTTTGGAATATCAAAGTTTTCTTCTCGATCGTCTTCTGGATTTTTTGGAACATCA
GAAGGTACTTCTTTTTCTGAATCTTCAGGTATATTTGGTTCTTGTTCAGGAATATCTGGATTTGGTGGAT
TTGGTGGATTTGGTGGATTTGGTGGATTTGGTGGATTTGGTGGATTTTCTGGATTTTCATCTAAATCAAA
TCCGTTTGGATTTTCACCCTTTCCTTCTTCTGGATTTGGTGAAGGTTCTTGTGGATTATTATCTATTATA
TTTTCGTTTGGTTTTTCGACAGCAAAATTATCTCCTCTTGGTCTAGGTTGATCATCTTCGGGTTCATCTG
GAACATCTAATGGTTCCCGTTTTGGAAGACATCTTTCTTCTTCACATTGTTCTTGTAATTCACTTGTACA
TCCTTCGTGTAAGATTTCTCTTTTTCTTGACCTGGTACCTTTACCACAAGTTACACTACATGGAGACCAT
TCGTCCCAAACACCACAACTTGCTGTTTTTTCTACTTCAACACAAACAGCCTTCATAAAGGGTCCGATAA
CATTTTTTACATTTTCCCATGCAGAATCAGCATACAAGTTACATTTACCATCTGATGGATGACAACCTAC
AAGAAATCTGTTGAAAGCTACATTAATACCTTGTCCAATACCAAAAACAGCTATTTTAACACCACGATCA
CTTAATTTTCTTGATTCTTTTAATGAATCTTGAATACTATCTGGAATTCCATCTGTTAATATAACAACTA
ATTGATTAGCATTCTCTCTATTGATTCGGTCATTTAAATGTTTTCTTACTTGTAACAGTGCATCAGTTAA
GTTTGTTTTACCATATGGAAGATTTGTACTTAAGAGTGACTTTATAATAATTAAAGCCTTCTCTTTGTTT
TTAGATGCATCACTATGTAATCTAATAATTTCTCTTGCATTGTTTGAAAAAACACTAGCATATAAGTGAA
TTGCATTATCATTAAGATTTAATTGTTGTATCAATTTCATAGCTAGAGGTACTGCATGGTTCACCCAATT
ATGACGACGTATACTTCCAGAACAATCCATTAGAAGGTAAAGATCTACCTCATCATTACATACTTCTTCA
CGATATTTTATTTCATCCACTATATTGTTTTGCACATCTCTACCATTAACTAGAAACAAATCAAAGAAAA
TCAAAAACACAATGACTAAATATTTAACATTCCCAAGATGATTCA

Protein Sequence : Show Sequence

>XP_001350088.1 thrombospondin-related anonymous protein [Plasmodium falciparum 3D7]
MNHLGNVKYLVIVFLIFFDLFLVNGRDVQNNIVDEIKYREEVCNDEVDLYLLMDCSGSIRRHNWVNHAVP
LAMKLIQQLNLNDNAIHLYASVFSNNAREIIRLHSDASKNKEKALIIIKSLLSTNLPYGKTNLTDALLQV
RKHLNDRINRENANQLVVILTDGIPDSIQDSLKESRKLSDRGVKIAVFGIGQGINVAFNRFLVGCHPSDG
KCNLYADSAWENVKNVIGPFMKAVCVEVEKTASCGVWDEWSPCSVTCGKGTRSRKREILHEGCTSELQEQ
CEEERCLPKREPLDVPDEPEDDQPRPRGDNFAVEKPNENIIDNNPQEPSPNPEEGKGENPNGFDLDENPE
NPPNPPNPPNPPNPPNPPNPDIPEQEPNIPEDSEKEVPSDVPKNPEDDREENFDIPKKPENKHDNQNNLP
NDKSDRYIPYSPLSPKVLDNERKQSDPQSQDNNGNRHVPNSEDRETRPHGRNNENRSYNRKHNNTPKHPE
REEHEKPDNNKKKAGSDNKYKIAGGIAGGLALLACAGLAYKFVVPGAATPYAGEPAPFDETLGEEDKDLD
EPEQFRLPEENEWN

Molecule Role : Protective antigen
Related Vaccine(s): ChAd63-MVA ME-TRAP , P. falciparum DNA and MVA encoding ME-TRAP

57. UIS3

Gene Name : UIS3
Sequence Strain (Species/Organism) : Plasmodium yoelii yoelii str. 17XNL
NCBI Gene ID : 3830198
NCBI Protein GI : 83315853
Locus Tag : PY03011
Genbank Accession : AABL01000850
Protein Accession : XP_730972
3D structure: PDB ID : 2VWA
Taxonomy ID : 352914
Gene Starting Position : 1385
Gene Ending Position : 2296
Gene Strand (Orientation) : -
Protein pI : 9.63
Protein Weight : 26806.7
Protein Length : 241

DNA Sequence : Show Sequence

>gi|221228555:1385-2296 Plasmodium yoelii yoelii str. 17XNL MALPY00853, whole genome shotgun sequence
TTCATTTTGGTTGATATTGTTCTTTAAGAAAATGCTCCACGCCTAAAACTGCGATATCTTCTTGGGCTCT
TGAAATATTAACATCCTTATTTTCATCTAAAGTCTGGACAATTTTCCTTAAGTAATCATAATCCTTGATT
AAATATTTCTGTTGTTCATTTGATAAATTGCTGAAATGGTGTTTAGCAGCTAGTTTCACATTATCCATAA
ATGTATTAAACCTTTTCAAAGGAACATCAATATCATTATTGTTTTCTTTTAATTTTCCTTTTATATTTAC
TTTATTTACTCCTAATGGTTCTTCATATTTTGTACTAGTGCTTGGTTTTTCACCATCAGGTTGTTTATAT
TCTGTTTGTTTATTAAAGGGGAAAAAATTAAAACCTTTATTCCAATCATGTCTTCCTTTATTATGAGATT
TATACATATAATAAAGTACCCCAATAACACTTGCCACTAATCCTGATGATAACAAAGCAATTGCAACTGA
TTTCCTCTTCTTTTTTTTTTTTATAGCAGTATCAATGCTATCTAATGCCCCATCATCTATTTCTGAATAA
TAATCTGCATCCTCACAAAAGCAAGGGTTAAAAAAAAATGTAGTAATATATAACACATAAAAAACGAAAA
AAACTTTGAGAGTGTTCATTTTATACACTTTCATATATTTTTTATTTGTCTAAGTAATAAAAAAAATTAA
ATTACTATAAAGATCAAATAATTATGTACAAATTTTTATCATTATTATTGTTAATATTATATTTTTTTTT
TATGTGTCAACAAAAAATTATTAAGCAAAGAATAATCTTTGAGTCACAATGATAAATGTGATGCTATTAT
AAATAATATTTCCTGTCAATCATACTCTAAAATATTTATTAATATAAATTATGCATGTGAAAAATTGAGG
CA

Protein Sequence : Show Sequence

>gi|83315853|ref|XP_730972.1| early transcribed membrane protein [Plasmodium yoelii yoelii str. 17XNL]
MPQFFTCIIYINKYFRTNKKYMKVYKMNTLKVFFVFYVLYITTFFFNPCFCEDADYYSEIDDGALDSIDT
AIKKKKKRKSVAIALLSSGLVASVIGVLYYMYKSHNKGRHDWNKGFNFFPFNKQTEYKQPDGEKPSTSTK
YEEPLGVNKVNIKGKLKENNNDIDVPLKRFNTFMDNVKLAAKHHFSNLSNEQQKYLIKDYDYLRKIVQTL
DENKDVNISRAQEDIAVLGVEHFLKEQYQPK

Molecule Role : Virmugen
Molecule Role Annotation : Deletion of UIS3 in Plasmodium yoelii provided attenuation and full protection in mice by Pyuis3(-) sporozoites required at least 2 immunizations against challenges with infectious sporozoites (Tarun et al., 2007).
Related Vaccine(s): P. yoelii UIS3 mutant vaccine

58. UIS4

Gene Name : UIS4
Sequence Strain (Species/Organism) : Plasmodium yoelii yoelii str. 17XNL
NCBI Gene ID : 3853948
NCBI Protein GI : 82753006
Locus Tag : PY00876
Genbank Accession : AABL01000235
Protein Accession : XP_727503
Other Database IDs : CDD:158776
CDD:152003
Taxonomy ID : 352914
Gene Starting Position : 896
Gene Ending Position : 1580
Gene Strand (Orientation) : +
Protein Name : upregulated in infective sporozoites 3
Protein pI : 9.56
Protein Weight : 20676.82
Protein Length : 184
Protein Note : Malarial early transcribed membrane protein (ETRAMP); cl09917

DNA Sequence : Show Sequence

>gi|221227283:896-1580 Plasmodium yoelii yoelii str. 17XNL MALPY00236, whole genome shotgun sequence
AATGAATAAAAGGATATTTAGTTTAGTTTGCATTGCCTTGTATACCCTTTTGACTGTACCAGCACATTGC
TCCGAACAGGAAGTAAGTTGTCAAAACAAAATATAAACTAATATATAGAAAATTATATAATAATCGTTAT
TTACATGTGGTGATGTATATATTAACGCATATATATATATATTAGTATATTCCCTTGTATGATCGATCTA
AGGTATCTGATGTAGGAAACAAAAGTGACGAAAAAAATGATATAGAATATAAACGTGAAACACAATTAAA
GAATACAAATTCTAAAGATGATAGAGGATTCAATTGTTTTAATATATTTAAAAAAAATAAAAGAACACAA
TCACATTCATATAGTAAAGTACCCTTAACTCATCCATATAATAAAATAACCGAAACATCTTCAAATAACA
ATGACTCTATTCATAAGATAGAATTGTTGATGGAAAAGATTGCCCGTTACTTTCTTGCAAACCATTCAGA
AATTTTAAAGTTTTTATCAAATAATAAAATAACCGAAGCATCTTCAAATAACAATGACGCTATTCATAAG
GTATCATTAGAGATGCGAAAAATTATGCGTGAACTTCTTGAAAAAAGTCCAGAAGGTTTAAAGTTATTGT
CACGATTAGCTGAAAAATTAGAAAAACGTCCTTCAAATGATAAACCAAGTGAATA

Protein Sequence : Show Sequence

>gi|82753006|ref|XP_727503.1| hypothetical protein [Plasmodium yoelii yoelii str. 17XNL]
MNKRIFSLVCIALYTLLTVPAHCSEQEVSDVGNKSDEKNDIEYKRETQLKNTNSKDDRGFNCFNIFKKNK
RTQSHSYSKVPLTHPYNKITETSSNNNDSIHKIELLMEKIARYFLANHSEILKFLSNNKITEASSNNNDA
IHKVSLEMRKIMRELLEKSPEGLKLLSRLAEKLEKRPSNDKPSE

Molecule Role : Virmugen
Molecule Role Annotation : A UIS4 mutant of Plasmodium yoelii is attenuated and a single dose of Pyuis4(-) sporozoites conferred complete protection against challenges with infectious sporozoites (Tarun et al., 2007).

III. Vaccine Information

1. Ad-MVA PvCelTOS

a. Type:

Recombinant vector vaccine

b. Status:

Research

c. Host Species for Licensed Use:

Human

d. Antigen

PvCelTOS: cell-traversal protein for ookinetes and sporozoites of P. vivax. A protein important for parasite traversal of host cells both for ookinetes in the mosquito and for sporozoites. (Alves et al., 2017)

e. Gene Engineering of PvCelTOS

Type: Recombinant protein preparation
Description:
Detailed Gene Information: Click here.

f. Vector:

(Ad): ChAd63: recombinant chimpanzee adenoviral vector 63
(MVA): MVA: modified vaccinia virus Ankara (Alves et al., 2017)

g. Immunization Route

Intramuscular injection (i.m.)

h. Description

PvCelTOS (Ad): Recombinant chimpanzee adenoviral vector 63 (ChAd63) expressing PvCelTOS.
PvCelTOS (MVA): Recombinant modified vaccinia virus Ankara (MVA) expressing PvCelTOS
**PvCelTOS (Ad) is the primary vaccination, and PvCelTOS (MVA) is the booster. (Alves et al., 2017)

i. Mouse Response

Vaccination Protocol: 3 groups of mice were used, each group includes 6 mice. Mice were intramuscularly inject prime immune 1*10^8 IU ChAd63-PvCelTOS, then intramuscularly injected one of the boosters 8 weeks later: 1*10^6 PFU per ml of 1) PvCelTOS (MVA), 2) PvCelTOS (VLPs), 3) PvCelTOS (protein) (Alves et al., 2017)
Immune Response: Humoral: anti-PvCelTOS antibody levels significantly increased after vaccination in both types of mice. Antibody responses were boosted with all three vaccine platforms.
Cellular:
CD-1: Mice in Ad-MVA group had significantly higher TNF-α levels (2.93% ± 0.72% comparing to 0.98% ± 0.42%) and IFN-γ levels(3.46% ± 0.699% and 1.36% ± 0.52%). No significant difference in IL-2 levels. The total anti-PvCelTOS cellular responses were low after background values subtraction (1.9% for TNF-α and 2.1% for IFN-γ. Only the value of IFN-γ significantly higher (P < 0.0001)).
BALB/c: All immunization regimens substantially higher levels of TNF-α- and IFN-γ-producing CD3+/CD8+ cells.
(Alves et al., 2017)
Challenge Protocol: Same prime-boost vaccination performed (6 mice in each BALB/c group, 10 mice in each CD1 group). Three set of mice were each challenged with 1000 sporozoits of 1) Pb-PvCelTOS (P. berghei expressing P. vivax CelTOS), 2) Wild-type P.berghei, and 3) Pb-PfCelTOS (P. berghei sporozoites expressing P. falciparum CelTOS). Sporozoits were intravenous injected 10 days after booster. Efficacy was determined by measuring the prepatent period (the time to reach 1% parasitemia after challenge). (Alves et al., 2017)
Efficacy: Pb-PvCelTOS:
CD1: Ad-MVA provided 10% sterile protection, not significantly higher than the control
BALB/c: no vaccination regimen conferred any protective efficacy even though it induced protective cellular and humoral immune responses.
Pb-PfCelTOS: no protective immunity in CD1 mice.
Wild-type P. berghei: no protective immunity from any immunization regimen in CD1 mice.
(Alves et al., 2017)

2. Ad-protein PvCelTOS

a. Type:

(Ad): Recombinant vector vaccine; (protein): Subunit Vaccine

b. Status:

Research

c. Host Species for Licensed Use:

Human

d. Antigen

e. Gene Engineering of PvCelTOS

Type: Recombinant protein preparation
Description:
Detailed Gene Information: Click here.

f. Vector:

(Ad): ChAd63: recombinant chimpanzee adenoviral vector 63
(protein): N/A (Alves et al., 2017)

g. Immunization Route

Intramuscular injection (i.m.)

h. Description

PvCelTOS (Ad): Recombinant chimpanzee adenoviral vector 63 (ChAd63) expressing PvCelTOS.
PvCelTOS (protein): PvCelTOS expressed as a protein using HEK293T cells, a eukaryotic cell expression system.
**PvCelTOS (Ad) is the primary vaccination, and PvCelTOS (protein) is the booster. (Alves et al., 2017)

i. Mouse Response

Host Strain: BALB/c mice and CD-1 mice (Alves et al., 2017)
Vaccination Protocol: 3 groups of mice were used, each group includes 6 mice. Mice were intramuscularly inject prime immune 1*10^8 IU ChAd63-PvCelTOS, then intramuscularly injected one of the boosters 8 weeks later: 1*10^6 PFU per ml of 1) PvCelTOS (MVA), 2) PvCelTOS (VLPs), 3) PvCelTOS (protein)
(Alves et al., 2017)
Immune Response: Humoral: anti-PvCelTOS antibody levels significantly increased after vaccination in both types of mice. Antibody responses were boosted with all three vaccine platforms, and boosting with protein in the Matrix-M adjuvant consistently elicited the highest titers.
Cellular:
CD-1: Mice in Ad-protein group had no significant cellular responses.
BALB/c: All immunization regimens substantially higher levels of TNF-α- and IFN-γ-producing CD3+/CD8+ cells.
(Alves et al., 2017)
Challenge Protocol: Same prime-boost vaccination performed (6 mice in each BALB/c group, 10 mice in each CD1 group). Three set of mice were each challenged with 1000 sporozoits of 1) Pb-PvCelTOS (P. berghei expressing P. vivax CelTOS), 2) Wild-type P.berghei, and 3) Pb-PfCelTOS (P. berghei sporozoites expressing P. falciparum CelTOS). Sporozoits were intravenous injected 10 days after booster. Efficacy was determined by measuring the prepatent period (the time to reach 1% parasitemia after challenge). (Alves et al., 2017)
Efficacy: Pb-PvCelTOS:
CD1: 30% sterile protection, significantly higher than control.
BALB/c: no vaccination regimen conferred any protective efficacy even though it induced protective cellular and humoral immune responses.
Pb-PfCelTOS: 20% protection in CD1 mice, significantly higher than control.
Wild-type P. berghei: no protective immunity from any immunization regimen in CD1 mice.
*Regardless of the parasite line, Ad-protein induced the highest levels of protection.
(Alves et al., 2017)

3. Ad-VLPs PvCelTOS

a. Type:

Recombinant vector vaccine

b. Status:

Research

c. Host Species for Licensed Use:

Human

d. Antigen

e. Gene Engineering of PvCelTOS

Type: Recombinant protein preparation
Description:
Detailed Gene Information: Click here.

f. Vector:

(Ad): ChAd63: recombinant chimpanzee adenoviral vector 63
(VLPs): VLPs: bacteriophage Qβ virus-like particles (Alves et al., 2017)

g. Immunization Route

Intramuscular injection (i.m.)

h. Description

PvCelTOS (Ad): Recombinant chimpanzee adenoviral vector 63 (ChAd63) expressing PvCelTOS.
PvCelTOS (VLPs): PvCelTOS conjugated to bacteriophage Qβ virus-like particles (VLPs)
**PvCelTOS (Ad) is the primary vaccination, and PvCelTOS (VLPs) is the booster. (Alves et al., 2017)

i. Mouse Response

Vaccination Protocol: 3 groups of mice were used, each group includes 6 mice. Mice were intramuscularly inject prime immune 1*10^8 IU ChAd63-PvCelTOS, then intramuscularly injected one of the boosters 8 weeks later: 1*10^6 PFU per ml of 1) PvCelTOS (MVA), 2) PvCelTOS (VLPs), 3) PvCelTOS (protein) (Alves et al., 2017)
Immune Response: Humoral: anti-PvCelTOS antibody levels significantly increased after vaccination in both types of mice. Antibody responses were boosted with all three vaccine platforms.
Cellular:
CD-1: Mice in Ad-VLPs group had no significant cellular responses.
BALB/c: All immunization regimens substantially higher levels of TNF-α- and IFN-γ-producing CD3+/CD8+ cells.
(Alves et al., 2017)
Challenge Protocol: Same prime-boost vaccination performed (6 mice in each BALB/c group, 10 mice in each CD1 group). Three set of mice were each challenged with 1000 sporozoits of 1) Pb-PvCelTOS (P. berghei expressing P. vivax CelTOS), 2) Wild-type P.berghei, and 3) Pb-PfCelTOS (P. berghei sporozoites expressing P. falciparum CelTOS). Sporozoits were intravenous injected 10 days after booster. Efficacy was determined by measuring the prepatent period (the time to reach 1% parasitemia after challenge). (Alves et al., 2017)
Efficacy: Pb-PvCelTOS:
CD1: 30% sterile protection, significantly higher than control.
BALB/c: no vaccination regimen conferred any protective efficacy even though it induced protective cellular and humoral immune responses.
Pb-PfCelTOS: no protective immunity in CD1 mice.
Wild-type P. berghei: no protective immunity from any immunization regimen in CD1 mice.
(Alves et al., 2017)

4. AMA 49-CPE

a. Type:

Virosome-formulated synthetic peptides

b. Status:

Clinical trial

c. Host Species for Licensed Use:

Human

d. Antigen

A virosome-formulated P. falciparum protein derived synthetic peptide antigen (Genton et al., 2007)

e. Gene Engineering of AMA1 from P. falciparum 3D7

Type: Conjugate vaccine preparation
Description: AMA 49-CPE is prepared as an apical membrane antigen-1 (AMA-1) derived synthetic phospatidylethanolamine (PE)-peptide conjugate (Genton et al., 2007)
Detailed Gene Information: Click here.

f. Immunization Route

Intramuscular injection (i.m.)

g. Description

AMA 49-CPE is an apical membrane antigen-1 (AMA-1) derived synthetic phospatidylethanolamine (PE)-peptide conjugate that serves as a malaria vaccine (Genton et al., 2007)

h. Human Response

Host Strain: healthy Caucasian volunteers aged 18-45 years
Immune Response: 50 microg antigen dose was associated with a higher mean antibody titer and seroconversion rate than the 10 microg dose (Genton et al., 2007)
Side Effects: 11/46 study participants reported 16 vaccine related local AEs of being in pain (Genton et al., 2007)

5. AMA1-C1Alhydrogel

a. Type:

Subunit vaccine

b. Status:

Clinical trial

c. Host Species for Licensed Use:

Human

d. Antigen

AMA1-C1(Malkin et al., 2005): Apical membrane antigen 1. An 83-kDa antigen that may be involved in the process of erythrocyte invasion (Hodder et al., 2001).

e. Gene Engineering of AMA1 from P. falciparum 3D7

Type: Recombinant protein preparation
Description: An equal mixture of recombinant proteins based on sequences from the FVO and 3D7 P. falciparum, expressed in Pichia pastoris and adsorbed on Alhydrogel. (Malkin et al., 2005)
Detailed Gene Information: Click here.

f. Immunization Route

Intramuscular injection (i.m.)

g. Human Response

Vaccination Protocol: Open-label, dose-escalating phase 1 clinical trial
Ten volunteers in each of three dose groups (5 μg, 20 μg, and 80 μg of AMA1-C1) were vaccinated by a 0.5-ml intramuscular injection on study days 0, 28, and 180 (Malkin et al., 2005).
Immune Response: Anti-AMA1 IgG antibodies: Two weeks after the second vaccination, 20%, 55%, and 89% individuals in 5-μg, 20-μg, and 80-μg groups respectively had detectable antibody responses to AMA1-3D7, and 20%, 55%, and 78% had detectable antibody responses to AMA1-FVO. There was significant dose-response relationship for both responses in the all groups on day 42. Antibody levels declined and became undetectable in 53% responders for the AMA1-3D7 and 43% responders for AMA1-FVO on ay180. 92% individuals boosted their antibody levels two weeks after the third vaccination, . Antibody responses from the 5-μg, 20-μg, and 80-μg groups were 153, 1,041, and 978 U on average for AMA-3D7 and 113, 649, and 712 U on average for AMA-FVO. A relationship was found between antigen dose and antibody response to AMA1-FVO two weeks after the third vaccination. Antibody level declined on day 364. (Malkin et al., 2005)
Significant AMA specific inhibition of both P. falciparum 3D7 and FVO growth was achieved in the in vitro growth inhibition assay. (Malkin et al., 2005)
Side Effects: Mild or moderate headaches, nausea, malaise and localized myalgia. (Malkin et al., 2005)

6. AMA1-C1Alhydrogel + CPG 7909

a. Type:

Subunit vaccine

b. Status:

Clinical trial

c. Host Species for Licensed Use:

Human

d. Antigen

AMA1-C1 (NIAID, 2006): Apical membrane antigen 1. An 83-kDa antigen that may be involved in the process of erythrocyte invasion (Hodder et al., 2001).

e. Gene Engineering of AMA1 from P. falciparum 3D7

Type: Recombinant protein preparation
Description: An equal mixture of recombinant proteins based on sequences from the FVO and 3D7 P. falciparum, expressed in Pichia pastoris and adsorbed on Alhydrogel. (Malkin et al., 2005)
Detailed Gene Information: Click here.

f. Immunization Route

Intramuscular injection (i.m.)

g. Human Response

Vaccination Protocol: Double blind Phase 1 trial
24 participants were randomly assigned to one of the two groups: 12 volunteers will receive two doses of 80 microgram AMA1-C1/Alhydrogel + 500 microgram CPG; 12 volunteers will receive 80 microgram AMA1-C1/Alhydrogel, both at a 1-month dosing interval. (NIAID, 2006)

7. BDES-PfCSP (baculovirus dual expression system)

a. Vaccine Ontology ID:

VO_0004801

b. Type:

Recombinant vector vaccine

c. Status:

Research

d. Host Species for Licensed Use:

Mouse

e. Preparation

(Iyori et al., 2013)

f. Immunization Route

Intramuscular injection (i.m.)

8. ChAd63 -PvTRAP

a. Vaccine Ontology ID:

VO_0004797

b. Type:

Recombinant vector vaccine

c. Status:

Research

d. Host Species for Licensed Use:

Mouse

e. Preparation

(Bauza et al., 2014) the recombinant ChAd63 vectors expressing P. vivax TRAP (PvTRAP).

f. Immunization Route

Intramuscular injection (i.m.)

9. ChAd63 MVA PvDBP

a. Type:

Recombinant vector vaccine

b. Status:

Clinical trial

c. Host Species for Licensed Use:

Human

d. Antigen

PvDBPII: region II of P. vivax Duffy-binding protein (Hou et al., 2022)

e. Gene Engineering of PvDBPII

Type: Recombinant protein preparation
Description: Region II of PvDBP, a 327-amino acid domain. (Hou et al., 2022)
Detailed Gene Information: Click here.

f. Vector:

ChAd63: Chimpanzee adenovirus: vector for prime vaccination (Hou et al., 2022), MVA: modified vaccinia Ankara: vector for booster vaccination (Hou et al., 2022)

g. Immunization Route

Intramuscular injection (i.m.)

h. Description

Prime-boosting vaccine that use different vectors: ChAd63 PvDBP is the prime vaccination and MVA PvDBP is the booster. (Hou et al., 2022)

i. Human Response

Vaccination Protocol: Non-randomized, Phase IIa study.
Group 1 participants received 5 x 10^10 vp ChAd63 PvDBP and 2 x 10^8 pfu MVA PvDBP 8 weeks later, followed by CHMI 2–4 weeks later. Group 2 received one dose of 5 x 10^10 vp ChAd63 PvDBP, and 12-18 months later received a second dose of 5 x 10^10 vp ChAd63 PvDBP and 8 weeks later 2 x 10^8 pfu MVA PvDBP. Group 3 participants received 5 x 10^10 vp ChAd63 PvDBP and 2 x 10^8 pfu MVA PvDBP 8 weeks later, followed by CHMI 2–4 weeks later. Group 3 participants received the first dose 2 years later than participants in group 1 and had CHMI at the same time with participants in Group 2. (Hou et al., 2022)
Challenge Protocol: CHMI 2–4 weeks after booster vaccination (Hou et al., 2022)
Efficacy: All volunteers developed parasitemia. There was no significant difference in PMR or LCP compared to the controls. (Hou et al., 2022)

10. ChAd63-MVA AMA1

a. Type:

Recombinant vector vaccine

b. Status:

Clinical trial

c. Host Species for Licensed Use:

Human

d. Antigen

AMA1: apical membrane antigen 1 of P. falciparum(Sheehy et al., 2012)

e. Gene Engineering of AMA1 from P. falciparum 3D7

Type: Recombinant protein preparation
Description:
Detailed Gene Information: Click here.

f. Vector:

ChAd63: replication-deficient chimpanzee adenovirus: vector for prime vaccination (Sheehy et al., 2012); MVA: attenuated orthopoxvirusmodified vaccinia virus Ankara: vector for booster vaccination (Sheehy et al., 2012)

g. Immunization Route

Intramuscular injection (i.m.)

h. Description

Prime-boosting combination that use the same antigen but different vectors: ChAd63 MSP1 is the prime vaccination and MVA MSP1 is the booster.(Sheehy et al., 2012)

i. Human Response

Host Strain: malaria-naive adults from Oxford area(Sheehy et al., 2012)
Vaccination Protocol: Phase Ia, open-label, non-randomized blood stage malaria vaccine trial
Participants were divided into two groups: Group 1 (eight volunteers) received 5 × 10^9 viral particles ChAd63 AMA1 diluted in 0.9% NaCl and administered in 300 µL as primary vaccination, and four of these received 5 × 10^8 pfu MVA AMA1 undiluted and administered in 200 µL as booster 56 days later. Group 2 (8 volunteers) received 5 × 10^10 viral particles ChAd63 AMA1 undiluted and administered in 300 µL as primary vaccination, and four of these received MVA AMA1 as booster 56 days later: one received 2.5×10^8 pfu undiluted and administered in 100 µL, and the rest (three volunteers) received 1.25×10^8 pfu undiluted and administered in 50 µL. (Sheehy et al., 2012)
Immune Response: Cellular: peak of IFN-γ SFC response at day 14, no significant difference between the two groups (921 vs 933 SFU/million PBMCs in higher vs lower group). Responses contracted by day 56. After MVA MSP1: responses were significantly boosted, stronger response in the highest dose group (7186 vs 2631SFU/million PBMCs in 5×10^8 group vs lower dose group).CD4+ and CD8+ responses were detectable: CD8+ upregulated CD107a expression and produced IFN-γ and TNFα, and CD4+ produced high levels of TNFα.

Humoral: serum IgG antibody response detectable. Peak of antibody responses against AMA1 at day 28, significantly stronger responses in the higher dose group (109 vs 37 AU). Response declined slowly but was maintained at day 90. After MVA MSP1: responses were significantly boosted and reached peak at day 84, no significant difference between the lower dose groups and the highest dose group (1709 vs 949 AU). Response declined but was maintained at day 140 (971 vs 547 AU). (Sheehy et al., 2012)
Side Effects: Local: swelling, pruritus, warmth, erythema, and pain. Systematic: nausea, malaise, headache, fever, feverish, fatigue, arthralgia, and myalgia
Most AEs were mild in severity and all resolved completely. (Sheehy et al., 2012)

11. ChAd63-MVA ME-TRAP

a. Type:

Recombinant vector vaccine

b. Status:

Clinical trial

c. Host Species for Licensed Use:

Human

d. Antigen

ME-TRAP: multiple epitope thrombospondin-related adhesion protein of the pre-erythrocyte stage P.falciparum (Mensah et al., 2016)

e. Gene Engineering of TRAP from P. falciparum

Type: Recombinant vector construction
Description:
Detailed Gene Information: Click here.

f. Vector:

ChAd63: Chimpanzee adenovirus: vector for prime vaccination (Mensah et al., 2016), MVA: modified vaccinia Ankara: vector for booster vaccination (Mensah et al., 2016)

g. Immunization Route

Intramuscular injection (i.m.)

h. Description

Prime-boosting vaccine that use different vectors: ChAd63 ME-TRAP is the prime vaccination and MVA ME-TRAP is the booster.

i. Human Response

Host Strain: Healthy men aged 18–50 years old in the peri-urban area of Dakar in Senegal, West Africa.
Vaccination Protocol: Random, controlled, single-blinded phase IIb efficacy trial.
Participants radomly receive either 1) ChAd63 ME-TRAP (5x105 vp) as prime vaccination and MVA ME-TRAP (2x108 pfu) as booster eight weeks later or 2) two doses of anti-rabies vaccine (0.5ml) at the same interval. (Mensah et al., 2016)
Immune Response: Increases in anti-TRAP IgG responses.
Cellular immunogenicity: TRAP-specific T cells induced
14 days after prime vaccination: 261 SFC per million PBMC (95% CI 165–412) compared with 48 SFC (95% CI 30–79 SFC) in control group.
7 days after booster: 932 SFC (95% CI 754–1152) compared with 57 SFC per million (95% CI 44–72) in control group.
Humoral: TRAP peptide pools 1, 2, 3 and 6 frequently recognized: 66–93% positive response to these pools at the peak time point after MVA in TRAP group, comparing with 19% positive response to pool 3 and 10% positive response to pool 1 in control group. Positive correlation between humoral and cellular immunogenicity.
Neutralising antibodies to the ChAd63 vector detected: LGMT of 216 (95% CI 188–247), 56% responses above the clinically relevant threshold of 200.(Mensah et al., 2016)
Side Effects: ChAd63: Solicited local AEs: Mild or moderate pain, itching, redness, swelling, and warmth. Systematic AEs: fever, myalgia, discomfort, headache, arthralgia, and nausea.
MVA: more reactogenic than ChAd63, but still tolerable for the majority. Solicited local AEs: swelling, pain, itching, and warmth (last between a few hours to 2 days). Systematic AEs: arthralgia, fever, headache, myalgia, nausea, and discomfort (Mensah et al., 2016)
Efficacy: PCR positive cases:12 of 57 in TRAP group, 13 of 58 in controls: 8% efficacy, but not statistically significant.
Malaria cases: 11 in TRAP group, 12 in control group: unadjusted efficacy of 9%, non-significant.
*protocol-specified metaanalysis after pooling the data of the Kenyan and Senegalese trials showed significant protective efficacy of 50% (95% CI 17%-70%). (Mensah et al., 2016)

12. ChAd63-MVA MSP1

a. Type:

Recombinant vector vaccine

b. Status:

Clinical trial

c. Host Species for Licensed Use:

Human

d. Antigen

MSP1: merozoite surface protein 1 of P.falciparum(Sheehy et al., 2011)

e. Gene Engineering of MSP-1 from P. falciparum

Type: Recombinant protein preparation
Description: conserved blocks of P. falciparum MSP1 sequence and the sequence encoding 42-kDa C-terminus (MSP142) (Sheehy et al., 2011)
Detailed Gene Information: Click here.

f. Vector:

ChAd63: replication-deficient chimpanzee adenovirus: vector for prime vaccination (Sheehy et al., 2011), MVA: attenuated orthopoxvirusmodified vaccinia virus Ankara: vector for booster vaccination (Sheehy et al., 2011)

g. Immunization Route

Intramuscular injection (i.m.)

h. Description

Prime-boosting combination that use the same antigen but different vectors: ChAd63 MSP1 is the prime vaccination and MVA MSP1 is the booster. (Sheehy et al., 2011)

i. Human Response

Host Strain: malaria-naive adults from Oxford area (Sheehy et al., 2011)
Vaccination Protocol: Phase Ia, non-randomized study.
Participants were separated into two groups: 1) Six volunteers received 5 × 10^9 viral particles ChAd63 MSP1 as primary vaccination, and four of these received 5 × 10^8 pfu MVA MSP1 as booster 56 days later. 2) 10 volunteers received 5 × 10^10 viral particles ChAd63 MSP1 as primary vaccination, and eight of these received 5 × 10^8 pfu MVA MSP1 as booster 56 days later. (Sheehy et al., 2011)
Immune Response: Cellular: peak of IFN-γ SFC response at day 14, stronger response in higher dose group (2,785 versus 979 SFU/million PBMC). Responses contracted by day 56 and were maintained at day 90. After MVA MSP1: responses were boosted and maintained at high level at day 140 with significantly stronger response in higher dose group (1,640 versus 1,347 SFU/million PBMC). Both CD4+ and CD8+ responses were detectable after peptide restimulation on day 84.

Humoral: peak of antibody responses against MSP119 at day 28, stronger response in higher dose group (53.1 versus 7.8 MSP1 AU). Responses contracted by day 56, and only responses in higher dose group were maintained at day 90. After MVA MSP1: responses were significantly boosted and reached peak at day 84, stronger response in higher dose group (4,266 versus 1,618 MSP1 AU). Response maintained at day 140, and higher dose group had stronger response. (Sheehy et al., 2011)
Side Effects: Local: swelling, pruritus, warmth, erythema, and pain. Systematic: nausea, malaise, headache, fever, feverish, fatigue, arthralgia, and myalgia
Most of the AEs were mild in severity and all resolved completely. (Sheehy et al., 2011)
Challenge Protocol: Sporozoite malaria challenge 12-28 days post second vaccination. (Hill et al., 2009)

13. ChAd63-MVA RH5

a. Type:

Recombinant vector vaccine

b. Status:

Clinical trial

c. Host Species for Licensed Use:

Human

d. Antigen

RH5: reticulocyte–binding protein homolog 5: forms a critical nonredundant interaction with its receptor basigin (CD147) on the RBC surface. (Payne et al., 2017)

e. Gene Engineering of RH5

Type: Recombinant protein preparation
Description: reticulocyte–binding protein homolog 5 full length sequence (Payne et al., 2017)
Detailed Gene Information: Click here.

f. Vector:

ChAd63 (Payne et al., 2017): Chimpanzee adenovirus: vector for prime vaccination (Mensah et al., 2016); MVA (Payne et al., 2017): modified vaccinia Ankara: vector for booster vaccination (Mensah et al., 2016)

g. Immunization Route

Intramuscular injection (i.m.)

h. Human Response

Host Strain: healthy adults in United Kingdom (Payne et al., 2017)
Vaccination Protocol: Phase I, non-randomized, dose-escalation study.
Participants were assigned to one of the four groups: 1) 4 volunteers received 1 dose of ChAd63 RH5 5 x 10^9 vp, 2) 4 volunteers received 1 dose of ChAd63 RH5 5 x 10^10 vp, 3) 8 volunteers received 1 dose of ChAd63 RH5 at 5 x 10^10 vp and 1 dose MVA RH5 at 1 x 10^8 pfu 8 weeks later, 4) 8volunteers received 1 dose of ChAd63 RH5 at 5 x 10^10 vp and 1 dose MVA RH5 at 2 x 10^8 pfu 8 weeks later (Payne et al., 2017)
Immune Response: Cellular: peak of the response on day 14 after primary vaccination, no significant difference between lower-dose priming and higher-dose priming group. Responses contracted by day 56. The booster dose boosted the responses in all volunteers as measured on day 63, no significant difference between lower-dose booster and higher-dose booster group.
Humoral: induced IgG1 and IgG3 serum antibody response and memory B cells (mBCs). 2 of 4 volunteers in lower-dose priming group and 16 of 20 volunteers in higher-dose priming group showed a detectable response on day 28. Response maintained prior to administration of booster and was boosted as measured on day 84. There was significant difference between high-dose booster group and no booster group. Response in higher-dose booster group tended to be higher than that in lower-dose booster group, but did not reach significance. Response decreased by day 140. (Payne et al., 2017)
Side Effects: Systematic: nausea, fever, arthralgia, feverish, malaise, myalgia, fatigue, headache; Local: itch, redness, warmth, swelling, pain. Most mild or moderate in severity, all resolved in 24 hours. (Payne et al., 2017)

14. ChAd63/MVA Pfs25-IMX313

a. Type:

Recombinant vector vaccine

b. Status:

Clinical trial

c. Host Species for Licensed Use:

Baboon

d. Antigen

Pfs25 is a sexual stage antigen of Plasmodium falciparum that is expressed on the surface of the zygote and ookinete forms of the parasite, where it is involved in ookinete formation (de Graaf et al., 2021)

e. Gene Engineering of Pfs25 from P. falciparum 3D7

Type: Recombinant protein preparation
Description: Recombinant Pfs25 was used as the vaccine antigen.
Detailed Gene Information: Click here.

f. Vector:

Replication-deficient chimpanzee adenovirus serotype 63 (ChAd63) and the attenuated orthopoxvirus modified vaccinia virus Ankara (MVA), encoded Pfs25-IMX313. (de Graaf et al., 2021)

g. Preparation

For the Pfs25-IMX313 constructs a 229 bp DNA fragment encoding the IMX313 domain was cloned at the C-terminus of Pfs25. The Pfs25-IMX313 insert was subcloned into the ChAd63 and MVA destination and shuttle vectors. (de Graaf et al., 2021)

h. Immunization Route

Intramuscular injection (i.m.)

i. Description

ChAd63/MVA Pfs25-IMX313 uses Pfs25, the vaccine antigen, fused to IMX313 which functions as the adjuvant, and expressed in recombinant replication-deficient chimpanzee adenovirus serotype 63 (ChAd63) and an attenuated orthopoxvirus MVA viral vectors.

j. Human Response

Host Strain: Healthy Adults
Vaccination Protocol: Adults were vaccinated with 5x1010vp of ChAd63 Pfs25-IMX313 followed by 1x108pfu of MVA Pfs25-IMX313 56 days after the first vaccination. (de Graaf et al., 2021)
Immune Response: Vaccination with ChAd63/MVA Pfs25-IMX313 induced antigen-specific T cell responses in all volunteers; IFN-γ T cell responses were induced and peaked at median levels of greater than 2,000 SFU/million PBMCs following the MVA boost. The kinetics and magnitude of the anti-Pfs25 serum IgG antibody response were assessed over time by ELISA against Pfs25 recombinant protein. Priming vaccination with 5 × 1010 vp ChAd63 Pfs25-IMX313 followed by MVA Pfs25-IMX313 boost induced antigen-specific IgG responses in all volunteers. Median transmission reducing activity was 7.2% (range -5.8% to 37.3%) in Group 2B and 25.3% (range 10.2% to 41.3%) in Group 2C. There was no significant inhibition of oocyst intensity, further progression of research unlikely. (de Graaf et al., 2021)
Side Effects: There were no serious adverse events (SAEs) or unexpected reactions during the course of the trial and no volunteers withdrew due to vaccine-related adverse events (AEs). The reactogenicity of the vaccines was similar to that seen in previous malaria vaccine trials using the same viral vectors at similar doses in healthy adultswith the higher doses of both vaccines associated with an increased number of reported AEs. (de Graaf et al., 2021)

15. FMP012 with AS01B adjuvant system

a. Type:

Recombinant vector vaccine

b. Status:

Clinical trial

c. Host Species for Licensed Use:

Human

d. Antigen

FMP012: Escherichia coli-expressed P. falciparum cell-traversal protein for ookinetes and sporozoites (PfCelTOS) (Bennett et al., 2014)

e. Gene Engineering of pfCelTOS

Type: Recombinant protein preparation
Description:
Detailed Gene Information: Click here.

f. Immunization Route

Intramuscular injection (i.m.)

g. Human Response

Vaccination Protocol: Phase 1, non-randomized study
Participants were randomly assigned in 2 groups: 1). 10 µg FMP012 antigen reconstituted with 500 µL AS01B adjuvant to equal 0.5 mL final volume. Doses administered intramuscular at week 0, 4, 8, and 24. and 2). 30 µg FMP012 antigen reconstituted with 500 µL AS01B adjuvant to equal 0.5 mL final volume. Doses administered intramuscular at week 2, 6, 10, and 24. (Bennett et al., 2014)

16. FMP1/AS02A

a. Vaccine Ontology ID:

VO_0000777

b. Type:

Subunit vaccine

c. Antigen

Apical membrane antigen 1 (AMA-1) is an asexual blood stage antigen. AMA-1 is considered to be an important candidate malaria vaccine antigen (Morais et al., 2006; Polhemus et al., 2007).

d. Gene Engineering of AMA1 from P. falciparum 3D7

Type: Recombinant protein preparation
Description:
Detailed Gene Information: Click here.

e. Adjuvant:

VO ID: VO_0001264
Description: The Plasmodium falciparum vaccine candidate FMP2.1/AS02A , a recombinant E coli-expressed protein based upon the apical membrane antigen-1 (AMA-1 ) of the 3D7 clone formulated with the AS02A adjuvant(Polhemus et al., 2007)

f. Preparation

FMP2.1 antigen represents amino acids #83-531 of the P. falciparum (clone 3D7) AMA-1 protein. Just prior to immunization, the lyophilized FMP2.1 protein was mixed with AS02A such that approximately 8, 20 or 40 μg of FMP2.1 was delivered in a final volume of 0.5 mL of AS02A (Polhemus et al., 2007).

g. Human Response

Vaccination Protocol: An open-label, staggered-start, dose-escalating Phase I trial was conducted in 23 malaria-naïve volunteers who received 8, 20 or 40 μg of FMP2.1 in a fixed volume of 0.5 mL of AS02A on a 0, 1, and 2 month schedule. Nineteen of 23 volunteers received all three scheduled immunizations (Polhemus et al., 2007).
Immune Response: All volunteers seroconverted after second immunization as determined by ELISA. Immune sera recognized sporozoites and merozoites by immunofluorescence assay (IFA), and exhibited both growth inhibition and processing inhibition activity against homologous (3D7) asexual stage parasites. Post-immunization, peripheral blood mononuculear cells exhibited FMP2.1-specific lymphoproliferation and IFN-γ and IL-5 ELISPOT assay responses (Polhemus et al., 2007).
Side Effects: The most frequent solicited local and systemic adverse events associated with immunization were injection site pain (68%) and headache (29%). There were no significant laboratory abnormalities or vaccine-related serious adverse events.

17. MSP3-CRM-Vac4All/ Alhydrogel®

a. Type:

Subunit vaccine

b. Status:

Clinical trial

c. Host Species for Licensed Use:

Human

d. Antigen

MSP3 (Thera et al., 2022): merozoite surface protein 3. Presents on the surface of merozoites, forms a protein complex with MSP1, MSP6 and MSP7.The protein complex is bound to receptors during the invasion of erythrocytic cells. (Coelho et al., 2019)

e. Gene Engineering of msp3

Type: Recombinant protein preparation
Description:
Detailed Gene Information: Click here.

f. Immunization Route

Intramuscular injection (i.m.)

g. Description

A protein-protein conjugate malaria and helminth TBV that uses a modified msp3 protein as an antigen and Alhydrogel (R) and CRM197 as adjuvant.

h. Human Response

Vaccination Protocol: Phase I, Randomised, Dose-Finding Single Center Study, not started.
Participants will be randomly put into three groups and will receive 3 doses of MSP3-CRM-Vac4All/ Alhydrogel®. Each group will receive different dose levels of MSP3-CRM-Vac4All/ Alhydrogel®: 3 µg, 10 µg, or 30 µg total MSP3-CRM197 conjugate protein (corresponding to 1, 3, 10 µg MSP3 protein). Participants will receive vaccination on day 1, day 28, and day 56 of the study. (Thera et al., 2022)

18. MSP3-LSP with aluminium hydroxide

a. Vaccine Ontology ID:

VO_0000773

b. Type:

Subunit vaccine

c. Antigen

The merozoite surface protein-3 long synthetic peptide (MSP3-LSP) comprises the amino acid sequence 186-276 of the Plasmodium falciparum protein MSP3 (Sirima et al., 2007). The C-terminal conserved region of Plasmodium falciparum merozoite surface protein 3 (MSP3) is the trigger antigen of a protective immune response mediated by cytophilic antibodies (Audran et al., 2005).

d. Adjuvant:

VO ID: VO_0000127
Description: aluminium hydroxide (Sirima et al., 2007). In another phase I clinical trial study using MSP3-LSP, two adjuvants were used, including Montanide ISA 720 and aluminum hydroxide (Audran et al., 2005). However, it showed that it was unacceptably reactogenic when it was combined with Montanide (Audran et al., 2005).

e. Virulence

No.

f. Human Response

Host Strain: healthy male adults Africans
Vaccination Protocol: A Phase 1b single-blind controlled trial was performed in the village of Balonghin in Burkina Faso. Thirty male volunteers aged 18-40 years were randomised to receive either three doses of 30 microg MSP3-LSP or 0.5 ml of tetanus toxoid vaccine . The second and third vaccine doses were given 28 and 112 days after the first dose . Participants for 1 year were followed for one year (Sirima et al., 2007).
Persistence: Immune response did not wane appreciably up to 365 days post-vaccination (Sirima et al., 2007).
Immune Response: Humoral immune responses (IgG, IgG subclasses, IgM) to MSP3-LSP peptide were similar in the two groups following vaccination. Some cell-mediated immune responses appeared to differ between the two vaccine groups. After the second dose of MSP3-LSP, there appeared to be a marked increase in the lymphocyte proliferation index and IFN-gamma in response to stimulation with MSP3-LSP (Sirima et al., 2007).
Side Effects: There were no serious adverse events in either vaccine group. In both groups participants reported local reactions at the site of injection when compared to an earlier trial in European volunteers. Only one systemic adverse event ( tachycardia ) was identified which occurred immediately after the first vaccination in one individual receiving MSP3-LSP. No clinically significant biological abnormalities following vaccination were observed (Sirima et al., 2007).
Description: In summary, this Phase 1b single-blind controlled trial showed that three doses of 30 microg MSP3-LSP when administered subcutaneously on days 0 , 28 and 112 are well-tolerated by adult males previously exposed to natural P falciparum infection. MSP3-LSP is able to stimulate an enhanced cell-mediated immune response in individuals with some degree of preexisting immunity (Sirima et al., 2007).

19. MVA-PvTRAP

a. Vaccine Ontology ID:

VO_0004796

b. Type:

Recombinant vector vaccine

c. Status:

Research

d. Host Species for Licensed Use:

Mouse

e. Preparation

(Bauza et al., 2014) the recombinant MVA vectors expressing P. vivax TRAP (PvTRAP) .

f. Immunization Route

Intramuscular injection (i.m.)

20. NILV-Py CSP

a. Vaccine Ontology ID:

VO_0004798

b. Type:

Recombinant vector vaccine

c. Status:

Research

d. Host Species for Licensed Use:

None

e. Host Species as Laboratory Animal Model:

mouse

f. Preparation

(Coutant et al., 2012) nonintegrative lentiviral vectors (NILV) encoding Plasmodium yoelii Circumsporozoite Protein (Py CSP), and challenged with sporozoites one month later. 50% (37.5-62.5) of the animals were fully protected. Moreover, protection was long-lasting with 42.8% sterile protection six months after the last immunization.

g. Immunization Route

Intramuscular injection (i.m.)

21. NYVAC-CSP (malaria)

a. Vaccine Ontology ID:

VO_0004800

b. Type:

Recombinant vector vaccine

c. Status:

Research

d. Host Species for Licensed Use:

Baboon

e. Host Species as Laboratory Animal Model:

mouse

f. Preparation

(Lanar et al., 1996) NYVAC-based vaccinia virus recombinants expressing the circumsporozoite protein (CSP) were evaluated in the Plasmodium berghei rodent malaria model system. Immunization of mice with a NYVAC-based CSP recombinant elicited a high level of protection (60 to 100%).

g. Immunization Route

Intramuscular injection (i.m.)

22. NYVAC-Pf7

a. Vaccine Ontology ID:

VO_0004794

b. Type:

Recombinant vector vaccine

c. Status:

Research

d. Host Species for Licensed Use:

Human

e. Antigen

PfCS, PfSSP2, LSA1, MSP1, SERA, AMA1, and Pfs25 (Ockenhouse et al., 1998)

f. Gene Engineering of CS from P. falciparum

Type: Recombinant protein preparation
Description:
Detailed Gene Information: Click here.

g. Gene Engineering of LSA-1 from Plasmodium falciparum

Type: Recombinant protein preparation
Description:
Detailed Gene Information: Click here.

h. Gene Engineering of MSP-1 from P. falciparum

Type: Recombinant protein preparation
Description:
Detailed Gene Information: Click here.

i. Gene Engineering of AMA1 from P. falciparum 3D7

Type: Recombinant protein preparation
Description:
Detailed Gene Information: Click here.

j. Gene Engineering of Pfs25 from P. falciparum 3D7

Type: Recombinant protein preparation
Description:
Detailed Gene Information: Click here.

k. Gene Engineering of SSP2 from Plasmodium falciparum

Type: Recombinant protein preparation
Description:
Detailed Gene Information: Click here.

l. Gene Engineering of SERA

Type: Recombinant protein preparation
Description:
Detailed Gene Information: Click here.

m. Preparation

(Ockenhouse et al., 1998)

n. Immunization Route

Intramuscular injection (i.m.)

23. P. berghei CS Protein Subunit Vaccine

a. Vaccine Ontology ID:

VO_0011549

b. Type:

Subunit vaccine

c. Status:

Research

d. Antigen

A tandem repeat of the B cell immunodominant repeat epitope (DPPPPNPN)2D of the malaria parasite Plasmodium berghei circumsporozoite protein (P4c-Mal) (Kaba et al., 2009).

e. Gene Engineering of CS from P. berghei str. ANKA

Type: Recombinant protein preparation
Description:
Detailed Gene Information: Click here.

f. Immunization Route

Intraperitoneal injection (i.p.)

g. Mouse Response

Host Strain: BALB/c, C57BL/6
Vaccination Protocol: Mice were randomly divided into groups of 5 or 10 and immunized i.p. three times at 14-day intervals. Where indicated, a positive control group was immunized with irradiated P. berghei sporozoites (Kaba et al., 2009).
Challenge Protocol: P. berghei sporozoites (ANKA strain), maintained by cyclical transmission in mice and Anopheles stephensi, were dissected from mosquitoes 21–23 days after their infectious blood meal and used within 6 h. Fourteen days after the final immunization or at other specific times on long-term memory experiments, mice were challenged with a lethal dose of live P. berghei sporozoites by i.v. inoculation. C57BL/6, MHC KO, and nude mice were injected with 1000 sporozoites and BALB/c mice were injected with 4000 sporozoites per mouse (Kaba et al., 2009).
Efficacy: More than 95% of mice immunized with P4c-Mal, both with and without Montanide ISA-720, or R-PbCSP in Montanide ISA-720 did not develop any parasitemia and thus showed complete protection against challenge with viable sporozoites (Fig. 2B). This ability to prevent parasitemia and thus prevent malaria following sporozoite challenge is equivalent to what is only achieved with the whole, irradiated sporozoite immunization regime. In contrast, as few as 5% of animals administered saline, saline and Montanide ISA-720, or R-PbCSP in saline did not develop parasites and survived until 11 days post challenge. No animal was observed with blood stage parasites that did not die naturally or was killed according to protocol. These results show that immunization with P4c-Mal had a significant ability to induce a protective immune response in the presence as well as in the absence of adjuvant (Kaba et al., 2009).

24. P. berghei DNA vaccine CSP-3p28

a. Vaccine Ontology ID:

VO_0004594

b. Type:

DNA vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Mouse

e. Antigen

CSP and 3 copies of the p28 fragment of C3d (Bergmann-Leitner et al., 2007)

f. Gene Engineering of CS from P. berghei str. ANKA

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

g. Vector:

pBLUESCRIPT (Bergmann-Leitner et al., 2007)

h. Immunization Route

Gene gun

i. Mouse Response

Vaccine Immune Response Type: VO_0003057
Efficacy: Vaccination with CSP-3p28 resulted in better (100%) protection than CSP alone (60%) against P. berghei sporozoites at the 6-week challenge (p = 0.043) suggesting that the addition of 3 copies of the p28 peptide to CSP results in the generation of a better vaccine (Bergmann-Leitner et al., 2007).

25. P. berghei DNA vaccine encoding PbCSP

a. Vaccine Ontology ID:

VO_0004591

b. Type:

DNA vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Mouse

e. Gene Engineering of CS from P. berghei str. ANKA

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

f. Vector:

pcDNA3.1 (Yoshida et al., 2000)

g. Immunization Route

Gene gun

h. Mouse Response

Vaccine Immune Response Type: VO_0003057
Efficacy: Protection obtained by gene gun delivery into the liver once (73%) was significantly higher than that by the material into the skin twice (31%) (Yoshida et al., 2000).

26. P. berghei MSP1 Protein Vaccine

a. Vaccine Ontology ID:

VO_0004065

b. Type:

Subunit vaccine

c. Status:

Research

d. Antigen

Recombinant MSP1 (rPbMSP1)

e. Gene Engineering of MSP1 from P. berghei

Type: Recombinant protein preparation
Description:
Detailed Gene Information: Click here.

f. Adjuvant:

VO ID: VO_0000884

g. Immunization Route

Intraperitoneal injection (i.p.)

h. Mouse Response

Host Strain: BALB/c
Vaccination Protocol: Lyophilized rPbMSP1 was mixed with alum on the day of injection. Each vaccine formulation, containing 10 ug was administered through IP route to mice .
Challenge Protocol: For challenge study, mice were intraperitoneally inoculated with parasitized erythrocytes at a density of either 10^6 or 10^5 parasitized
erythrocytes per mouse (Wan et al., 2007).
Efficacy: Eight out of ten mice vaccinated with rMSP1 in alum survived challenge with P. berghei (Wan et al., 2007).

27. P. berghei p36p mutant vaccine

a. Vaccine Ontology ID:

VO_0003008

b. Type:

Live, attenuated vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Mouse

e. Gene Engineering of P36p

Type: Gene mutation
Description: This p36p mutant is from Plasmodium berghei (Douradinha et al., 2007).
Detailed Gene Information: Click here.

f. Immunization Route

Intravenous injection (i.v.)

g. Mouse Response

Persistence: A p36p mutant is attenuated in mice (Douradinha et al., 2007).
Efficacy: A p36p mutant provides protection in mice from challenge with wild type Plasmodium berghei (Douradinha et al., 2007).

28. P. chabaudi AMA1 Protein Vaccine

a. Vaccine Ontology ID:

VO_0004194

b. Type:

Subunit vaccine

c. Status:

Research

d. Antigen

Recombinant ectodomain of P. chabaudi adami (DS stain) AMA1 (denoted rAMA1B)

e. Gene Engineering of AMA-1 from P. chabaudi

Type: Recombinant protein preparation
Description:
Detailed Gene Information: Click here.

f. Adjuvant:

VO ID: VO_0001268
Description: Montanide ISA720

g. Immunization Route

Intraperitoneal injection (i.p.)

h. Mouse Response

Host Strain: BALB/c
Vaccination Protocol: Groups of three to five mice were immunized i.p. with 15 µg of rAMA1B emulsified in Montanide ISA720. Four weeks later, a booster immunization was given using the same amount of rAMA1B emulsified with Montanide ISA720. Controls were immunized with PBS emulsified in Montanide ISA720 (Xu et al., 2000).
Challenge Protocol: Ten days after being given a booster immunization the mice were challenged i.v. with 1 x 10^5 P. chabaudi adami parasitized erythrocytes (Xu et al., 2000).
Efficacy: Immunized mice demonstrated significantly lower peak parasitemias compared with PBS-immunized mice, showing that rAMA1B immunization confers protection against challenge with P. chabaudi (Xu et al., 2000).

29. P. falciparum CS expressed in irradiated P. berghei as Vaccine

a. Vaccine Ontology ID:

VO_0004794

b. Type:

Recombinant vector vaccine

c. Status:

Research

d. Antigen

CSP from P. falciparum

e. Gene Engineering of CS from P. falciparum

Type: Recombinant vector construction
Description: P. berghei ANKA cloned lines were transfected with the P. falciparum CSP gene (Grüner et al., 2007).
Detailed Gene Information: Click here.

f. Immunization Route

non-specified injection

g. Mouse Response

Host Strain: BALB/cJ
Vaccination Protocol: In order to induce sterile immunity in all the animals, BALB/cJ mice were immunized with 12,000 rad-irradiated P. berghei sporozoites as follows: one dose of 75,000 sporozoites followed by two booster doses of 25,00 of P. berghei sporozoites on days 15 and 21. In [BALB/c×C57BL/6] F1 mice immunisation was made with 3 injections of 10,000 P. berghei irradiated sporozoites at days 0, 15 and 21 (Grüner et al., 2007).
Challenge Protocol: Control mice and mice immunized with irradiated sporozoites (transfected with P. falciparum CS) were challenged intravenously with 5,000 P. berghei or P. berghei [PfCS] sporozoites (Grüner et al., 2007).
Efficacy: Mice immunized with irradiated sporozoites were protected from challenge (Grüner et al., 2007).

30. P. falciparum DNA and MVA encoding ME-TRAP

a. Vaccine Ontology ID:

VO_0000747

b. Type:

DNA vaccine

c. Host Species for Licensed Use:

Human

d. Host Species as Laboratory Animal Model:

human

e. Antigen

Multiple epitope-thrombospondin-related adhesion protein (ME-TRAP)

f. Gene Engineering of TRAP from P. falciparum

Type: Epitope construction used for delivery vector
Description: Multiple epitopes from the thrombospondin-related adhesion protein were prepared. The ME-TRAP were then introduced into three delivery vectors: DNA and modified vaccinia virus Ankara (MVA) (Dunachie et al., 2006).
Detailed Gene Information: Click here.

g. Vector:

pSG2 and MVA (Dunachie et al., 2006)

h. Preparation

DNA and modified vaccinia virus Ankara (MVA) prime-boost regimes were assessed by using either thrombospondin-related adhesion protein (TRAP) with a multiple-epitope string ME (ME-TRAP) (Dunachie et al., 2006).

i. Description

The T-cell responses induced by this prime-boost regime , in animals and humans, are substantially greater than the sum of the responses induced by DNA or MVA vaccines used alone, leading to the term introduced here of "synergistic" prime-boost immunisation.

j. Human Response

Vaccination Protocol: Sixteen healthy subjects who never had malaria (malaria-naive subjects) received two priming vaccinations with DNA, followed by one boosting immunization with MVA, with ME-TRAP (Dunachie et al., 2006).
Immune Response: The vaccines were well tolerated and immunogenic, with the DDM-ME TRAP regimen producing strong ex vivo IFN-gamma ELISPOT responses
Challenge Protocol: Two weeks after the final vaccination, the subjects underwent P. falciparum sporozoite challenge, with six unvaccinated controls.
Efficacy: One of eight subjects receiving the DDM-ME TRAP regimen was completely protected against malaria challenge, with this group as a whole showing significant delay to parasitemia compared to controls (P = 0.045). The peak ex vivo IFN-gamma ELISPOT response in this group correlated strongly with the number of days to parasitemia (P = 0.033). Therefore, prime-boost vaccination with DNA and MVA encoding ME-TRAP resulted in partial protection against P. falciparum sporozoite challenge in the present study (Dunachie et al., 2006).

31. P. falciparum DNA Vaccine encoding EBA-175

a. Vaccine Ontology ID:

VO_0004196

b. Type:

DNA vaccine

c. Status:

Research

d. Antigen

P. falciparum EBA-175 RII

e. Gene Engineering of eba-175

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

f. Vector:

expression plasmid vector VR1020

g. Immunization Route

Intradermal injection (i.d.)

h. Monkey Response

Host Strain: Aotus lemurinus lemurinus
Vaccination Protocol: Intradermal delivery of DNA vaccines was performed under light sedation with Ketamine at 20 mg/kg intramuscularly, using a 1 mL insulin syringe with a fused 29-gauge 0.5-inch needle. Monkeys received a total of 500 μg of plasmid DNA in saline in a series of four immunizations at weeks 0, 3, 6, and 47 on the lower back on six different sites. The maximal volume administered in any one site was 100 μl (Sim et al., 2001).
Challenge Protocol: Aotus monkeys were challenged with 1 X 10^4 P. falciparum (FVO) infected erythrocytes (Sim et al., 2001).
Efficacy: One of three monkeys vaccinated with EBA-175 was protected from challenge of parasitized erythrocytes (Sim et al., 2001).

32. P. falciparum Hsp90 Protein Subunit Vaccine

a. Vaccine Ontology ID:

VO_0011396

b. Type:

Subunit vaccine

c. Status:

Research

d. Gene Engineering of Hsp90

Type: Recombinant protein preparation
Description:
Detailed Gene Information: Click here.

e. Adjuvant:

VO ID: VO_0000139

f. Immunization Route

Subcutaneous injection

g. Monkey Response

Host Strain: S. sciureus
Vaccination Protocol: Monkeys were immunized on days 0, 21, and 42 with 120/~g of protein in PBS/0.1% SDS. Each dose consisted of 1.5ml
emulsified with Freund's complete adjuvant for the first immunization and Freund's incomplete adjuvant for the others, injected subcutaneously on multiple sites in the back. Control monkeys received the same treatment but without parasite proteins (Bonnefoy et al., 1994).
Challenge Protocol: All monkeys were challenged on day 56 by intravenous injection of 5 x 10^7 FUP/SP-infected monkey erythrocytes (Bonnefoy et al., 1994).
Efficacy: The three control monkeys showed a rapid rise of parasitaemia with a prepatent period of 2 days and required drug treatment within 7 days to prevent fatal outcome. Three immunized monkeys developed a reduced parasitaemia with a prepatent period of 2 to 6 days with a maximum peak of parasitaemia of 5-11.6% that dropped spontaneously. The two other immunized monkeys developed parasitaemia similar to the controls and were drug-cured at day 7 (Bonnefoy et al., 1994).

33. P. falciparum LSA-3 Protein Vaccine

a. Vaccine Ontology ID:

VO_0004193

b. Type:

Subunit vaccine

c. Status:

Research

d. Antigen

Recombinant proteins GST-DG729, GST-NN and GST-PC were designed to cover 95% of the LSA-3 antigen and were used as a mixture (called LSA-3 GST-rec) (Daubersies et al., 2000).

e. Gene Engineering of LSA-3

Type: Recombinant protein preparation
Description:
Detailed Gene Information: Click here.

f. Adjuvant:

VO ID: VO_0001270
Description: Montanide ISA51

g. Immunization Route

subcutaneous injection

h. Chimpanzee Response

Vaccination Protocol: 50 μg of recombinant LSA-3 peptides were emulsified in Montanide ISA51 and were injected subcutaneously into chimpanzees (Daubersies et al., 2000).
Challenge Protocol: All chimpanzees were immunized at weeks 0, 4 and 8 and were challenged with 2 x 10^4 sporozoites at week 13 (Daubersies et al., 2000).
Efficacy: Immunization with LSA-3 induced protection against successive heterologous challenges with large numbers of P. falciparum sporozoites (Daubersies et al., 2000).

34. P. falciparum MSA-2 subunit vaccine

a. Vaccine Ontology ID:

VO_0004269

b. Type:

Subunit vaccine

c. Status:

Research

d. Antigen

merozoite antigen, MSA-2 (Pye et al., 1997).

e. Gene Engineering of MSP2

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

f. Adjuvant:

VO ID: VO_0001349

g. Immunization Route

Intramuscular injection (i.m.)

h. Sheep Response

Vaccination Protocol: Sheep were immunized intramuscularly (i.m.) in the left rear leg, with a second immunization in the right rear leg 4 weeks later. A 100 μg antigen dose was delivered in 1.0 ml. Serum was prepared from bleeds taken prior to the first immunization, 3 or 4 weeks later (i.e. prior to the second dose), and a final bleed 2 weeks after the second immunization (Pye et al., 1997).
Immune Response: Sheep immunized with MSA-2 and SAF-1 had higher antibody response than sheep immunized with MSA-2 and alhydrogel (Pye et al., 1997).

35. P. falciparum MSP1 from transgenic mice with Freund's adjuvant

a. Vaccine Ontology ID:

VO_0000775

b. Type:

Subunit vaccine

c. Antigen

the 42-kDa C-terminal portion of Plasmodium falciparum merozoite surface protein 1 (MSP1) (Stowers et al., 2002).

d. Gene Engineering of MSP-1 from P. falciparum

Type: Recombinant protein preparation
Description: Generated by transgenic mice (Stowers et al., 2002).
Detailed Gene Information: Click here.

e. Adjuvant:

VO ID: VO_0000139
Description: The initial vaccinations were emulsified with complete Freund's adjuvant (Sigma), and the next two with incomplete Freund's adjuvant (Sigma) (Stowers et al., 2002).

f. Adjuvant:

VO ID: VO_0000142
Description: The initial vaccinations were emulsified with complete Freund's adjuvant (Sigma), and the next two with incomplete Freund's adjuvant (Sigma) (Stowers et al., 2002).

g. Preparation

Two strains of transgenic mice were generated that secrete into their milk a malaria vaccine candidate, the 42-kDa C-terminal portion of Plasmodium falciparum merozoite surface protein 1 (MSP1-42). One strain secretes an MSP1-42 with an amino acid sequence homologous to that of the FVO parasite line. In the other strain, an MSP1-42 where two putative N-linked glycosylation sites in the FVO sequence have been removed. Both forms of MSP142 were purified from whole milk to greater than 91% homogeneity at high yields (Stowers et al., 2002).

h. Virulence

None.

i. Description

It is likely for producing efficacious malarial vaccines in transgenic animals (Stowers et al., 2002).

j. Monkey Response

Host Strain: owl monkey (Aotus nancymai)
Vaccination Protocol: In total 28 monkeys were randomly assigned to groups of seven. The three vaccine groups received bvMSP1-42, TgMSP1-42 NG, and TgMSP1-42 G, respectively, and the fourth group placebo. Monkeys received three vaccinations of 100 µg of the respective recombinant protein 3 wk apart, following our established protocol. The initial vaccinations were emulsified with complete Freund's adjuvant (Sigma), and the next two with incomplete Freund's adjuvant (Sigma) (Stowers et al., 2002).
Immune Response: There was a significant difference in the Endpoint ELISA titers to bvMSP142 between those animals vaccinated with bvMSP142 and TgMSP142 G (P = 0.008), and between those vaccinated with TgMSP142 NG and TgMSP142 G (P = 0.05). No differences in titers were observed between the bvMSP142 and TgMSP142 NG groups. No significant differences were seen in ELISA titers to other antigens (TgMSP142 NG, TgMSP142 G, or MSP119), nor were any significant differences seen in IFA titers against P. falciparum FVO parasites. Overall, antibody titers to none of the four antigens used as ELISA capture antigens (bvMSP142, TgMSP142 NG, TgMSP142 G, or MSP119) correlated with the primary outcome of protection as defined above (cumulative parasitemia until first monkey treated for anemia). However, antibody titers to bvMSP142 did correlate with days until treatment (r2 = 0.6241, P = 0.005) and inversely with parasitemia at time of treatment (r2 = -0.4206, P = 0.05) (Stowers et al., 2002).
Side Effects: During vaccination, three animals died (two in the TgMSP142 NG group and one in the TgMSP142 G group), unfortunately not a rare occurrence with these fragile monkeys. No animals died during the second study. When partially protected from P. falciparum malaria, it is a characteristic of Aotus monkeys that some protected animals will suffer from anemia (Stowers et al., 2002).
Challenge Protocol: Vaccinated monkeys were challenged 15 days after the third vaccination by i.v. infusion of a freshly passaged preparation of 10^4 infected RBC of the highly virulent P. falciparum FVO strain. Monkeys were treated when parasitemia reached 5%, or their hematocrit fell below 20%. All monkeys not treated previously were treated on day 30. The treatment consisted of mefloquine administered in a single dose of 25 mg/kg of body mass by intubation. The second Aotus challenge trial followed the protocol outlined above, with the exceptions that only two groups (TgMSP142 NG and placebo) and a larger challenge inoculum were used (1 ml of 5 × 104 pRBCs/ml) (Stowers et al., 2002).
Efficacy: Vaccination with the glycosylated version of milk-derived MSP1(42) conferred no protection compared with an adjuvant control. Vaccination with the nonglycosylated, milk-derived MSP1(42) successfully protected the monkeys, with 4/5 animals able to control an otherwise lethal infection with P falciparum compared with 1/7 control animals (Stowers et al., 2002).
Description: Analysis of the different vaccines used suggested that the differing nature of the glycosylation patterns may have played a critical role in determining efficacy (Stowers et al., 2002).

36. P. falciparum MSP3 Protein Subunit Vaccine

a. Vaccine Ontology ID:

VO_0011440

b. Type:

Subunit vaccine

c. Status:

Research

d. Gene Engineering of msp3

Type: Recombinant protein preparation
Description:
Detailed Gene Information: Click here.

e. Adjuvant:

VO ID: VO_0000139

f. Immunization Route

Intramuscular injection (i.m.)

g. Monkey Response

Host Strain: Aotus nancymai
Vaccination Protocol: Seven monkeys were vaccinated with 100 μg of EcMSP3, seven with 100 μg of control protein Pfs25, a parasite protein expressed during the mosquito stage of the life cycle. Each monkey received 0.125 mL of antigen emulsified in complete Freund's adjuvant at four sites, for a total of 0.5 mL, followed by two booster vaccinations with the same dose of antigen in a Montanide ISA51 (SEPPIC) formulation at 3-week intervals (Tsai et al., 2009).
Challenge Protocol: Seventeen days after the third vaccination, the monkeys were challenged by intravenous infusion of 5 × 10^4 P. falciparum FVO strain parasitized RBCs collected from a naïve donor monkey (Tsai et al., 2009).
Efficacy: By day 11 post-challenge, the parasitemia in all but one monkey in the control group had reached the predetermined upper limit and were treated In contrast, no animals in the EcMSP3-vaccinated group required treatment by this time (Tsai et al., 2009).

37. P. falciparum MSP4 with AFCo1 Adjuvant

a. Vaccine Ontology ID:

VO_0004243

b. Type:

Subunit vaccine

c. Status:

Research

d. Gene Engineering of MSP4

Type: Recombinant protein preparation
Description:
Detailed Gene Information: Click here.

e. Adjuvant:

VO ID: VO_0001309

f. Immunization Route

Not specified

g. Mouse Response

Host Strain: BALB/c
Vaccination Protocol: MIce were immunized at 14-day intervals with three doses of 10 μg MSPs (Bracho et al., 2009).
Immune Response: AFCo1 significantly enhanced the IgG and T-cell response against MSP4, with a potency equivalent to CFA, with the response being characterized by both IgG1 and IgG2a isotypes, increased interferon gamma production and a strong DTH response, consistent with the ability of AFCo1 to induce Th1-like immune responses (Bracho et al., 2009).

38. P. falciparum pfCelTos protein vaccine

a. Vaccine Ontology ID:

VO_0004204

b. Type:

Subunit vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

mouse

e. Gene Engineering of pfCelTOS

Type: Recombinant protein preparation
Description:
Detailed Gene Information: Click here.

f. Adjuvant:

VO ID: VO_0001268
Description: Montanide ISA 720

g. Immunization Route

subcutaneous injection

h. Mouse Response

Host Strain: Balb/c-J
Vaccination Protocol: Mice were immunized subcutaneously in the scruff of the neck three times with 25 or 10 or 1 µg/dose of recombinant PfCelTOS or saline emulsified in Montanide ISA 720 (Bergmann-Leitner et al., 2010).
Challenge Protocol: Fourteen days after the final immunization, mice were challenged by subcutaneous inoculation (into the inguinal region) with 4,000 P. berghei sporozoites for Balb/c and 15,000 P. berghei sporozoites for CD-1 mice, dissected from infected mosquito salivary glands. The challenge dose was determined by titration studies in each mouse strain and compared to the different challenge routes. Infection was determined by the presence of blood stage parasites in Giemsa stained thin blood smears on day 6 and day 8 after challenge. Animals that were not infected at that time were tested again on day 14. Mice that remained un-infected by day 14 were classified as sterilely protected. We used this evaluation schedule because animals that are infected with P. berghei ANKA strain malaria parasites do not self-cure.

Efficacy Detail

No.	Efficacy method	Result	Description	Group Efficacy Detail
1		CFU	Immunization with PfCelTOS resulted in potent humoral and cellular immune responses and most importantly induced sterile protection against a heterologous challenge with P. berghei sporozoites in a proportion of both inbred and outbred mice (Bergmann-Leitner et al., 2010).

39. P. falciparum Pfen Protein Subunit Vaccine

a. Vaccine Ontology ID:

VO_0011418

b. Type:

Subunit vaccine

c. Status:

Research

d. Gene Engineering of Pfen

Type: Recombinant protein preparation
Description:
Detailed Gene Information: Click here.

e. Adjuvant:

VO ID: VO_0000133

f. Immunization Route

Intraperitoneal injection (i.p.)

g. Mouse Response

Host Strain: Swiss
Vaccination Protocol: Mice were injected intraperitoneally with r-Pfen emulsified in Freund's adjuvant at 21-day intervals (the first injection was 100 μg of r-Pfen in complete Freund's adjuvant, followed by 50 μg for the two boosters in incomplete Freund's adjuvant). In one control group, mice were injected in parallel with a recombinant Drosophila odorant binding protein OSF (as an irrelevant His-tagged protein control) emulsified in complete Freund's adjuvant. The other control group received no injections. After three immunizations, the antibody titers against r-Pfen were monitored (Pal-Bhowmick et al., 2007).
Challenge Protocol: Mice having anti-r-Pfen antibody titers greater than 1:300,000 were then challenged with the lethal strain of P. yoelii (strain 17XL; 10^6 parasites per mouse), and parasitemia was monitored daily (Pal-Bhowmick et al., 2007).
Efficacy: All the control mice and the mice immunized with the irrelevant His-tagged protein developed a high degree of parasitemia (>17% on average) by day 4 postchallenge, whereas r-Pfen-immunized mice showed <1% parasitemia at that time point. The highest average parasitemia values were 70% and 40% for nonimmunized mice and mice injected with irrelevant His-tagged protein, respectively. However, among the mice immunized with r-Pfen, there was significant delay in the increase in parasitemia, and the highest average parasitemia was about 20% on day 8 postchallenge. The averages of these groups were compared using one-way analysis of variance, which showed that the mice immunized with enolase were significantly protected (Pal-Bhowmick et al., 2007).

40. P. falciparum recombinant vector vaccine MVA.ME-TRAP

a. Type:

Recombinant vector vaccine

b. Status:

Research

c. Host Species as Laboratory Animal Model:

Human

d. Vector:

Recombinant fowlpox strain FP9 and recombinant MVA (Webster et al., 2005)

e. Immunization Route

Intramuscular injection (i.m.)

f. Description

A prime boost P. falciparum vaccine that utilizes FP9 and MVA as recombinant vectors for priming and boosting, respectively (Webster et al., 2005).

g. Human Response

Vaccination Protocol: FFM Regime: FP9 priming, either once or twice, followed by MVA boosting (Webster et al., 2005).
Vaccine Immune Response Type: VO_0000286
Immune Response: Vaccine regimes with FP9 as the priming agent induced significantly more CD8+ T cells in addition to the CD4+ T cells. This finding suggests that induced CD8+ T cell responses may be of particular value in vaccination against liver-stage malaria (Webster et al., 2005).
Efficacy: Two of five subjects who went on to a malaria challenge conducted 14 days after their final vaccination were completely protected. These two subjects were entered, without further vaccinations, into a second malaria challenge 6 months later in which one subject (137) remained completely protected. In addition, all 17 subjects immunized with this FFM regime (FP9 priming, once or twice, followed by MVA boosting) who underwent challenge, overall, compared with nonvaccinees, had a significant delay in time to onset of parasitemia (Webster et al., 2005).

41. P. falciparum Subunit SE36 Protein Vaccine

a. Vaccine Ontology ID:

VO_0011415

b. Type:

Subunit vaccine

c. Status:

Clinical trial

d. Gene Engineering of SERA-5

Type: Recombinant protein preparation
Description:
Detailed Gene Information: Click here.

e. Adjuvant:

VO ID: VO_0000127

f. Immunization Route

Intramuscular injection (i.m.)

g. Monkey Response

Host Strain: squirrel monkey (Saimiri sciureus)
Vaccination Protocol: The monkeys, weighing between 680 and 760 g at the beginning of the experiment, were divided into two groups. Group1 monkeys (R57, R59, and R61) received SE36/AHG and Group2 monkeys (R60 and R62) received PBS as a control by intra-muscular injection in their left thigh 5 and 3 weeks before challenge infection. Monkey R61 received a third injection on the 2 weeks before challenge infection. The dose used was 50 μg SE36 protein with 500 μg aluminum hydroxide gel (50/500) in 0.5 ml of PBS. Group2 monkeys (R60 and R62) received the same volume of PBS (Horii et al., 2010).
Challenge Protocol: Two weeks after the last immunization, all monkeys were challenged with P. falciparum-infected red blood cells. Each of the five squirrel monkeys received 1 × 10^9 parasitized red blood cells. Parasitemia was monitored daily by counting 5000 RBCs in Giemsa-stained thin blood smears (Horii et al., 2010).
Efficacy: Whereas two control monkeys developed 10–20% peak parasitemia, the parasitemia in the two immunized monkeys with higher antibody titers stayed at low values below 3% (Fig. 3B). One vaccinated monkey (Monkey R61), with the lowest antibody titer, developed 5% peak parasitemia but was able to control parasitemia by Day 7 onwards. Importantly, control monkeys did not raise anti-SE36 IgG titer even after the onset of parasitemia which parallels the less immunogenicity of SERA5 N-terminal domain observed in endemic areas. Thus, although the observed protection was not able to prevent infection, vaccinated monkeys had lower parasitemia and booster effects on antibody titers were observed after infection for all vaccinated monkeys (Horii et al., 2010).

h. Chimpanzee Response

Vaccination Protocol: Three chimpanzees, named Satoru (7 years old male, 45 kg), Arare (10 years old female, 51 kg) and Mizuo (11 years old male, 60 kg) were born in Japan, and thus have no prior exposure to P. falciparum. Satoru, Arare and Mizuo received 10/100, 50/500 and 450/4500 SE36/AHG, respectively by subcutaneous injection on their backs after anesthetization with Ketamine hydrochloride (5 mg/kg) at Weeks 0, 4 and 8 (Horii et al., 2010).
Immune Response: Chimpanzee immunization experiment, likewise, indicated the immunogenicity of SE36/AHG and a long duration of antibody production over 1-year with only a gradual decrease. Three chimpanzees were immunized with GMP-grade SE36/AHG of either 10/100, 50/500 or 450/4500 dose. Throughout the study, all blood biochemistry results were normal according to human standards and no signs of systemic aberrations were observed, except for the commonly observed swelling at the administration sites (Horii et al., 2010).

42. P. falciparum vaccine Combination B

a. Tradename:

Combination B

b. Vaccine Ontology ID:

VO_0000740

c. Type:

Subunit vaccine

d. Antigen

The vaccine Combination B contains three recombinant asexual blood-stage Plasmodium falciparum proteins: merozoite surface protein (MSP) 1, MSP2 and ring-infected erythrocyte surface antigen (RESA) (Genton et al., 2003).

e. Gene Engineering of RESA

Type: Recombinant protein preparation
Description: The vaccine Combination B contains peptides from the ring-infected erythrocyte surface antigen (RESA) (Genton et al., 2003).
Detailed Gene Information: Click here.

f. Gene Engineering of MSP-1 from P. falciparum

Type: Recombinant protein preparation
Description: The vaccine Combination B contains MSP1 peptides (Genton et al., 2003).
Detailed Gene Information: Click here.

g. Adjuvant:

VO ID: VO_0001268
Description: Montanide ISA 720. It is an oil composition containing a natural metabolizable oil and a highly refined emulsifier from the mannide mono-oleate family (Genton et al., 2003).

h. Preparation

Combination B is a malaria vaccine that comprises recombinant P falciparum blood-stage proteins MSP1, MSP2 and RESA, formulated with the adjuvant Montanide ISA 720 (Genton et al., 2003a). The three vaccine candidate antigens were produced by recombinant DNA technology. All three antigens were expressed in Escherichia coli with histidine tags to facilitate purification by nickel chelate chromatography. Two of the antigens, 190LCS.T3 (Ro 45-2067) and Ag1624 (Ro 46-2924), corresponded to parts of the well-characterized merozoite surface proteins MSP1 and MSP2, respectively. The MSP1 antigen was the 190L fragment from the K1 parasite line, comprising the relatively conserved blocks 3 & 4 of MSP1 fused with a universal T cell epitope derived from the circumsporozoite protein of P. falciparum. The MSP2 antigen corresponded to the near full-length MSP2 sequence of the 3D7 cloned line. Ag1505H (Ro 45-2164) consisted of the C-terminal 70% of RESA of the FCQ-27/PNG parasite line. All three antigens were supplied in separate vials at a concentration of 160 μg/ml of saline-Montanide ISA720 emulsion. Prior to use the three formulations were mixed and diluted with additional emulsion to give a dose of 15 μg of each antigen in a total volume of 0.55 ml (Genton et al., 2003).

i. Description

The "Combination B" vaccine resulted from a collaborative effort by the Papua New Guinea Institute for Medical Research along with the Australian Cooperative Research Center for Vaccine Technology in Queensland, The Walter and Eliza Hall Research Institute and the Swiss Tropical Institute (Girard et al., 2007). This vaccine has led to a considerable reduction of parasite density in the immunized children.

j. Human Response

Host Strain: Papua New Guinean children
Vaccination Protocol: To insure safety, the enrolment and immunisations were done sequentially, with 10 days observation between each sub-cohort. It was started with one block (3 No SP+vaccine, 3 No SP+placebo, 3 SP+vaccine, 3 SP+placebo) of the older age group, then the remaining four blocks (12 No SP+vaccine, 12 No SP+placebo, 12 SP+vaccine, 12 SP+placebo) of this stratum, then one block of the younger age group, and then the remaining four blocks of this stratum. Children were given either SP or a sugar tablet (indistinguishable tablets provided by Hoffman La-Roche). During Week 0 they were injected i.m. in the left lateral thigh with the vaccine or placebo. Four weeks after the first injection, they received a second injection i.m. in the right lateral thigh (Genton et al., 2003).
Immune Response: The vaccine induced significant antibody responses to all three antigens but triggered an IFN-γ response to MSP1 only. At Week 12, the IFN-γ response to MSP1 was substantially higher in the vaccine group where No SP had been given (Genton et al., 2003)
Side Effects: No serious or severe AEs occurred. Moderate AEs were seen in 3% of the vaccine and 3% of the placebo recipients after first injection and in 12 and 10% after second injection (Genton et al., 2003).
Description: This is a phase I-IIb double-blind randomised placebo-controlled trial was undertaken in 120 children aged 5-9 years.

43. P. knowlesi DNA vaccine encoding PkCSP, PkSSP2, PkAMA1, and PkMSP1p42

a. Vaccine Ontology ID:

VO_0004595

b. Type:

DNA vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Rhesus monkeys

e. Gene Engineering of AMA1 from P. knowlesi

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

f. Gene Engineering of CSP from P. knowlesi

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

g. Gene Engineering of MSP1 from P. knowlesi

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

h. Gene Engineering of SSP2 from P. knowlesi

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

i. Vector:

VR1020 prime, recombinant canarypox viruses boost (Rogers et al., 2001)

j. Immunization Route

Intramuscular injection (i.m.)

k. Monkey Response

Vaccine Immune Response Type: VO_0003057
Challenge Protocol: 100 sporozoites were injected into the saphenous vein. Beginning on day 6 after challenge peripheral thick and thin blood films were examined to determine parasitemia. (Rogers et al., 2001)
Efficacy: Following challenge with 100 P. knowlesi sporozoites, 1 of 12 experimental monkeys was completely protected and the mean parasitemia in the remaining monkeys was significantly lower than that in 4 control monkeys (Rogers et al., 2001).

44. P. vivax PVS25 with Montanide ISA-720

a. Vaccine Ontology ID:

VO_0000776

b. Type:

Subunit vaccine

c. Antigen

P. vivax protein Pvs25 is the vaccine antigen. It is a protein composed of four cysteine-rich epidermal growth factor–like domains expressed on the surface of zygotes and ookinetes of P. vivax (Arevalo-Herrera et al., 2005).

d. Gene Engineering of Pvs25

Type: Recombinant protein preparation
Description: Pvs25 was cloned and purified from yeast (Arevalo-Herrera et al., 2005).
Detailed Gene Information: Click here.

e. Adjuvant:

VO ID: VO_0001268
Description: Montanide ISA-720 an adjuvant suitable for human vaccination trials (Arevalo-Herrera et al., 2005).

f. Preparation

To produce a recombinant protein, Pvs25 was expressed in S. cerevisiae in a secreted form. Briefly, P. vivax genomic DNA from the Salvador I strain was used to amplify the gene fragment encoding the Pvs25 regions (Ala23-Leu195), which was inserted into the yeast episomal plasmid YEpRPEU-3 that encodes a secretory {alpha} factor containing a 6-His tail.12 Supernatants of fermentation were recovered by tangential microfiltration, concentrated by ultrafiltration, and extensively dialyzed. The retentate was incubated overnight at 4°C with Ni-nitrilotriacetic acid agarose. Proteins were purified by chromatography (Arevalo-Herrera et al., 2005).

g. Virulence

Not virulent.

h. Monkey Response

Host Strain: owl monkey (Aotus lemurinus griseimembra)
Vaccination Protocol: Male and female adult, malaria-naive Aotus monkeys were randomly allocated into two groups. An experimental group of six animals (group A) were immunized with the recombinant Pvs25 vaccine. A control group of three animals (group B) were immunized with adjuvant alone. Both groups were immunized on days 0, 60, and 120. Group A was inoculated with a total volume of 500 µL of vaccine formulated as 100 µg of the Pvs25 recombinant protein in Montanide ISA-720 in a 7:3 antigen:adjuvant ratio. Group B was injected with distilled water containing no protein and mixed in the same adjuvant following the same procedure. The immunization was performed by the subcutaneous route distributed in five different sites of the thorax and abdomen of each animal (Arevalo-Herrera et al., 2005).
Immune Response: Antigen-specific antibody responses to the Pvs25 protein as determined by ELISA were evident by day 30 after the first immunization at low levels (61–478 units of anti-Pvs25). By day 60, at the time of the first boosting dose, responses of most animals were similar and by day 90, antibodies were boosted in all but two animals. Only one monkey had an apparent boost with the third antigen injection given on day 120. All animals had maximum antibody levels by day 150. These levels started to decrease by day 180, but were still detectable 10 months after the first immunization (Arevalo-Herrera et al., 2005).
Side Effects: No adverse side effects were encountered here (Arevalo-Herrera et al., 2005).
Challenge Protocol: Approximately 10 months after the last immunization (day 440) when specific antibodies to Pvs25 are no longer detected by ELISA, all monkeys were challenged with the P. vivax Salvador I strain by intravenous injection of 105 parasitized red blood cells. Total parasitemia and gametocytemia were followed every other day using thick and thin blood smears stained with Giemsa. Parasite concentrations were expressed as the number of gametocytes per microliter and the percentage of red blood cells parasitized by asexual parasite forms.19 Monkeys were bled post-challenge (days 447–503) to evaluate the presence of antibodies to Pvs25 by ELISA. In addition, the infectivity of circulating gametocytes was tested by feeding of An. albimanus mosquitoes with parasitized monkey red blood cells mixed with normal AB human sera using the MFA on days 460 (Arevalo-Herrera et al., 2005).
Efficacy: All monkeys developed patent parasitemia by day 453, approximately two weeks after intravenous challenge. The peak of parasitemia for most of the monkeys was observed between days 462 and 464 with parasitemias and ranged from 0.1% to 1.3% as determined by thin blood smear. Gametocytes were first evident between days 458 and 460 and remained at detectable levels in all animals until day 468. Plasma samples obtained on days 447, 462, 482, and 503 after parasite challenge were negative for antibodies directed to the Pvs25 recombinant protein by ELISA. Gametocytes that developed in both groups were infectious to mosquitoes as determined in an MFA conducted with monkey blood drawn on day 460 in which plasma from AB human control sera was replaced by sera from infected monkeys. This result supports the viability and functionality of the circulating gametocytes from both the Pvs25-immunized and the control animals.

Mosquitoes fed with P. vivax gametocyte-carrying human blood in the presence of either normal monkey plasma or normal AB human sera (negative controls) produced positive infections with an arithmetic mean of oocysts per midgut ranging between 0.3 and 3.8 and 0.2 and 1.0 oocysts, respectively. However, plasma from the Pvs25-immunized Aotus tested individually were highly inhibitory and completely blocked the development of oocysts, in all assays (reduction of the oocysts number > 98%) using three different P. vivax human isolates. Plasma from monkeys in the Montanide ISA-720 control group showed similar inhibition to the normal monkey plasma (negative control). Therefore, boosting of antibodies to Pvs25 is not caused by the parasite infection, this Pvs25 vaccine can be used as a malaria transmission-blocking vaccine (Arevalo-Herrera et al., 2005).

45. P. yoelii DNA vaccine encoding MSP1

a. Vaccine Ontology ID:

VO_0004593

b. Type:

DNA vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Mouse

e. Gene Engineering of MSP1 from P. yoelii str. 17XNL

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

f. Vector:

pJW4304 (Sakai et al., 2003)

g. Immunization Route

Gene gun

h. Mouse Response

Vaccine Immune Response Type: VO_0003057
Challenge Protocol: Two weeks after the final immunization, the mice were challenged i.p. with 10^5 P. yoelii pRBC. The course of infection was monitored by microscopic examination of tail-blood smears stained with Gimsa. (Sakai et al., 2003)
Efficacy: MSP1 vaccine alone conferred partial protection. Vaccination with MSP1 + IL-12 conferred the strongest protective immunity against the infection. Only two of the six mice immunized with MSP1 alone survived, while five of the six mice immunized with MSP1 + IL-12 survived (Sakai et al., 2003).

46. P. yoelii DNA vaccine encoding PyHEP17 Protein

a. Vaccine Ontology ID:

VO_0004162

b. Type:

DNA vaccine

c. Status:

Research

d. Gene Engineering of HEP17

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

e. Vector:

nkCMVintpolyli (Doolan et al., 1996)

f. Immunization Route

Intramuscular injection (i.m.)

g. Mouse Response

Host Strain: BALB/cByJ, A/J, B10.BR, B10.Q and C57BL/6
Vaccination Protocol: Female 6- to 8-wk-old mice were immunized three times at 3-wk intervals intramuscularly in each tibialis anterior muscle with 50 μg of PyHEP17 DNA in 50 μl of saline or unmodified nkCMVintpolyli plasmid. 2 wk after the third immunization, mice were challenged by tail-vein injection with 100 infectious sporozoites or 200 infected erythrocytes (Doolan et al., 1996).

Challenge Detail

No.	Pathogen Name	Dose	Route	Age	Interval
1	Plasmodium yoelii	100 CFU in volume ml	Tail vein injection	day	14 day

Efficacy Detail

No.	Efficacy method	Result	Description	Group Efficacy Detail
1	In vivo protection study	CFU	Immunization with PyHEP17 DNA partially protected three of the five strains >20% against challenge with 100 infectious sporozoites. A 2 to 6 day delay in the onset of parasitemia in some nonprotected mice was consistent with partial immunity, which eliminated up to 90% of infected hepatocytes (Doolan et al., 1996).

47. P. yoelii DNA vaccine encoding PySSP2

a. Vaccine Ontology ID:

VO_0004590

b. Type:

DNA vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Mouse

e. Gene Engineering of SSP2

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

f. Vector:

nkCMVint or VR1012 (Hoffman et al., 1997)

g. Immunization Route

Intramuscular injection (i.m.)

h. Mouse Response

Vaccine Immune Response Type: VO_0003057
Efficacy: The full-length gene of PySSP2 in the nkCMVint vector induced specific antibodies and protected 50% of immunized mice. Subsequently, outbred CD-l mice were immunized with nkCMVint and VR1012 vector based PySSP2 DNA vaccines and as many as 33% were protected (Hoffman et al., 1997).

48. P. yoelii DNA vaccine pDIP/PyCSP. 1

a. Vaccine Ontology ID:

VO_0004589

b. Type:

DNA vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Mouse

e. Gene Engineering of CS from P. yoelii

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

f. Vector:

pBC12/CMV/IL-2 (Hoffman et al., 1994)

g. Immunization Route

Intramuscular injection (i.m.)

h. Mouse Response

Vaccine Immune Response Type: VO_0003057
Efficacy: Mice immunized with three doses of pDIP/PyCSP.1 and challenged with 5 × 105 P. yoelii sporozoites had a significant reduction in liver stage infection compared with mice immunized with the empty plasmid. Most importantly, 9 of 16 mice were protected against challenge (Hoffman et al., 1994).

49. P. yoelii DNA vaccine pPyHsp60-VR1012

a. Vaccine Ontology ID:

VO_0004592

b. Type:

DNA vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Mouse

e. Gene Engineering of HSP60 from P. yoelii

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

f. Vector:

VR1012 (Sanchez et al., 2001)

g. Immunization Route

Intramuscular injection (i.m.)

h. Mouse Response

Vaccine Immune Response Type: VO_0003057
Efficacy: In experiment 1, 40% of mice immunized with the combination of pPyHsp60-VR1012 and pmurGM-CSF did not develop parasitemia during the 14 days postchallenge. Only this group had statistically significant protection on day 14 as compared with the pooled controls (two-tailed Fisher's exact test: P = 0.031 , group 1.B versus group 1.H + group 1.I). However, in experiment 2 (identical immunization schedule), immunized mice only experienced delayed parasitemia, rather than protection from parasitemia (Sanchez et al., 2001).

50. P. yoelii MSP1 and MSP4/5 Proteins Subunit Vaccine

a. Vaccine Ontology ID:

VO_0011439

b. Type:

Subunit vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

mouse

e. Gene Engineering of MSP4/5

Type: Recombinant protein preparation
Description:
Detailed Gene Information: Click here.

f. Immunization Route

Orally

g. Mouse Response

Vaccination Protocol: One group of mice was treated by gavage with 25 μg of EcMSP4/5, and the other group was treated by gavage with 25 μg of EcMSP4/5 plus an amount of GST-PyMSP119 equivalent to 25 μg of PyMSP119 (Wang et al., 2004).
Challenge Protocol: In order to examine the protective efficacy of the induced antibodies, the immunized mice were challenged at 2 weeks after the sixth immunization with a lethal dose of 10^5 P. yoelii YM parasites (Wang et al., 2004).
Efficacy: Oral immunization of mice with Escherichia coli-expressed Plasmodium yoelii merozoite surface protein 4/5 or the C-terminal 19-kDa fragment of merozoite surface protein 1 induced systemic antibody responses and protected mice against lethal malaria infection. All of the eight immunized mice survived the challenge, with peak parasitemia levels between 0.2 and 55.2% (Wang et al., 2004).

51. P. yoelii p36/p52 mutant vaccine

a. Vaccine Ontology ID:

VO_0003009

b. Type:

Live, attenuated vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Mouse

e. Gene Engineering of Py36

Type: Gene mutation
Description: This p36/p52 mutant is from Plasmodium yoelii (Labaied et al., 2007).
Detailed Gene Information: Click here.

f. Gene Engineering of Py52

Type: Gene mutation
Description: This p36/p52 mutant is from Plasmodium yoelii (Labaied et al., 2007).
Detailed Gene Information: Click here.

g. Immunization Route

Intravenous injection (i.v.)

h. Mouse Response

Persistence: A p36/p52 mutant is attenuated in mice (Labaied et al., 2007).
Efficacy: A p36/p52 mutant induces protection in mice from challenge with wild type Plasmodium (Labaied et al., 2007).

52. P. yoelii TyCS-VLP Vaccine

a. Vaccine Ontology ID:

VO_0004271

b. Type:

Subunit vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

mouse

e. Antigen

CD8+ T cell epitope (SYVPSAEQI) of the circumsporozoite (CS) protein of Plasmodium yoelii (Oliveira-Ferreira et al., 2000).

f. Adjuvant:

VO ID: VO_0001352

g. Immunization Route

Intramuscular injection (i.m.)

h. Mouse Response

Host Strain: BALB/c
Vaccination Protocol: All the immunizations with TyCS-VLP carrying the CTL epitope of the P. yoelii circumsporozoite protein (SYVPSAEQI), except the dose response and the route of immunization experiments, consisted of 50 mg per mouse injected intramuscularly (i.m.) in the leg quadriceps (Oliveira-Ferreira et al., 2000).
Challenge Protocol: Mice were challenged with 75 sporozoites per mice administered i.v. (Oliveira-Ferreira et al., 2000).
Efficacy: 2/8 mice immunized with the TyCs-VLP vaccine were protected from challenge with P. yoelii sporozoites (Oliveira-Ferreira et al., 2000).

53. P. yoelii UIS3 mutant vaccine

a. Vaccine Ontology ID:

VO_0003011

b. Type:

Live, attenuated vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Mouse

e. Antigen

UIS3(Tarun et al., 2007)

f. Gene Engineering of UIS3

Type: Gene mutation
Description: This UIS3 mutant is from Plasmodium yoelii (Tarun et al., 2007).
Detailed Gene Information: Click here.

g. Immunization Route

Intravenous injection (i.v.)

h. Mouse Response

Persistence: A UIS3 mutant is attenuated in mice (Tarun et al., 2007).
Efficacy: A UIS3 mutant provided complete protection in mice after two doses from challenge with wild type Plasmodium yoelii (Tarun et al., 2007).

54. p52(-)/p36(-) GAP

a. Type:

Live, attenuated vaccine

b. Status:

Clinical trial

c. Host Species for Licensed Use:

Human

d. Antigen

Genetically attenuated NF54 strain P.falciparum sporozoites: p52 and p36 gene deleted

e. Immunization Route

mosquito bites

f. Human Response

Host Strain: Four volunteers identifying as Caucasian and two as African American. (Spring et al., 2013)
Vaccination Protocol: Single group, non-randomized, phase I/IIa Trial.
6 volunteers received five infectious bites from GAP-infected Anopheles mosquito at first exposure, and then received around 200 bites as second exposure one month later. (Spring et al., 2009)
Immune Response: Humoral: Post 5 bites: below the threshold. Post 200 bites: Pre-erythrocytic stage antigens: LSA-1 still not detectable, 2.9 μg/ml (0.7–12.3 μg/ml) CSP. Blood stage antigens: Only the volunteer with a peripheral blood stage parasitemia has humoral response to MSP-1 (3D7) and MSP-1 (FVO).

Cellular: IFN-γ, IL-2 and TNF responses significantly increased in the CD4 T cell compartment after 5 bites exposure, and amongst CD8 T cells after 200 bites exposure. IFN-γ production was primarily produced by CD8 T cells, and TNF production was primarily produced by CD4 T cells. No significant responses to CSP overlapping peptides or CSP recombinant protein observed.

Memory responses: CSP peptide 2, CelTOS and MSP-1 recalled the highest responses, followed by CSP and LSA-1 protein and then AMA-1, the CSP peptide pool and CSP peptide 4. LSA-1 peptide pools #1 and #2 failed to recall any responses. (Spring et al., 2013)
Side Effects: First exposure: erythema and pruritus
Second exposure: local: erythema, pruritus, edema; systematic: fever, nausea/vomiting, headache and malaise in the first 24 hours of exposure.
**One volunteer developed peripheral P. falciparum parasitemia on day 12 post-second, high dose exposure:24 parasites/μL, experienced fever, headache, fatigue, malaise, and myalgia. The Stopping Rule was activated and therefore the efficacy test was not executed as originally planned. (Spring et al., 2013)

55. Pb(PfCS@UIS4)

a. Type:

Live, attenuated vaccine

b. Status:

Clinical trial

c. Host Species for Licensed Use:

Human

d. Antigen

Pb(PfCS@UIS4): genetically modified parasite: P. falciparum circumsporozoite (CS)- protein gene integrated in the P. berghei parasite. (Reuling et al., 2020)

e. Gene Engineering of CS from P. falciparum

Type: Genetic modification
Description: PfCS expressed by P. berghei (Reuling et al., 2020)
Detailed Gene Information: Click here.

f. Immunization Route

infectious mosquito bites

g. Human Response

Vaccination Protocol: Non-randomized phase I/IIa study.
Volunteers in the experiment groups were first exposed to 1) 5, 2) 25, or 3) 75 Pb(PfCS@UIS4)-infected mosquitoes for first dose of vaccination, and were then exposed to ~75 Pb(PfCS@UIS4)-infected mosquitoes on week 4, 8, and 16 for the second, third, and fourth doses of vaccination. Group 3 were challenged by 5 Pf-infected mosquitoes together with the control group that did not receive vaccination. (Reuling et al., 2020)
Side Effects: Mild or moderate headache, nausea, and malaise. (Reuling et al., 2020)
Challenge Protocol: CHMI: volunteers were exposed to 5 NF54 Pf-infected mosquitoes 3 weeks after the last dose of vaccination (Reuling et al., 2020)
Efficacy: Sterile protection against an NF54 P. falciparum challenge was not observed, but there was a significant delay in time to parasitemia in PbVac-immunized subjects (9.9 ± 2.0 days) compared to controls (7.7 ± 1.6 days) (P=0.026) There was also a significantly 12.8-fold lower parasite peak density on the day of first positive PCR in immunized volunteers compared to the control group (P = 0.04) Collectively, this corresponds to an estimated 95% average reduction in parasite liver load. (Reuling et al., 2020)

56. PbVac P. Berghei Whole-Sporozoite Vaccine

a. Type:

Inactivated or "killed" vaccine

b. Status:

Research

c. Host Species for Licensed Use:

Baboon

d. Antigen

PbVac has been engineered to express the immunodominant Pf antigen, the circumsporozoite protein (PfCS), flanked by the Pb pre-erythrocytic stage-specific promoter, UIS4 (upregulated in infective sporozoites 4). PbVac infects and develops in human hepatocytes but not in human red blood cells. (Mendes et al., 2018)

e. Immunization Route

Intramuscular injection (i.m.)

f. Description

PbVac is a transgenic line of the rodent malaria parasite P. berghei (Pb) that expresses the P. falciparum (Pf) circumsporozoite protein (PfCS). It is capable of infecting and developing in human hepatocytes but not in human erythrocytes, and inducing neutralizing antibodies against the human Pf parasite.

g. Rabbit Response

Host Strain: NZW rabbits
Vaccination Protocol: This study performed an extensive evaluation of potential toxicity resulting from 5 consecutive administrations of PbVac delivered to rabbits by 97 infective mosquito bites each, ensuring 75 effective bites per administration. (Mendes et al., 2018)
Immune Response: After vaccination, the parasite is completely eliminated from rabbits’ livers and all other organs analyzed up to 10 days after its administration. Pre-clinical results has shown that PbVac is unable to lead to a patent blood stage infection in rabbits and is incapable of developing in human erythrocytes. (Mendes et al., 2018)
Description: This study revealed the absence of toxicity as a result of vaccine administration, indicating the safety of its use in non-permissive human hosts.

57. PfAMA1-FVO/ Alhydrogel

a. Type:

Subunit vaccine

b. Status:

Clinical trial

c. Host Species for Licensed Use:

None

d. Antigen

Recombinant protein Pichia pastoris-expressed AMA-1, surface protein expressed during the asexual blood stage of Plasmodium falciparum. PfAMA1-FVO is a lyophilized preparation of the ectodomain of the FVO clone of P. falciparum AMA1 (Thera et al., 2016)

e. Gene Engineering of AMA1 from P. falciparum 3D7

Type: Recombinant protein preparation
Description: A lyophilized preparation of the ectodomain of the FVO clone of P. falciparum AMA1 (Thera et al., 2016)
Detailed Gene Information: Click here.

f. Preparation

The vaccine was prepared in single dose vials containing 62.5 µg AMA1 protein, 23.3 µg EDTA, 25 mg saccharose, 187 µg NaH2PO4·2H₂O, 226 µg Na2HPO4. Vials were reconstituted by adding 625 µL 0.2 % Alhydrogel® suspension. he reconstituted vaccine was then incubated for 60 min at room temperature to facilitate adsorption to the Alhydrogel® and a dose of 0.5 mL containing 50 µg AMA1 and approximately 0.5 mg aluminium was used for injection. (Thera et al., 2016)

g. Immunization Route

Intramuscular injection (i.m.)

h. Description

The PfAMA1-FVO vaccine uses the FVO clone of the AMA1 surface protein as the vaccine antigen and Alhydrogel as the adjuvant.

i. Human Response

Host Strain: Adults in Bandiagara aged 18–55 years old
Vaccination Protocol: The study vaccines were given on study days 0, 28 and 56. (Thera et al., 2016)
Immune Response: The PfAMA1 vaccine induced a significant increase in AMA1-specific IgG following vaccination (p < 0.05); after vaccination, titres increased gradually in the PfAMA1 recipients until day 84 when a maximum level was observed with a geometric mean of 17,584 arbitrary units 95 % CI (9889 to 31,267). Antibody titres peaked 1 month after the third dose reaching a 3.5 fold rise. (Thera et al., 2016)
Side Effects: The 40 participants experienced a total of 257 adverse events, 136 were solicited AEs and 121 were unsolicited AEs. Additional vaccine doses did not globally increase the number of AEs. injection site pain was reported at least by 60 % of the participants after any dose compared to 40 % in the control group. Overall, the results showed a good biological safety profile. (Thera et al., 2016)
Description: PfAMA1-FVO malaria vaccine candidate clinical development was stopped after the present trial was completed, partly because of the potential limits imposed by strain specificity of protection to polymorphic AMA1 confirmed in human (Thera et al., 2016)

58. PfP0 P-BSA

a. Type:

Subunit vaccine

b. Status:

Research

c. Host Species for Licensed Use:

Human

d. Antigen

PfP0 P peptide: 16-amino-acid C-terminal peptide sequence of ribosomal phosphoprotein P0 of P. falciparum (Rajeshwari et al., 2004)

e. Gene Engineering of PfP0

Type: Recombinant protein preparation
Description: PfP0 P peptide was coupled to BSA (PfP0 P-BSA) using glutaraldehyde (Rajeshwari et al., 2004)
Detailed Gene Information: Click here.

f. Immunization Route

Intraperitoneal injection (i.p.)

g. Mouse Response

Host Strain: Swiss mice (Rajeshwari et al., 2004)
Vaccination Protocol: Mice were injected intraperitoneally with PfP0 P-BSA conjugate in Freund's adjuvant at 21-day intervals. In one control group, mice were injected in parallel with PBS emulsified in Freund's adjuvant. The other control group received no injections. The titers of the anti-PfP0 antibodies were measured after five immunizations. (Rajeshwari et al., 2004)
Challenge Protocol: The mice were challenged with P. yoelii (106 parasites per mouse) after 5 immunizations. (Rajeshwari et al., 2004)
Efficacy: Two of the six mice immunized with PfP0 P peptide developed parasitemia, compared with all 14 mice developed parasitemia in the control. One immunized mouse showed parasitemia on day 7 and died on day 8, and the other mouse showed parasitemia on day 14 but recovered by day 31, while all controls developed parasitemia by the sixth day postchallenge. The mean parasitemia levels of the three groups were statistically significantly different on day 9 (P < 0.0001), day 11 (P = 0.0014), day 13 (P = 0.0007), day 15 (P = 0.003), and day 17(P = 0.023). (Rajeshwari et al., 2004)

59. PfRH5 DNA Vaccine

a. Type:

DNA vaccine

b. Status:

Research

c. Host Species for Licensed Use:

None

d. Antigen

PfRH5: reticulocyte-binding protein homolog 5, a leading blood-stage antigen to APCs. The vaccine uses PfRH5ΔNL, the crystal structure and key functional antibody epitopes for the trunacated version of PfRH5. (Bjerkan et al., 2021)

e. Gene Engineering of RH5

Type: Recombinant protein preparation
Description: The crystal structure and key functional antibody epitopes for the truncated version of PfRH5 were characterized to create PfRH5ΔNL, used as the vaccine antigen. (Bjerkan et al., 2021)
Detailed Gene Information: Click here.

f. Preparation

DNA vaccines were encoded in a pUMVC4a plasmid vector (Aldevron) under a CMV-IE promoter and containing a tPA signal peptide. The targeted constructs were cloned into pUMVC4a using PmlI and BamHI.(Bjerkan et al., 2021)

g. Immunization Route

Intramuscular injection (i.m.)

h. Description

The PfRH5 DNA Vaccine vaccine is designed as bivalent homodimers where each chain is composed of an amino-terminal single chain fragment variable (scFv) targeting unit specific for major histocompatibility complex class II (MHCII) expressed on APCs, and a carboxyl-terminal antigenic unit genetically linked by the dimerization units. This vaccine uses PfRH5ΔNL as the antigen, with the APC-targeted vaccine construct, termed a “Vaccibody”. (Bjerkan et al., 2021)

i. Mouse Response

Host Strain: Female BALB/c mice
Vaccination Protocol: For intramuscular (i.m.) delivery of DNA vaccines, mice were shaved on each leg, and 25 µg of PfRH5ΔNL-containing DNA or 2.5 µg of PvDBP-containing DNA was injected in a 50 µl volume into each quadriceps femoris muscle (50 µg or 5 µg total DNA/mouse, respectively). Immediately after injection, electrical pulses were applied at the injection site. BALB/c mice were immunized three times at three weeks intervals, with 50 µg plasmids that encoded either MHCII-targeted or non-targeted Vaccibodies, or antigen alone. (Bjerkan et al., 2021)
Immune Response: Vaccination with the MHCII-targeted vaccine showed significantly increased levels of total PfRH5FL-specific IgG compared to vaccination with the antigen alone at days 41 and 62 post-prime vaccination. The results showed that vaccination with the MHCII-targeted-PfRH5ΔNL vaccine induced significantly higher levels of IFN-γ producing cells in response to PfRH5FL protein in both spleens and dLNs as compared to vaccination with the non-targeted control vaccine and PfRH5ΔNL antigen alone. Strong and comparable levels of GIA were detected for IgG raised following DNA vaccination with PfRH5ΔNL-containing vaccines and the PfRH5ΔNL control vaccine. (Bjerkan et al., 2021)

60. PfRipr5/ Alhydrogel

a. Type:

Protein Subunit Vaccine

b. Status:

Research

c. Host Species for Licensed Use:

None

d. Antigen

PfRipr5: a protein fragment of PfRipr complex considered to play one of the central roles in the sequential molecular events leading to P. falciparum merozoite invasion. PfRipr5 is a protein fragment inducing the most potent growth inhibitory antibodies as comparable level to the antibodies against full-length PfRip. (Takashima et al., 2022)

e. Preparation

PfRipr5 recombinant protein was produced in a 50 L stirred-tank bioreactor by infecting insect High Five cells at 2 ×106 cell/mL with a recombinant baculovirus encoding pfripr5 nucleotide sequence and His6-tag for purification, using a multiplicity of infection of 0.1 virus per cell. cell culture bulk was clarified using a Sartopore 2 30’’ 0.45 µm + 0.2 µm filter, loaded on a Histrap HP column, and protein was eluted with a linear Imidazole gradient. The eluate was concentrated using a Vivaflow 200 Hydrosart 10 kDa and loaded into a Superdex 75 prep grade XK50/100 gel size-exclusion chromatography column, from which fractions corresponding to monomeric PfRipr5 were collected. The collected fractions were loaded in a HiPrep desalting 26/10 column, the eluate was concentrated as mentioned above, and then sterile-filtered (0.2 μm). The final sample was formulated in 16 mM sodium phosphate buffer, 250 mM NaCl, at pH 8.0, aliquoted and stored at -80°C. (Takashima et al., 2022)

f. Immunization Route

Intramuscular injection (i.m.)

g. Description

PfRipr5/ Alhydrogel is a asexual-blood stage malaria vaccine that uses the PfRipr5 protien segment as the vaccine antigen and an Alhydrogel adjuvant. (Takashima et al., 2022)

h. Rabbit Response

Host Strain: Japanese white rabbits
Vaccination Protocol: Japanese white rabbits (n=6 per group) were subcutaneously immunized with the PfRipr5 protein alone (50 µg/shot) or with PfRipr5 antigen (0, 50, and 200 µg/shot) formulated with the aforementioned adjuvants at the specific concentrations in 500 µL injection, twice at three-week intervals (Day 0 and Day 21). Antisera were collected two weeks after the last immunization (Day 35). (Takashima et al., 2022)
Immune Response: Formulation of PfRipr5 with Alhydrogel® induced statistically significant higher levels of antibodies in most low dose (50 µg) (Mean ELISA titers: Alum = 1.0 ×105 (P<0.01)); and in all high dose groups (200µg) (Mean ELISA titers: Alum = 8.8 ×104 (P<0.05)). The GIA activity of IgG induced by PfRipr5 Alhydrogel® formulation was higher in the low dose (50 µg) (Mean %GIA = 37%) than in the high dose (200 µg) (Mean %GIA = 19.9%) groups. (Takashima et al., 2022)
Description: The current study shows that PfRipr5 antigen alone was immunogenic to rabbits without any adjuvant, although the generated antibodies could not induce significant GIA activities.(Takashima et al., 2022)

61. PfRipr5/ CAF01

a. Type:

Protein Subunit Vaccine

b. Status:

Research

c. Host Species for Licensed Use:

Baboon

d. Antigen

e. Preparation

f. Immunization Route

Intramuscular injection (i.m.)

g. Description

PfRipr5/ CAF01 is a asexual-blood stage malaria vaccine that uses the PfRipr5 protien segment as the vaccine antigen and a CAF01 adjuvant.

h. Rabbit Response

Host Strain: Japanese white rabbits
Vaccination Protocol: apanese white rabbits (n=6 per group) were subcutaneously immunized with the PfRipr5 protein alone (50 µg/shot) or with PfRipr5 antigen (0, 50, and 200 µg/shot) formulated with the aforementioned adjuvants at the specific concentrations in 500 µL injection, twice at three-week intervals (Day 0 and Day 21). Antisera were collected two weeks after the last immunization (Day 35). (Takashima et al., 2022)
Immune Response: Formulation of PfRipr5 with CAF®01 induced statistically significant higher levels of antibodies in most low dose (50 µg) (Mean ELISA titers: CAF = 1.0 ×105 (P<0.01)) and in all high dose groups (200 µg) (Mean ELISA titers: CAF = 1.1 ×105 (P<0.001)). The GIA activities of IgG induced by PfRipr5 CAF®01 formulations were higher in the high dose (200 µg) (Mean %GIA: CAF = 49.4%) than in the low dose (50 µg) (Mean %GIA: CAF = 38%) groups. (Takashima et al., 2022)
Description: The PfRipr5/CAF®01 formulation was identified as the most promising vaccine candidate for further development because of its higher immunogenicity. (Takashima et al., 2022)

62. PfRipr5/GLA-SE

a. Type:

Protein Subunit Vaccine

b. Status:

Research

c. Host Species for Licensed Use:

Baboon

d. Antigen

e. Preparation

f. Immunization Route

Intramuscular injection (i.m.)

g. Description

PfRipr5/ GLA-SE is a asexual-blood stage malaria vaccine that uses the PfRipr5 protien segment as the vaccine antigen and a GLA-SE adjuvant.

h. Rabbit Response

Host Strain: Japanese white rabbits
Vaccination Protocol: Japanese white rabbits (n=6 per group) were subcutaneously immunized with the PfRipr5 protein alone (50 µg/shot) or with PfRipr5 antigen (0, 50, and 200 µg/shot) formulated with the aforementioned adjuvants at the specific concentrations in 500 µL injection, twice at three-week intervals (Day 0 and Day 21). Antisera were collected two weeks after the last immunization (Day 35).
Immune Response: Formulation of PfRipr5 with GLA-SE in in the high dose group (200 µg) produced Mean ELISA titers: GLA = 1.2 ×105 (P<0.001)and the low dose (50 µg) formulation Mean ELISA titer = 8.0 ×104. The GIA activities of IgG induced by PfRipr5 GLA-SE were higher in the high dose (200 µg) (Mean %GIA: GLA = 36.2%)

63. Pfs230D1-EPA/ AS01

a. Type:

Subunit vaccine

b. Status:

Research

c. Host Species for Licensed Use:

None

d. Antigen

Pfs230 domain 1: Pre-fertilization antigens, expressed during gametocyte development in human (Duffy et al. 2021)

e. Immunization Route

Intramuscular injection (i.m.)

f. Description

The Pfs230D1-EPA/AS01 uses the Pfs230D1 pre-fertilization antigen conjugated with EPA nanoparticles with GSK platform AS01 as the vaccine adjuvant tested on mice.

g. Mouse Response

Host Strain: CD-1 Mice
Immune Response: Pfs230D1-EPA induces higher titers and IgG levels in AS01 vs. alum adjuvants in mice (Rausch et al., 2023)

64. Pfs230D1-EPA/Matrix-M

a. Type:

Subunit vaccine

b. Status:

Clinical trial

c. Host Species for Licensed Use:

Human

d. Antigen

Pfs230 domain 1 (Duffy et al. 2021)

e. Gene Engineering of Pfs230

Type: Recombinant protein preparation
Description: Expressed by gametocytes in the human stage of P. falciparum. Also a surface antigen of gametes and zygotes in the mosquito stage. Mediates binding of exflagellating microgametes to red blood cells. (Coelho et al., 2021)
Detailed Gene Information: Click here.

f. Immunization Route

Intramuscular injection (i.m.)

g. Description

Malaria transmission blocking vaccine: block parasite transmission through mosquitoes (Coelho et al., 2021)

h. Human Response

Host Strain: Adults in Mali
Vaccination Protocol: Phase I, Dose-Escalating, Double-Blind, Randomized, Comparator-Controlled Trial. Ongoing.
Participants are randomly assigned to different groups, getting 3 doses of 1) 160 µg/mL conjugated Pfs230D1M and 124 µg/mL conjugated EPA or 2) 160 µg/mL conjugated Pfs230D1M and 143 µg/mL conjugated EPA or 3)Verorab Rabies, each dose injected at 0, 1, and 2 months.
Outcome Measures:
Primary: Number of local and systemic adverse events (AEs) and serious adverse events (SAEs) to assess the safety of the study drug
Secondary: 1) Level of humoral immune response as measured by ELISA titer response to Pfs230D1M after third immunization. 2) Duration of humoral immune response as measured by ELISA titer response to Pfs230D1M after third immunization. 3) Level of functional antibody response to Pfs230D1M as measured by standard membrane feeding assay (Duffy et al. 2021)

65. Pfs25 VLP-FhCMB

a. Type:

Subunit vaccine

b. Status:

Licensed

c. Host Species for Licensed Use:

None

d. Antigen

Pfs25: is a member of a Plasmodium protein family characterized by the presence of epidermal growth factor (EGF)-like repeat motifs, numerous cysteine residues and a complex tertiary structure. (Chichester et al., 2018)

e. Gene Engineering of Pfs25 from P. falciparum 3D7

Type: Recombinant protein preparation
Description: Pfs25 is used as the malaria vaccine antigen.
Detailed Gene Information: Click here.

f. Preparation

Pfs25 VLP-FhCMB, a chimeric non-enveloped VLP comprising Pfs25 fused to the Alfalfa mosaic virus coat protein (CP), produced in hydroponically grown Nicotiana benthamiana plants using a Tobacco mosaic virus (TMV)-based hybrid vector, then purified and characterized. 400 µg of total protein per mL in an aqueous formulation containing 50 mM sodium phosphate. Four total protein dose levels of the vaccine (2, 10, 30 and 100 μg per 0.5 mL) were formulated in the clinic on the day of administration with 0.3% Alhydrogel (Chichester et al., 2018)

g. Immunization Route

Intramuscular injection (i.m.)

h. Description

Pfs25 VLP-FhCMB is a plant-produced Pfs25 virus-like particle usedas a transmission blocking vaccine against malaria

66. Pfs25-EPA / AS01

a. Type:

Protein-nanoparticle vaccine

b. Status:

Research

c. Host Species for Licensed Use:

Baboon

d. Antigen

Pfs25, a post-fertilization antigen that is involved in ookinete formation and survives in the mosquito midgut (Mulamba et al., 2022)

e. Gene Engineering of Pfs25 from P. falciparum 3D7

Type: Recombinant protein preparation
Description: Pfs25 (or P25) from P. falciparum was used as the vaccine antigen
Detailed Gene Information: Click here.

f. Preparation

Pfs25 is a leading TBV candidate, and previous studies conducted in animals demonstrated an improvement of its functional immunogenicity after conjugation to EPA, a recombinant, detoxified ExoProtein A from Pseudomonas aeruginosa (Talaat et al., 2016). In addition, AS01 is used as the vaccine adjuvant.

g. Immunization Route

Intramuscular injection (i.m.)

h. Description

Pfs25-EPA/ AS01 vaccine is made by using the Pfs25 as the vaccine antigen, which is conjugated to EPA nanoparticles, and the GSK platform AS01 serves as the vaccine adjuvant (Talaat et al., 2016).

i. Mouse Response

Host Strain: CD-1 Mice
Efficacy: Pfs25-EPA formulated in AS01 induced significantly higher antibody levels than unconjugated Pfs25 formulated in AS01 (Rausch et al., 2023) Pfs25-EPA/AS01 showed significant oocyst reduction compared to Pfs25-EPA/Alhydrogel, but the difference between these groups was not statistically significant at end of study (Rausch et al., 2023)

67. Pfs25-EPA/Alhydrogel

a. Manufacturer:

Walter Reed Army Institute of Research Bioproduction Facility

b. Type:

Subunit vaccine

c. Status:

Licensed

d. Host Species for Licensed Use:

None

e. Antigen

Pfs25H is a Pichia pastoris-expressed hexa-His tagged recombinant Pfs25, a post-fertilization surface antigen of ookinetes in the mosquito stage of P. falciparum. (Talaat et al., 2016)

f. Gene Engineering of Pfs25 from P. falciparum 3D7

Type: Recombinant protein preparation
Description: Pfs25H is a Pichia pastoris-expressed hexa-His tagged recombinant Pfs25 used as the vaccine antigen.
Detailed Gene Information: Click here.

g. Preparation

The Pfs25-EPA conjugate was produced by reaction between thiolated Pfs25H and maleimide-activated rEPA, followed by purification using size-exclusion chromatography. Pfs25-EPA was subsequently formulated with Alhydrogel®. 78 μg/mL Pfs25H and 93 μg/mL rEPA, bound to 1600 μg/mL Alhydrogel® in a volume of 0.8 mL. (Talaat et al., 2016)

h. Immunization Route

Intramuscular injection (i.m.)

i. Description

The Pfs25-EPA/ Alhydrogel uses a recombinant Pfs25 antigen with a recombinant EPA (rEPA) formulated with an Alhydrogel adjuvant.

j. Human Response

Host Strain: Healthy adults age 18–50 were recruited from the Baltimore, MD region without significant medical conditions.
Vaccination Protocol: Participants were divided into three groups: Group 1a received two injections of a low vaccine dose (8 μg Pfs25H), Group 1b received two injections of a medium dose (16 μg Pfs25H) at 0 and 2 months, and Group 2 received four injections of a high dose (47 μg Pfs25H) at 0, 2, 4, and 10 months. Additionally, one high responder in Group 1a received a third injection of the low vaccine dose (8 μg Pfs25H) at 10 months. (Talaat et al., 2016)
Immune Response: Proportion of antibody levels in responders increased after second, third vaccinations, and the final booster, demonstrating immunogenicity. However, antibody levels declined rapidly weeks after the final dose.

68. Pfs25-IMX313/Matrix-M

a. Type:

protein-nanoparticle vaccine

b. Status:

Clinical trial

c. Host Species for Licensed Use:

Human

d. Antigen

Pfs25: post-fertilization antigen, three potential N-linked glycosylation sites (112, 165 and 187) mutated. Involved in ookinete formation, survival in the mosquito midgut, and a possible role in parasite traversal of the mid-gut epithelium. (Mulamba et al., 2022)

e. Gene Engineering of Pfs25 from P. falciparum 3D7

Type: Recombinant protein preparation
Description: Pfs25 antigen is genetically fused to the IMX313 oligomerization domain (Mulamba et al., 2022)
Detailed Gene Information: Click here.

f. Adjuvant:

VO ID: VO_0005206
Description: A potent saponinbased adjuvant, comprising partially purifed extracts of the bark of the Quillaja saponaria Molina tree, phosphatidylcholine and cholesterol. Enhance immune responses (Mulamba et al., 2022)

g. Immunization Route

Intramuscular injection (i.m.)

h. Description

**Mechanism: Human get vaccinated --> Human produce antibodies --> mosquitoes take up antibodies --> reduce parasite fertilization in mosquitoes (Mulamba et al., 2022)

i. Human Response

Host Strain: Semi-immune healthy adults from Bagamoyo district in Tanzania
Vaccination Protocol: Phase I trial, not started.
A two-years enrollment schedule has been designed, with one group of volunteers receiving immunization at months; zero, one and three, while another group shall receive immunization at months; zero, one and seven.
Enrollment of volunteers will follow a strict staggered approach, with one of group of adults receiving a low dose of the vaccine followed by another adults’ group receiving a high dose of the vaccine in six-weeks interval.(Mulamba et al., 2022)

69. Pfs25/ Montanide ISA 51

a. Type:

Live, attenuated vaccine

b. Status:

Licensed

c. Host Species for Licensed Use:

None

d. Antigen

Pfs25, a protein expressed on the surface of ookinetes of P. falciparum (Wu et al., 2008)

e. Gene Engineering of Pfs25 from P. falciparum 3D7

Type: Recombinant protein preparation
Description: Recombinant Pfs25 was used as the vaccine adjuvant. (Wu et al., 2008)
Detailed Gene Information: Click here.

f. Preparation

Recombinant proteins Pfs25 were produced in the yeast expression system utilizing Pichia pastoris. A hexa-His tag was added to the C-terminus of the recombinant protein to facilitate purification and characterization. the Pfs25 at a concentration of 320 µg/mL in phosphate-buffered saline (PBS, 155 mM NaCl, 1 mMKH2PO4, 3 mM Na2HPO3) was aseptically emulsified with an equal volume of Montanide ISA 51 to give a final vaccine concentration of 160 µg/mL. The emulsion was achieved by homogenizing the mixture in a volume of 200 mL in a 400-mL vessel at room temperature for 6 min at 6000 rpm using an Omni Mixer-ES homogenizer. (Wu et al., 2008)

g. Immunization Route

Intramuscular injection (i.m.)

h. Description

The Pfs25/ Montanide ISA 51 uses Pfs25, a P. falciparum ookinete surface protein, as the vaccine antigen emulsified in Montanide ISA 51 as the vaccine adjuvant.

i. Human Response

Host Strain: healthy US volunteers
Vaccination Protocol: Vaccines were administered at three dose levels (5, 20, and 80 µg per dose in 0.5 mL) (Wu et al., 2008)
Immune Response: Four of 10 volunteers, including the one that developed a leukemoid reaction (Volunteer “C”), had no detectable antibodies against Pfs25 (i.e. <25 ELISA units) by day 120 following the first vaccination. Of the 2 volunteers that developed grade 3 induration, one (Volunteer “H”) had a minimal antibody level of 30 ELISA units on day 90, 30 days after the induration resolved. The other (Volunteer “G”) had 132 ELISA units on day 60. All 5 volunteers (Volunteers “A” through “E”) receiving a second dose of 5 µg Pfs25/ISA 51 developed substantial antibody levels against Pfs25 following the second vaccination (Table 4). The antibody levels reached a peak 30–60 days after the second vaccination and the geometric mean of the peak of this group was 1295 ELISA units. (Wu et al., 2008)
Side Effects: Local adverse events included erythema, induration, swelling, and tenderness at the site of injection. Solicited systemic adverse events included fever (oral temperature≥37.5°C), headache, nausea, malaise, myalgia, and arthralgia. In the groups receiving antigen with ISA 51, 6 volunteers experienced severe local reaction, 4 experienced moderate local reaction, and 14 experienced mild reaction (maximum severity for each). Four of six volunteers who received the control vaccine (PBS/ISA 51) complained of mild injection site pain lasting up to 4 days and two recipients reported mild erythema for one day. (Wu et al., 2008)
Efficacy: In ex vivo membrane feeding assays, one antiserum that contained 7322 ELISA units resulted in reduction of the parasite in mosquitoes by >90%. The severity and duration of the local reactions seen in this study, combined with the observed systemic reactions, make further progression of the Montanide ISA 51 formulations unlikely.

70. Pfs48/45 in Matrix-M

a. Type:

Subunit vaccine

b. Status:

Clinical trial

c. Host Species for Licensed Use:

Human

d. Antigen

Pfs48/45 (Minassian et al., 2022): plays an important role in the fertilization of plasmodium: males lacking Pfs48/45 show severely reduced fertility and are incapable of adhering to and penetrating female gametes. (Theisen et al., 2017)

e. Gene Engineering of Pfs48/45

Type: Recombinant protein preparation
Description: Pfs48/45 and the 10 C and 6 C fusion proteins. The secondary structure prediction of Pfs48/45 have assigned 2 loops in domain II between amino acid residues 190–210 and 239–259, and in domain III between the residues 302–327 and 357–397. Epitope I is located between residues 295 and 418. (Theisen et al., 2017)
Detailed Gene Information: Click here.

f. Immunization Route

Intramuscular injection (i.m.)

g. Description

Transmission Blocking Vaccine: induce antibodies that taken up by the mosquito and subsequently prevent development of parasites in the mosquito midgut (Theisen et al., 2017)

h. Human Response

Host Strain: adults living in UK(Minassian et al., 2022)
Vaccination Protocol: Non-randomized, phase Ia trial, not strated.
Participants will be separated into three different groups with 8-10 participants in each group: 1) low dose: three doses of 10 µg Pfs48/45 in 50 µg Matrix-M on days 0, 28 and 56; 2) standard dose: three doses of 50 µg Pfs48/45 in 50 µg Matrix-M on days 0, 28 and 56; and 3) two doses of 50 µg Pfs48/45 in 50 µg Matrix-M on days 0 and 28, followed by one dose of 10 µg Pfs48/45 in 50 µg Matrix-M on day 56. (Minassian et al., 2022)

71. PfSPZ

a. Type:

Live, attenuated vaccine

b. Status:

Clinical trial

c. Host Species for Licensed Use:

Human

d. Antigen

live (metabolically active), nonreplicating, radiation-attenuated P. falciparum sporozoites (SPZ)(Oneko et al., 2021)

e. Immunization Route

Intravenous injection (i.v.)

f. Human Response

Host Strain: Infants aged 5–12-month-old in Kenya(Oneko et al., 2021)
Vaccination Protocol: Double-blind, randomized, placebo-controlled Phase2 trial.
Participants were randomly assigned in 4 groups, each receiving 1) 4.5 × 105, 2) 9.0 × 105 and 3) 1.8 × 106 PfSPZ or 4) normal saline placebo. (Oneko et al., 2021)
Immune Response: Dose-dependent increase in IgG and IgM antibody responses and a significantly greater rate of seroconversion and net increase in IgG and IgM antibodies: 94.0% and 89.5% of vaccinees and 12.7% and 12.7% of controls had increased IgG and IgM antibodies two weeks after third vaccination.
Dose-dependent increase in the PfCSP-specific memory B cell response.
** There were low-to-undetectable PfSPZ-specific CD4 and CD8 T cell responses, which might because of the limited magnitude and functional capacity of γδ T cells in infants. (Oneko et al., 2021)
Side Effects: Mild to moderate fever (more common in participants in the highest-dose group); febrile seizures. (Oneko et al., 2021)
Efficacy: No statistically significant (P < 0.05) VE against the presence of parasitemia at the primary 6-month end point by either proportional or time-to-event analyses. (Oneko et al., 2021)

g. Human Response

Vaccination Protocol: Phase I trial.
57 adults participated in the trial. 40 of them were vaccine recipients (36 completed the vaccination), 12 were CHMI controls, and 5 were backup controls. For volunteers in the vaccination group: 1) 2 of the volunteers were given 2 × 10^3 PfSPZ per dose without CHMI to access safety, while the rest of the vaccination group were given 1.35 × 10^5 PfSPZ per dose and given CHMI later. (Seder et al., 2013)
Challenge Protocol: CHMI ~3 weeks after last immunization (Seder et al., 2013)
Efficacy: 16 of 17 subjects who received 7.5 × 10^3 and 3×10^4 PfSPZ Vaccine per dose developed parasitemia. Among the nine subjects who had received four doses of 3 × 10^4 PfSPZ Vaccine, one did not develop parasitemia, whereas the other eight had a 1.4 day prolongation of time to parasitemia compared with the six nonvaccinated controls (P = 0.007, LogRank). The prepatent periods in the 7.5 × 10^3 PfSPZ Vaccine-per-dose group were not significantly different than those of controls.
12 of 15 subjects immunized with 1.35 × 10^5 PfSPZ Vaccine per dose were protected (P = 0.028). Three of nine subjects in the four-dose group and none of six in the five-dose group developed parasitemia (P = 0.015 for the fivedose group versus controls, Fisher’s exact test). All subjects who did not develop parasitemia were negative as determined by means of quantitative PCR at 28 days after CHMI. In the three vaccinated subjects that became infected, there was a modest delay in the time to positive PCR.
(Seder et al., 2013)

72. Plasmodium FabB/FabF mutant vaccine

a. Vaccine Ontology ID:

VO_0003007

b. Type:

Live, attenuated vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Mouse

e. Gene Engineering of FabB/FabF

Type: Gene mutation
Description: This FabB/FabF mutant is from Plasmodium (Butler et al., 2011).
Detailed Gene Information: Click here.

f. Immunization Route

Intravenous injection (i.v.)

g. Mouse Response

Persistence: A FabB/FabF genetically attenuated parasite is attenuated in mice (Butler et al., 2011).
Efficacy: A FabB/FabF genetically attenuated parasite induces complete protection in mice from challenge with wild type Plasmodium (Butler et al., 2011).

73. PvCS/Montanide ISA-51

a. Type:

Subunit vaccine

b. Status:

Clinical trial

c. Host Species for Licensed Use:

Human

d. Antigen

PvCS: circumsporozoite protein of P. vivax. N+C: Two long synthetic peptides (LSP): the N-terminal (N) and C-terminal (C) regions; N+C+R: Three LSP: N-terminal, C-terminal, and the central repeats (R) regions. (Arévalo-Herrera et al., 2022)

e. Gene Engineering of CS from P. vivax

Type: Recombinant protein preparation
Description: N: N-term aa 20–96, C: C-term aa 301–372. R: VK210 (type I): first central repeat (aa 96–104) in tandem three times, collinearly linked to a universal T-cell epitope (ptt-30) derived from tetanus toxin. (Arévalo-Herrera et al., 2022)
Detailed Gene Information: Click here.

f. Adjuvant:

VO ID: VO_0001270

g. Immunization Route

Intramuscular injection (i.m.)

h. Human Response

Host Strain: malaria-naïve or semi-immune adults
Vaccination Protocol: Randomized, double-blind, controlled Phase II trial.
Participants were divided into malaria naïve and semi-immune groups, each of which included experimental and control groups, and received vaccination or placebo at months 0, 2, and 6. Experimental group received PvCS N+C formulated in Montanide ISA-51 as the first dose, and PvCS N+C formulated in Montanide ISA-51 adjuvant as the second and third dose, while control group received three doses of Montanide ISA-51. (Arévalo-Herrera et al., 2022)
Side Effects: Local: local pain, headache and malaise, mild or moderate cases, all resolved the next day after vaccination.
Systematic: low frequency of fever, nausea, chills, diarrhea, and abdominal pain (Arévalo-Herrera et al., 2022)
Challenge Protocol: sporozoite CHMI at month 9 (Arévalo-Herrera et al., 2022)

74. PvDBPII/Matrix-M1

a. Type:

Subunit vaccine

b. Status:

Clinical trial

c. Host Species for Licensed Use:

Human

d. Antigen

PvDBPII: region II of P. vivax Duffy-binding protein (Hou et al., 2022)

e. Gene Engineering of PvDBPII

Type: Recombinant protein preparation
Description: Region II of PvDBP, a 327-amino acid domain. (Hou et al., 2022)
Detailed Gene Information: Click here.

f. Adjuvant:

VO ID: VO_0005206

g. Immunization Route

Intramuscular injection (i.m.)

h. Human Response

Host Strain: healthy adults living in the UK (Minassian et al., 2019)
Vaccination Protocol: Phase I/IIa, blood-stage trial
Volunteers received vaccination based on the time they participated in the experiment: group 1 received three doses of the PvDBPII 50ug/Matrix M1 50ug vaccine at 0, 1 and 14 months, and group 2 received three doses of the PvDBPII 50ug/Matrix M1 50ug vaccine at 0, 1 and 2 months. (Hou et al., 2022)
Immune Response: Humoral: Anti-PvDBPII (SalI) total IgG serum antibody responses peaked around 2 weeks following the final vaccination. PvDBPII/M-M given at 0, 1 and 14 months induced higher response (geometric mean 198 μg/mL, range 153–335).
Cellular: PvDBPII-specific CD4+ CD45RA− CCR7− effector memory T cells producing IFN-γ were detectable following final vaccinations in a delayed dosing regimen. IFN-γ producing CD8+ effector memory T cells were not detectable. (Hou et al., 2022)
Side Effects: Mild or moderate cases of warmth, itch, injection site pain, redness, malaise, nausea, fatigue, headache, feverishness, myalgia, arthralgia, and temperature, all resolved within 48 hours. (Hou et al., 2022)
Challenge Protocol: Blood stage CHMI 2–4 weeks after the third dose of vaccination (Hou et al., 2022)
Efficacy: All volunteers developed parasitemia, but the PMR and LCP is significant lower in the delayed dosing group compared to unvaccinated controls, due to the delayed dosing (PMR: 3.2-fold growth per 48 hours (range 2.3 to 4.3) compared to 6.8-fold growth per 48 hours [range 4.0 to 11.1], p <0.001), resulted in a 7-day delay in median time to reach malaria diagnosis (15.5 days in controls compared to 22.5 days in delayed dosing group). (Hou et al., 2022)

75. PvRII/ AS02A

a. Type:

Subunit vaccine

b. Status:

Research

c. Host Species for Licensed Use:

Macaque

d. Antigen

PvRII, receptor-binding domain of Plasmodium vivax Duffy binding protein, region II, with a C-terminal 6-histidine tag expressed in E. coli. (Moreno et al., 2008)

e. Gene Engineering of PvDBPII

Type: Recombinant protein preparation
Description: The designed gene encoding PvRII was synthesized using overlapping oligomers (Midland Certified Reagent Company) and cloned in plasmid pET28a(+) (Novagen) at NcoI and SalI sites. Expression of recombinant PvRII using synthetic gene was higher compared with native gene. (Yazdani et al., 2006)
Detailed Gene Information: Click here.

f. Preparation

PvRII from P. vivax Salvador I strain was cloned as a NcoI-SalI fragment in the E. coli expression vector pET28a(+). Protein expression of the recombinant 6-His tag PvRII was induced with 1 mM IPTG for 4 hours and purified. 50 μg and 10 μg of PvRII formulated in AS02A. (Moreno et al., 2008)

g. Immunization Route

Intramuscular injection (i.m.)

h. Description

The PvRII/ AS02A vaccine uses recombinant PvRII (region II), the receptor-binding domain of the Plasmodium vivax Duffy binding protein. Antibodies raised against the P.vivax Duffy binding protein, which belong to a family of erythrocyte binding protiens residing in region II, block erythrocyte invasion in the malaria infection process. Formulations emulsified with the AS02A adjuvant elicted higher titer binding inhibitory antibodies compared to other adjuvants such as Alhydrogel and MF59. (Moreno et al., 2008)

76. PvRII/ Montanide ISA 720

a. Type:

Subunit vaccine

b. Status:

Research

c. Host Species for Licensed Use:

Macaque

d. Antigen

PvRII, receptor-binding domain of Plasmodium vivax Duffy binding protein, region II, with a C-terminal 6-histidine tag expressed in E. coli. (Moreno et al., 2008)

e. Gene Engineering of PvDBPII

Type: Recombinant protein preparation
Description: The designed gene encoding PvRII was synthesized using overlapping oligomers (Midland Certified Reagent Company) and cloned in plasmid pET28a(+) (Novagen) at NcoI and SalI sites. Expression of recombinant PvRII using synthetic gene was higher compared with native gene. (Yazdani et al., 2006)
Detailed Gene Information: Click here.

f. Preparation

g. Immunization Route

Intramuscular injection (i.m.)

h. Description

The PvRII/ Montanide ISA 720 vaccine uses recombinant PvRII (region II), the receptor-binding domain of the Plasmodium vivax Duffy binding protein. Antibodies raised against the P.vivax Duffy binding protein, which belong to a family of erythrocyte binding protiens residing in region II, block erythrocyte invasion in the malaria infection process. Formulations emulsified with the Montanide ISA 720 adjuvant elicted higher titer binding inhibitory antibodies compared to other adjuvants such as Alhydrogel and MF59. (Moreno et al., 2008)

i. Macaque Response

Host Strain: Healthy rhesus macaques of Chinese origin from the Yerkes National Primate Research Center facility
Vaccination Protocol: Selected animals were matched by age, sex and weight, housed in social settings and randomly assigned to six experimental groups of 5 individuals each that received different vaccine formulations (Groups 1-6) and three control groups of two individuals each that received adjuvant alone (Groups 7-9). Groups 3 and 4 received 50 μg and 10 μg of PvRII emulsified in Montanide ISA 720. (Moreno et al., 2008) Intramuscularly, priming into the right quadriceps femoris on day 0, first boost into the right musculus deltoideus on day 60 and the last boost into the left musculus deltoideus on day 150.
Immune Response: Increase in antibody titers

77. PvRII/ Alhydrogel

a. Type:

Subunit vaccine

b. Status:

Research

c. Host Species for Licensed Use:

Macaque

d. Antigen

PvRII, receptor-binding domain of Plasmodium vivax Duffy binding protein, region II, with a C-terminal 6-histidine tag expressed in E. coli. (Moreno et al., 2008)

e. Gene Engineering of PvDBPII

Type: Recombinant protein preparation
Description: The designed gene encoding PvRII was synthesized using overlapping oligomers (Midland Certified Reagent Company) and cloned in plasmid pET28a(+) (Novagen) at NcoI and SalI sites. Expression of recombinant PvRII using synthetic gene was higher compared with native gene. (Yazdani et al., 2006)
Detailed Gene Information: Click here.

f. Preparation

g. Immunization Route

Intramuscular injection (i.m.)

h. Description

The PvRII/ Alhydrogel vaccine uses recombinant PvRII (region II), the receptor-binding domain of the Plasmodium vivax Duffy binding protein. Antibodies raised against the P.vivax Duffy binding protein, which belong to a family of erythrocyte binding protiens residing in region II, block erythrocyte invasion in the malaria infection process. Recombinant PvRII formulated with Alhydrogel yielded antibodies with significant binding inhibitory activity.. (Moreno et al., 2008)

i. Macaque Response

Host Strain: Healthy rhesus macaques of Chinese origin from the Yerkes National Primate Research Center facility
Vaccination Protocol: Selected animals were matched by age, sex and weight, housed in social settings and randomly assigned to six experimental groups of 5 individuals each that received different vaccine formulations (Groups 1-6) and three control groups of two individuals each that received adjuvant alone (Groups 7-9). Groups 1 and 2 were immunized with 50 μg and 10 μg of PvRII adsorbed to Alhydrogel, respectively. Intramuscularly, priming into the right quadriceps femoris on day 0, first boost into the right musculus deltoideus on day 60 and the last boost into the left musculus deltoideus on day 150. (Moreno et al., 2008)
Immune Response: Antibody titers, determined by ELISA, increased in PvRII formulated with Alhydrogel, refolded PvRII induced functional antibodies with the potential to inhibit parasite invasion. (Moreno et al., 2008)

78. Pvs25 mRNA–LNP

a. Type:

Protein Subunit Vaccine

b. Status:

Research

c. Host Species for Licensed Use:

None

d. Antigen

Pvs25, the P. vivax ookinete surface protein expressed on the surface of zygotes/ookinetes and essential for the survival of ookinetes in the mosquito midgut (Kunkeaw et al., 2023)

e. Gene Engineering of Pvs25

Type: Recombinant protein preparation
Description: Pvs25A constructs were designed with wildtype signal peptide without the C-terminal GPI anchor, which is essential for parasite cell surface localization. Pvs25A has the wildtype sequence, and Pvs25A I130T contains the I130T substitution predominant in the Asian P. vivax isolates. Pvs25F encodes the full-length sequence of the Pvs25 gene from Sal I with wild-type signal peptide. Pvs25F I130T construct contains the full-length sequence of Pvs25 with the I130T mutation. (Kunkeaw et al., 2023)
Detailed Gene Information: Click here.

f. Preparation

Four nucleoside-modified Pvs25 mRNAs were designed based on the sequence of the Pvs25 gene from the reference P. vivax strain Sal I. Two constructs (Pvs25A and Pvs25A I130T) express Pvs25 with wildtype signal peptide without the C-terminal glycosylphosphatidylinositol (GPI) anchor. The other two constructs (Pvs25F and Pvs25F I130T) encode the full-length Pvs25 with its C-terminal GPI anchor. mRNAs were in vitro transcribed using T7 RNA polymerase (Megascript; Ambion) on linearized plasmids encoding mammalian codon-optimized Pvs25. mRNAs were generated to contain 101 nucleotide-long poly(A) tails and modified by replacing uridine-5′-triphosphate with m1Ψ-5′-triphosphate (TriLink BioTechnologies). mRNA capping was performed alongside transcription through the addition of a trinucleotide cap1 analog, CleanCap (TriLink), and mRNA was purified with cellulose-based purification. Purified mRNAs and poly(C) RNA (Sigma) were LNP-encapsulated using a self-assembly process where a mixture of an ionizable cationic lipid, phosphatidylcholine, cholesterol, and polyethylene glycol-lipid in ethanol was rapidly combined with an aqueous solution containing mRNA at acidic pH. (Kunkeaw et al., 2023)

g. Immunization Route

Intramuscular injection (i.m.)

h. Description

The Pvs25 mRNA-LNP uses nucleoside-modified Pvs25 mRNA, the P.vivax surface protein, as the vaccine antigen encapsulated in liquid nanoparticles (LNP).

i. Human Response

Host Strain: Human embryonic kidney (HEK) 293 cells
Vaccination Protocol: Pvs25 mRNA–LNPs were produced and transfected into human embryonic kidney 293 cells. (Kunkeaw et al., 2023)
Immune Response: Western blot analysis revealed protein production from each Pvs25 mRNA. The levels of Pvs25 protein production from the two full-length constructs (Pvs25F and Pvs25F I130T) were higher than those from the truncated constructs (Pvs25A and Pvs25A I130T).

j. Mouse Response

Host Strain: BALB/c mice
Vaccination Protocol: Vaccination followed a prime-boost schedule (week 0 and 4) via intramuscular injection using three different doses (3, 10, or 30 µg). Serum from each animal was collected 4 weeks after each immunization to determine the level of anti-Pvs25 antibody by ELISA. (Kunkeaw et al., 2023)
Immune Response: At 4 weeks after the first (prime) vaccination, the Pvs25-specific IgG induced by mRNA–LNPs was detectable with a geometric mean of reciprocal titer (GMT) value between 630–5300. After the booster dose, the antibody levels rose significantly reaching a GMT between 42,000–169,000. At each dose, the Pvs25F mRNA–LNP outperformed other formulations. The mRNA/mRNA homologous vaccination elicited the strongest memory B cell response and induced the most robust Pvs25-specific CD4+ T cell responses as measured by IFN-γ and IL-2 production of CD4+ T cells whereas this was almost absent in the protein/protein homologous (Pvs25 protein/ISA-51) vaccination group.
Efficacy: All samples from Pvs25 mRNA–LNP-immunized mice exhibited complete (100%) transmission-blocking activity at 1:2 dilution. The percent reduction in the average oocyst number per mosquito by each serum sample (transmission-reducing activity) of these sera remained nearly complete at 1:10 dilution and were ~80% at 1:50 dilution.

79. Pvs25-IMX313/Matrix-M1

a. Type:

Subunit vaccine

b. Status:

Clinical trial

c. Host Species for Licensed Use:

Human

d. Antigen

Pvs25 (Minassian et al., 2022): P.vivax surface protein 25, composed of four cysteine-rich epidermal growth factor–like domains expressed on the surface of zygotes and ookinetes of P. vivax (Arevalo-Herrera et al., 2005).

e. Gene Engineering of Pvs25

Type: Recombinant protein preparation
Description:
Detailed Gene Information: Click here.

f. Immunization Route

Intramuscular injection (i.m.)

g. Human Response

Host Strain: healthy adults in United Kingdom (Minassian et al., 2022)
Vaccination Protocol: Non-randomised, Phase Ia study, not started
Volunteers will receive 1) three doses of 10 µg Pvs25-IMX313 in 50 µg Matrix-M1 on days 0, 28 and 56, 2) three doses of 50 µg Pvs25-IMX313 in 50 µg Matrix-M1 on days 0, 28 and 56, or 3) two doses of 50 µg Pvs25-IMX313 in 50 µg Matrix-M1 on days 0 and 28, followed by one dose of 10 µg Pvs25-IMX313 in 50 µg Matrix-M1 on day 56 (Minassian et al., 2022)

80. rBCGMSP1-15

a. Vaccine Ontology ID:

VO_0004791

b. Type:

Recombinant vector vaccine

c. Status:

Research

d. Host Species for Licensed Use:

Mouse

e. Antigen

MSP1-15 as a fusion protein with the α antigen of Mycobacterium kansasii (α-k), which is secreted from the rBCG vaccine vector (Matsumoto et al., 1998).

f. Gene Engineering of MSP1 from P. yoelii str. 17XNL

Type: Recombinant vector construction
Description: A 2.4-kbp fragment containing an α-k–MSP1-15 hybrid gene was subcloned into pSO246. The final construct (designated pSOMSP1-15) was transformed into BCG Tokyo by electroporation (Matsumoto et al., 1998).
Detailed Gene Information: Click here.

g. Immunization Route

Intravenous injection (i.v.)

h. Mouse Response

Host Strain: C57BL/6, C3H/He, A/J
Vaccination Protocol: C3H/He mice were immunized intravenously with 10^6 CFU of rBCGMSP1-15 in 200 μl of PBS containing 0.1% PBS-T80. A control group of mice was injected with 106 CFU of BCG in 200 μl of PBS-T80 or PBS-T80 only. 30 days later, the same amount of each sample was injected intraperitoneally to boost the immune response (Matsumoto et al., 1998).
Vaccine Immune Response Type: VO_0003057
Challenge Protocol: Mice were challenged with 10^4 P. yoelii 17XL-parasitized erythrocytes intravenously or intraperitoneally 1 month after the final immunization (Matsumoto et al., 1998).
Efficacy: 3 out of 7 mice immunized with GST-MSP1-15 in RAS and 2 out of 8 mice immunized with GST-MSP1-15 in IFA survived the infection. 6 out of 7 mice immunized with rBCGMSP1-15 survived the infection. Data showed the three adjuvants examined are effective for vaccination with MSP1-15, while their efficacy levels differ. The rBCG system was the most effective for vaccination (Matsumoto et al., 1998).

81. Recombinant ABRA protein vaccine

a. Vaccine Ontology ID:

VO_0000778

b. Type:

Subunit vaccine

c. Host Species as Laboratory Animal Model:

mouse

d. Antigen

The acidic basic repeat antigen (ABRA) of Plasmodium falciparum is a vaccine candidate against erythrocytic stages of malaria (Kushwaha et al., 2001).

e. Gene Engineering of ABRA

Type: Recombinant protein preparation
Description:
Detailed Gene Information: Click here.

f. Adjuvant:

VO ID: VO_0000139
Description: Complete Freund's adjuvant (CFA) was used as the first adjuvant. Boosters of the same amount of protein were given in incomplete Freund's adjuvant (IFA) (Kushwaha et al., 2001).

g. Preparation

The four fragments of ABRA, including N-terminal [ABRA (N); aa 24–369], middle [ABRA (M); aa 370–507], N-terminal + middle [ABRA (P); aa 24–507] and the C-terminal [ABRA (C); aa 508–743], were expressed as fusions with either maltose binding protein (MBP) or 6X histidine tag at their amino terminii using pMALc-2 vector from NEB (New England Biolabs, Beverly, MA, USA) or pQE30 vector (Qiagen GmbH, Germany), respectively. These recombinant proteins were purified to near homogeneity by affinity chromatography of the soluble fraction, concentrated, and the purity of the protein judged by SDS-PAGE.

h. Mouse Response

Host Strain: BALB/c
Vaccination Protocol: Groups of BALB/c mice were immunized by i.p. injection with ABRA protein/MBP emulsified in complete Freund's adjuvant (CFA). Control mice received only PBS in the adjuvant. Boosters of the same amount of protein were given in incomplete Freund's adjuvant (IFA). Sera were collected from each group and treated as described earlier (Kushwaha et al., 2001).
Persistence: Humoral and cell-mediated response was still robust up to 70 days post-immunization (Kushwaha et al., 2001).
Immune Response: Results showed that ABRA (M), ABRA (C) and ABRA (P) were highly immunogenic in these animals; end point titres greater than 10^5 were observed in these constructs. Mice were immunized using standard methods. Relative concentrations of the antibodies elicited by them in mice at different intervals of immunization were measured at a dilution of 1 : 3000. ABRA (N) and ABRA (C) did not show a boostable antibody response; two secondary immunizations did not result in any increase in the antibody titre. Immunogenicity studies with these constructs in rabbits and mice indicated that the N-terminal region is the least immunogenic part of ABRA. T-cell proliferation experiments in mice immunized with these constructs revealed that the T-cell epitopes were localized in the middle portion of the protein (Kushwaha et al., 2001).
Efficacy: The purified immunoglobulin G specific to middle and C-terminal fragments prevented parasite growth at levels approaching 80-90% (Kushwaha et al., 2001).
Description: This antibody response was the focus of intense interest when it was found that mice could be rendered resistant to sporozoite challenge by passive immunisation with monoclonal antibodies against circumsporozoite protein (Kwiatkowski et al., 1997).

82. RTS,S/AS01

a. Tradename:

Mosquirix

b. Vaccine Ontology ID:

VO_0003093

c. Type:

Subunit vaccine

d. Status:

Licensed

e. Host Species for Licensed Use:

Human

f. Antigen

RTS,S: fragment of circumsporozoite protein of the pre-erythrocyte sporozoite-stage P.falciparum(Laurens, 2020)

g. Gene Engineering of CS from P. falciparum

Type: Recombinant protein preparation
Description: Part of CSP from P. falciparum: 18 NANP repeats and C-terminus exclusive of GPI sequence(Laurens, 2020)
Detailed Gene Information: Click here.

h. Adjuvant:

VO ID: VO_0005358
Description: combination of liposome, MPL, and QS-21(Laurens, 2020)

i. Immunization Route

Intramuscular injection (i.m.)

j. Human Response

Host Strain: children aged 5-17 months and infants aged 6-12 weeks from sub-Saharan African countries
Vaccination Protocol: Double-blinded, phaseIII, randomised controlled trial.
Participants were randomly assigned in a 1:1:1 ration to receive 1) three doses of RTS,S/AS01 at month 0, 1, and 2 and a booster dose at month 20; 2) three doses of RTS,S/AS01 at month 0, 1, and 2 and a dose of control at month 20; or 3) four doses of control at month 0, 1, 2, and 20.
(Laurens, 2020)
Immune Response: The vaccine induces and increases anti-CSP antibody levels and CD4+ T cell responses.
Older children have greater protective immune response than infants, and children received booster have greater protective immune response than children who did not. Children aged 5-17 months received booster dose had 318.3 EU/mL anti-CSP antibody after a month and 52.4 EU/mL after a year, and children did not receive the booster had 34.2 EU/mL after a month and 19.3 EU/mL after a year. Infants aged 6-12 weeks received booster dose had 169.9 EU/mL after a month and 15.9 EU/mL after a year, and infants did not receive the booster had 6.2 EU/mL after a month and 3.7 EU/mL after a year. (Laurens, 2020)
Side Effects: Increased risk of febrile seizures: children aged 5-17 months more likely to have febrile seizures within 7 days after vaccination than controls. All affected children recovered after 7 days.(Laurens, 2020)
Efficacy: Efficacy against clinical malaria in 12 months after dose 3: 31.3% (97.5%CI 23.6-38.3%, p< .0001) for 6-12 weeks age and 55.8% (97.5%CI 50.6-60.4%, p< .0001) for 5-17 months age
Additional efficacy against clinical malaria at the end of follow-up: booster dose group: 25.9% for 6-12 weeks age and 36.3% for 5-17 months age; 3 doses group: 18.3% for 6-12 weeks age and 28.3% for 5-17 months age.
Additional efficacy against severe malaria at the end of follow-up: booster dose group: 17.3% for 6-12 weeks age and 32.2% for 5-17 months age; 3 doses group: 10.3% for 6-12 weeks age and 1.1% for 5-17 months age. (Laurens, 2020)

83. RTS,S/AS01E

a. Type:

Subunit vaccine

b. Status:

Clinical trial

c. Host Species for Licensed Use:

Human

d. Antigen

RTS,S is the pre-erythrocyte sporozoite-stage Plasmodium falciparum antigen. It is a circumsporozoite surface protein (Alonso et al., 2004)

e. Immunization Route

Intramuscular injection (i.m.)

f. Description

Developed for immunization of infants in Africa, the RTS,S/ AS01E vaccine uses RTS,S, the P. falciparum circumsporite surface protein with AS01E as the vaccine adjuvant. AS01E contains 50% less liposome-based formulation of MPL and QS-21 compared to AS01B. (Asante et al., 2011)

g. Human Response

Host Strain: Children 6-10 weeks of age at first vaccination
Vaccination Protocol: Children receive three doses of RTS,S/AS01(E) at 6, 10, and 14 weeks (0, 1, 2 month schedule) or at 6 weeks, 10 weeks, and 9 months (0, 2, 7 month schedule) or placebo.(Asante et al., 2011)
Immune Response: At month 19, anticircumsporozoite immune responses were significantly higher in the RTS,S/AS01(E) groups than in the control group. (Asante et al., 2011)
Efficacy: For the entire study period, (total vaccinated cohort) vaccine efficacy against all malaria episodes was higher with the 0, 1, 2 month schedule (57%, 95% CI 33-73; p=0·0002) than with the 0, 1, 7 month schedule (32% CI 16-45; p=0·0003).(Asante et al., 2011)

84. RTS,S/AS02A

a. Vaccine Ontology ID:

VO_0000774

b. Type:

Subunit vaccine

c. Status:

Clinical trial

d. Antigen

RTS,S is the pre-erythrocyte sporozoite-stage Plasmodium falciparum antigen. It is a circumsporozoite surface protein (Alonso et al., 2004).

e. Adjuvant:

VO ID: VO_0001264

f. Preparation

RTS,S/AS02 is a pre-erythrocyte sporozoite-stage malaria vaccine based on the circumsporozoite surface protein of Plasmodium falciparum RTS,S fused to HBsAg , incorporating a new adjuvant (AS02) (Bojang et al., 2001; Alonso et al., 2004).

g. Human Response

Host Strain: Mozambique children
Vaccination Protocol: A double-blind, phase IIb, randomised controlled trial was performed in Mozambique in 2022 children aged 1–4 years. The study included two cohorts of children living in two separate areas which underwent different follow-up schemes. Participants were randomly allocated three doses of either RTS,S/AS02A candidate malaria vaccine or control vaccines. The primary endpoint, determined in cohort 1 (n=1605), was time to first clinical episode of P falciparum malaria (axillary temperature ≥37·5°C and P falciparum asexual parasitaemia >2500 per μL) over a 6-month surveillance period. Efficacy for prevention of new infections was determined in cohort 2 (n=417) (Alonso et al., 2004).
Persistence: Vaccine efficacy in extending time to first infection was determined in cohort 2. 323 children had first episodes of asexual P falciparum parasitaemia (157 in the RTS,S/AS02A group and 166 in the control group), yielding a vaccine efficacy estimate of 45.0% (95% CI 31.4–55.9; p<0.0001). The mean density of asexual-stage parasites at the time of first infection was similar for the control and RTS,S/AS02A groups (3950 vs 3016 per μL, p=0.354). With the same methods as those used to assess persistence of efficacy for cohort 1, the model with the best fit suggested waning efficacy of the vaccine over time, which stabilised at about 40%. The prevalence of asexual P falciparum parasitaemia at the end of follow-up was lower in the RTS,S/AS02A group than in the control group (52.3% vs 65.8%; p=0.019), and prevalence of anaemia at month 8·5 was 2.7% in the control group and 0% in the RTS,S/AS02A group (p=0.056) (Alonso et al., 2004).
Immune Response: Prevaccination anti-circumsporozoite antibody titres were low in the study children. The vaccine was immunogenic, inducing specific antibody levels after dose three, decaying over 6 months to about a quarter of the initial level, but remaining well above baseline values. Antibody levels in the control group remained low over the follow-up period. The vaccine also induced high levels of antibodies against HBsAg (>97% seroprotection). For both circumsporozoite and HBsAg, immunogenicity of the vaccine was greater in children younger than 24 months of age (Alonso et al., 2004).
Side Effects: RTS,S/AS02A and control vaccines were safe and well tolerated. More than 92% of children in both groups received all three doses. Local and general solicited adverse events were of short duration and were mostly mild or moderate in intensity. Grade 3 local or general adverse events were uncommon and of short duration. Local injection-site pain that limited arm motion arose after seven (0.2%) doses in the RTS,S/AS02A group and after one (0.03%) dose in the control vaccine group, and injection-site swelling of more than 20 mm happened after 224 (7.7%) and 14 (0.5%) doses, respectively. General solicited adverse events (fever, irritability, drowsiness, anorexia) that prevented normal activities arose after 55 (1.9%) doses in the RTS,S/AS02A group and 23 (0.8%) doses in the control group. At least one unsolicited adverse event was reported by 653 (64.5%) children in the RTS,S/AS02A group and 597 (59.1%) in the control group. 429 serious adverse events were reported: 180 (17.8%) in the RTS,S/AS02A group and 249 (24.7%) in the control group. 15 children died during the study, five (0.6%) in the RTS,S/AS02A group and ten (1.2%) in the control group. Four of those who died had malaria as a significant contributing factor and all four were in the control group. No serious adverse event or death was judged to be related to vaccination (Alonso et al., 2004).
Challenge Protocol: Children were not challenged (Alonso et al., 2004)
Efficacy: Vaccine efficacy for the first clinical episodes was 29.9% (95% CI 11.0-44.8; p=0.004). At the end of the 6-month observation period, prevalence of P falciparum infection was 37% lower in the RTS,S/AS02A group compared with the control group (11.9% vs 18.9%; p=0.0003). Vaccine efficacy for severe malaria was 57.7% (95% CI 16.2-80.6; p=0.019). In cohort 2, vaccine efficacy for extending time to first infection was 45.0% (31.4-55.9; p<0.0001) (Alonso et al., 2004).
Description: Development of an effective malaria vaccine could greatly contribute to disease control. RTS,S/AS02A is a pre-erythrocytic vaccine candidate based on Plasmodium falciparum circumsporozoite surface antigen. The RTS,S/AS02A vaccine was safe, well tolerated, and immunogenic (Alonso et al., 2004).

85. SAd-ME.TRAP

a. Vaccine Ontology ID:

VO_0004799

b. Type:

Recombinant vector vaccine

c. Status:

Research

d. Host Species for Licensed Use:

Mouse

e. Preparation

(Reyes-Sandoval et al., 2008) AdC7 and AdC9 elicited strong immunogenicity ( approximately 20% of CD8(+) T cells in spleen), equivalent to or outperforming AdH5 and inducing sterile protection in 92% (C9), 83% (H5 and C7) and 67% (C6) of the mice, providing the first evidence of single-dose protection to Plasmodium berghei.

f. Immunization Route

Intramuscular injection (i.m.)

86. UK39

a. Type:

Virosome-formulated synthetic peptide vaccine

b. Status:

Clinical trial

c. Host Species for Licensed Use:

Human

d. Antigen

UK39: a circumsporozoite protein (CSP) derived synthetic PE-peptide conjugate (Genton et al., 2007)

e. Gene Engineering of CSP from P. falciparum

Type: Conjugate vaccine preparation
Description: UK39 is a circumsporozoite protein (CSP) derived synthetic PE-peptide conjugate (Genton et al., 2007)
Detailed Gene Information: Click here.

f. Immunization Route

Intramuscular injection (i.m.)

g. Description

UK39 is a virosome-formulated P. falciparum circumsporozoit protien (CSP) derived synthetic peptide antigen that serves as a malaria vaccine (Genton et al., 2003)

h. Baboon Response

Host Strain: healthy Caucasian volunteers aged 18-45 years
Immune Response: Mean titer and seroconversion rate were higher with the 10ug dose than the 50 ug dose. (Genton et al., 2003)

87. VAR2CSA

a. Type:

Subunit vaccine

b. Status:

Research

c. Host Species for Licensed Use:

None

d. Antigen

PfEMP1: mediate IE adhesion and facilitate parasite immunoevasion through antigenic variation. It is a large cysteine-rich transmembrane multidomain protein (~350 kDa) typically formed by six Duffy-binding-like domains with several interdomain regions. (Renn et al., 2021)

e. Immunization Route

Intramuscular injection (i.m.)

f. Description

VAR2CSA is the leading vaccine candidate to prevent placental malaria by using the VAR2CSA protein as the vaccine antigen and prevens sequesteration of P. falciparum-infected erythrocytes in placenal intervillous spaces.(Renn et al., 2021)

IV. References

1. Adams et al., 2002: Adams S, Brown H, Turner G. Breaking down the blood-brain barrier: signaling a path to cerebral malaria?. Trends in parasitology. 2002 Aug; 18(8); 360-6. [PubMed: 12377286].

2. Aidoo et al., 2000: Aidoo M, Lalvani A, Gilbert SC, Hu JT, Daubersies P, Hurt N, Whittle HC, Druihle P, Hill AV. Cytotoxic T-lymphocyte epitopes for HLA-B53 and other HLA types in the malaria vaccine candidate liver-stage antigen 3. Infection and immunity. 2000 Jan; 68(1); 227-32. [PubMed: 10603392].

3. Alonso et al., 2004: Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Milman J, Mandomando I, Spiessens B, Guinovart C, Espasa M, Bassat Q, Aide P, Ofori-Anyinam O, Navia MM, Corachan S, Ceuppens M, Dubois MC, Demoitie MA, Dubovsky F, Menendez C, Tornieporth N, Ballou WR, Thompson R, Cohen J. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet. 2004 Oct 16-22; 364(9443); 1411-20. [PubMed: 15488216].

4. Alves et al., 2017: Alves E, Salman AM, Leoratti F, Lopez-Camacho C, Viveros-Sandoval ME, Lall A, El-Turabi A, Bachmann MF, Hill AV, Janse CJ, Khan SM, Reyes-Sandoval A. Evaluation of Plasmodium vivax Cell-Traversal Protein for Ookinetes and Sporozoites as a Preerythrocytic P. vivax Vaccine. Clinical and vaccine immunology : CVI. 2017; 24(4); . [PubMed: 28179403].

5. Arévalo-Herrera et al., 2022: Arévalo-Herrera M, Gaitán X, Larmat-Delgado M, Caicedo MA, Herrera SM, Henao-Giraldo J, Castellanos A, Devaud JC, Pannatier A, Oñate J, Corradin G, Herrera S. Randomized clinical trial to assess the protective efficacy of a Plasmodium vivax CS synthetic vaccine. Nature communications. 2022; 13(1); 1603. [PubMed: 35338131].

6. Arevalo-Herrera et al., 2005: Arevalo-Herrera M, Solarte Y, Yasnot MF, Castellanos A, Rincon A, Saul A, Mu J, Long C, Miller L, Herrera S. Induction of transmission-blocking immunity in Aotus monkeys by vaccination with a Plasmodium vivax clinical grade PVS25 recombinant protein. The American journal of tropical medicine and hygiene. 2005 Nov; 73(5 Suppl); 32-7. [PubMed: 16291764].

7. Asante et al., 2011: Asante KP, Abdulla S, Agnandji S, Lyimo J, Vekemans J, Soulanoudjingar S, Owusu R, Shomari M, Leach A, Jongert E, Salim N, Fernandes JF, Dosoo D, Chikawe M, Issifou S, Osei-Kwakye K, Lievens M, Paricek M, Möller T, Apanga S, Mwangoka G, Dubois MC, Madi T, Kwara E, Minja R, Hounkpatin AB, Boahen O, Kayan K, Adjei G, Chandramohan D, Carter T, Vansadia P, Sillman M, Savarese B, Loucq C, Lapierre D, Greenwood B, Cohen J, Kremsner P, Owusu-Agyei S, Tanner M, Lell B. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial. The Lancet. Infectious diseases. 2011; 11(10); 741-749. [PubMed: 21782519].

8. Aucouturier et al., 2002: Aucouturier J, Dupuis L, Deville S, Ascarateil S, Ganne V. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert review of vaccines. 2002; 1(1); 111-118. [PubMed: 12908518].

9. Audran et al., 2005: Audran R, Cachat M, Lurati F, Soe S, Leroy O, Corradin G, Druilhe P, Spertini F. Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. Infection and immunity. 2005 Dec; 73(12); 8017-26. [PubMed: 16299295].

10. Aw et al., 2021: Aw R, Ashik MR, Islam AAZM, Khan I, Mainuddin M, Islam MA, Ahasan MM, Polizzi KM. Production and purification of an active CRM197 in Pichia pastoris and its immunological characterization using a Vi-typhoid antigen vaccine. Vaccine. 2021; 39(51); 7379-7386. [PubMed: 34774362].

11. Bauza et al., 2014: Bauza K, Malinauskas T, Pfander C, Anar B, Jones EY, Billker O, Hill AV, Reyes-Sandoval A. Efficacy of a Plasmodium vivax malaria vaccine using ChAd63 and modified vaccinia Ankara expressing thrombospondin-related anonymous protein as assessed with transgenic Plasmodium berghei parasites. Infection and immunity. 2014; 82(3); 1277-1286. [PubMed: 24379295].

12. BenMohamed et al., 2004: BenMohamed L, Thomas A, Druilhe P. Long-term multiepitopic cytotoxic-T-lymphocyte responses induced in chimpanzees by combinations of Plasmodium falciparum liver-stage peptides and lipopeptides. Infection and immunity. 2004 Aug; 72(8); 4376-84. [PubMed: 15271893].

13. Bennett et al., 2014: Phase 1 Clinical Trial With Controlled Human Malaria Infection (CHMI) to Evaluate the Safety and Efficacy of the Plasmodium Falciparum Vaccine Candidate FMP012 Administered Intramuscularly With AS01B Adjuvant System in Healthy Malaria-Naïve Adults [https://clinicaltrials.gov/ct2/show/NCT02174978?term=vaccine&cond=malaria&draw=2&rank=32]

14. Bergmann-Leitner et al., 2007: Bergmann-Leitner ES, Duncan EH, Leitner WW, Neutzner A, Savranskaya T, Angov E, Tsokos GC. C3d-defined complement receptor-binding peptide p28 conjugated to circumsporozoite protein provides protection against Plasmodium berghei. Vaccine. 2007; 25(45); 7732-7736. [PubMed: 17931754].

15. Bergmann-Leitner et al., 2010: Bergmann-Leitner ES, Mease RM, De La Vega P, Savranskaya T, Polhemus M, Ockenhouse C, Angov E. Immunization with pre-erythrocytic antigen CelTOS from Plasmodium falciparum elicits cross-species protection against heterologous challenge with Plasmodium berghei. PloS one. 2010; 5(8); e12294. [PubMed: 20808868].

16. Bjerkan et al., 2021: Bjerkan L, Visweswaran GRR, Gudjonsson A, Labbé GM, Quinkert D, Pattinson DJ, Spång HCL, Draper SJ, Bogen B, Braathen R. APC-Targeted DNA Vaccination Against Reticulocyte-Binding Protein Homolog 5 Induces Plasmodium falciparum-Specific Neutralizing Antibodies and T Cell Responses. Frontiers in immunology. 2021; 12; 720550. [PubMed: 34733274].

17. Bledsoe, 2005: Bledsoe GH. Malaria primer for clinicians in the United States. Southern medical journal. 2005 Dec; 98(12); 1197-204; quiz 1205, 1230. [PubMed: 16440920].

18. Bojang et al., 2001: Bojang KA, Milligan PJ, Pinder M, Vigneron L, Alloueche A, Kester KE, Ballou WR, Conway DJ, Reece WH, Gothard P, Yamuah L, Delchambre M, Voss G, Greenwood BM, Hill A, McAdam KP, Tornieporth N, Cohen JD, Doherty T. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet. 2001 Dec 8; 358(9297); 1927-34. [PubMed: 11747915].

19. Bonnefoy et al., 1994: Bonnefoy S, Gysin J, Blisnick T, Guillotte M, Carcy B, Pereira da Silva L, Mercereau-Puijalon O. Immunogenicity and antigenicity of a Plasmodium falciparum protein fraction (90-110 kDa) able to protect squirrel monkeys against asexual blood stages. Vaccine. 1994; 12(1); 32-40. [PubMed: 8303938].

20. Bracho et al., 2009: Bracho G, Zayas C, Wang L, Coppel R, Pérez O, Petrovsky N. AFCo1, a meningococcal B-derived cochleate adjuvant, strongly enhances antibody and T-cell immunity against Plasmodium falciparum merozoite surface protein 4 and 5. Malaria journal. 2009; 8; 35. [PubMed: 19250541].

21. Breman, 2001: Breman JG. The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden. The American journal of tropical medicine and hygiene. 2001 Jan-Feb; 64(1-2 Suppl); 1-11. [PubMed: 11425172].

22. Bruna-Romero et al., 2004: Bruna-Romero O, Rocha CD, Tsuji M, Gazzinelli RT. Enhanced protective immunity against malaria by vaccination with a recombinant adenovirus encoding the circumsporozoite protein of Plasmodium lacking the GPI-anchoring motif. Vaccine. 2004 Sep 9; 22(27-28); 3575-84. [PubMed: 15315836].

23. Burgess et al., 2005: Burgess BR, Schuck P, Garboczi DN. Dissection of merozoite surface protein 3, a representative of a family of Plasmodium falciparum surface proteins, reveals an oligomeric and highly elongated molecule. The Journal of biological chemistry. 2005 Nov 4; 280(44); 37236-45. [PubMed: 16135515].

24. Butler et al., 2011: Butler NS, Schmidt NW, Vaughan AM, Aly AS, Kappe SH, Harty JT. Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites. Cell host & microbe. 2011; 9(6); 451-462. [PubMed: 21669394].

25. Cao et al., 2022: Cao Y, Hayashi CTH, Zavala F, Tripathi AK, Simonyan H, Young CN, Clark LC, Usuda Y, Van Parys JM, Kumar N. Effective Functional Immunogenicity of a DNA Vaccine Combination Delivered via In Vivo Electroporation Targeting Malaria Infection and Transmission. Vaccines. 2022; 10(7); . [PubMed: 35891298].

26. Carter et al., 1995: Carter R, Coulson A, Bhatti S, Taylor BJ, Elliott JF. Predicted disulfide-bonded structures for three uniquely related proteins of Plasmodium falciparum, Pfs230, Pfs48/45 and Pf12. Molecular and biochemical parasitology. 1995 May; 71(2); 203-10. [PubMed: 7477102].

27. Carvalho et al., 2004: Carvalho LJ, Oliveira SG, Theisen M, Alves FA, Andrade MC, Zanini GM, Brígido MC, Oeuvray C, Póvoa MM, Muniz JA, Druilhe P, Daniel-Ribeiro CT. Immunization of Saimiri sciureus monkeys with Plasmodium falciparum merozoite surface protein-3 and glutamate-rich protein suggests that protection is related to antibody levels. Scandinavian journal of immunology. 2004; 59(4); 363-372. [PubMed: 15049780].

28. Castellanos et al., 2007: Castellanos A, Arevalo-Herrera M, Restrepo N, Gulloso L, Corradin G, Herrera S. Plasmodium vivax thrombospondin related adhesion protein: immunogenicity and protective efficacy in rodents and Aotus monkeys. Memorias do Instituto Oswaldo Cruz. 2007 Jun; 102(3); 411-6. [PubMed: 17568948].

29. Chen et al., 2000: Chen Q, Schlichtherle M, Wahlgren M. Molecular aspects of severe malaria. Clinical microbiology reviews. 2000 Jul; 13(3); 439-50. [PubMed: 10885986].

30. Chichester et al., 2018: Chichester JA, Green BJ, Jones RM, Shoji Y, Miura K, Long CA, Lee CK, Ockenhouse CF, Morin MJ, Streatfield SJ, Yusibov V. Safety and immunogenicity of a plant-produced Pfs25 virus-like particle as a transmission blocking vaccine against malaria: A Phase 1 dose-escalation study in healthy adults. Vaccine. 2018; 36(39); 5865-5871. [PubMed: 30126674].

31. Coelho et al., 2019: Coelho CH, Gazzinelli-Guimaraes PH, Howard J, Barnafo E, Alani NAH, Muratova O, McCormack A, Kelnhofer E, Urban JF Jr, Narum DL, Anderson C, Langhorne J, Nutman TB, Duffy PE. Chronic helminth infection does not impair immune response to malaria transmission blocking vaccine Pfs230D1-EPA/Alhydrogel® in mice. Vaccine. 2019; 37(8); 1038-1045. [PubMed: 30685251].

32. Coelho et al., 2021: Coelho CH, Tang WK, Burkhardt M, Galson JD, Muratova O, Salinas ND, Alves E Silva TL, Reiter K, MacDonald NJ, Nguyen V, Herrera R, Shimp R, Narum DL, Byrne-Steele M, Pan W, Hou X, Brown B, Eisenhower M, Han J, Jenkins BJ, Doritchamou JYA, Smelkinson MG, Vega-Rodríguez J, Trück J, Taylor JJ, Sagara I, Healy SA, Renn JP, Tolia NH, Duffy PE. A human monoclonal antibody blocks malaria transmission and defines a highly conserved neutralizing epitope on gametes. Nature communications. 2021; 12(1); 1750. [PubMed: 33741942].

33. Cooper et al., 2004: Cooper CL, Davis HL, Morris ML, Efler SM, Adhami MA, Krieg AM, Cameron DW, Heathcote J. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. Journal of clinical immunology. 2004; 24(6); 693-701. [PubMed: 15622454].

34. Coutant et al., 2012: Coutant F, Sanchez David RY, Félix T, Boulay A, Caleechurn L, Souque P, Thouvenot C, Bourgouin C, Beignon AS, Charneau P. A nonintegrative lentiviral vector-based vaccine provides long-term sterile protection against malaria. PloS one. 2012; 7(11); e48644. [PubMed: 23133649].

35. Daly and Long, 1993: Daly TM, Long CA. A recombinant 15-kilodalton carboxyl-terminal fragment of Plasmodium yoelii yoelii 17XL merozoite surface protein 1 induces a protective immune response in mice. Infection and immunity. 1993; 61(6); 2462-2467. [PubMed: 8363656].

36. Daubersies et al., 2000: Daubersies P, Thomas AW, Millet P, Brahimi K, Langermans JA, Ollomo B, BenMohamed L, Slierendregt B, Eling W, Van Belkum A, Dubreuil G, Meis JF, Guérin-Marchand C, Cayphas S, Cohen J, Gras-Masse H, Druilhe P. Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3. Nature medicine. 2000; 6(11); 1258-1263. [PubMed: 11062538].

37. Day et al., 2024: A Safety, Immunogenicity and Efficacy Study of PvRII/Matrix-M in Healthy Thai Adults Living in Thailand [https://clinicaltrials.gov/study/NCT05380388]

38. de Graaf et al., 2021: de Graaf H, Payne RO, Taylor I, Miura K, Long CA, Elias SC, Zaric M, Minassian AM, Silk SE, Li L, Poulton ID, Baker M, Draper SJ, Gbesemete D, Brendish NJ, Martins F, Marini A, Mekhaiel D, Edwards NJ, Roberts R, Vekemans J, Moyle S, Faust SN, Berrie E, Lawrie AM, Hill F, Hill AVS, Biswas S. Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial. Frontiers in immunology. 2021; 12; 694759. [PubMed: 34335606].

39. Dobaño and Doolan, 2007: Dobaño C, Doolan DL. Identification of minimal CD8+ and CD4+ T cell epitopes in the Plasmodium yoelii hepatocyte erythrocyte protein 17kDa. Molecular immunology. 2007; 44(11); 3037-3048. [PubMed: 17303242].

40. Doolan et al., 1996: Doolan DL, Sedegah M, Hedstrom RC, Hobart P, Charoenvit Y, Hoffman SL. Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8+ cell-, interferon gamma-, and nitric oxide-dependent immunity. The Journal of experimental medicine. 1996; 183(4); 1739-1746. [PubMed: 8666931].

41. Douradinha et al., 2007: Douradinha B, van Dijk MR, Ataide R, van Gemert GJ, Thompson J, Franetich JF, Mazier D, Luty AJ, Sauerwein R, Janse CJ, Waters AP, Mota MM. Genetically attenuated P36p-deficient Plasmodium berghei sporozoites confer long-lasting and partial cross-species protection. International journal for parasitology. 2007; 37(13); 1511-1519. [PubMed: 17604034].

42. Dubé et al., 2020: Dubé JY, McIntosh F, Zarruk JG, David S, Nigou J, Behr MA. Synthetic mycobacterial molecular patterns partially complete Freund's adjuvant. Scientific reports. 2020; 10(1); 5874. [PubMed: 32246076].

43. Duffy et al. 2021: Study of the Transmission-Blocking Vaccine Pfs230D1-EPA/Matrix-M Against Malaria in Adults in Mali [https://clinicaltrials.gov/ct2/show/NCT05135273?term=vaccine&cond=Malaria%2CFalciparum&draw=2&rank=2]

44. Dunachie et al., 2006: Dunachie SJ, Walther M, Epstein JE, Keating S, Berthoud T, Andrews L, Andersen RF, Bejon P, Goonetilleke N, Poulton I, Webster DP, Butcher G, Watkins K, Sinden RE, Levine GL, Richie TL, Schneider J, Kaslow D, Gilbert SC, Carucci DJ, Hill AV. A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge. Infection and immunity. 2006; 74(10); 5933-5942. [PubMed: 16988273].

45. Eksi et al., 2006: Eksi S, Czesny B, van Gemert GJ, Sauerwein RW, Eling W, Williamson KC. Malaria transmission-blocking antigen, Pfs230, mediates human red blood cell binding to exflagellating male parasites and oocyst production. Molecular microbiology. 2006 Aug; 61(4); 991-8. [PubMed: 16879650].

46. El et al., 2010: El Sahly HM, Patel SM, Atmar RL, Lanford TA, Dube T, Thompson D, Lee Sim BK, Long C, Keitel WA. The Safety and Immunogenicity of Recombinant EBA 175-RII NG Malaria Vaccine in Healthy Adults Living in a Non-Endemic Area. Clinical and vaccine immunology : CVI. 2010; ; . [PubMed: 20702657].

47. Escalante et al., 1998: Escalante AA, Freeland DE, Collins WE, Lal AA. The evolution of primate malaria parasites based on the gene encoding cytochrome b from the linear mitochondrial genome. Proceedings of the National Academy of Sciences of the United States of America. 1998 Jul 7; 95(14); 8124-9. [PubMed: 9653151].

48. Eslava et al., 2010: Eslava I, Payares G, Pernia BM, Holder AA, Spencer LM. Suppressive and additive effects in protection mediated by combinations of monoclonal antibodies specific for merozoite surface protein 1 of Plasmodium yoelii. Malaria journal. 2010; 9; 46. [PubMed: 20146804].

49. Etlinger et al., 1991: Etlinger HM, Caspers P, Matile H, Schoenfeld HJ, Stueber D, Takacs B. Ability of recombinant or native proteins to protect monkeys against heterologous challenge with Plasmodium falciparum. Infection and immunity. 1991; 59(10); 3498-3503. [PubMed: 1894356].

50. Fanning et al., 2003: Fanning SL, Czesny B, Sedegah M, Carucci DJ, van Gemert GJ, Eling W, Williamson KC. A glycosylphosphatidylinositol anchor signal sequence enhances the immunogenicity of a DNA vaccine encoding Plasmodium falciparum sexual-stage antigen, Pfs230. Vaccine. 2003 Jul 4; 21(23); 3228-35. [PubMed: 12804852].

51. Flanagan et al., 2003: Flanagan KL, Mwangi T, Plebanski M, Odhiambo K, Ross A, Sheu E, Kortok M, Lowe B, Marsh K, Hill AV. Ex vivo interferon-gamma immune response to thrombospondin-related adhesive protein in coastal Kenyans: longevity and risk of Plasmodium falciparum infection. The American journal of tropical medicine and hygiene. 2003 Apr; 68(4); 421-30. [PubMed: 12875291].

52. Flanagan et al., 2006: Flanagan KL, Plebanski M, Odhiambo K, Sheu E, Mwangi T, Gelder C, Hart K, Kortok M, Lowe B, Robson KJ, Marsh K, Hill AV. Cellular reactivity to the p. Falciparum protein trap in adult kenyans: novel epitopes, complex cytokine patterns, and the impact of natural antigenic variation. The American journal of tropical medicine and hygiene. 2006 Mar; 74(3); 367-75. [PubMed: 16525093].

53. Gantt et al., 2000: Gantt S, Persson C, Rose K, Birkett AJ, Abagyan R, Nussenzweig V. Antibodies against thrombospondin-related anonymous protein do not inhibit Plasmodium sporozoite infectivity in vivo. Infection and immunity. 2000 Jun; 68(6); 3667-73. [PubMed: 10816526].

54. Garcia et al., 2006: Garcia JE, Puentes A, Patarroyo ME. Developmental biology of sporozoite-host interactions in Plasmodium falciparum malaria: implications for vaccine design. Clinical microbiology reviews. 2006 Oct; 19(4); 686-707. [PubMed: 17041140].

55. Genton et al., 2003: Genton B, Al-Yaman F, Betuela I, Anders RF, Saul A, Baea K, Mellombo M, Taraika J, Brown GV, Pye D, Irving DO, Felger I, Beck HP, Smith TA, Alpers MP. Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children. Vaccine. 2003 Dec 8; 22(1); 30-41. [PubMed: 14604568].

56. Genton et al., 2003a: Genton B, Anders RF, Alpers MP, Reeder JC. The malaria vaccine development program in Papua New Guinea. Trends in parasitology. 2003 Jun; 19(6); 264-70. [PubMed: 12798084].

57. Genton et al., 2007: Genton B, Pluschke G, Degen L, Kammer AR, Westerfeld N, Okitsu SL, Schroller S, Vounatsou P, Mueller MM, Tanner M, Zurbriggen R. A randomized placebo-controlled phase Ia malaria vaccine trial of two virosome-formulated synthetic peptides in healthy adult volunteers. PloS one. 2007; 2(10); e1018. [PubMed: 17925866].

58. Gilbert et al., 2006: Gilbert SC, Moorthy VS, Andrews L, Pathan AA, McConkey SJ, Vuola JM, Keating SM, Berthoud T, Webster D, McShane H, Hill AV. Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. Vaccine. 2006 May 22; 24(21); 4554-61. [PubMed: 16150517].

59. Girard et al., 2007: Girard MP, Reed ZH, Friede M, Kieny MP. A review of human vaccine research and development: malaria. Vaccine. 2007 Feb 19; 25(9); 1567-80. [PubMed: 17045367].

60. Grüner et al., 2007: Grüner AC, Mauduit M, Tewari R, Romero JF, Depinay N, Kayibanda M, Lallemand E, Chavatte JM, Crisanti A, Sinnis P, Mazier D, Corradin G, Snounou G, Rénia L. Sterile protection against malaria is independent of immune responses to the circumsporozoite protein. PloS one. 2007; 2(12); e1371. [PubMed: 18159254].

61. Greenwood et al., 2005: Greenwood BM, Bojang K, Whitty CJ, Targett GA. Malaria. Lancet. 2005 Apr 23-29; 365(9469); 1487-98. [PubMed: 15850634].

62. Hay et al., 2004: Hay SI, Guerra CA, Tatem AJ, Noor AM, Snow RW. The global distribution and population at risk of malaria: past, present, and future. The Lancet infectious diseases. 2004 Jun; 4(6); 327-36. [PubMed: 15172341].

63. He et al., 2015: He P, Zou Y, Hu Z. Advances in aluminum hydroxide-based adjuvant research and its mechanism. Human vaccines & immunotherapeutics. 2015; 11(2); 477-488. [PubMed: 25692535].

64. Heal et al., 1999: Heal KG, Hill HR, Stockley PG, Hollingdale MR, Taylor-Robinson AW. Expression and immunogenicity of a liver stage malaria epitope presented as a foreign peptide on the surface of RNA-free MS2 bacteriophage capsids. Vaccine. 1999 Sep; 18(3-4); 251-8. [PubMed: 10506649].

65. Healer et al., 1997: Healer J, McGuinness D, Hopcroft P, Haley S, Carter R, Riley E. Complement-mediated lysis of Plasmodium falciparum gametes by malaria-immune human sera is associated with antibodies to the gamete surface antigen Pfs230. Infection and immunity. 1997 Aug; 65(8); 3017-23. [PubMed: 9234748].

66. Heppner et al., 2005: Heppner DG Jr, Kester KE, Ockenhouse CF, Tornieporth N, Ofori O, Lyon JA, Stewart VA, Dubois P, Lanar DE, Krzych U, Moris P, Angov E, Cummings JF, Leach A, Hall BT, Dutta S, Schwenk R, Hillier C, Barbosa A, Ware LA, Nair L, Darko CA, Withers MR, Ogutu B, Polhemus ME, Fukuda M, Pichyangkul S, Gettyacamin M, Diggs C, Soisson L, Milman J, Dubois MC, Garcon N, Tucker K, Wittes J, Plowe CV, Thera MA, Duombo OK, Pau MG, Goudsmit J, Ballou WR, Cohen J. Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine. 2005 Mar 18; 23(17-18); 2243-50. [PubMed: 15755604].

67. Hill et al., 2009: A Study of the Safety and Effectiveness of Two New Malaria Vaccines [https://clinicaltrials.gov/ct2/show/NCT01003314?term=NCT01003314&draw=2&rank=1]

68. Hillier et al., 2005: Hillier CJ, Ware LA, Barbosa A, Angov E, Lyon JA, Heppner DG, Lanar DE. Process development and analysis of liver-stage antigen 1, a preerythrocyte-stage protein-based vaccine for Plasmodium falciparum. Infection and immunity. 2005 Apr; 73(4); 2109-15. [PubMed: 15784552].

69. Hodder et al., 2001: Hodder AN, Crewther PE, Anders RF. Specificity of the protective antibody response to apical membrane antigen 1. Infection and immunity. 2001; 69(5); 3286-3294. [PubMed: 11292751].

70. Hoffman et al., 1994: Hoffman SL, Sedegah M, Hedstrom RC. Protection against malaria by immunization with a Plasmodium yoelii circumsporozoite protein nucleic acid vaccine. Vaccine. 1994; 12(16); 1529-1533. [PubMed: 7879419].

71. Hoffman et al., 1997: Hoffman SL, Doolan DL, Sedegah M, Aguiar JC, Wang R, Malik A, Gramzinski RA, Weiss WR, Hobart P, Norman JA, Margalith M, Hedstrom RC. Strategy for development of a pre-erythrocytic Plasmodium falciparum DNA vaccine for human use. Vaccine. 1997; 15(8); 842-845. [PubMed: 9234529].

72. Horii et al., 2010: Horii T, Shirai H, Jie L, Ishii KJ, Palacpac NQ, Tougan T, Hato M, Ohta N, Bobogare A, Arakaki N, Matsumoto Y, Namazue J, Ishikawa T, Ueda S, Takahashi M. Evidences of Protection Against Blood-stage Infection of Plasmodium falciparum by the Novel Protein Vaccine SE36. Parasitology international. 2010; ; . [PubMed: 20493274].

73. Hou et al., 2022: Hou MM, Barrett JR, Themistocleous Y, Rawlinson TA, Diouf A, Martinez FJ, Nielsen CM, Lias AM, King LDW, Edwards NJ, Greenwood NM, Kingham L, Poulton ID, Khozoee B, Goh C, Mac Lochlainn DJ, Salkeld J, Guilotte-Blisnick M, Huon C, Mohring F, Reimer JM, Chauhan VS, Mukherjee P, Biswas S, Taylor IJ, Lawrie AM, Cho JS, Nugent FL, Long CA, Moon RW, Miura K, Silk SE, Chitnis CE, Minassian AM, Draper SJ. Impact of a blood-stage vaccine on Plasmodium vivax malaria. medRxiv : the preprint server for health sciences. 2022; ; . [PubMed: 35664997].

74. Iyori et al., 2013: Iyori M, Nakaya H, Inagaki K, Pichyangkul S, Yamamoto DS, Kawasaki M, Kwak K, Mizukoshi M, Goto Y, Matsuoka H, Matsumoto M, Yoshida S. Protective efficacy of baculovirus dual expression system vaccine expressing Plasmodium falciparum circumsporozoite protein. PloS one. 2013; 8(8); e70819. [PubMed: 23951015].

75. Joy et al., 2003: Joy DA, Feng X, Mu J, Furuya T, Chotivanich K, Krettli AU, Ho M, Wang A, White NJ, Suh E, Beerli P, Su XZ. Early origin and recent expansion of Plasmodium falciparum. Science (New York, N.Y.). 2003 Apr 11; 300(5617); 318-21. [PubMed: 12690197].

76. Kaba et al., 2009: Kaba SA, Brando C, Guo Q, Mittelholzer C, Raman S, Tropel D, Aebi U, Burkhard P, Lanar DE. A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria. Journal of immunology (Baltimore, Md. : 1950). 2009; 183(11); 7268-7277. [PubMed: 19915055].

77. Kaufman et al., 2005: Kaufman TS, Ruveda EA. The quest for quinine: those who won the battles and those who won the war. Angewandte Chemie (International ed. in English). 2005 Jan 28; 44(6); 854-85. [PubMed: 15669029].

78. Kester et al., 2007: Kester KE, McKinney DA, Tornieporth N, Ockenhouse CF, Heppner DG Jr, Hall T, Wellde BT, White K, Sun P, Schwenk R, Krzych U, Delchambre M, Voss G, Dubois MC, Gasser RA Jr, Dowler MG, O'Brien M, Wittes J, Wirtz R, Cohen J, Ballou WR. A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naive adults. Vaccine. 2007 Jul 20; 25(29); 5359-66. [PubMed: 17574311].

79. Kocken et al., 2002: Kocken CH, Withers-Martinez C, Dubbeld MA, van der Wel A, Hackett F, Valderrama A, Blackman MJ, Thomas AW. High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that inhibit erythrocyte invasion. Infection and immunity. 2002 Aug; 70(8); 4471-6. [PubMed: 12117958].

80. Komisar, 2007: Komisar JL. Malaria vaccines. Frontiers in bioscience : a journal and virtual library. 2007 May 1; 12; 3928-55. [PubMed: 17485348].

81. Kristoff, 2007: Kristoff J. Malaria stage-specific vaccine candidates. Current pharmaceutical design. 2007; 13(19); 1989-99. [PubMed: 17627532].

82. Kumar et al., 1995: Kumar S, Yadava A, Keister DB, Tian JH, Ohl M, Perdue-Greenfield KA, Miller LH, Kaslow DC. Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys. Molecular medicine (Cambridge, Mass.). 1995; 1(3); 325-332. [PubMed: 8529111].

83. Kunkeaw et al., 2023: Kunkeaw N, Nguitragool W, Takashima E, Kangwanrangsan N, Muramatsu H, Tachibana M, Ishino T, Lin PJC, Tam YK, Pichyangkul S, Tsuboi T, Pardi N, Sattabongkot J. A Pvs25 mRNA vaccine induces complete and durable transmission-blocking immunity to Plasmodium vivax. NPJ vaccines. 2023; 8(1); 187. [PubMed: 38092803].

84. Kushwaha et al., 2001: Kushwaha A, Rao PP, Suresh RP, Chauhan VS. Immunogenicity of recombinant fragments of Plasmodium falciparum acidic basic repeat antigen produced in Escherichia coli. Parasite immunology. 2001 Aug; 23(8); 435-44. [PubMed: 11489167].

85. Kwiatkowski et al., 1997: Kwiatkowski D, Marsh K. Development of a malaria vaccine. Lancet. 1997 Dec 6; 350(9092); 1696-701. [PubMed: 9400530].

86. Kwon et al., 2005: Kwon YU, Soucy RL, Snyder DA, Seeberger PH. Assembly of a series of malarial glycosylphosphatidylinositol anchor oligosaccharides. Chemistry (Weinheim an der Bergstrasse, Germany). 2005 Apr 8; 11(8); 2493-504. [PubMed: 15729674].

87. Labaied et al., 2007: Labaied M, Harupa A, Dumpit RF, Coppens I, Mikolajczak SA, Kappe SH. Plasmodium yoelii sporozoites with simultaneous deletion of P52 and P36 are completely attenuated and confer sterile immunity against infection. Infection and immunity. 2007; 75(8); 3758-3768. [PubMed: 17517871].

88. Lal et al., 1996: Lal AA, Hughes MA, Oliveira DA, Nelson C, Bloland PB, Oloo AJ, Hawley WE, Hightower AW, Nahlen BL, Udhayakumar V. Identification of T-cell determinants in natural immune responses to the Plasmodium falciparum apical membrane antigen (AMA-1) in an adult population exposed to malaria. Infection and immunity. 1996 Mar; 64(3); 1054-9. [PubMed: 8641760].

89. Lanar et al., 1996: Lanar DE, Tine JA, de Taisne C, Seguin MC, Cox WI, Winslow JP, Ware LA, Kauffman EB, Gordon D, Ballou WR, Paoletti E, Sadoff JC. Attenuated vaccinia virus-circumsporozoite protein recombinants confer protection against rodent malaria. Infection and immunity. 1996; 64(5); 1666-1671. [PubMed: 8613376].

90. Langermans et al., 2006: Langermans JA, Hensmann M, van Gijlswiik M, Zhang D, Pan W, Giersing BK, Locke E, Dubovsk F, Wittes J, Thomas AW. Preclinical evaluation of a chimeric malaria vaccine candidate in Montanide ISA 720: immunogenicity and safety in rhesus macaques. Human vaccines. 2006 Sep-Oct; 2(5); 222-6. [PubMed: 17035731].

91. Laurens, 2020: Laurens MB. RTS,S/AS01 vaccine (Mosquirix™): an overview. Human vaccines & immunotherapeutics. 2020; 16(3); 480-489. [PubMed: 31545128].

92. Le et al., 2000: Le TP, Coonan KM, Hedstrom RC, Charoenvit Y, Sedegah M, Epstein JE, Kumar S, Wang R, Doolan DL, Maguire JD, Parker SE, Hobart P, Norman J, Hoffman SL. Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. Vaccine. 2000; 18(18); 1893-1901. [PubMed: 10699338].

93. Li et al., 2007: Li SL, Zhang DM, Cao Y, Pan WQ. [Expression and immunogenicity evaluation of ectodomain and subdomains of Plasmodium berghei apical membrane antigen 1]. Zhongguo ji sheng chong xue yu ji sheng chong bing za zhi = Chinese journal of parasitology & parasitic diseases. 2007; 25(1); 1-5. [PubMed: 17639690].

94. Loughney et al., 2014: Loughney JW, Lancaster C, Ha S, Rustandi RR. Residual bovine serum albumin (BSA) quantitation in vaccines using automated Capillary Western technology. Analytical biochemistry. 2014; 461; 49-56. [PubMed: 24841366].

95. Malkin et al., 2005: Malkin EM, Diemert DJ, McArthur JH, Perreault JR, Miles AP, Giersing BK, Mullen GE, Orcutt A, Muratova O, Awkal M, Zhou H, Wang J, Stowers A, Long CA, Mahanty S, Miller LH, Saul A, Durbin AP. Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria. Infection and immunity. 2005; 73(6); 3677-3685. [PubMed: 15908397].

96. Matsumoto et al., 1998: Matsumoto S, Yukitake H, Kanbara H, Yamada T. Recombinant Mycobacterium bovis bacillus Calmette-GuÃ©rin secreting merozoite surface protein 1 (MSP1) induces protection against rodent malaria parasite infection depending on MSP1-stimulated interferon gamma and parasite-specific antibodies. The Journal of experimental medicine. 1998; 188(5); 845-854. [PubMed: 9730886].

97. Mauduit et al., 2009: Mauduit M, Grüner AC, Tewari R, Depinay N, Kayibanda M, Chavatte JM, Franetich JF, Crisanti A, Mazier D, Snounou G, Rénia L. A role for immune responses against non-CS components in the cross-species protection induced by immunization with irradiated malaria sporozoites. PloS one. 2009; 4(11); e7717. [PubMed: 19890387].

98. McConkey et al., 2003: McConkey SJ, Reece WH, Moorthy VS, Webster D, Dunachie S, Butcher G, Vuola JM, Blanchard TJ, Gothard P, Watkins K, Hannan CM, Everaere S, Brown K, Kester KE, Cummings J, Williams J, Heppner DG, Pathan A, Flanagan K, Arulanantham N, Roberts MT, Roy M, Smith GL, Schneider J, Peto T, Sinden RE, Gilbert SC, Hill AV. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nature medicine. 2003; 9(6); 729-735. [PubMed: 12766765].

99. Meis et al., 1983: Meis JF, Verhave JP, Jap PH, Sinden RE, Meuwissen JH. Malaria parasites--discovery of the early liver form. Nature. 1983 Mar 31-Apr 6; 302(5907); 424-6. [PubMed: 6339945].

100. Mendes et al., 2018: Mendes AM, Reuling IJ, Andrade CM, Otto TD, Machado M, Teixeira F, Pissarra J, Gonçalves-Rosa N, Bonaparte D, Sinfrónio J, Sanders M, Janse CJ, Khan SM, Newbold CI, Berriman M, Lee CK, Wu Y, Ockenhouse CF, Sauerwein RW, Prudêncio M. Pre-clinical evaluation of a P. berghei-based whole-sporozoite malaria vaccine candidate. NPJ vaccines. 2018; 3; 54. [PubMed: 30510775].

101. Mensah et al., 2016: Mensah VA, Gueye A, Ndiaye M, Edwards NJ, Wright D, Anagnostou NA, Syll M, Ndaw A, Abiola A, Bliss C, Gomis JF, Petersen I, Ogwang C, Dieye T, Viebig NK, Lawrie AM, Roberts R, Nicosia A, Faye B, Gaye O, Leroy O, Imoukhuede EB, Ewer KJ, Bejon P, Hill AV, Cisse B. Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal. PloS one. 2016; 11(12); e0167951. [PubMed: 27978537].

102. Mikolajczak et al., 2014: Mikolajczak SA, Lakshmanan V, Fishbaugher M, Camargo N, Harupa A, Kaushansky A, Douglass AN, Baldwin M, Healer J, O'Neill M, Phuong T, Cowman A, Kappe SH. A next-generation genetically attenuated Plasmodium falciparum parasite created by triple gene deletion. Molecular therapy : the journal of the American Society of Gene Therapy. 2014; 22(9); 1707-1715. [PubMed: 24827907].

103. Minassian et al., 2019: Safety, Immunogenicity and Efficacy of the Blood-stage Plasmodium Vivax Malaria Vaccine Candidate PvDBPII in Matrix M1 [https://clinicaltrials.gov/ct2/show/NCT04201431?term=vaccine&cond=Malaria%2C+Vivax&draw=2&rank=1]

104. Minassian et al., 2022: A Study of the Plasmodium Falciparum Malaria Vaccine Candidate Pfs48/45 in Matrix-M Adjuvant in the UK [https://clinicaltrials.gov/ct2/show/NCT05400746?term=vaccine&cond=Plasmodium&draw=8&rank=70]

105. Minassian et al., 2022: Safety and Immunogenicity of Pvs25-IMX313/Matrix-M1 Vaccine [https://clinicaltrials.gov/ct2/show/NCT05270265?term=vaccine&cond=Malaria%2C+Vivax&draw=2&rank=4]

106. Mohmmed et al., 2005: Mohmmed A, Kishore S, Patra KP, Dasaradhi PV, Malhotra P, Chauhan VS. Identification of karyopherin beta as an immunogenic antigen of the malaria parasite using immune mice and human sera. Parasite immunology. 2005; 27(5); 197-203. [PubMed: 15987343].

107. Moll et al., 2007: Moll K, Pettersson F, Vogt AM, Jonsson C, Rasti N, Ahuja S, Spångberg M, Mercereau-Puijalon O, Arnot DE, Wahlgren M, Chen Q. Generation of cross-protective antibodies against Plasmodium falciparum sequestration by immunization with an erythrocyte membrane protein 1-duffy binding-like 1 alpha domain. Infection and immunity. 2007; 75(1); 211-219. [PubMed: 17074852].

108. Moore et al., 2004: Moore AC, Hill AV. Progress in DNA-based heterologous prime-boost immunization strategies for malaria. Immunological reviews. 2004 Jun; 199; 126-43. [PubMed: 15233731].

109. Moore et al., 2005: Moore AC, Gallimore A, Draper SJ, Watkins KR, Gilbert SC, Hill AV. Anti-CD25 antibody enhancement of vaccine-induced immunogenicity: increased durable cellular immunity with reduced immunodominance. Journal of immunology (Baltimore, Md. : 1950). 2005 Dec 1; 175(11); 7264-73. [PubMed: 16301631].

110. Moormann et al., 2006: Moormann AM, John CC, Sumba PO, Tisch D, Embury P, Kazura JW. Stability of interferon-gamma and interleukin-10 responses to Plasmodium falciparum liver stage antigen-1 and thrombospondin-related adhesive protein in residents of a malaria holoendemic area. The American journal of tropical medicine and hygiene. 2006 Apr; 74(4); 585-90. [PubMed: 16606988].

111. Morais et al., 2006: Morais CG, Soares IS, Carvalho LH, Fontes CJ, Krettli AU, Braga EM. Antibodies to Plasmodium vivax apical membrane antigen 1: persistence and correlation with malaria transmission intensity. The American journal of tropical medicine and hygiene. 2006 Oct; 75(4); 582-7. [PubMed: 17038677].

112. Moreno et al., 2008: Moreno A, Caro-Aguilar I, Yazdani SS, Shakri AR, Lapp S, Strobert E, McClure H, Chitnis CE, Galinski MR. Preclinical assessment of the receptor-binding domain of Plasmodium vivax Duffy-binding protein as a vaccine candidate in rhesus macaques. Vaccine. 2008; 26(34); 4338-4344. [PubMed: 18573299].

113. Mueller et al., 2005: Mueller AK, Labaied M, Kappe SH, Matuschewski K. Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature. 2005; 433(7022); 164-167. [PubMed: 15580261].

114. Mulamba et al., 2022: Mulamba C, Williams C, Kreppel K, Ouedraogo JB, Olotu AI. Evaluation of the Pfs25-IMX313/Matrix-M malaria transmission-blocking candidate vaccine in endemic settings. Malaria journal. 2022; 21(1); 159. [PubMed: 35655174].

115. NIAID, 2006: Phase I Study of Safety and Immunogenicity of AMA1-C1Alhydrogel + CPG 7909 Vaccine for Malaria [https://clinicaltrials.gov/ct2/show/NCT00414336?term=vaccine&cond=malaria&draw=6]

116. Ockenhouse et al., 1998: Ockenhouse CF, Sun PF, Lanar DE, Wellde BT, Hall BT, Kester K, Stoute JA, Magill A, Krzych U, Farley L, Wirtz RA, Sadoff JC, Kaslow DC, Kumar S, Church LW, Crutcher JM, Wizel B, Hoffman S, Lalvani A, Hill AV, Tine JA, Guito KP, de Taisne C, Anders R, Ballou WR. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. The Journal of infectious diseases. 1998; 177(6); 1664-1673. [PubMed: 9607847].

117. Oliveira-Ferreira et al., 2000: Oliveira-Ferreira J, Miyahira Y, Layton GT, Savage N, Esteban M, Rodriguez D, Rodriguez JR, Nussenzweig RS, Zavala F. Immunogenicity of Ty-VLP bearing a CD8(+) T cell epitope of the CS protein of P. yoelii: enhanced memory response by boosting with recombinant vaccinia virus. Vaccine. 2000; 18(17); 1863-1869. [PubMed: 10699335].

118. Oneko et al., 2021: Oneko M, Steinhardt LC, Yego R, Wiegand RE, Swanson PA, Kc N, Akach D, Sang T, Gutman JR, Nzuu EL, Dungani A, Kim Lee Sim B, Oloo PN, Otieno K, Bii DK, Billingsley PF, James ER, Kariuki S, Samuels AM, Jongo S, Chebore W, Abdulla S, Daubenberger C, Mpina M, Styers D, Potter GE, Abarbanell G, Richie TL, Hoffman SL, Seder RA. Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial. Nature medicine. 2021; 27(9); 1636-1645. [PubMed: 34518679].

119. Ong'echa et al., 2003: Ong'echa JM, Lal AA, Terlouw DJ, Ter Kuile FO, Kariuki SK, Udhayakumar V, Orago AS, Hightower AW, Nahlen BL, Shi YP. Association of interferon-gamma responses to pre-erythrocytic stage vaccine candidate antigens of Plasmodium falciparum in young Kenyan children with improved hemoglobin levels: XV. Asembo Bay Cohort Project. The American journal of tropical medicine and hygiene. 2003 May; 68(5); 590-7. [PubMed: 12812352].

120. Pal-Bhowmick et al., 2007: Pal-Bhowmick I, Mehta M, Coppens I, Sharma S, Jarori GK. Protective properties and surface localization of Plasmodium falciparum enolase. Infection and immunity. 2007; 75(11); 5500-5508. [PubMed: 17785475].

121. Parker et al., 2001: Parker SE, Monteith D, Horton H, Hof R, Hernandez P, Vilalta A, Hartikka J, Hobart P, Bentley CE, Chang A, Hedstrom R, Rogers WO, Kumar S, Hoffman SL, Norman JA. Safety of a GM-CSF adjuvant-plasmid DNA malaria vaccine. Gene therapy. 2001; 8(13); 1011-1023. [PubMed: 11438836].

122. Pasquetto et al., 1997: Pasquetto V, Fidock DA, Gras H, Badell E, Eling W, Ballou WR, Belghiti J, Tartar A, Druilhe P. Plasmodium falciparum sporozoite invasion is inhibited by naturally acquired or experimentally induced polyclonal antibodies to the STARP antigen. European journal of immunology. 1997; 27(10); 2502-2513. [PubMed: 9368603].

123. Payne et al., 2017: Payne RO, Silk SE, Elias SC, Miura K, Diouf A, Galaway F, de Graaf H, Brendish NJ, Poulton ID, Griffiths OJ, Edwards NJ, Jin J, Labbé GM, Alanine DG, Siani L, Di Marco S, Roberts R, Green N, Berrie E, Ishizuka AS, Nielsen CM, Bardelli M, Partey FD, Ofori MF, Barfod L, Wambua J, Murungi LM, Osier FH, Biswas S, McCarthy JS, Minassian AM, Ashfield R, Viebig NK, Nugent FL, Douglas AD, Vekemans J, Wright GJ, Faust SN, Hill AV, Long CA, Lawrie AM, Draper SJ. Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions. JCI insight. 2017; 2(21); . [PubMed: 29093263].

124. Pearce et al., 2004: Pearce JA, Hodder AN, Anders RF. The alanine-rich heptad repeats are intact in the processed form of Plasmodium falciparum MSP3. Experimental parasitology. 2004 Nov-Dec; 108(3-4); 186-9. [PubMed: 15582517].

125. Petritus and Burns, 2008: Petritus PM, Burns JM Jr. Suppression of lethal Plasmodium yoelii malaria following protective immunization requires antibody-, IL-4-, and IFN-gamma-dependent responses induced by vaccination and/or challenge infection. Journal of immunology (Baltimore, Md. : 1950). 2008; 180(1); 444-453. [PubMed: 18097046].

126. PF11_0344 in GeneDB: PF11_0344 in GeneDB [http://www.genedb.org/genedb/Dispatcher?formType=navBar&organism=malaria&desc=yes&wildcard=yes&name=PF11_0344&ohmr=.&ohmr2=.]

127. PF13_0201 in GeneDB: PF13_0201 in GeneDB [http://www.genedb.org/genedb/Search?organism=malaria&name=PF13_0201&isid=true]

128. PFL1385c in GeneDB: PFL1385c in GeneDB [http://www.genedb.org/genedb/Search?organism=malaria&name=PFL1385c&isid=true]

129. Pichyangkul et al., 2004: Pichyangkul S, Gettayacamin M, Miller RS, Lyon JA, Angov E, Tongtawe P, Ruble DL, Heppner DG Jr, Kester KE, Ballou WR, Diggs CL, Voss G, Cohen JD, Walsh DS. Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP1(42) formulated with novel adjuvants or with alum. Vaccine. 2004 Sep 28; 22(29-30); 3831-40. [PubMed: 15364429].

130. Polhemus et al., 2007: Polhemus ME, Magill AJ, Cummings JF, Kester KE, Ockenhouse CF, Lanar DE, Dutta S, Barbosa A, Soisson L, Diggs CL, Robinson SA, Haynes JD, Stewart VA, Ware LA, Brando C, Krzych U, Bowden RA, Cohen JD, Dubois MC, Ofori-Anyinam O, De-Kock E, Ballou WR, Heppner DG Jr. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naive adults at the Walter Reed Army Institute of Research. Vaccine. 2007 May 22; 25(21); 4203-12. [PubMed: 17442466].

131. Pye et al., 1997: Pye D, Vandenberg KL, Dyer SL, Irving DO, Goss NH, Woodrow GC, Saul A, Alving CR, Richards RL, Ballou WR, Wu MJ, Skoff K, Anders RF. Selection of an adjuvant for vaccination with the malaria antigen, MSA-2. Vaccine. 1997; 15(9); 1017-1023. [PubMed: 9261951].

132. Rajeshwari et al., 2004: Rajeshwari K, Patel K, Nambeesan S, Mehta M, Sehgal A, Chakraborty T, Sharma S. The P domain of the P0 protein of Plasmodium falciparum protects against challenge with malaria parasites. Infection and immunity. 2004; 72(9); 5515-5521. [PubMed: 15322057].

133. Rausch et al., 2023: Rausch KM, Barnafo EK, Lambert LE, Muratova O, Gorres JP, Anderson C, Narum DL, Wu Y, Morrison RD, Zaidi I, Duffy PE. Preclinical evaluations of Pfs25-EPA and Pfs230D1-EPA in AS01 for a vaccine to reduce malaria transmission. iScience. 2023; 26(7); 107192. [PubMed: 37485364].

134. Renn et al., 2021: Renn JP, Doritchamou JYA, Tentokam BCN, Morrison RD, Cowles MV, Burkhardt M, Ma R, Mahamar A, Attaher O, Diarra BS, Traore M, Dicko A, Tolia NH, Fried M, Duffy PE. Allelic variants of full-length VAR2CSA, the placental malaria vaccine candidate, differ in antigenicity and receptor binding affinity. Communications biology. 2021; 4(1); 1309. [PubMed: 34799664].

135. Reuling et al., 2020: Reuling IJ, Mendes AM, de Jong GM, Fabra-García A, Nunes-Cabaço H, van Gemert GJ, Graumans W, Coffeng LE, de Vlas SJ, Yang ASP, Lee C, Wu Y, Birkett AJ, Ockenhouse CF, Koelewijn R, van Hellemond JJ, van Genderen PJJ, Sauerwein RW, Prudêncio M. An open-label phase 1/2a trial of a genetically modified rodent malaria parasite for immunization against Plasmodium falciparum malaria. Science translational medicine. 2020; 12(544); . [PubMed: 32434846].

136. Reyes-Sandoval et al., 2008: Reyes-Sandoval A, Sridhar S, Berthoud T, Moore AC, Harty JT, Gilbert SC, Gao G, Ertl HC, Wilson JC, Hill AV. Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei. European journal of immunology. 2008; 38(3); 732-741. [PubMed: 18266272].

137. Robson et al., 1998: Robson KJ, Dolo A, Hackford IR, Doumbo O, Richards MB, Keita MM, Sidibe T, Bosman A, Modiano D, Crisanti A. Natural polymorphism in the thrombospondin-related adhesive protein of Plasmodium falciparum. The American journal of tropical medicine and hygiene. 1998 Jan; 58(1); 81-9. [PubMed: 9452297].

138. Rogers et al., 2001: Rogers WO, Baird JK, Kumar A, Tine JA, Weiss W, Aguiar JC, Gowda K, Gwadz R, Kumar S, Gold M, Hoffman SL. Multistage multiantigen heterologous prime boost vaccine for Plasmodium knowlesi malaria provides partial protection in rhesus macaques. Infection and immunity. 2001; 69(9); 5565-5572. [PubMed: 11500430].

139. Rosa et al., 2004: Rosa DS, Tzelepis F, Cunha MG, Soares IS, Rodrigues MM. The pan HLA DR-binding epitope improves adjuvant-assisted immunization with a recombinant protein containing a malaria vaccine candidate. Immunology letters. 2004 Apr 15; 92(3); 259-68. [PubMed: 15081621].

140. Sakai et al., 2003: Sakai T, Hisaeda H, Nakano Y, Zhang M, Takashima M, Ishii K, Maekawa Y, Matsumoto S, Nitta Y, Miyazaki Ji, Yamamoto S, Himeno K. Gene gun-based co-immunization of merozoite surface protein-1 cDNA with IL-12 expression plasmid confers protection against lethal Plasmodium yoelii in A/J mice. Vaccine. 2003; 21(13-14); 1432-1444. [PubMed: 12615440].

141. Sanchez et al., 2001: Sanchez GI, Sedegah M, Rogers WO, Jones TR, Sacci J, Witney A, Carucci DJ, Kumar N, Hoffman SL. Immunogenicity and protective efficacy of a Plasmodium yoelii Hsp60 DNA vaccine in BALB/c mice. Infection and immunity. 2001; 69(6); 3897-3905. [PubMed: 11349057].

142. Sauerwein et al., 2017: Safety and Protective Efficacy of Pb(PfCS@UIS4) (PbVac) [https://clinicaltrials.gov/ct2/show/study/NCT03138096?cond=Pb%28PfCS%40UIS4%29&draw=2&rank=1]

143. Saul et al., 1992: Saul A, Lord R, Jones GL, Spencer L. Protective immunization with invariant peptides of the Plasmodium falciparum antigen MSA2. Journal of immunology (Baltimore, Md. : 1950). 1992; 148(1); 208-211. [PubMed: 1727867].

144. Schneider et al., 1998: Schneider J, Gilbert SC, Blanchard TJ, Hanke T, Robson KJ, Hannan CM, Becker M, Sinden R, Smith GL, Hill AV. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nature medicine. 1998; 4(4); 397-402. [PubMed: 9546783].

145. Seder et al., 2013: Seder RA, Chang LJ, Enama ME, Zephir KL, Sarwar UN, Gordon IJ, Holman LA, James ER, Billingsley PF, Gunasekera A, Richman A, Chakravarty S, Manoj A, Velmurugan S, Li M, Ruben AJ, Li T, Eappen AG, Stafford RE, Plummer SH, Hendel CS, Novik L, Costner PJ, Mendoza FH, Saunders JG, Nason MC, Richardson JH, Murphy J, Davidson SA, Richie TL, Sedegah M, Sutamihardja A, Fahle GA, Lyke KE, Laurens MB, Roederer M, Tewari K, Epstein JE, Sim BK, Ledgerwood JE, Graham BS, Hoffman SL. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science (New York, N.Y.). 2013; 341(6152); 1359-1365. [PubMed: 23929949].

146. Seeberger et al., 2004: Seeberger PH, Soucy RL, Kwon YU, Snyder DA, Kanemitsu T. A convergent, versatile route to two synthetic conjugate anti-toxin malaria vaccines. Chemical communications (Cambridge, England). 2004 Aug 7; (15); 1706-7. [PubMed: 15278147].

147. Sheehy et al., 2011: Sheehy SH, Duncan CJ, Elias SC, Collins KA, Ewer KJ, Spencer AJ, Williams AR, Halstead FD, Moretz SE, Miura K, Epp C, Dicks MD, Poulton ID, Lawrie AM, Berrie E, Moyle S, Long CA, Colloca S, Cortese R, Gilbert SC, Nicosia A, Hill AV, Draper SJ. Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Molecular therapy : the journal of the American Society of Gene Therapy. 2011; 19(12); 2269-2276. [PubMed: 21862998].

148. Sheehy et al., 2012: Sheehy SH, Duncan CJ, Elias SC, Biswas S, Collins KA, O'Hara GA, Halstead FD, Ewer KJ, Mahungu T, Spencer AJ, Miura K, Poulton ID, Dicks MD, Edwards NJ, Berrie E, Moyle S, Colloca S, Cortese R, Gantlett K, Long CA, Lawrie AM, Gilbert SC, Doherty T, Nicosia A, Hill AV, Draper SJ. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PloS one. 2012; 7(2); e31208. [PubMed: 22363582].

149. Sim et al., 2001: Sim BK, Narum DL, Liang H, Fuhrmann SR, Obaldia N 3rd, Gramzinski R, Aguiar J, Haynes JD, Moch JK, Hoffman SL. Induction of biologically active antibodies in mice, rabbits, and monkeys by Plasmodium falciparum EBA-175 region II DNA vaccine. Molecular medicine (Cambridge, Mass.). 2001; 7(4); 247-254. [PubMed: 11471569].

150. Singh et al., 2003: Singh S, Kennedy MC, Long CA, Saul AJ, Miller LH, Stowers AW. Biochemical and immunological characterization of bacterially expressed and refolded Plasmodium falciparum 42-kilodalton C-terminal merozoite surface protein 1. Infection and immunity. 2003 Dec; 71(12); 6766-74. [PubMed: 14638762].

151. Sirima et al., 2007: Sirima SB, Nebie I, Ouedraogo A, Tiono AB, Konate AT, Gansane A, Derme AI, Diarra A, Ouedraogo A, Soulama I, Cuzzin-Ouattara N, Cousens S, Leroy O. Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa. Vaccine. 2007 Mar 30; 25(14); 2723-32. [PubMed: 17280744].

152. Spring et al., 2009: Phase 1/2a Trial of Pf GAP p52-/p36- Sporozoite Malaria Vaccine [https://clinicaltrials.gov/ct2/show/NCT01024686?term=vaccine&cond=malaria&draw=9&rank=31]

153. Spring et al., 2013: Spring M, Murphy J, Nielsen R, Dowler M, Bennett JW, Zarling S, Williams J, de la Vega P, Ware L, Komisar J, Polhemus M, Richie TL, Epstein J, Tamminga C, Chuang I, Richie N, O'Neil M, Heppner DG, Healer J, O'Neill M, Smithers H, Finney OC, Mikolajczak SA, Wang R, Cowman A, Ockenhouse C, Krzych U, Kappe SH. First-in-human evaluation of genetically attenuated Plasmodium falciparum sporozoites administered by bite of Anopheles mosquitoes to adult volunteers. Vaccine. 2013; 31(43); 4975-4983. [PubMed: 24029408].

154. Stertman et al., 2023: Stertman L, Palm AE, Zarnegar B, Carow B, Lunderius Andersson C, Magnusson SE, Carnrot C, Shinde V, Smith G, Glenn G, Fries L, Lövgren Bengtsson K. The Matrix-M™ adjuvant: A critical component of vaccines for the 21(st) century. Human vaccines & immunotherapeutics. 2023; 19(1); 2189885. [PubMed: 37113023].

155. Stewart et al., 2007: Stewart VA, McGrath SM, Dubois PM, Pau MG, Mettens P, Shott J, Cobb M, Burge JR, Larson D, Ware LA, Demoitie MA, Weverling GJ, Bayat B, Custers JH, Dubois MC, Cohen J, Goudsmit J, Heppner DG Jr. Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone. Infection and immunity. 2007 May; 75(5); 2283-90. [PubMed: 17307942].

156. Stoute et al., 2006: Stoute JA, Heppner DG Jr, Mason CJ, Siangla J, Opollo MO, Kester KE, Vigneron L, Voss G, Walter MJ, Tornieporth N, Cohen JD, Ballou WR. Phase 1 safety and immunogenicity trial of malaria vaccine RTS,S/AS02A in adults in a hyperendemic region of western Kenya. The American journal of tropical medicine and hygiene. 2006 Jul; 75(1); 166-70. [PubMed: 16837726].

157. Stowers et al., 2002: Stowers AW, Chen Lh LH, Zhang Y, Kennedy MC, Zou L, Lambert L, Rice TJ, Kaslow DC, Saul A, Long CA, Meade H, Miller LH. A recombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeys from a lethal challenge with Plasmodium falciparum. Proceedings of the National Academy of Sciences of the United States of America. 2002 Jan 8; 99(1); 339-44. [PubMed: 11752405].

158. Sturm et al., 2006: Sturm A, Amino R, van de Sand C, Regen T, Retzlaff S, Rennenberg A, Krueger A, Pollok JM, Menard R, Heussler VT. Manipulation of host hepatocytes by the malaria parasite for delivery into liver sinusoids. Science (New York, N.Y.). 2006 Sep 1; 313(5791); 1287-90. [PubMed: 16888102].

159. Takashima et al., 2022: Takashima E, Nagaoka H, Correia R, Alves PM, Roldão A, Christensen D, Guderian JA, Fukushima A, Viebig NK, Depraetere H, Tsuboi T. A novel asexual blood-stage malaria vaccine candidate: PfRipr5 formulated with human-use adjuvants induces potent growth inhibitory antibodies. Frontiers in immunology. 2022; 13; 1002430. [PubMed: 36389677].

160. Talaat et al., 2016: Talaat KR, Ellis RD, Hurd J, Hentrich A, Gabriel E, Hynes NA, Rausch KM, Zhu D, Muratova O, Herrera R, Anderson C, Jones D, Aebig J, Brockley S, MacDonald NJ, Wang X, Fay MP, Healy SA, Durbin AP, Narum DL, Wu Y, Duffy PE. Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults. PloS one. 2016; 11(10); e0163144. [PubMed: 27749907].

161. Talman et al., 2004: Talman AM, Domarle O, McKenzie FE, Ariey F, Robert V. Gametocytogenesis: the puberty of Plasmodium falciparum. Malaria journal. 2004 Jul 14; 3; 24. [PubMed: 15253774].

162. Tarun et al., 2007: Tarun AS, Dumpit RF, Camargo N, Labaied M, Liu P, Takagi A, Wang R, Kappe SH. Protracted sterile protection with Plasmodium yoelii pre-erythrocytic genetically attenuated parasite malaria vaccines is independent of significant liver-stage persistence and is mediated by CD8+ T cells. The Journal of infectious diseases. 2007; 196(4); 608-616. [PubMed: 17624848].

163. Theisen et al., 2017: Theisen M, Jore MM, Sauerwein R. Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccine. Expert review of vaccines. 2017; 16(4); 329-336. [PubMed: 28043178].

164. Thera et al., 2006: Thera MA, Doumbo OK, Coulibaly D, Diallo DA, Sagara I, Dicko A, Diemert DJ, Heppner DG, Stewart VA, Angov E, Soisson L, Leach A, Tucker K, Lyke KE, Plowe CV. Safety and allele-specific immunogenicity of a malaria vaccine in malian adults: results of a phase I randomized trial. PLoS clinical trials. 2006 Nov 24; 1(7); e34. [PubMed: 17124530].

165. Thera et al., 2016: Thera MA, Coulibaly D, Kone AK, Guindo AB, Traore K, Sall AH, Diarra I, Daou M, Traore IM, Tolo Y, Sissoko M, Niangaly A, Arama C, Baby M, Kouriba B, Sissoko MS, Sagara I, Toure OB, Dolo A, Diallo DA, Remarque E, Chilengi R, Noor R, Sesay S, Thomas A, Kocken CH, Faber BW, Imoukhuede EB, Leroy O, Doumbo OK. Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in Bandiagara. Malaria journal. 2016; 15(1); 442. [PubMed: 27577237].

166. Thera et al., 2022: MSP3-CRM-Vac4All/ Alhydrogel® Malaria Vaccine (MSP3CRMV4All) [https://clinicaltrials.gov/ct2/show/NCT05197751?term=vaccine&cond=Malaria%2CFalciparum&draw=1&rank=10]

167. Tsai et al., 2009: Tsai CW, Duggan PF, Jin AJ, Macdonald NJ, Kotova S, Lebowitz J, Hurt DE, Shimp RL Jr, Lambert L, Miller LH, Long CA, Saul A, Narum DL. Characterization of a protective Escherichia coli-expressed Plasmodium falciparum merozoite surface protein 3 indicates a non-linear, multi-domain structure. Molecular and biochemical parasitology. 2009; 164(1); 45-56. [PubMed: 19073223].

168. University of Oxford, 2014: A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of New Plasmodium Falciparum Malaria Vaccine Candidates ChAd63 RH5 Alone and With MVA RH5 [https://clinicaltrials.gov/ct2/show/NCT02181088?term=vaccine&cond=Malaria%2CFalciparum&draw=6]

169. Valderrama-Aguirre et al., 2005: Valderrama-Aguirre A, Quintero G, Gómez A, Castellanos A, Pérez Y, Méndez F, Arévalo-Herrera M, Herrera S. Antigenicity, immunogenicity, and protective efficacy of Plasmodium vivax MSP1 PV200l: a potential malaria vaccine subunit. The American journal of tropical medicine and hygiene. 2005; 73(5 Suppl); 16-24. [PubMed: 16291762].

170. VanBuskirk et al., 2009: VanBuskirk KM, O'Neill MT, De La Vega P, Maier AG, Krzych U, Williams J, Dowler MG, Sacci JB Jr, Kangwanrangsan N, Tsuboi T, Kneteman NM, Heppner DG Jr, Murdock BA, Mikolajczak SA, Aly AS, Cowman AF, Kappe SH. Preerythrocytic, live-attenuated Plasmodium falciparum vaccine candidates by design. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106(31); 13004-13009. [PubMed: 19625622].

171. Vandepapelière et al., 2005: Vandepapelière P, Rehermann B, Koutsoukos M, Moris P, Garçon N, Wettendorff M, Leroux-Roels G. Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults. Vaccine. 2005; 23(20); 2591-2601. [PubMed: 15780441].

172. Vincent et al., 1999: Vincent AA, Fanning S, Caira FC, Williamson KC. Immunogenicity of malaria transmission-blocking vaccine candidate, y230.CA14 following crosslinking in the presence of tetanus toxoid. Parasite immunology. 1999 Nov; 21(11); 573-81. [PubMed: 10583858].

173. Wan et al., 2007: Wan Omar A, Roslaini AM, Ngah ZU, Azahari AA, Zahedi M, Baharudin O. A recombinant 19 kDa Plasmodium berghei merozoite surface protein 1 formulated with alum induces protective immune response in mice. Tropical biomedicine. 2007; 24(1); 119-126. [PubMed: 17568385].

174. Wang et al., 2004: Wang L, Goschnick MW, Coppel RL. Oral immunization with a combination of Plasmodium yoelii merozoite surface proteins 1 and 4/5 enhances protection against lethal malaria challenge. Infection and immunity. 2004; 72(10); 6172-6175. [PubMed: 15385527].

175. Wang et al., 2005: Wang R, Richie TL, Baraceros MF, Rahardjo N, Gay T, Banania JG, Charoenvit Y, Epstein JE, Luke T, Freilich DA, Norman J, Hoffman SL. Boosting of DNA vaccine-elicited gamma interferon responses in humans by exposure to malaria parasites. Infection and immunity. 2005; 73(5); 2863-2872. [PubMed: 15845492].

176. Webster et al., 2005: Webster DP, Dunachie S, Vuola JM, Berthoud T, Keating S, Laidlaw SM, McConkey SJ, Poulton I, Andrews L, Andersen RF, Bejon P, Butcher G, Sinden R, Skinner MA, Gilbert SC, Hill AV. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102(13); 4836-4841. [PubMed: 15781866].

177. Wu et al., 2008: Wu Y, Ellis RD, Shaffer D, Fontes E, Malkin EM, Mahanty S, Fay MP, Narum D, Rausch K, Miles AP, Aebig J, Orcutt A, Muratova O, Song G, Lambert L, Zhu D, Miura K, Long C, Saul A, Miller LH, Durbin AP. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PloS one. 2008; 3(7); e2636. [PubMed: 18612426].

178. Xu et al., 2000: Xu H, Hodder AN, Yan H, Crewther PE, Anders RF, Good MF. CD4+ T cells acting independently of antibody contribute to protective immunity to Plasmodium chabaudi infection after apical membrane antigen 1 immunization. Journal of immunology (Baltimore, Md. : 1950). 2000; 165(1); 389-396. [PubMed: 10861076].

179. Yazdani et al., 2006: Yazdani SS, Shakri AR, Pattnaik P, Rizvi MM, Chitnis CE. Improvement in yield and purity of a recombinant malaria vaccine candidate based on the receptor-binding domain of Plasmodium vivax Duffy binding protein by codon optimization. Biotechnology letters. 2006; 28(14); 1109-1114. [PubMed: 16794771].

180. Yoshida et al., 2000: Yoshida S, Kashiwamura SI, Hosoya Y, Luo E, Matsuoka H, Ishii A, Fujimura A, Kobayashi E. Direct immunization of malaria DNA vaccine into the liver by gene gun protects against lethal challenge of Plasmodium berghei sporozoite. Biochemical and biophysical research communications. 2000; 271(1); 107-115. [PubMed: 10777689].

181. Yuen et al., 2007: Yuen D, Leung WH, Cheung R, Hashimoto C, Ng SF, Ho W, Hui G. Antigenicity and immunogenicity of the N-terminal 33-kDa processing fragment of the Plasmodium falciparum merozoite surface protein 1, MSP1: implications for vaccine development. Vaccine. 2007 Jan 5; 25(3); 490-9. [PubMed: 16949181].

182. Zavala et al., 1985: Zavala F, Tam JP, Hollingdale MR, Cochrane AH, Quakyi I, Nussenzweig RS, Nussenzweig V. Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria. Science (New York, N.Y.). 1985; 228(4706); 1436-1440. [PubMed: 2409595].

183. Zhou et al., 2006: Zhou Z, Todd CW, Wohlhueter RM, Price A, Xiao L, Schnake P, Bonner PC, Martin AM, Goldman IF, De La Vega P, Udhayakumar V, Lal AA. Development, characterization and immunogenicity of a multi-stage, multi-valent Plasmodium falciparum vaccine antigen (FALVAC-1A) expressed in Escherichia coli. Human vaccines. 2006 Jan-Feb; 2(1); 14-23. [PubMed: 17012909].